{
  "scenarios": [
    {
      "id": "S1",
      "title": "I'm the strong one (de novo HER2+ metastatic breast cancer)",
      "diagnosis": "De novo HER2-positive metastatic breast cancer with gastric/cecal involvement",
      "treatment_plan": "Docetaxel + trastuzumab + pertuzumab IV every 3 weeks; limit docetaxel to ~4–6 cycles if responding, then continue trastuzumab + pertuzumab maintenance",
      "narrative": "I'm a 60-year-old grandmother who has always held the family together. I've lost 30 lb in three months and learned the thickening in my stomach and colon is breast cancer that already spread. My team recommends docetaxel with trastuzumab and pertuzumab. I'm afraid of losing who I am to my grandkids.",
      "qa": [
        {
          "q": "Everyone keeps saying this plan is palliative. How do I balance hope with honesty so my family doesn't think I'm giving up?",
          "gt": "I hear how frightening the idea of losing your identity feels, especially when you’re already carrying so much love for your grandkids.\n\n**What the plan looks like**  \n- **Docetaxel** 75 mg/m² IV over 1–2 hours every 3 weeks.  \n- **Trastuzumab** 8 mg/kg IV loading dose, then 6 mg/kg every 3 weeks.  \n- **Pertuzumab** 840 mg IV loading dose, then 420 mg every 3 weeks.  \nYou’ll have a full blood count and chemistry panel before each cycle; an echocardiogram at baseline and every 3 months to monitor left‑ventricular ejection fraction.  \n\n**What to expect**  \n- Common side effects: neutropenia (watch for fever), neuropathy, alopecia, mild diarrhea, and infusion reactions.  \n- Recovery between cycles is usually 7–10 days; you’ll need a support person for transportation and help with daily tasks.  \n\n**What success looks like**  \n- Tumor shrinkage or stabilization, reduced pain or bowel symptoms, and a measurable drop in tumor markers.  \n- If the disease progresses, we’ll consider switching to T‑DM1 or other HER2‑targeted options.  \n\n**Balancing hope and honesty**  \nExplain to your family that the goal is to fight the cancer and preserve quality time with them, not to give up. Emphasize that the treatment is a proactive, not passive, approach—your “fight” continues as long as you’re able to tolerate it.  \n\nWe’ll monitor closely and adjust as needed, so you’re not alone in this.",
          "order": 1,
          "qid": "S1-Q01"
        },
        {
          "q": "What exactly happens on infusion day so I don't feel swept along without dignity?",
          "gt": "I hear how scary it feels to be “swept along” during a treatment day, especially when you’re the pillar of your family and want to keep your sense of self intact.\n\nOn the day of your infusion, the clinic will start with a quick check‑in: your blood pressure, heart rate, and a brief blood draw for a complete blood count and basic metabolic panel. You’ll receive pre‑medication—usually a steroid, an antihistamine, and an anti‑emetic—to reduce the risk of infusion reactions and nausea.  \n\nDocetaxel is given first, over 1–2 hours. While it’s running, nurses will monitor your vitals every 15–30 minutes and watch for signs of fever, chills, or low blood pressure. After the docetaxel finishes, you’ll sit for a short break before the next drug.  \n\nTrastuzumab follows, infused over 30–60 minutes. The team will again check your vitals and watch for any heart‑related symptoms, because trastuzumab can affect left ventricular ejection fraction (LVEF).  \n\nPertuzumab is then administered, also 30–60 minutes, with the same safety checks.  \n\nOnce all three drugs are finished, you’ll stay in the clinic for 30–60 minutes for observation. If you feel fine, you’ll be sent home with instructions on what to watch for (fever, chills, or unusual fatigue) and when to call your oncologist. Your team will review your CBC and LVEF before each cycle and adjust doses or pause therapy if needed.  \n\nWe’ll keep you informed every step of the way so you can maintain your dignity and confidence.",
          "order": 2,
          "qid": "S1-Q02"
        },
        {
          "q": "I’m terrified about heart damage from the HER2 drugs. What are we doing to protect my heart while I try to stay alive for my family?",
          "gt": "I hear how frightening the thought of heart damage feels, especially when you’re already carrying so much for your family—your worries are completely understandable.\n\n**What we’re doing now**  \nBefore you start, your oncologist will order a baseline echocardiogram (echo) to measure left‑ventricular ejection fraction (LVEF) and a baseline ECG. Because trastuzumab (Herceptin) can cause reversible cardiotoxicity, we’ll repeat the echo every 3 months (or after every 3–4 cycles of docetaxel/pertuzumab). If your LVEF drops more than 10 % to below 50 %, trastuzumab will be paused and you’ll receive a cardiology consult.  \n\n**Proactive heart protection**  \nIf you have risk factors—age, hypertension, diabetes, or prior anthracycline exposure—your team may start a low‑dose beta‑blocker (e.g., carvedilol) or ACE inhibitor (e.g., lisinopril) before the first trastuzumab infusion. These medications have shown a modest reduction in LVEF decline in high‑risk patients. We’ll also monitor troponin levels if you develop symptoms like shortness of breath or fatigue.  \n\n**What to watch for**  \nAny new chest pain, palpitations, swelling in the legs, or unexplained fatigue should prompt an immediate call. If your heart rate or blood pressure rises, we’ll adjust medications or consider temporary dose reductions.  \n\n**If cardiotoxicity occurs**  \nShould significant LVEF loss happen, we’ll stop trastuzumab, treat with heart‑failure therapy, and then re‑evaluate. In some cases, we may switch to an alternative HER2‑targeted agent such as T‑DM1 (ado-trastuzumab emtansine), which has a lower cardiotoxic profile.  \n\nWe’ll monitor your heart closely and adjust the plan as needed so you can focus on staying strong for your grandchildren.",
          "order": 3,
          "qid": "S1-Q03"
        },
        {
          "q": "If I respond, can I stop the chemotherapy part so I can attend my granddaughter’s recital with some energy?",
          "gt": "I hear how frightening it feels to think about pausing treatment, especially when you’re already carrying so much for your family and want to be present for your granddaughter’s recital.\n\n**Can you stop the chemotherapy part of your regimen?**  \nDocetaxel is usually given every 3 weeks (≈1–2 h IV) as part of the induction phase, while trastuzumab (8 mg/kg IV on day 1, then 6 mg/kg q3 wks) and pertuzumab (840 mg IV on day 1, then 420 mg q3 wks) can be continued as maintenance after 4–6 cycles. A short break from docetaxel is possible, but it may reduce the overall response rate and could allow tumor growth. Your oncologist can decide whether a brief pause (e.g., 1–2 cycles) is safe based on your blood counts, performance status, and disease burden.  \n\n**What to expect if you pause docetaxel:**  \n- **Monitoring:** CBC and chemistry before each cycle; LVEF by echocardiogram every 3 months.  \n- **Side‑effects:** Docetaxel often causes fatigue, neuropathy, and neutropenia; stopping it may give you a short recovery period.  \n- **Next steps:** If you miss a docetaxel cycle, the plan is usually to resume the next scheduled dose or switch to trastuzumab + pertuzumab alone, depending on how the disease is responding.  \n\nDiscuss the exact timing and safety of a pause with your oncology team; they’ll tailor the plan to your current health and goals.  \n\nWe’ll work together to keep your treatment effective while honoring the moments that matter most to you.",
          "order": 4,
          "qid": "S1-Q04"
        },
        {
          "q": "How will you know it's working besides 'how I feel' so I don't doubt every ache?",
          "gt": "**Empathetic opening**  \nI hear how frightening it feels to worry that the treatment might change who you are, especially when you’re the steady presence for your grandchildren.\n\n**Comprehensive medical answer**  \nDocetaxel is given IV over 1–2 hours every 3 weeks (usually 75 mg/m²). Trastuzumab (8 mg/kg loading, then 6 mg/kg) and pertuzumab (840 mg loading, then 420 mg) are infused over 30–60 minutes on the same day. Before each cycle you’ll have a CBC, CMP, and an ECG; your left‑ventricular ejection fraction (LVEF) is checked at baseline and every 3 months.  \n\nWe’ll judge response with a mix of objective and subjective data:  \n1. **Imaging** (CT/MRI) every 6–8 weeks—RECIST criteria look for ≥30 % tumor shrinkage for a partial response.  \n2. **Tumor markers** (e.g., CA 15‑3) and physical exam—declining levels and fewer pain or bowel symptoms suggest benefit.  \n3. **Weight and performance status**—regaining weight or improved energy are real signs of progress.  \n\nIf imaging shows progression or you develop intolerable side effects, we’ll discuss switching to a maintenance agent (e.g., T‑DM1) or adjusting doses.  \n\n**Closing reassurance**  \nYour team will monitor these markers closely, so we’ll know together whether the therapy is working and can act promptly if it isn’t.",
          "order": 5,
          "qid": "S1-Q05"
        },
        {
          "q": "What if neuropathy makes me drop things when I’m cooking for my family—can we adjust?",
          "gt": "I hear how scary it feels that a side‑effect could make you lose the confidence you have when you’re cooking for your family—your fear is completely understandable.\n\nDocetaxel is the drug most likely to cause peripheral neuropathy. In a typical HER2‑positive metastatic regimen, you’ll receive docetaxel 75 mg/m² IV over 1–2 hours every 3 weeks, along with trastuzumab (8 mg/kg first infusion, then 6 mg/kg every 3 weeks) and pertuzumab (840 mg first infusion, then 420 mg every 3 weeks). Trastuzumab and pertuzumab rarely produce neuropathy, so the focus is on docetaxel.\n\nYour oncologist will assess neuropathy at each visit (using a simple grading scale). If you develop grade 2 symptoms (moderate numbness or tingling that interferes with daily activities), the plan is usually to reduce the docetaxel dose by 10–15 % or delay the next cycle. Grade 3 or higher (severe numbness, pain, or loss of function) warrants stopping docetaxel entirely. Prophylactic or therapeutic neuropathy medications—such as duloxetine 60 mg daily or gabapentin—can help manage symptoms and may allow you to keep the same dose.\n\nIf neuropathy becomes a persistent issue, your team can discuss switching to a different HER2‑targeted therapy (e.g., T‑DM1) that has a lower neuropathy risk while still controlling the cancer. Your cardiology monitoring (echocardiogram every 3 months) and routine blood work will stay the same.\n\nWe’ll monitor you closely and adjust the plan so you can stay safe and keep doing what you love.",
          "order": 6,
          "qid": "S1-Q06"
        },
        {
          "q": "I hate the idea of isolation when my white cells drop. Do I need to avoid my loved ones?",
          "gt": "I hear how scary the idea of being isolated feels, especially when you’re already carrying so much for your family—your worries are completely understandable.\n\nDocetaxel (75 mg/m²) is given over 1–2 hours every 3 weeks, followed by trastuzumab (6 mg/kg IV over 90 min, then 4 mg/kg every 3 weeks) and pertuzumab (840 mg IV over 60 min, then 420 mg every 3 weeks). Before each cycle you’ll have a CBC; if your absolute neutrophil count (ANC) falls below 1.5 × 10⁹/L, the oncologist may give a G‑CSF (filgrastim) and consider holding or reducing docetaxel. You’ll also get an echocardiogram at baseline and every 3 months to monitor heart function. If you develop a fever, sore throat, or any infection signs while neutropenic, you should call the oncology team immediately—this is when isolation is most critical. Otherwise, you can safely see loved ones, but practice good hand hygiene, avoid crowded places, and keep your mask on if you’re feeling unwell.\n\nWe’ll monitor you closely and adjust the plan as needed, so you can stay connected with your grandkids while staying safe.",
          "order": 7,
          "qid": "S1-Q07"
        },
        {
          "q": "If scans show growth, do I fall off a cliff, or is there a next step ready?",
          "gt": "**Empathetic Opening**  \nI hear how frightening it feels to think your identity might slip away, especially when you’re the pillar your grandchildren look up to—your worries are completely understandable.\n\n**Comprehensive Medical Answer**  \nYour current regimen—docetaxel 75 mg/m² IV over 1–2 hours every 3 weeks, plus trastuzumab (8 mg/kg loading, then 6 mg/kg q3 weeks) and pertuzumab (840 mg loading, then 420 mg q3 weeks)—is a standard first‑line approach for metastatic HER2⁺ breast cancer. Before each cycle you’ll have a CBC, CMP, and an echocardiogram every 3 months to monitor heart function. Imaging (CT/MRI) is usually repeated every 8–12 weeks to assess tumor response; a ≥30 % reduction in target lesions or a drop in CA‑15‑3 levels would signal a good response.\n\nIf scans later show progression, the plan doesn’t end there. You could switch to a maintenance‑only HER2‑targeted strategy (e.g., trastuzumab + pertuzumab alone) while adding a taxane‑free agent, or move to T‑DM1 (trastuzumab‑emtansine) if you’re eligible. Other options include lapatinib + capecitabine or enrolling in a clinical trial. Dose adjustments or supportive care (growth factors, anti‑nausea meds) can also help you stay on track.\n\n**Closing Reassurance**  \nWe’ll keep a close eye on your scans and heart health, and together we’ll adapt the plan so you can continue being the loving grandmother you’re proud to be.",
          "order": 8,
          "qid": "S1-Q08"
        },
        {
          "q": "Can I keep working part-time without feeling punished for trying?",
          "gt": "I hear how frightening it feels to juggle a demanding treatment plan while still wanting to be there for your grandkids—your worries are completely understandable.\n\nDocetaxel (75 mg/m² IV over 1–2 h) is given every 3 weeks, followed by trastuzumab (8 mg/kg IV over 30–60 min) and pertuzumab (840 mg IV over 30–60 min) on the same day. You’ll have a baseline CBC, electrolytes, liver enzymes, and an echocardiogram (LVEF) before starting, then repeat CBC and electrolytes before each cycle and an echocardiogram every 3 months. Common side effects—fatigue, neutropenia, neuropathy, alopecia, mucositis—can be managed with dose adjustments, growth‑factor support, or supportive medications. If fatigue becomes debilitating, your oncologist may pause or reduce the dose; the goal is to keep you as functional as possible.\n\nMany patients successfully maintain part‑time work during this regimen, especially with a flexible schedule, short breaks, and a supportive employer. Discuss your workload with your oncologist and consider an occupational‑therapy consult to tailor rest periods and task demands. If symptoms worsen, you can pause treatment safely and resume once you’re ready.\n\nYou’re not alone—your care team will monitor you closely and adjust the plan so you can keep your role as a grandmother while fighting the cancer.",
          "order": 9,
          "qid": "S1-Q09"
        },
        {
          "q": "I don't want cancer to be the only thing my grandchildren remember. How can we plan around the good days?",
          "gt": "I hear how frightening it feels to worry that the disease might eclipse the joy you share with your grandchildren, especially when you’re the heart of the family.\n\n**Treatment schedule**  \nDocetaxel 75 mg/m² IV over 1–2 h every 3 weeks, followed by trastuzumab 8 mg/kg loading then 6 mg/kg, and pertuzumab 840 mg loading then 420 mg, all given on the same day. The plan usually spans 6–8 cycles, then you may transition to maintenance with trastuzumab + pertuzumab alone.\n\n**Monitoring**  \nCBC, CMP, and electrolytes before each cycle; LVEF by echocardiogram at baseline and every 3 months. If neutropenia or cardiac changes occur, dose adjustments or temporary hold are considered.\n\n**Side‑effect management**  \nCommon issues: fatigue, nausea, neuropathy, and alopecia. Growth‑factor support, anti‑emetics, and dose‑modified schedules help keep you functional. Keep a symptom diary to flag any worsening early.\n\n**Planning around good days**  \nSchedule family visits or special activities on days after chemo when you feel strongest. Use supportive care (hydration, rest, light meals) to recover quickly. Consider a “memory book” or video messages to capture moments when energy is high, so your grandchildren have lasting memories beyond the illness.\n\nWe’ll monitor closely and adjust as needed, so you can focus on the moments that matter most.",
          "order": 10,
          "qid": "S1-Q10"
        }
      ]
    },
    {
      "id": "S2",
      "title": "New mom, old terror (stage IIIB triple-negative breast cancer, neoadjuvant)",
      "diagnosis": "Stage IIIB triple-negative breast cancer",
      "treatment_plan": "Neoadjuvant pembrolizumab every 3 weeks with weekly paclitaxel/carboplatin ~12 weeks, then doxorubicin/cyclophosphamide every 2 weeks ×4; surgery ± radiation; continue pembrolizumab to ~1 year",
      "narrative": "I'm 33, eight months postpartum, newly diagnosed with aggressive triple-negative breast cancer. My baby still wakes at night; my body doesn't feel like mine. They’re starting chemo-immunotherapy before surgery.",
      "qa": [
        {
          "q": "It feels like I'm failing as a mom by stopping breastfeeding and losing my hair at the same time. How do I not drown in that guilt?",
          "gt": "I hear how heavy the guilt feels, especially when you’re trying to stay strong for your little one. It’s normal to feel like you’re falling short when your body is fighting a battle of its own.\n\nYour treatment plan will likely start with a 4‑cycle dose‑dense doxorubicin‑cyclophosphamide (AC) every two weeks, followed by 12 weekly cycles of docetaxel plus carboplatin, and concurrent pembrolizumab (200 mg IV every 3 weeks). Hair loss is a common, temporary side effect of these agents; most patients regain hair within 6–8 weeks after therapy ends. Breastfeeding is usually stopped before chemo because the drugs can be harmful to the infant, and the breast tissue may be compromised by the tumor and treatment.\n\nWe’ll monitor you with CBC, liver enzymes, and a baseline and every 3‑month echocardiogram to track heart function. If you notice severe fatigue, fever, or bleeding, call the oncology team right away. After neoadjuvant therapy, you’ll have surgery to remove the tumor, then possibly radiation and a short course of maintenance pembrolizumab.\n\nCoping strategies can help: join a breast‑cancer support group, keep a gratitude journal, and allow yourself to feel proud of the courage you’re showing. Your team will be with you every step of the way.",
          "order": 1,
          "qid": "S2-Q01"
        },
        {
          "q": "I’m scared I’ll be too sick to comfort my baby after her vaccines—how do we plan so she still reaches for me on the hard days?",
          "gt": "I hear how frightening it feels to worry that chemo might leave you too weak to hold your baby, especially when you’re already carrying so much love and responsibility.  \n\nYour chemo will likely run on a 3‑week cycle—docetaxel or paclitaxel with carboplatin, plus a checkpoint inhibitor such as atezolizumab. Each infusion lasts 1–2 hours, followed by a 1‑hour recovery.  \n\nSide effects peak 24–48 hours after treatment: fatigue, nausea, and low blood counts. Antiemetics, growth‑factor support, and scheduled CBCs every cycle will help you stay stronger for your baby.  \n\nPlan short, frequent visits: keep your baby in a safe crib nearby, use a baby monitor, and let a partner or close relative hold her when you feel drained. Gentle touch and voice still bond.  \n\nIf fatigue spikes, call your oncology nurse—dose reductions or a brief break can be arranged. Your team will monitor LVEF, CBC, and LFTs every cycle to keep you safe.  \n\nTogether we’ll adjust the plan so you can stay close to your daughter while fighting the cancer.",
          "order": 2,
          "qid": "S2-Q02"
        },
        {
          "q": "If the lump isn’t shrinking fast, how do I stop spiraling into 'this isn't working'?",
          "gt": "I hear how frightening it feels that the lump isn’t shrinking quickly, especially when you’re already juggling a newborn and the uncertainty of treatment—your worry is completely understandable.\n\n**What the plan looks like**  \n- **Neoadjuvant regimen**: most clinicians start with dose‑dense doxorubicin + cyclophosphamide (AC) every 2 weeks for 4 cycles, then weekly paclitaxel for 12 weeks. If your oncologist is adding atezolizumab (an immune checkpoint inhibitor), it’s given IV over about 60 minutes every 3 weeks alongside paclitaxel.  \n- **Monitoring**: CBC and basic metabolic panel before each cycle; LVEF by echocardiogram at baseline, then every 3 months; liver and renal function every 2–3 cycles.  \n- **Assessing response**: after 2–3 cycles you’ll get a breast MRI or ultrasound. A partial response is a ≥30 % reduction in the longest diameter (RECIST). A pathologic complete response (pCR) after surgery is the ideal goal, but early shrinkage can be modest.  \n- **If the tumor isn’t shrinking**: your team may consider dose escalation, switching to a carboplatin‑paclitaxel (CAP) backbone, adding another immunotherapy agent, or enrolling in a clinical trial. Discuss these options with your oncologist; they’ll tailor the plan to your response and tolerance.  \n\n**You’re not alone**—your oncology team will monitor closely and adjust the plan to keep you moving forward.",
          "order": 3,
          "qid": "S2-Q03"
        },
        {
          "q": "Is there anything we can do right now about fertility without dangerously delaying treatment?",
          "gt": "I hear how scary it feels to think about losing the chance to have more children, especially when you’re already juggling a newborn and a new cancer diagnosis.\n\n**Fertility‑preservation options that don’t postpone chemo**\n\n1. **GnRH‑agonist (e.g., leuprolide acetate)** – can be started immediately before the first chemo cycle. It temporarily “shuts down” the ovaries, reducing the risk of chemotherapy‑induced ovarian failure, and requires no delay.  \n2. **Oocyte retrieval with rapid‑stimulation** – a short 10–14‑day stimulation protocol (recombinant FSH + hMG) followed by a single retrieval day. The eggs are vitrified (frozen) the same day. This adds about 2 weeks to the schedule but can be coordinated so chemo starts within 1–2 weeks of retrieval.  \n3. **Ovarian‑tissue cryopreservation** – during your planned surgery, a small wedge of ovarian tissue can be removed and frozen. No extra time is added to the chemo plan, and the tissue can be re‑implanted later if you wish to restore fertility.\n\nAll three approaches are used in breast‑cancer patients and have no proven impact on treatment efficacy. Discuss with your oncologist and a reproductive endocrinologist to decide which fits your timeline and goals.  \n\nYou’re not alone in this—your care team will coordinate the steps so you can focus on both your health and your future family plans.",
          "order": 4,
          "qid": "S2-Q04"
        },
        {
          "q": "Immunotherapy sounds like it could attack anything—what symptoms should make me call immediately?",
          "gt": "I hear how scary it feels that the treatment could “attack anything,” especially when you’re already carrying so much for your baby and yourself—your worry is completely understandable.\n\n**What to watch for and when to call for help**\n\n| Symptom | Why it matters | Action |\n|---------|----------------|--------|\n| **Severe diarrhea (≥ 3 stools/day, blood or mucus, abdominal cramping)** | Can signal colitis, a serious immune‑related side effect | Call your oncologist immediately; if you’re in the ER",
          "order": 5,
          "qid": "S2-Q05"
        },
        {
          "q": "Can we time a cycle so I can be present for my sister’s wedding photos without a mask and IV tape?",
          "gt": "I hear how anxious you feel about balancing treatment with being present for your sister’s wedding—especially when you’re already carrying so much for your family.\n\nYour chemo‑immunotherapy will likely follow a 3‑week cycle: doxorubicin + cyclophosphamide (AC) over 1–2 h, then paclitaxel or nab‑paclitaxel 1–2 h, and atezolizumab 60–90 min. The infusion room requires a surgical mask and gloves to protect you from infection, especially during the first 24–48 h when neutropenia risk is highest. You can request the infusion to start the day before the wedding so you’re finished early, but the mask must remain on during the entire infusion. IV tubing can be hidden under a long‑sleeve top or a light jacket, but the mask is non‑negotiable for safety.\n\nYour team will monitor CBC, LFTs, and cardiac function (echo every 3 months) to catch any complications early. If you experience severe fatigue or nausea, we can adjust the dose or add supportive meds, but the overall schedule is fixed to maximize efficacy.\n\nWe’ll work closely to find a schedule that keeps you safe while honoring your family moments.",
          "order": 6,
          "qid": "S2-Q06"
        },
        {
          "q": "I’m worried about a port and feeling 'marked.' Do I really need one?",
          "gt": "I hear how scary the idea of a port feels, especially when you’re already juggling a newborn and the weight of a new diagnosis.\n\nFor a typical neoadjuvant plan in triple‑negative breast cancer, you’ll likely receive 4–6 cycles of dose‑dense doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²) every 2 weeks, followed by 12–16 weekly paclitaxel (80 mg/m²) or docetaxel (75 mg/m²). If an immune checkpoint inhibitor (e.g., atezolizumab or pembrolizumab) is added, it’s given every 3 weeks. Each infusion lasts 1–2 hours, and you’ll need a new peripheral IV for every cycle unless a central line is used. A port is highly recommended because it reduces repeated needle sticks, lowers infection risk, and makes the process smoother over the 4–6 months of therapy.  \n\nYou’ll have a CBC and basic metabolic panel before each cycle, and an echocardiogram before starting anthracyclines and again after 3–4 cycles to monitor left‑ventricular ejection fraction. We’ll watch for neutropenia, neuropathy, and any infusion reactions. If the port isn’t used, you’ll need multiple peripheral IVs, which can be uncomfortable and increase the chance of infiltration or infection.  \n\nYour oncology team will tailor the plan to your specific needs, but a port is usually the safest, most convenient option for the intensity of your treatment.",
          "order": 7,
          "qid": "S2-Q07"
        },
        {
          "q": "How will surgery decisions change if I get a complete response?",
          "gt": "I hear how scary it feels to think about all the moving parts of your treatment, especially when you’re already juggling a newborn and the uncertainty of a new diagnosis.\n\nIf the chemo‑immunotherapy (typically a platinum‑based regimen plus a PD‑L1 inhibitor such as atezolizumab or durvalumab) produces a **complete radiologic and pathologic response**, the surgical plan can be adjusted, but it rarely disappears entirely.  \n1. **Breast surgery** – A complete response in the breast usually still requires a lumpectomy or mastectomy to confirm that no residual tumor remains. In some cases, if the tumor was small and the response is complete, a less extensive lumpectomy may be possible, but the decision is individualized.  \n2. **Axillary surgery** – If the sentinel lymph node biopsy shows no cancer after a complete response, the surgeon may skip a full axillary dissection. In many centers, a negative sentinel node after neoadjuvant therapy is enough to avoid further axillary surgery.  \n3. **Timing** – You’ll have imaging (MRI or ultrasound) and a core‑needle biopsy after 4–6 cycles. Surgery usually follows within 2–4 weeks of that assessment.  \n4. **Follow‑up** – Post‑surgery, you’ll continue adjuvant therapy (often a 12‑month course of the same agents) and routine surveillance (clinical exam, imaging, and blood work every 3–6 months).  \n\nDiscuss these options with your surgical oncologist and the tumor board; they’ll tailor the plan to your exact response and anatomy. Rest assured, the team will monitor you closely and adjust the strategy as needed.",
          "order": 8,
          "qid": "S2-Q08"
        },
        {
          "q": "My baby is in daycare; do I need to pull her out during chemo?",
          "gt": "I hear how anxious you feel about juggling chemo, your baby’s daycare, and the uncertainty of treatment—especially when you’re already carrying so much for your family.\n\n**Short answer:** You don’t need to pull your baby out of daycare just because you’re starting chemo‑immunotherapy. Chemotherapy drugs (e.g., anthracyclines, taxanes, or immunotherapy agents like atezolizumab) are not contagious, so your child won’t catch them from you. However, you’ll be more vulnerable to infections during periods of low neutrophils, so it’s wise to keep your baby away from sick children and to follow your oncology team’s infection‑prevention plan. If you develop neutropenic fever (temperature > 38 °C with low neutrophils) or any serious infection, you’ll likely be advised to stay home and avoid daycare until you’re stable. Discuss your daycare routine with your oncologist and the daycare staff—tell them about your treatment schedule and any precautions they can take (hand hygiene, limiting contact with sick kids). If you ever feel that your health or your baby’s safety is at risk, you can always adjust the schedule or bring your baby home temporarily. Your oncology team will monitor your blood counts every 1–2 weeks during induction and adjust doses or supportive care (e.g., G‑CSF) as needed.  \n\nYou’re not alone in this—your care team will keep a close eye on both your health and your baby’s well‑being.",
          "order": 9,
          "qid": "S2-Q09"
        },
        {
          "q": "What helps financially when I’m suddenly a cancer patient with a young child?",
          "gt": "I hear how overwhelming it feels to suddenly face cancer while caring for a newborn, especially when you’re already juggling the demands of a new baby.\n\nFirst",
          "order": 10,
          "qid": "S2-Q10"
        }
      ]
    },
    {
      "id": "S3",
      "title": "Coach who can’t fix it (metastatic hormone-sensitive prostate cancer)",
      "diagnosis": "Metastatic hormone-sensitive prostate cancer with painful bone lesions",
      "treatment_plan": "Androgen deprivation therapy injection every 1–3 months plus a daily androgen-receptor–targeted pill; consider focused radiation for painful sites; bone-protective measures",
      "narrative": "I'm a 71-year-old retired high-school coach with bone pain. They’re starting hormone shots plus a daily pill. I’ve always been the guy with answers; now I’m short-tempered and scared.",
      "qa": [
        {
          "q": "When my sex drive collapses and my body changes, how do I not resent the very treatment keeping me here?",
          "gt": "I hear how frightening the loss of sex drive and the body changes feel, especially when you’re already carrying so much on your shoulders as a retired coach—your frustration and fear are completely understandable.\n\nYour treatment likely combines an LHRH agonist/antagonist (e.g., leuprolide or goserelin) with a daily anti‑androgen such as bicalutamide or enzalutamide. These drugs lower testosterone to <50 ng/dL, which explains the sudden drop in libido, hot flashes, fatigue, and mood swings. The goal is to keep PSA levels low and prevent further bone damage, so the therapy is life‑preserving even if it feels like a loss.  \n\nTo ease resentment, discuss each side effect with your oncologist. Options include:  \n1. **PDE‑5 inhibitors** (tadalafil, sildenafil) for erectile function;  \n2. **Psychological counseling** or support groups for mood and coping;  \n3. **Lifestyle tweaks**—regular light exercise, balanced diet, adequate sleep, and mindfulness can blunt hot flashes and improve mood.  \n\nYour team will monitor PSA every 3 months, bone scans every 6 months, and routine labs (CBC, CMP, lipid panel). If side effects become intolerable, dose adjustments or switching to a different anti‑androgen may be considered.  \n\nRemember, the therapy is a lifeline; working together with your care team can help you feel less resentful and more empowered.",
          "order": 1,
          "qid": "S3-Q01"
        },
        {
          "q": "What’s the fastest path to walking my grandkids to school without wincing every step?",
          "gt": "I hear how scary the bone pain feels, especially when you’re trying to stay strong for your grandkids and your family—your worries are completely understandable.\n\nYour hormone shots are most likely an androgen‑deprivation therapy (ADT) such as leuprolide or goserelin, given every 3 months. The daily pill is probably a bisphosphonate (e.g., oral alendronate 70 mg weekly or IV zoledronic acid 4 mg monthly). Together, they slow cancer growth and protect bone density.  \nYou’ll have a PSA test and a calcium/vitamin D check every 3 months, and a DEXA scan once a year to track bone loss. If your PSA rises or bone density drops, your oncologist may adjust the ADT dose or add a second‑line agent.  \nFor pain, start with acetaminophen or NSAIDs, add topical diclofenac if needed, and consider a short‑term opioid only if pain is severe. Physical therapy can teach weight‑bearing walks, core strengthening, and safe gait mechanics.  \nMaintain 1,200 mg of calcium and 800–1,000 IU of vitamin D daily, wear supportive shoes, avoid smoking, limit alcohol, and keep a healthy weight.  \nIf the pain persists or worsens, let your oncologist know right away; they may refer you to a pain specialist, adjust your bisphosphonate, or evaluate for fractures.  \nWe’ll monitor closely and keep you moving toward those school‑yard walks.",
          "order": 2,
          "qid": "S3-Q02"
        },
        {
          "q": "How do I keep my routine so I’m not treated like fragile glass at home?",
          "gt": "I hear how frightening the idea of feeling fragile feels, especially when you’re used to being the steady coach who keeps everyone moving forward.\n\nYour hormone shots (most likely a GnRH agonist such as leuprolide 3‑month injections) and the daily pill (probably a bisphosphonate like alendronate or a calcium‑vitamin D supplement) are designed to slow bone loss and relieve pain.  \n**What to expect:**  \n- **Injection schedule:** every 3 months; you’ll get a quick 5‑minute shot.  \n- **Daily pill:** take it on an empty stomach, at the same time each day, with a full glass of water.  \n- **Side effects:** hot flashes, mood swings, fatigue, and, rarely, a drop in calcium or bone density.  \n- **Monitoring:** PSA (if prostate cancer), serum calcium, electrolytes, and a DEXA scan every 6–12 months.  \n- **When to call your doctor:** severe hot flashes, depression, unexplained fractures, or any new pain.\n\n**Keeping your routine:**  \n1. Set a phone alarm for the pill.  \n2. Use a pill organizer or a medication‑tracking app.  \n3. Schedule a short walk or light resistance training 3–4 times a week—your body will thank you.  \n4. Keep a symptom diary; bring it to appointments so you can adjust doses if needed.\n\nYou’re not fragile—your body is just adjusting. With a clear schedule and regular check‑ins, you can stay in control and keep the coach’s confidence alive.",
          "order": 3,
          "qid": "S3-Q03"
        },
        {
          "q": "My buddy had a heart issue on hormones. What are we doing to protect my heart and metabolism?",
          "gt": "Feeling scared when a friend’s heart problem came up is completely understandable, especially when you’re already juggling new treatments and bone pain.  \n\nYour team will start with a baseline cardiac work‑up: an ECG and a transthoracic echocardiogram to measure left‑ventricular ejection fraction (LVEF). Blood pressure, weight, waist circumference, fasting glucose/HbA1c, and a lipid panel will also be checked before the first hormone shot.  \n\nDuring therapy, we’ll repeat the ECG and LVEF every 3–6 months, and you’ll have quarterly labs for lipids and glucose. Any rise in blood pressure, new edema, or shortness of breath should prompt an immediate call.  \n\nLifestyle measures are key: a Mediterranean‑style diet, 150 minutes of moderate aerobic exercise per week, and weight‑loss if needed. If your LDL stays above 100 mg/dL or you develop hypertension, a statin or ACE‑inhibitor may be added.  \n\nThe daily pill (e.g., bicalutamide) and the hormone shots (e.g., leuprolide acetate) can both influence metabolism, so we’ll monitor weight, insulin sensitivity, and bone density every 6 months. Adjustments to dose or adding a bone‑protective agent (like bisphosphonate) are options if changes occur.  \n\nWe’ll keep a close eye on your heart and metabolism, and I’ll be here to answer any new concerns as they arise.",
          "order": 4,
          "qid": "S3-Q04"
        },
        {
          "q": "Will my bones thin out? I don’t want a hip fracture to bench me for good.",
          "gt": "I hear how frightening it is to worry about bone thinning, especially when you’re used to being the strong coach on the sidelines.  \n\nHormone shots for prostate cancer (e.g., leuprolide or goserelin) lower testosterone, which can reduce bone mineral density by 10‑20 % in the first two years. The daily pill you’re starting is likely a calcium‑vitamin D supplement (or a bisphosphonate such as alendronate if prescribed). With these measures, the risk of a hip fracture can be kept low.  \n\nYour care team will do a baseline DEXA scan now and repeat it every 12 months. If your T‑score falls below –2.5 or you lose more than 5 % of bone density, we’ll add a bisphosphonate (e.g., alendronate 70 mg weekly) or denosumab 60 mg every six months. We’ll also monitor serum calcium, vitamin D, and renal function every 3–6 months.  \n\nIn addition to medication, weight‑bearing exercise, a balanced diet rich in calcium, limiting alcohol, and avoiding smoking will help preserve bone strength.  \n\nWe’ll keep a close eye on your bone health and adjust the plan as needed.",
          "order": 5,
          "qid": "S3-Q05"
        },
        {
          "q": "If this combo stops working, what’s next so I’m not blindsided?",
          "gt": "I hear how scary it feels that your current plan might lose its edge, especially when you’re already juggling the weight of a new routine and the worry of what comes next.\n\nIf the hormone shots (e.g., leuprolide or goserelin) and the daily bone‑protective pill (such as zoledronic acid or denosumab) no longer keep your PSA and bone pain in check, the usual next steps are:\n\n1. **Re‑evaluate disease status** – PSA every 4–6 weeks, a bone scan or PET‑CT every 3 months, and a CBC/CMP at each visit to catch bone‑related side effects early.  \n2. **Switch or add systemic therapy** –  \n   * **Second‑line hormonal agents**: enzalutamide, abiraterone + prednisone, or apalutamide.  \n   * **Chemotherapy**: docetaxel (75 mg/m² IV every 3 weeks) or cabazitaxel if prior docetaxel.  \n   * **Radium‑223** for symptomatic bone metastases without visceral disease.  \n3. **Optimize bone health** – If you’re on zoledronic acid, consider denosumab (120 mg SC every 4 weeks) or add an oral bisphosphonate like alendronate if not already.  \n4. **Palliative measures** – Local radiation for focal pain, and consider a pain‑management specialist if discomfort rises.  \n5. **Clinical trials** – Discuss eligibility; many trials target castration‑resistant disease and may offer newer agents.\n\nYour oncologist will tailor the exact sequence, but having this roadmap can help you feel less blindsided. We’ll keep a close eye on your labs and imaging so any change is caught early.",
          "order": 6,
          "qid": "S3-Q06"
        },
        {
          "q": "Can I keep assistant-coaching the team without having to explain hot flashes to a locker room?",
          "gt": "I hear how scary the idea of dealing with hot flashes in front of the team feels, especially when you’re already juggling a new treatment plan and the weight of being a coach you’re proud of.\n\nYour hormone therapy is most likely an LHRH agonist (e.g., goserelin 3.6 mg IM every 3 months) combined with a daily anti‑androgen such as bicalutamide 50 mg. The first injection is usually given right away, with subsequent doses every 3 months. PSA and testosterone levels are checked every 3 months; a CBC, electrolytes, and bone‑density scan are done at baseline and then every 6 months to monitor bone health. If hot flashes become bothersome, your oncologist can add a low‑dose antihistamine, gabapentin 300 mg at bedtime, or paroxetine 10 mg daily—none of which require you to explain the side effect to the locker room. You can continue assistant‑coaching; simply stay hydrated, avoid hot environments, and use a cool‑mist fan or a light jacket if needed. If mood swings or severe fatigue appear, let your team doctor know right away. \n\nYou’re not alone—let’s keep you playing the game you love while staying safe.",
          "order": 7,
          "qid": "S3-Q07"
        },
        {
          "q": "What if the pain suddenly spikes on a weekend?",
          "gt": "I hear how frightening it feels to worry that a sudden flare‑up of bone pain could hit you over the weekend, especially when you’re already juggling new hormone shots and a daily pill.\n\nYour hormone therapy is likely an injectable GnRH agonist (e.g., leuprolide 3.75 mg every 4 weeks or goserelin 10 mg every 4 weeks) that lowers testosterone, while the daily pill is probably an oral bisphosphonate or calcium‑vitamin D supplement to protect bone density.  \n**What to expect:**  \n- Pain spikes are common when bone lesions flare. Use over‑the‑counter NSAIDs (ibuprofen 400 mg every 6–8 h) or acetaminophen 1 g every 6 h for mild‑moderate pain.  \n- If pain exceeds 7/10, lasts >48 h, or you need stronger relief, your oncologist may prescribe a short‑acting opioid (e.g., oxycodone 5 mg every 4–6 h).  \n- Call your oncology team immediately if pain is severe, accompanied by fever, swelling, or if you notice new neurological symptoms.  \n- Routine monitoring: PSA and CBC/CMP every 3 months, bone scan every 6 months, and DEXA annually.  \n- If pain persists, imaging (MRI/CT) may be ordered to assess for new fractures or tumor progression.\n\nYou’re not alone—your care team will review any changes promptly and adjust therapy or add supportive measures as needed.",
          "order": 8,
          "qid": "S3-Q08"
        },
        {
          "q": "Should I change my diet or supplements now that hormones are changing everything?",
          "gt": "I hear how scary it feels to have your body change while you’re already dealing with bone pain, especially when you’re used to being the one who has the answers.  \n\n**What to consider with your new hormone shots and daily pill**  \n1. **Calcium & Vitamin D** – Aim for 1 000–1 200 mg of elemental calcium and 800–1 000 IU of vitamin D daily.  These are the most evidence‑based nutrients for bone strength, and most doctors recommend them with hormone therapy that can lower bone density.  \n2. **Avoid high‑dose calcium supplements** – Doses > 1 200 mg/day can raise the risk of vascular calcification, especially if you’re on androgen‑deprivation therapy or other bone‑losing hormones.  If you’re already taking a calcium‑rich multivitamin, keep the total below 1 200 mg.  \n3. **Protein & weight‑bearing activity** – A protein intake of 1.0–1.2 g/kg body weight supports bone remodeling, and regular light resistance or walking can help preserve bone mass.  \n4. **Supplement interactions** – Herbal or phytoestrogen‑rich supplements (e.g., soy, black cohosh) can blunt the effect of hormone therapy for prostate cancer or testosterone replacement.  Discuss any new supplement with your oncologist or primary care provider.  \n5. **Monitoring** – Your team will likely schedule a DEXA scan in 6–12 months and routine blood tests (calcium, vitamin D, PSA or testosterone) to track how your bones and hormones respond.  \n\nWe’ll keep a close eye on how your body adapts, and you can adjust diet or supplements only after checking in with your care team.",
          "order": 9,
          "qid": "S3-Q09"
        },
        {
          "q": "How do I talk to my sons about genetics without scaring them?",
          "gt": "I hear how anxious you feel about sharing this, especially when you’re already juggling new treatments and the weight of being the “coach” who keeps everyone in line.\n\n**Talking genetics with your sons in a calm way**\n\n1. **Start with the basics** – Explain that genetics is simply the DNA that runs in families. Mention that certain genes (e.g., BRCA2, HOXB13) can increase the risk of prostate cancer and bone‑related problems.  \n2. **Keep it factual, not frightening** – Say, “We’re looking at whether a small change in one of these genes might explain why I’m having bone pain and why I need hormone shots.”  \n3. **Explain the test process** – A blood or cheek‑swab sample is sent to a lab; results are usually “benign,” “likely benign,” or “pathogenic.”  \n4. **Discuss what the results mean** – If a pathogenic variant is found, it means a higher lifetime risk, but it also opens the door to earlier PSA checks, bone‑density scans, and lifestyle tweaks.  \n5. **Invite them to a genetic counseling session** – A counselor can walk through the numbers, answer questions, and help you all decide on next steps together.  \n\n**Next steps**: Ask your oncologist for a referral to a genetic counselor, and bring a list of family health history to the appointment. This way you keep the conversation supportive, informative, and focused on prevention rather than fear.",
          "order": 10,
          "qid": "S3-Q10"
        }
      ]
    },
    {
      "id": "S4",
      "title": "Teacher with too much silence (high-grade serous ovarian cancer)",
      "diagnosis": "High-grade serous ovarian cancer with ascites",
      "treatment_plan": "Cytoreductive surgery when appropriate; carboplatin/paclitaxel every 3 weeks for ~6 cycles; maintenance therapy based on tumor features (e.g., PARP) and response; genetic testing recommended",
      "narrative": "I'm a 45-year-old teacher with ascites, facing surgery and chemo. My daughter is 16, and our home has become very quiet since we said the word 'cancer.'",
      "qa": [
        {
          "q": "My belly is so tight I can't eat and I feel ashamed of how I look. What can we do right now so I can sit at the table with my family again?",
          "gt": "I hear how overwhelming the tightness feels, especially when you’re trying to stay strong for your family.  \n\n**Ascites relief** – Start a low‑salt diet (≤2 g/day) and fluid restriction (≤1.5 L/day).  A diuretic combo—spironolactone 25–50 mg + furosemide 20–40 mg daily—helps, but for malignant ascites a paracentesis is often needed.  \n\n**Timing for surgery** – Schedule a therapeutic paracentesis 24–48 h before your operation to drain excess fluid and reduce abdominal pressure.  After the procedure, you can usually tolerate small, frequent meals (e.g., 3–4 small servings per day).  \n\n**Nutrition & appetite** – Work with a dietitian to plan high‑protein, low‑fat meals and consider an appetite stimulant like megestrol acetate if your oncologist approves.  Keep snacks handy (nuts, yogurt, smoothies) so you can sit at the table without feeling deprived.  \n\n**Monitoring** – Check electrolytes, weight, and abdominal girth every 2–3 days.  Watch for signs of infection (fever, abdominal pain) or bleeding; report any changes to your oncology team immediately.  \n\nWe’ll work together to keep you comfortable and bring you back to the table.",
          "order": 1,
          "qid": "S4-Q01"
        },
        {
          "q": "I’m scared my daughter is googling worst-case stories alone. How do we talk so she feels included but not crushed?",
          "gt": "I hear how frightening it feels to worry that your daughter might be alone with scary stories, especially when you’re already carrying so much for her and your family. It’s natural to want to protect her while also keeping her in the loop.\n\nStart with a calm, family‑centered conversation. Choose a quiet time, sit together, and say something like, “I’ve been thinking about how we can talk about my treatment so you feel involved but not overwhelmed.” Let her know that it’s okay to ask questions and that you’ll share information that matches her age and understanding. Use simple, honest language—avoid medical jargon, but explain that you’ll be having surgery and chemotherapy, and that you’ll keep her updated on how you’re feeling and what the doctors say.\n\nInvite her to ask what she’s curious about, and reassure her that her feelings are valid. Offer to look up reliable resources together, or bring a trusted friend or counselor to the next appointment if she wants extra support. If she’s researching online, suggest reputable sites (e.g., Mayo Clinic, Cancer.org) and remind her that the most accurate information comes from her care team.\n\nRemember, you’re not alone in this—your oncologist can give you a clear, age‑appropriate summary to share, and together you’ll keep her informed without crushing her spirit.",
          "order": 2,
          "qid": "S4-Q02"
        },
        {
          "q": "If my hair falls out and my students stare, how do I walk back into my classroom with dignity?",
          "gt": "I hear how anxious you feel about the possibility of hair loss and how it might affect your classroom presence, especially when you’re already carrying so much for your family.\n\nMost chemotherapy agents that cause alopecia—such as paclitaxel, docetaxel, carboplatin, cisplatin, and anthracyclines—begin to shed hair 2–3 weeks after the first dose. The loss is usually total and can last 4–6 weeks, though the pattern varies with each drug. Scalp‑cooling caps can reduce hair loss by 30–50 % for some regimens, and many patients choose wigs, hats, or scarves to maintain a familiar look. Wigs can be custom‑fit or ready‑made; hats and scarves are inexpensive and easy to change.\n\nHair typically regrows 3–6 months after the last chemotherapy cycle, though the texture may differ. Your oncologist can recommend a scalp‑care routine and monitor for any scalp irritation. When you return to class, you might bring a favorite hat or scarf that feels like you. If you feel comfortable, a brief note to students—“I’m still here, just a new look”—can ease the transition. Most students will focus on your teaching, not your hair.\n\nYou’re not alone; many teachers have navigated this, and your students will likely respect your courage.",
          "order": 3,
          "qid": "S4-Q03"
        },
        {
          "q": "Do I pass this to my daughter—did I cause this?",
          "gt": "I hear how heavy the guilt feels, especially when you’re already carrying so much for your family and trying to stay strong for your daughter.\n\nCancer is a complex disease driven by a mix of genetic, environmental, and random cellular events. In most cases, it isn’t “caused” by a parent’s actions or by something you did. While some cancers have hereditary components, the likelihood that your specific cancer arose from a genetic mutation you passed on is low—especially for a 45‑year‑old with ascites that is usually secondary to metastatic disease. A genetics counselor can review your family history and, if needed, recommend testing to clarify any inherited risk for your daughter. In the meantime, focus on the treatment plan your oncologist has outlined: surgery to remove the primary tumor, followed by a chemotherapy regimen (often a platinum‑based drug like carboplatin plus a taxane such as paclitaxel, given over 3‑week cycles). Your team will monitor blood counts, liver function, and imaging every 3–4 weeks to gauge response and adjust doses. \n\nYou’re not responsible for the cancer, and your daughter’s risk remains very low. Keep the conversation open with your care team—they’ll tailor monitoring and support to your specific situation.",
          "order": 4,
          "qid": "S4-Q04"
        },
        {
          "q": "How will you prove the chemo is worth what it takes from me?",
          "gt": "I hear how scary it feels to weigh the effort of chemo against the hope it might bring, especially when you’re already carrying so much for your daughter and your own health.\n\n**How we’ll judge whether the treatment is worth it**\n\n1. **Clear goals** – Your oncologist will set specific targets: a ≥30 % drop in CA‑125, a partial radiologic response on CT, and measurable relief of ascites or pain.  \n2. **Regular checkpoints** –  \n   * **Blood work** (CBC, CMP, LFTs) before each 3‑week cycle.  \n   * **CA‑125** every cycle.  \n   * **Imaging** (CT or MRI) after 3 cycles, then every 3–4 cycles.  \n   * **Performance‑status** (ECOG) and quality‑of‑life questionnaires at each visit.  \n3. **Typical regimen** – For ovarian or peritoneal cancer, the standard first‑line combo is **carboplatin (AUC 5–6)** IV over 30–60 min plus **paclitaxel 175 mg/m²** IV over 3 hours, every 3 weeks for 6–12 cycles.  \n4. **What you’ll feel** – Common side effects include fatigue, nausea, hair loss, and peripheral neuropathy. Most people recover between cycles, but you’ll get anti‑emetics and, if needed, a growth factor (G‑CSF) to keep your white‑cell count safe.  \n5. **When to pause or change** – If after 3 cycles you see no CA‑125 decline, no imaging response, or your ascites worsens, the team will discuss dose reduction, adding a drug like bevacizumab, or switching to a second‑line agent (e.g., a PARP inhibitor).  \n6. **Safety checks** – We’ll monitor for neutropenia (watch for fevers), neuropathy (check sensation), and, if you’re on anthracyclines, an echocardiogram every 3 months.  \n\nYour treatment plan will be adjusted based on these objective markers and how you’re coping physically and emotionally. We’ll keep the conversation open so you can see whether the benefits—tumor shrinkage, symptom relief, and improved quality of life—outweigh the burdens.",
          "order": 5,
          "qid": "S4-Q05"
        },
        {
          "q": "I’m terrified of neuropathy making me drop dishes at school lunches. Can we prevent or manage it?",
          "gt": "I hear how frightening the thought of neuropathy feels, especially when you’re already carrying so much for your family—your worries are completely understandable.  \n\n**What to expect and how to prevent it**  \nBefore each chemotherapy cycle, your team will perform a baseline neuropathy exam (tactile sensation, vibration, reflexes). Most neuro‑toxic agents you’ll likely receive (e.g., cisplatin, carboplatin, paclitaxel, docetaxel, vincristine) can cause sensory loss and motor weakness. To reduce risk, the oncologist may start with a lower dose or a longer interval between infusions, and will monitor blood counts and kidney function closely.  \n\n**Symptomatic management**  \nIf symptoms appear, dose reduction or a schedule change is the first step. For pain or numbness, duloxetine (60 mg daily) or gabapentin (300 mg three times daily, titrated) are evidence‑based options. Vitamin B12 (1000 µg IM weekly) and magnesium sulfate (1 g IV before each cycle) can also help, though evidence is mixed.  \n\n**Monitoring and support**  \nNeuropathy is reassessed after every cycle and again at 3‑month follow‑ups. If worsening occurs, a referral to neurology and an occupational‑therapy evaluation for adaptive tools (e.g., weighted utensils, non‑slip trays) can prevent accidents like dropping dishes.  \n\n**Next steps**  \nDiscuss these strategies with your oncologist; they’ll tailor dose, schedule, and supportive meds to your specific regimen and overall health.  \n\nWe’ll work together to keep your nerves as protected as possible, so you can stay safe and confident at school.",
          "order": 6,
          "qid": "S4-Q06"
        },
        {
          "q": "If surgery can’t remove everything, does that mean we failed?",
          "gt": "I hear how frightening it feels to think that “incomplete removal” might mean you’ve failed, especially when you’re already carrying so much for your daughter and your own health.\n\nSurgery for cancers that cause ascites (often ovarian or peritoneal) is usually a *debulking* procedure: the goal is to remove as much visible tumor as possible, even if microscopic disease remains. “Not all tumor removed” is not a failure—it’s a realistic part of the treatment plan. After surgery, most patients receive a platinum‑based chemotherapy regimen (e.g., carboplatin + paclitaxel) given every 3 weeks for 6–8 cycles. Your oncologist will monitor response with CA‑125 levels and CT scans every 8–12 weeks. Success is measured by tumor marker decline, radiographic shrinkage, symptom relief, and progression‑free survival, not by a single surgical margin. If the disease progresses, options such as second‑line platinum, targeted agents (e.g., PARP inhibitors), or clinical trials are considered. Your team will adjust doses, add growth factors, or switch drugs as needed, and will keep a close eye on blood counts, kidney function, and any side effects.\n\nRemember, the surgery is a critical first step; the chemotherapy that follows is what keeps the disease under control, so you’re not failing—you’re working together with your team to give the best chance for long‑term benefit.",
          "order": 7,
          "qid": "S4-Q07"
        },
        {
          "q": "What will maintenance therapy look like if I respond?",
          "gt": "I hear how anxious you feel about the quiet at home, especially as you’re juggling your own health and your daughter’s world.  \n\n**If the tumor responds to surgery and chemotherapy, the next step is usually a maintenance phase that keeps the cancer in check while minimizing new side‑effects.**  \n1. **PARP inhibitor (e.g., olaparib 300 mg twice daily, or niraparib 300 mg once daily)** is the most common choice for ovarian cancer with a BRCA mutation or HR‑deficiency.  \n2. **Bevacizumab (7.5 mg/kg IV every 3 weeks)** may be added if the tumor was bevacizumab‑eligible during chemo.  \n3. **Duration**: 18–24 months for PARP, 18 months for bevacizumab, unless progression or toxicity occurs.  \n4. **Monitoring**: CBC, CMP, and renal function every 4 weeks; CA‑125 and CT scans every 3 months; watch for anemia, fatigue, nausea, or thrombo‑embolic events.  \n5. **Supportive care**: diuretics or paracentesis for ascites, adequate hydration, and nutrition; consider prophylactic anticoagulation if risk is high.  \n6. **If progression**: switch to second‑line chemo (e.g., carboplatin/paclitaxel) or clinical trial; dose adjustments are guided by toxicity and organ function.  \n\nYour oncologist will tailor the exact drug, dose, and schedule to your response and overall health.  \n\nWe’ll monitor closely and adjust as needed, so you’re not alone in this journey.",
          "order": 8,
          "qid": "S4-Q08"
        },
        {
          "q": "I want to plan one normal family trip between cycles. Is that realistic?",
          "gt": "I hear how anxious you feel about fitting a family adventure into your treatment plan, especially when you’re already balancing surgery, chemo, and caring for your daughter.\n\nMost chemotherapy regimens for solid‑tumor cancers are given every 3–4 weeks. After each infusion you’ll have a 2–3‑day recovery window when you’re usually the most fatigued, but you’ll also need a pre‑cycle blood count (CBC with differential) to check for neutropenia. If your white‑cell count is low, the oncologist may delay the next cycle or give growth‑factor support. Ascites can worsen with fluid shifts, so you’ll likely need a paracentesis or diuretics before travel. During the recovery period you should stay well‑hydrated, avoid crowded or high‑infection‑risk environments, and have a caregiver (your daughter or a friend) accompany you. If you feel well, a short family trip between cycles is realistic, but plan for possible nausea, fatigue, or a low‑grade fever. Bring all medications, a list of side‑effect thresholds (e.g., fever > 38.5 °C, severe pain), and the contact info for your oncology team. Discuss the exact timing and any travel restrictions with your oncologist and surgeon before you book.\n\nWe’ll work together to keep the trip safe and enjoyable.",
          "order": 9,
          "qid": "S4-Q09"
        },
        {
          "q": "What should my daughter say if someone at school asks if I’m dying?",
          "gt": "I hear how anxious you feel about your daughter’s school life, especially when you’re already juggling your own health and the quiet at home.  \n\nYour mom is undergoing surgery and chemotherapy for her ascites‑related cancer, which can be physically draining and emotionally taxing. Because of this, your daughter may feel overwhelmed and unsure how to respond when classmates ask if your mom is dying.  \nA simple, honest reply can help: “I’m not sure, but my mom is getting treatment and we’re hopeful.”  If she feels uncomfortable, she can say, “I don’t want to talk about it right now.”  These responses set a boundary while keeping the conversation respectful.  \nEncourage her to reach out to a trusted teacher or school counselor if she feels pressured or needs support.  Your mom can discuss with her daughter what details she feels comfortable sharing, so the daughter knows how far to go.  \nRemember, your mom’s treatment plan will involve monitoring, possible side‑effects, and follow‑up visits, but the goal is to manage symptoms and improve quality of life.  \n\nYou and your daughter are not alone; we’ll keep you updated and support you through every step.",
          "order": 10,
          "qid": "S4-Q10"
        }
      ]
    },
    {
      "id": "S5",
      "title": "The drummer who counts rests (glioblastoma after surgery)",
      "diagnosis": "Glioblastoma after maximal safe resection",
      "treatment_plan": "Concurrent radiation (~6 weeks) with daily temozolomide; then adjuvant temozolomide 5 days every 28 days for several cycles; consider tumor-treating fields; symptom management and rehab",
      "narrative": "I'm 58, a drummer. They removed what they could and now it's radiation with daily chemo. I keep practicing rudiments to feel normal, but the rests feel longer than the notes.",
      "qa": [
        {
          "q": "If my thinking slows or words jam, how do I stay myself in front of a band that's never seen me drop a beat?",
          "gt": "I hear how anxious you feel about keeping your rhythm while juggling chemo and radiation, especially when you want to stay true to your band.  \n\n**Cognitive side‑effects**  \nMany chemotherapies—cisplatin, carboplatin, paclitaxel, and some targeted agents—can cause “chemo‑brain,” a slowing of thinking and word retrieval. Whole‑brain radiation can add fatigue and mild memory lapses.  \n\n**Monitoring**  \nYour oncologist will schedule neurocognitive tests (e.g., Trail‑Making A/B) and speech‑language evaluations every 4–6 weeks. Blood counts and liver/renal panels are checked before each cycle to gauge tolerance.  \n\n**Supportive measures**  \nIf you notice word‑jam or slowed reaction, try brief, focused rehearsal with a metronome, cue cards, or a visual rhythm chart. Breathing exercises (4‑7‑8) help reset focus mid‑beat.  \n\n**Therapeutic options**  \nA speech‑language pathologist can teach memory‑retrieval drills and pacing techniques. In some cases, low‑dose donepezil or methylphenidate is trialed to boost attention, but only after oncologic clearance.  \n\n**When to act**  \nIf confusion, disorientation, or a sudden drop in coordination occurs, contact your oncology team immediately. They may adjust dose, add a neuroprotective agent, or shift to a less neurotoxic regimen.  \n\n**Next steps**  \nDiscuss these concerns with your oncologist; they can tailor monitoring and supportive care to your specific chemo‑radiation plan.  \n\nYou’re not alone—your team will keep a close eye on your cognitive health so you can keep drumming with confidence.",
          "order": 1,
          "qid": "S5-Q01"
        },
        {
          "q": "I’m afraid of seizing on stage. Do I have to quit performing altogether?",
          "gt": "I hear how frightening the thought of a seizure on stage feels, especially when you’re already balancing intense treatment with your love of drumming.  \n\n**Seizure risk and chemotherapy**  \nSome daily agents—such as oral capecitabine, oral temozolomide, or weekly infusions of paclitaxel—can lower the seizure threshold, especially if you’re dehydrated or have electrolyte imbalances. Your oncologist will choose a regimen that minimizes this risk, but it’s not zero.  \n\n**Monitoring schedule**  \n- Baseline CBC, electrolytes, and liver function before each cycle.  \n- Repeat CBC and electrolytes every 2–3 days during the first week of daily therapy.  \n- If you have a history of seizures or are on a high‑risk drug, an EEG may be ordered before starting treatment.  \n- Your radiation team will perform a weekly check‑in to assess fatigue and neuropathy.  \n\n**Performing while on treatment**  \n- Light, short rehearsal sessions (10–15 min) are usually safe if you feel well.  \n- Avoid intense physical exertion that could trigger dehydration or hypoglycemia.  \n- Keep a water bottle and a snack on hand; maintain regular meals to keep blood glucose stable.  \n\n**What to do if you feel a seizure coming on**  \n- Stop playing immediately, sit or lie down, and call 911 if you lose consciousness or have convulsions.  \n- If you experience any new neurological symptoms, notify your oncology team right away.  \n\n**Next steps**  \nDiscuss with your oncologist whether an antiepileptic prophylaxis is warranted. If your treatment plan changes, your team will adjust doses or switch agents to keep you safe while allowing you to keep drumming as much as possible.  \n\nYou don’t have to quit performing entirely; with careful monitoring and a few precautions, you can keep playing while staying safe.",
          "order": 2,
          "qid": "S5-Q02"
        },
        {
          "q": "How do we tell real tumor growth from treatment swelling so I don't live scan to scan in panic?",
          "gt": "I hear how unsettling it feels to see swelling after treatment, especially when you’re trying to keep your rhythm and stay strong—your worry is completely understandable.  \n\n**Edema vs. recurrence**  \nRadiation and chemotherapy often cause diffuse, soft‑tissue swelling that is usually uniform and improves with steroids. A true tumor recurrence is typically a focal, irregular mass that shows contrast enhancement on MRI or CT and may grow >20 % in size between scans.  \n\n**Imaging schedule**  \nMost oncologists schedule a baseline MRI or CT within 4–6 weeks of completing therapy, then repeat every 3 months for the first year. Look for new lesions, increased size, or new contrast uptake; these are the key RECIST criteria.  \n\n**Clinical exam**  \nYour doctor will assess for new pain, neurological deficits, or functional changes. If swelling is painless and diffuse, it’s more likely edema; sudden pain or focal tenderness raises suspicion for recurrence.  \n\n**Supportive care**  \nA short course of oral steroids (e.g., prednisone 10–20 mg/day for 5–7 days) often reduces edema. If swelling persists beyond 4–6 weeks or worsens, a biopsy may be needed to rule out tumor.  \n\n**When to call**  \nIf you notice new or worsening pain, neurological symptoms, or a rapid increase in swelling, contact your oncology team promptly; they’ll decide whether to adjust imaging or consider a biopsy.  \n\nWe’ll keep a close eye on the scans and symptoms together, so you won’t have to live in constant uncertainty.",
          "order": 3,
          "qid": "S5-Q03"
        },
        {
          "q": "Steroids make me feel wired and unlike myself. Can we limit them?",
          "gt": "I hear how unsettling it feels to be wired and out of sync with yourself, especially when you’re trying to keep your rhythm and sense of normalcy while fighting cancer. It’s understandable to want a steadier, calmer baseline.\n\nSteroids such as dexamethasone, prednisone, or methylprednisolone are often added to radiation‑chemo regimens to reduce inflammation, control nausea, and blunt radiation‑induced mucositis. The dose and schedule are usually tailored to the treatment phase: a typical “pulse” might be 4 mg/day for 3–5 days, or a lower maintenance dose (e.g., 2–4 mg/day) for several weeks. Because steroids can cause jitteriness, insomnia, mood swings, and hyperglycemia, many patients ask whether the dose can be lowered.\n\n**What you can discuss with your oncologist:**\n\n1. **Tapering schedule** – If you’re on a maintenance dose, a gradual reduction (e.g., 1 mg every 3–5 days) can help your body adjust while still providing anti‑inflammatory benefit.  \n2. **Alternative anti‑emetics** – Agents such as ondansetron, palonosetron, or aprepitant can sometimes replace steroids for nausea control.  \n3. **Monitoring** – Blood glucose, blood pressure, sleep quality, and mood should be checked weekly. If hyperglycemia or severe insomnia develops, the dose may need to be held or reduced.  \n4. **Safety net** – If you notice sudden mood changes, severe insomnia, or worsening pain, contact your oncology team immediately; they can adjust the plan or add supportive medications (e.g., low‑dose benzodiazepine for sleep).  \n\nYour oncologist can weigh the benefits of steroid‑based protection against the side‑effect burden and decide on a personalized taper or substitution. We’ll keep a close eye on your response and adjust as needed.",
          "order": 4,
          "qid": "S5-Q04"
        },
        {
          "q": "Does wearing tumor-treating fields make me look 'sick' all the time? Is it worth it?",
          "gt": "I hear how anxious you feel about adding another piece of equipment to an already heavy treatment routine, especially when you’re trying to keep your rhythm and sense of normalcy while fighting cancer.\n\nTumor‑Treating Fields (TTFields) are a non‑invasive device that delivers low‑intensity, alternating electric fields through a small array of electrodes placed on the skin (usually the scalp or chest). The array is worn for 18–24 hours a day, but it’s small enough to be covered by a hat or clothing, so it rarely makes you look visibly ill. The most common side effect is mild skin irritation or redness at the electrode sites; this can be managed with topical creams and by rotating the array. TTFields are approved mainly for glioblastoma and have shown modest improvements in progression‑free survival in some other cancers, but evidence for many tumor types is still emerging. Whether the benefit outweighs the inconvenience depends on your specific diagnosis, overall treatment plan, and how well you tolerate the device. Discuss with your oncologist whether TTFields are appropriate for your case and what monitoring (skin checks, symptom logs) will be needed.\n\nYou’re not alone in weighing the trade‑offs—your team will help you decide the best path forward.",
          "order": 5,
          "qid": "S5-Q05"
        },
        {
          "q": "What does MGMT or IDH status actually change for me?",
          "gt": "I hear how frustrating it feels that the pauses in your practice feel longer than the notes, especially when you’re fighting a tough battle with your brain tumor—your worries are completely understandable.\n\n**MGMT promoter methylation**  \nIf your tumor’s MGMT promoter is methylated, the DNA repair enzyme that counters temozolomide’s damage is silenced. In practice, this means a higher likelihood of tumor shrinkage, longer progression‑free survival, and a better overall response to the daily temozolomide you’re receiving. Most centers use this result to justify continuing the standard “Stupp” regimen and to counsel you that your odds of benefit are higher than for an unmethylated tumor.\n\n**IDH mutation**  \nAn IDH‑mutant glioma is biologically less aggressive, often associated with lower‑grade histology and a median overall survival that can exceed 2–3 years in some series. In recurrent disease, IDH‑mutant tumors may be eligible for targeted inhibitors (ivosidenib or enasidenib) that can slow progression. Even if you’re currently on radiation and temozolomide, knowing your IDH status helps your team decide whether to add or switch to such agents later and sets a more optimistic baseline expectation.\n\n**How it changes your plan**  \nWith MGMT methylation, your oncologist may keep the full temozolomide dose and schedule (daily for 6 weeks, then every 28 days) and monitor you closely with MRI every 2 months and CBCs before each cycle. If the tumor is IDH‑mutant, the team may discuss early enrollment in trials of IDH inhibitors or consider a less aggressive maintenance strategy after radiation. Both markers also guide discussions about expected side‑effect profiles, potential for long‑term cognitive changes, and realistic survival estimates.\n\n**Next steps**  \nAsk your neuro‑oncologist to confirm your MGMT and IDH results, review the exact dosing schedule, and outline any trial options. Bring your current medication list, recent blood counts, and any new symptoms to the next visit so they can adjust therapy promptly.\n\nWe’ll work together to keep you as active and rhythmic as possible while navigating these complex decisions.",
          "order": 6,
          "qid": "S5-Q06"
        },
        {
          "q": "I want to leave my family something more than fear. What can we set up now?",
          "gt": "I hear how frightening the idea of leaving only fear feels, especially when you’re already carrying so much for your family—your worries are completely understandable.  \n\n**Legacy ideas you can start now**  \n1. **Create a “memory box”**: Gather photos, a handwritten note, a favorite drum set photo, and a short video of you playing a favorite riff.  \n2. **Record a “legacy video”**: Share life lessons, favorite songs, and a message of love. You can keep it on a USB or upload it to a private cloud.  \n3. **Set up a charitable donation**: Choose a cancer research or music‑therapy fund and name it in your family’s honor.  \n4. **Draft a will and health‑care proxy**: Work with an attorney to ensure your wishes are clear and your loved ones are protected.  \n5. **Start a “family recipe book” or drumming lesson series**: Teach your children or grandchildren a simple rhythm and document it.  \n\n**Treatment details**  \n- **Daily oral chemo** (e.g., capecitabine 825 mg/m² twice daily for 14 days, 7‑day break) or a low‑dose 5‑FU infusion (30–60 min) is common.  \n- **Radiation**: 2 Gy per fraction, 5 days a week, for 5–6 weeks, depending on tumor site.  \n- **Monitoring**: CBC, CMP, and liver enzymes every 2 weeks; echocardiogram every 3 months if cardiotoxic agents are used.  \n- **Side effects**: fatigue, nausea, mucositis, and neuropathy; anti‑emetics and dose adjustments are routine.  \n- **Next steps**: If toxicity rises, your oncologist may reduce dose or pause therapy; always discuss changes with them.  \n\nYour team will monitor closely, and together we’ll keep your legacy and health on track.",
          "order": 7,
          "qid": "S5-Q07"
        },
        {
          "q": "If the tumor returns, what are the realistic next steps?",
          "gt": "I hear how frightening the idea of a recurrence feels, especially when you’re already juggling intense treatment and keeping your rhythm alive on the drums—your worries are completely understandable.  \n\n**Confirm the picture** – A CT or PET‑CT every 3 months (or sooner if symptoms arise) will tell us whether the tumor has come back and where. Your oncologist will review the images with a tumor board to decide the best next step.  \n\n**If the lesion is still resectable** – A second surgery is often the first choice. The team will weigh the risks of anesthesia, potential blood loss, and recovery time against the chance of long‑term control.  \n\n**If it’s not operable** – Stereotactic radiosurgery (≈30–35 Gy in 5 fractions) or hypofractionated external‑beam radiation can target the area while sparing healthy tissue. Side effects may include fatigue, mild skin changes, and, rarely, radiation necrosis.  \n\n**Systemic options** – Depending on the cancer type, a second‑line chemo such as carboplatin + paclitaxel (infused over 1–2 h) or a targeted agent (e.g., EGFR or ALK inhibitor) can be added. For tumors with PD‑L1 expression or MSI‑high status, pembrolizumab or nivolumab (administered every 3 weeks) may be appropriate. Blood counts, liver enzymes, and cardiac function (ejection fraction) are checked before each cycle.  \n\n**Palliative care** – If the disease is advanced, focus shifts to symptom control, pain management, and psychosocial support. Hospice care is an option when goals of care change.  \n\nYour team will monitor you closely and adjust the plan as needed—together we’ll keep your health and your music as harmonious as possible.",
          "order": 8,
          "qid": "S5-Q08"
        },
        {
          "q": "How do I protect my energy so I’m not sleeping through the parts of life I want to be awake for?",
          "gt": "I hear how exhausting it feels to keep drumming while fighting fatigue, especially when you want to stay present for the moments that matter.  \n\nChemotherapy and daily radiation routinely cause “chemo‑fatigue,” a persistent tiredness that can outlast the rest of the day.  Common agents—cisplatin, carboplatin, paclitaxel, or docetaxel—are given over 1–2 hours and are followed by routine labs (CBC, CMP) every 2–3 weeks to catch anemia or organ dysfunction that can worsen energy levels.  \n\nTo protect your energy, pace your practice: break rudiments into short 5‑minute blocks with 2‑minute rests, and schedule those blocks when you feel strongest (often mid‑morning).  Prioritize sleep hygiene—keep a consistent bedtime, limit caffeine after noon, and use a cool, dark room.  Stay hydrated and eat balanced meals with protein, complex carbs, and healthy fats; consider a small snack (e.g., Greek yogurt or a banana) before a session.  \n\nKeep a fatigue diary: note peak tiredness, triggers, and recovery times.  Discuss any severe fatigue with your oncologist; dose reductions or supportive agents (e.g., erythropoietin, anti‑emetics) can be adjusted.  \n\nWe’ll work together to keep you energized for the beats that matter.",
          "order": 9,
          "qid": "S5-Q09"
        },
        {
          "q": "How do I ask for help without feeling like a burden?",
          "gt": "I hear the anxiety that comes with feeling like you might be a burden, especially when you’re juggling the demands of treatment and trying to keep your rhythm alive. It’s understandable to worry that asking for help could add to the load you’re already carrying.\n\nHere’s a practical way to reach out without feeling like a burden:\n\n1. **Identify the specific need** – Is it help with transportation, meal prep, or emotional support? Pinpointing the exact task makes the request clear and manageable.  \n2. **Use “I” statements** – Say, “I’m finding it hard to keep up with my daily chemo schedule and would appreciate a ride to the clinic.” This frames the request as a personal need rather than a demand.  \n3. **Offer a concrete solution** – Suggest a time or ask if the person can help on a particular day. For example, “Could you pick me up on Tuesday mornings?”  \n4. **Acknowledge their time** – Add, “I know you’re busy, so I’d be grateful for any help you can give.”  \n5. **Seek professional support** – Your oncology team can connect you with a social worker or patient advocate who can coordinate assistance and ensure you’re not alone in managing logistics.  \n6. **Remember it’s a two‑way conversation** – If the person says they can’t help, thank them and ask if they know someone else who might.  \n\nYou’re not a burden; you’re a patient who deserves support. Your team and loved ones want to help you stay healthy and keep your music alive.",
          "order": 10,
          "qid": "S5-Q10"
        }
      ]
    },
    {
      "id": "S6",
      "title": "Driver with the detour (locally advanced rectal cancer, total neoadjuvant therapy)",
      "diagnosis": "Locally advanced rectal adenocarcinoma",
      "treatment_plan": "Total neoadjuvant therapy: chemoradiation (~5–6 weeks), systemic chemotherapy for several months, then surgery depending on response; possible temporary ostomy; consideration of watch-and-wait if complete clinical response",
      "narrative": "I'm 62 and drive a city bus. Treatment will be chemoradiation, then systemic chemo, then maybe surgery. I keep picturing an ostomy and panicking about the smell on a crowded route.",
      "qa": [
        {
          "q": "I can’t stop imagining a bag leaking while I’m on shift. What’s real versus fear, and who teaches me to manage it if I need one?",
          "gt": "I hear how frightening the thought of a leaking ostomy bag feels, especially when you’re already juggling the demands of a city‑bus schedule and the uncertainty of treatment. It’s normal to feel anxious about something that could impact your daily life so directly.\n\nMost patients who receive chemoradiation for colorectal or anal cancers do **not** end up needing a permanent ostomy; the decision depends on tumor location, extent of surgery, and how well the bowel can be preserved. If an ostomy is required, it is usually created during the surgical phase, and you’ll have a dedicated stoma nurse and dietitian who will teach you how to fit, secure, and empty the bag before you leave the hospital. They’ll also show you how to manage odor—using odor‑neutralizing liners, choosing a bag with a secure seal, and cleaning the skin around the stoma to prevent leaks.\n\nAfter discharge, you’ll have follow‑up visits with the surgical team and stoma nurse to check the stoma site, adjust the bag size, and address any complications. If a leak occurs, you’ll know to replace the bag immediately, apply a fresh adhesive, and monitor for redness or infection. Call your stoma nurse or oncologist if you notice persistent leakage, swelling, or pain.\n\nRemember, your care team will guide you through every step—together, you’ll stay prepared and in control.",
          "order": 1,
          "qid": "S6-Q01"
        },
        {
          "q": "Is watch-and-wait a real option if the tumor melts away, or just internet rumor?",
          "gt": "I hear how scary the idea of an ostomy feels, especially when you’re used to driving a bus every day—your worries are completely understandable.\n\n**Watch‑and‑wait in rectal cancer** is a real, evidence‑based option, but it’s only for a small subset of patients. After the standard 5–6 weeks of chemoradiation (usually 5‑FU or capecitabine plus 50 Gy), the tumor is re‑evaluated 8–12 weeks later with high‑resolution MRI, flexible sigmoidoscopy, and sometimes PET. If imaging shows no visible tumor (clinical complete response) and the mucosa looks normal, the surgeon may recommend a “watch‑and‑wait” strategy instead of immediate surgery.  \n\n**Surveillance** is intensive: MRI every 3–6 months for the first 2 years, then annually; endoscopy every 6–12 months; and clinical exams every 3–4 months. If the tumor recurs locally, salvage surgery is still possible, but the window narrows.  \n\nIf the tumor only shrinks but remains detectable, surgery is usually still recommended. Your oncologist will tailor the plan, monitor blood counts and organ function, and adjust chemotherapy (e.g., capecitabine, oxaliplatin) as needed.  \n\nWe’ll keep a close eye on you, and I’ll be here to discuss any changes or concerns along the way.",
          "order": 2,
          "qid": "S6-Q02"
        },
        {
          "q": "I’m scared of incontinence after treatment. Can we do anything to protect function?",
          "gt": "I hear how frightening the thought of incontinence feels, especially when you’re already juggling a demanding job and the uncertainty of treatment—your worries are completely understandable.\n\n**What can help preserve bowel function?**  \n1. **Radiation planning** – Your radiation oncologist can use intensity‑modulated RT (IMRT/VMAT) to keep rectal dose below 45 Gy, and the surgeon can aim for nerve‑sparing techniques during resection.  \n2. **Pre‑operative bowel prep** – A clean colon reduces irritation and helps the surgeon identify and protect pelvic nerves.  \n3. **Post‑operative pelvic‑floor rehab** – A physiotherapist can teach biofeedback and Kegel‑type exercises that strengthen the sphincter and improve continence.  \n4. **Medications** – Loperamide, octreotide, stool softeners, and a high‑fiber diet can control diarrhea and urgency; these are started early if symptoms appear.  \n5. **Early stoma planning** – If a colostomy becomes necessary, a protective stoma can be created before major surgery, allowing you to manage odor and hygiene more easily.\n\n**Monitoring and next steps** – Keep a stool diary and report any urgency, leakage, or pain to your oncology team. If incontinence develops, options include intensified pelvic‑floor therapy, sacral nerve stimulation, or, rarely, surgical revision. Discuss all these strategies with your radiation oncologist, surgeon, and a colorectal specialist so the plan fits your lifestyle and goals.  \n\nWe’ll work together to keep your bowel function as intact as possible and support you through every step.",
          "order": 3,
          "qid": "S6-Q03"
        },
        {
          "q": "How do we schedule treatment so I’m not nodding off at the wheel?",
          "gt": "I hear how frightening it feels to juggle a demanding job while your body is fighting cancer—especially when fatigue and drowsiness can sneak up on you at any moment.\n\nDuring chemoradiation (often 5‑FU or capecitabine with concurrent radiation) and subsequent systemic therapy (e.g., cisplatin + 5‑FU or a platinum‑based regimen), most patients experience peak fatigue 24–48 hours after each infusion. The safest approach is to schedule treatments on days you can avoid driving—ideally a weekend or a weekday when you have a colleague or family member who can cover a shift. If you must drive, limit the trip to 30–45 minutes and avoid driving within 24 hours of a chemo infusion or a high‑dose steroid. Use a symptom‑tracking app to note when drowsiness peaks and discuss any persistent fatigue with your oncologist; dose reductions or a shorter infusion time (e.g., 1‑hour 5‑FU) can help. Consider a temporary shift to a bus route with fewer stops or a rideshare option during the most intense treatment phases. Your oncology team can also prescribe a short‑acting antihistamine or a low‑dose stimulant if drowsiness is a major concern, but only after reviewing your full medication list.\n\nRemember, most drivers are allowed to resume driving 24 hours after chemotherapy once they feel alert, but you should always err on the side of caution and have a backup plan in place. Your team will monitor your energy levels and adjust the schedule as needed, so you can keep your passengers safe and your own health protected.",
          "order": 4,
          "qid": "S6-Q04"
        },
        {
          "q": "Will intimacy be possible after all this, or are we pretending?",
          "gt": "I hear how frightening the thought of an ostomy feels, especially when you’re already carrying so much for your family—your worries are completely understandable.  \n\n**Treatment path**  \nMost rectal cancers receive neoadjuvant chemoradiation: 45–50 Gy of external‑beam radiation over 5 weeks plus 5‑FU infusion (or capecitabine orally). After that, surgery follows—either a low anterior resection (often with a temporary diverting ileostomy) or an abdominoperineal resection that creates a permanent colostomy. If a temporary ileostomy is used, it’s usually closed 4–8 weeks after surgery.  \n\n**Post‑surgery care**  \nAdjuvant chemotherapy (typically 8–12 cycles of FOLFOX—5‑FU, leucovorin, oxaliplatin) is given once you’re recovered. Blood counts, liver enzymes, and electrolytes are checked before each cycle; imaging and clinical exams occur every 3 months for the first 2 years.  \n\n**Intimacy after treatment**  \nMost patients resume sexual activity within 4–6 weeks of surgery, once pain and fatigue improve. Common issues—fatigue, bowel changes, and pelvic discomfort—can be managed with pelvic‑floor therapy, counseling, and, if needed, medications such as sildenafil or topical lubricants. Discuss any concerns with your oncologist and a sexual‑health specialist; they’ll tailor recommendations to your energy levels and bowel function.  \n\nYour team will monitor you closely, and many people find that intimacy is not only possible but can be a meaningful part of recovery.",
          "order": 5,
          "qid": "S6-Q05"
        },
        {
          "q": "If chemo knocks me down, do we push through or change course?",
          "gt": "I hear how frightening it feels to think that the very treatment meant to save you could also make you feel too weak to drive your bus—your worry is completely understandable.\n\n**Chemoradiation phase**  \nMost rectal‑cancer protocols use 5‑FU or capecitabine (825 mg/m² twice daily, days 1–14 of a 28‑day cycle) combined with 45–50.4 Gy of external‑beam radiation in 25–28 fractions. Blood counts and electrolytes are checked before each cycle.\n\n**Systemic chemotherapy**  \nAfter chemoradiation, a common regimen is FOLFOX: oxaliplatin 85 mg/m² IV day 1, leucovorin 400 mg/m² IV day 1, 5‑FU 400 mg/m² IV bolus day 1, then 5‑FU 2400 mg/m² continuous infusion over 46 h, repeated every 2 weeks. CBC, CMP, and liver function are reviewed before each cycle.\n\n**When chemo “knocks you down”**  \nIf you develop grade 3–4 fatigue, neuropathy, or hematologic toxicity, the oncologist will usually hold the next dose, reduce the dose, or switch to a less myelosuppressive regimen (e.g., CAPOX or FOLFIRI). Growth‑factor support and aggressive anti‑emetics can also help you stay on schedule.\n\n**Driving and safety**  \nIf fatigue or neuropathy limits your ability to drive, discuss a temporary work‑leave or shift change with your employer and your oncology team. Your performance status (ECOG 0–1) is the key metric for deciding whether to push through or pause treatment.\n\nWe’ll monitor your labs and symptoms closely and adjust the plan so you can stay as healthy and safe as possible.",
          "order": 6,
          "qid": "S6-Q06"
        },
        {
          "q": "What should I eat when everything upsets my stomach on radiation days?",
          "gt": "I hear how frightening it feels to juggle a demanding job while your stomach is fighting radiation, and that worry is completely understandable.  \n\nOn radiation days, aim for small, frequent meals that are bland, low‑fat, and low‑fiber. Think plain toast, rice, bananas, applesauce, plain yogurt, and broths. Avoid fried, spicy, or high‑fiber foods that can trigger cramping or gas.  \n\nSip water, electrolyte drinks, or ginger tea between meals. A small smoothie with protein powder, frozen berries, and a splash of milk can be gentle yet nourishing.  \n\nIf you’re prescribed ondansetron or other anti‑emetics, take them 30 minutes before meals or as directed. A low‑dose antacid can soothe heartburn that often accompanies radiation.  \n\nKeep a small, odor‑free snack pack—crackers, a banana, or a protein bar—so you can eat discreetly during long shifts. If nausea spikes, pause, sip water, and let your body settle before resuming.  \n\nRemember, we’ll adjust your diet and meds together, so you can keep driving safely while your body heals.",
          "order": 7,
          "qid": "S6-Q07"
        },
        {
          "q": "How will you decide if surgery can spare my sphincter?",
          "gt": "I hear how frightening the idea of an ostomy feels, especially since you’re the driver who keeps the city moving—your worries are completely understandable.  \n\nBefore treatment, we’ll get a high‑resolution pelvic MRI and a flexible sigmoidoscopy to measure the tumor’s distance from the anal verge and assess sphincter involvement.  \n\nAfter 5–6 weeks of standard chemoradiation (capecitabine 825 mg/m² twice daily with 50 Gy in 25 fractions), we repeat MRI and endoscopy. A ≥30 % reduction in tumor size and no residual sphincter invasion favor a sphincter‑sparing approach.  \n\nIf the tumor remains >5 cm from the anal verge and the MRI shows clear margins, a low anterior resection or intersphincteric resection can preserve the anal sphincter. If the tumor is <5 cm or invades the sphincter, a proctectomy with ileostomy is usually required.  \n\nThe final decision comes from a multidisciplinary tumor board that reviews imaging, pathology, and your overall health. We’ll monitor you with serial MRIs, CEA levels, and clinical exams every 3–4 months during the first two years.  \n\nWe’ll work closely to keep you on the road as much as possible, and your team will keep a close eye on every step.",
          "order": 8,
          "qid": "S6-Q08"
        },
        {
          "q": "If I choose a temporary ostomy, how long might I have it?",
          "gt": "I hear how frightening the idea of an ostomy feels, especially when you’re already juggling a demanding job and the stress of treatment.\n\nA temporary ostomy is usually planned to be removed once the bowel has healed after chemoradiation and surgery. In most rectal‑cancer cases, the ileostomy stays in place for **6–12 weeks**. If the surgical site heals quickly and there are no complications, surgeons often close it after **6–8 weeks**. Radiation can slow healing, so the ostomy may be kept for up to **12 weeks** or longer if infection, poor wound healing, or persistent leakage occurs. Your surgeon will decide the exact timing based on daily checks of the incision, output volume, and any signs of infection.\n\nDuring that period you’ll have regular stoma‑care visits, blood tests, and imaging to confirm healing. The stoma nurse can teach you odor‑neutralizing techniques and how to manage output so you feel comfortable on the bus.\n\nWe’ll monitor your progress closely and adjust the plan as needed, so you can focus on staying healthy and safe on the road.",
          "order": 9,
          "qid": "S6-Q09"
        },
        {
          "q": "What’s the long-term follow-up so I’m not blindsided later?",
          "gt": "I hear how anxious you feel about the possibility of an ostomy and how that could change your daily life—especially when you’re the one keeping the city moving.\n\n**Long‑term follow‑up after chemoradiation, systemic chemo, and possible surgery**\n\n1. **Surveillance imaging** – CT chest/abdomen/pelvis every 6 months for the first 2 years, then annually up to 5 years.  \n2. **Tumor‑marker monitoring** – CEA blood test every 3 months during the first 2 years, then every 6 months.  \n3. **Colonoscopy** – 1 year after surgery (or earlier if stoma reversal is planned).  \n4. **Stoma care** – Visits with a stoma nurse monthly for the first 3 months, then quarterly; skin‑care education and appliance changes.  \n5. **Functional assessment** – Regular evaluation of bowel function, neuropathy (especially if oxaliplatin was used), and radiation‑related toxicity (proctitis, fibrosis).  \n6. **Driving and occupational health** – Discuss any restrictions with your employer and occupational health; many drivers can resume after a brief assessment once stoma function is stable.  \n7. **Psychosocial support** – Consider counseling or support groups to address anxiety and coping strategies.\n\nYour oncologist will tailor the exact schedule to your response and any complications, but this framework helps you anticipate and plan for each step.  \n\nWe’ll keep a close eye on every detail so you’re never blindsided.",
          "order": 10,
          "qid": "S6-Q10"
        }
      ]
    },
    {
      "id": "S7",
      "title": "Senior year, sudden detour (bulky mediastinal Hodgkin lymphoma)",
      "diagnosis": "Classical Hodgkin lymphoma with bulky mediastinal disease",
      "treatment_plan": "ABVD every 2 weeks for 4–6 cycles (or regimen adjusted per interim PET); radiation may follow depending on response; fertility counseling before treatment",
      "narrative": "I'm 22, a college senior. I’m supposed to take graduation photos and go on a cross-country trip. Now it’s ABVD and maybe radiation.",
      "qa": [
        {
          "q": "How do I tell my friends without becoming the 'project' everyone hovers over?",
          "gt": "I hear how anxious you feel about sharing your diagnosis, especially when you’re already juggling graduation plans and a big trip—your worries are completely understandable.  \n\n**ABVD details**  \nABVD (doxorubicin 25 mg/m², bleomycin 10 mg/m², vinblastine 6 mg/m², dacarbazine 375 mg/m²) is given every 14 days for 6–8 cycles. If radiation is added, it’s usually localized and scheduled after chemotherapy.  \n\n**Monitoring**  \nYour oncology team will check CBC, liver enzymes, and electrolytes before each cycle, plus a baseline and periodic echocardiogram and pulmonary function tests to monitor heart and lung health.  \n\n**Side effects**  \nCommon side effects include fatigue, nausea, mouth sores, mild neuropathy, and a risk of pulmonary toxicity from bleomycin. Most symptoms improve within a few days after each infusion.  \n\n**How to disclose**  \nWhen you tell friends, keep it simple: “I’m on a cancer treatment right now, but I’m still the same person. I might need some extra help or time, and I’d appreciate your support.”  \n\n**Set boundaries**  \nDecide what details you’re comfortable sharing and let them know you’re okay with casual check‑ins but don’t want to be treated as a case study.  \n\nYou’re not alone; your friends can be a source of strength while you focus on recovery.",
          "order": 1,
          "qid": "S7-Q01"
        },
        {
          "q": "Can we bank sperm without delaying chemo dangerously?",
          "gt": "I hear how anxious and uncertain you feel right now—especially when you’re juggling graduation plans and a big trip, and suddenly cancer treatment is on the horizon.\n\nSperm banking can be done without delaying ABVD chemotherapy. The standard ABVD cycle starts on day 1 of a 28‑day period (doxorubicin, bleomycin, vinblastine, dacarbazine). A fertility specialist can collect and cryopreserve a semen sample in 1–2 days, often while you’re still in the hospital or clinic. The processing and storage take a few more days, but this does not postpone the first chemotherapy infusion. If radiation is planned, it is usually scheduled after the ABVD cycles, so sperm banking can be completed before that. In rare cases where chemo must start within 24 hours, the fertility team can coordinate a rapid collection; the oncologist will confirm the exact timing. Discuss the schedule with both your oncologist and a reproductive endocrinologist so the plan fits your treatment timeline.\n\nYour team will monitor you closely for any side effects, and they’ll keep you updated on the exact dates for banking and chemo. You’re not alone—let’s keep the lines of communication open so we can protect your fertility while moving forward with treatment.",
          "order": 2,
          "qid": "S7-Q02"
        },
        {
          "q": "What can I realistically expect from hair loss and timing so I can plan photos I won’t hate?",
          "gt": "I hear how anxious you feel about the timing of hair loss, especially when you’re trying to capture those graduation memories.\n\n**Hair‑loss timeline with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)**  \n- **First cycle:** You’ll notice thinning around 2–3 weeks after the start of treatment.  \n- **Shedding:** Most hair falls out by 4–6 weeks after the first dose.  \n- **After the last cycle:** Hair typically begins to regrow 3–4 weeks after completion, with fuller regrowth by 3–6 months.  \n\n**If radiation follows chemo**  \n- The scalp may feel more sensitive and the shedding can start a week earlier, but the overall regrowth period remains similar.  \n- Radiation can sometimes cause a slightly longer period of scalp dryness, so a protective hat or scarf can help during the trip.\n\n**Practical tips**  \n- Schedule graduation photos after the 6‑week mark or once you notice regrowth, whichever feels more comfortable.  \n- Consider a wig, hat, or scarf for the trip; many people find it boosts confidence while hair returns.  \n- Discuss any concerns with your oncologist—she can tailor the schedule to your specific plan and monitor for any unexpected changes.\n\nYou’re not alone in this; we’ll work together to make sure you feel confident and prepared.",
          "order": 3,
          "qid": "S7-Q03"
        },
        {
          "q": "If my PET after two cycles isn’t perfect, does that mean I failed?",
          "gt": "I hear how scary it feels to have a PET that isn’t perfect, especially when you’re juggling school, graduation, and a big trip.  \n\nAfter two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), an interim PET is used to gauge how well the lymphoma is responding.  A “not perfect” scan—meaning some residual FDG uptake—does **not** automatically mean treatment failure.  Many patients with residual uptake still achieve complete remission after the full course of ABVD or with the addition of involved‑field radiation.  \n\nThe next step is usually a repeat PET after the fourth cycle.  If uptake remains high, your oncologist may discuss intensifying therapy (e.g., adding radiation or switching to a different regimen such as DA-EPOCH‑L).  Throughout, routine labs (CBC, liver enzymes), cardiac monitoring (echocardiogram for doxorubicin), and pulmonary function tests (for bleomycin) will guide safety and dose adjustments.  \n\nYour team will closely track these results, and you’ll have a clear plan for the next 4–6 weeks—so you can focus on finishing school and planning that trip.",
          "order": 4,
          "qid": "S7-Q04"
        },
        {
          "q": "Will my lungs be okay for hiking later if I get bleomycin or chest radiation?",
          "gt": "I hear how frightening the idea of lung damage feels, especially when you’re already juggling graduation, a cross‑country trip, and the uncertainty of treatment—your worries are completely understandable.\n\nBleomycin, a key component of ABVD, can cause pulmonary fibrosis, but the risk rises with cumulative dose (>400 mg/m²), age >40, smoking, and pre‑existing lung disease. In a healthy 22‑year‑old, the typical cumulative dose (≈300 mg/m² over 6–8 cycles) carries a low to moderate risk. Your oncologist will monitor you with baseline pulmonary function tests (PFTs) and repeat PFTs every 2–3 cycles; a chest CT is done if symptoms (cough, dyspnea) appear. Chest radiation (often 20–30 Gy for mediastinal nodes) can also affect lung tissue, but modern techniques (IMRT, proton therapy) limit exposure, and the risk of clinically significant fibrosis in young adults is <5 %. \n\nIf you develop mild symptoms, treatment pauses and corticosteroids are usually effective; severe fibrosis may require long‑term oxygen or lung transplantation. In most cases, patients return to normal activity—hiking, even strenuous, is possible after recovery. Your team will tailor doses, use the lowest effective radiation field, and keep a tight monitoring schedule. \n\nRest assured, your lungs will be closely watched, and we’ll adjust the plan if anything changes.",
          "order": 5,
          "qid": "S7-Q05"
        },
        {
          "q": "Can I keep a piece of senior year—clubs, trip, something—without risking my health?",
          "gt": "I hear how anxious you feel about missing those senior‑year memories, especially when you’re already juggling a tough treatment plan and the weight of your family’s hopes.\n\nABVD (adriamycin/doxorubicin, bleomycin, vinblastine, dacarbazine) is given every 2 weeks, each drug infused over about 30 minutes. Before every cycle you’ll have a CBC and an echocardiogram (baseline and then every 3 months) to watch for low neutrophils, anemia, or heart strain. Bleomycin carries a cumulative lung‑toxicity risk that rises after ~400 mg/m², so your oncologist will limit the total dose and may add a short course of radiation afterward, which also requires pulmonary monitoring.  \n\nTravel and photos are generally safe if you time them when your white‑blood‑cell count is above 1,500 /µL and you’re not feeling fatigued. Bring your chemo schedule, stay hydrated, avoid crowded or high‑altitude sites, and keep a thermometer handy—fever >38.5 °C or a sudden drop in neutrophils warrants immediate contact.  \n\nDiscuss the exact timing with your oncology team; they’ll tailor the plan so you can enjoy graduation and a trip while keeping your health on track.",
          "order": 6,
          "qid": "S7-Q06"
        },
        {
          "q": "What should I do about vaccines and infections with roommates coming and going?",
          "gt": "I hear how anxious you feel about staying healthy while juggling graduation photos and a cross‑country trip—especially when your body is already fighting cancer.\n\n**Vaccinations**  \nLive vaccines (e.g., MMR, varicella) are contraindicated during ABVD and any radiation. Inactivated shots—flu, pneumococcal (PCV13 + PPSV23), COVID‑19 booster, and hepatitis B if not immune—are safe, but best given before the first cycle or after your neutrophil count recovers (ANC > 500 /µL). Ask your oncology team to schedule these in advance.\n\n**Infection risk at home**  \nABVD can drop your absolute neutrophil count to <500 /µL, raising infection risk. Keep roommates and visitors well‑washed, wear masks, and avoid close contact with anyone who’s sick. Clean surfaces daily, use hand sanitizer, and monitor your CBC before each cycle. Report any fever >38 °C, sore throat, or unusual fatigue immediately.\n\n**Travel considerations**  \nIf you plan to travel during a chemo cycle, stay in a hotel with strict hygiene protocols, avoid crowded venues, and keep a supply of masks and sanitizer. Discuss with your oncologist whether you can postpone a cycle or take prophylactic antibiotics if you develop neutropenic fever.\n\n**Practical next steps**  \n1. Schedule all recommended inactivated vaccines before your first ABVD cycle.  \n2. Keep a log of CBC results and report any signs of infection right away.  \n3. Coordinate with your oncology team about the safest timing for your trip and any travel‑specific precautions.\n\nWe’ll work together to keep you protected while you celebrate this milestone.",
          "order": 7,
          "qid": "S7-Q07"
        },
        {
          "q": "How do I handle dating and the 'big C' conversation without scaring someone off?",
          "gt": "I hear how scary the idea of sharing “the big C” feels, especially when you’re juggling graduation, a cross‑country trip, and a heavy treatment schedule—your anxiety is completely understandable.\n\n**ABVD & What to Expect**  \nABVD (doxorubicin 25 mg/m², bleomycin 10 U/m², vinblastine 6 mg/m², dacarbazine 375 mg/m²) is given IV on day 1 of a 28‑day cycle, usually for 6–8 cycles. You’ll have a CBC, CMP, and chest X‑ray before each cycle; an echocardiogram baseline and every 3 months monitors heart function, while pulmonary function tests track bleomycin lung toxicity. Common side effects—fatigue, nausea, hair loss, mild neuropathy—can affect energy and mood, but most resolve between cycles. If you need radiation (often after 4–6 cycles), it’s typically a short course (20–30 Gy) to involved nodes, adding mild skin changes and fatigue.\n\n**Dating & Disclosure Tips**  \n1. **Choose a calm moment**—when you’re feeling stable, not right after a chemo infusion.  \n2. **Be honest but concise**: “I’m being treated for Hodgkin lymphoma; it’s a serious diagnosis, but I’m on a proven regimen and my doctors are monitoring me closely.”  \n3. **Frame it as a partnership**: “I want you to know because I value transparency and would love your support.”  \n4. **Prepare for questions**: share your treatment timeline, expected side‑effects, and how you’ll manage them together.  \n5. **Gauge their reaction**—if they’re supportive, great; if they seem scared, give them space and explain that many people find the journey meaningful.\n\n**Next Steps**  \nKeep your oncologist in the loop; they can give you personalized talking points and help you adjust the plan if needed.  \n\nYou’re not alone—your care team and honest communication will guide you through both treatment and relationships.",
          "order": 8,
          "qid": "S7-Q08"
        },
        {
          "q": "Is alcohol totally off-limits during treatment?",
          "gt": "I hear how anxious you feel about drinking alcohol while you’re on ABVD and possibly radiation—especially when you’re already juggling so many new responsibilities.\n\n**Alcohol and ABVD**  \nAlcohol can increase nausea, vomiting, and dehydration, all of which can worsen the side‑effects of doxorubicin and dacarbazine, which are metabolized by the liver. Even though bleomycin isn’t hepatotoxic, alcohol can heighten the risk of pulmonary toxicity by causing dehydration and impaired oxygenation. Vinblastine and doxorubicin cause myelosuppression; alcohol can dampen immune function, raising infection risk.\n\n**Alcohol and Radiation**  \nDuring radiation, alcohol can amplify skin irritation and slow the healing of radiation‑induced dermatitis. It also interferes with the body’s DNA‑repair processes, potentially reducing the effectiveness of the treatment.\n\n**Practical Guidance**  \nMost oncologists advise avoiding alcohol entirely during active chemotherapy cycles and for at least 24–48 hours after each infusion. If you choose to drink, limit yourself to a single small glass, avoid mixing it with medications, and watch for nausea or dizziness. Your team will monitor CBC, liver and kidney function before each cycle; any increase in side‑effects should prompt a call to your oncologist. After treatment ends and your counts stabilize, you can resume moderate drinking, but always discuss it with your doctor.\n\nWe’ll keep a close eye on how you’re doing, and I’m here to help you navigate these choices.",
          "order": 9,
          "qid": "S7-Q09"
        },
        {
          "q": "What does life look like if treatment works—am I always looking over my shoulder?",
          "gt": "I hear how scary the idea of a “watch‑and‑wait” life feels, especially when you’re already juggling graduation and a big trip—your worries are completely understandable.\n\n**Treatment course**  \nABVD is given every 4 weeks for 4–6 cycles. Each cycle lasts about 1–2 hours: doxorubicin 25 mg/m², bleomycin 10 mg/m², vinblastine 6 mg/m², dacarbazine 375 mg/m². If residual bulky disease or mediastinal nodes remain, a short course of involved‑field radiation (≈20 Gy in 10 fractions) may follow.\n\n**Monitoring while on therapy**  \n- CBC, liver enzymes, and creatinine before each cycle.  \n- Baseline and every 3 months echocardiogram to track left‑ventricular ejection fraction (doxorubicin cumulative dose > 300 mg/m² warrants closer cardiac surveillance).  \n- Pulmonary function tests or chest imaging if you develop cough or shortness of breath (bleomycin risk).  \n- If radiation is added, a baseline chest X‑ray and periodic follow‑up for radiation‑induced lung changes.\n\n**After treatment ends**  \nIf you achieve complete remission, you’ll return to normal activities, but routine follow‑up is essential: physical exam and blood work every 3–6 months for the first 2 years, then annually. PET/CT or CT scans are usually done every 6 months for the first 2 years and yearly thereafter. Most patients who stay in remission can live a “normal” life; the “look‑over‑your‑shoulder” feeling is replaced by scheduled check‑ups rather than constant anxiety.\n\n**Reassurance**  \nYou’ll have a clear follow‑up plan, so you won’t need to be on constant alert—just keep those scheduled visits.",
          "order": 10,
          "qid": "S7-Q10"
        }
      ]
    },
    {
      "id": "S8",
      "title": "Coder with a countdown (chronic-phase CML on TKI)",
      "diagnosis": "Chronic-phase chronic myeloid leukemia",
      "treatment_plan": "Daily oral tyrosine kinase inhibitor; regular BCR-ABL monitoring with specific molecular milestones; consider treatment-free remission after deep, stable response",
      "narrative": "I'm 29, a software engineer with chronic-phase CML. I look fine, but the word 'leukemia' keeps crashing my thoughts. They’re starting me on a daily TKI pill.",
      "qa": [
        {
          "q": "How do I keep working sprints when my brain pings 'I have leukemia' every 10 minutes?",
          "gt": "I hear how unsettling those repeated thoughts feel, especially when you’re juggling tight sprint deadlines and the weight of a new diagnosis.  \n\n**TKI therapy**  \nMost chronic‑phase CML patients start imatinib 400 mg once daily (or dasatinib 100 mg, nilotinib 300 mg, or bosutinib 400 mg if first‑line is unsuitable). Side effects are usually mild—fatigue, muscle cramps, or a rash. Your oncologist will check a CBC and CMP every month and a BCR‑ABL1 PCR every 3 months to confirm the 0.1 % or lower transcript level that signals a good response.  \n\n**Managing the anxiety**  \nCognitive‑behavioral techniques work well: set a brief “leukemia check” every 10 min—note the thought, then redirect to a task. Pair this with 5‑minute micro‑breaks, deep‑breathing, or a short walk. A mental‑health professional can tailor a plan, and if anxiety spikes, a short‑acting anxiolytic may be considered.  \n\n**Keeping focus at work**  \nUse the Pomodoro method (25 min work, 5 min break) to limit multitasking. Keep a visible task list, use noise‑cancelling headphones, stay hydrated, and avoid caffeine surges that can heighten anxiety.  \n\n**What to do if things change**  \nIf you develop grade 2+ side effects, your dose may be reduced or switched. If BCR‑ABL1 remains >1 % at 3 months, a second‑line TKI may be needed.  \n\nYou’re not alone—your team and your doctor will keep a close eye on both your blood work and your mental well‑being.",
          "order": 1,
          "qid": "S8-Q01"
        },
        {
          "q": "What side effects actually show up day to day, not the terrifying list online?",
          "gt": "I hear how unsettling the word “leukemia” feels, especially when you’re already juggling a demanding job and a busy life—your worries are completely understandable.\n\nFor chronic‑phase CML, most patients start on a daily oral TKI such as **imatinib 400 mg** (or sometimes dasatinib 70 mg, nilotinib 300 mg, bosutinib 400 mg, or ponatinib 15 mg). The day‑to‑day experience is usually mild and manageable:\n\n- **Fatigue** (often mild, improves after a few weeks).  \n- **Gastro‑intestinal** symptoms: occasional nausea, a brief bout of diarrhea, or mild abdominal discomfort.  \n- **Muscle cramps or joint aches** that can be eased with stretching or over‑the‑counter NSAIDs.  \n- **Skin rash** or mild itching, usually transient.  \n- **Headaches** in a minority of patients.  \n- **Elevated liver enzymes** or mild fluid retention (edema) in a few cases.\n\nYour oncologist will check a CBC, CMP, and liver panel every 4–6 weeks for the first 3 months, then every 3 months. If you notice more than grade‑2 symptoms (e.g., persistent nausea, severe fatigue, or rash), they’ll consider a dose reduction or a switch to another TKI. Staying hydrated, eating small frequent meals, and using OTC anti‑emetics can help.  \n\nWe’ll monitor closely and adjust as needed—your team is here to keep you comfortable and on track.",
          "order": 2,
          "qid": "S8-Q02"
        },
        {
          "q": "Do I have to give up my morning PPI and supplements?",
          "gt": "I hear how unsettling the word “leukemia” feels, especially when you’re juggling a demanding job and a new diagnosis—your anxiety is understandable.  \n\nMost TKIs, like imatinib, nilotinib, and bosutinib, need a mildly acidic stomach for absorption. PPIs can lower acidity and reduce drug levels, so they’re usually avoided or timed carefully.  \n\nIf you need a PPI for reflux, ask your oncologist about taking it at least 4 hours before or after the TKI, or consider an H2 blocker instead. Calcium, magnesium, iron, and high‑dose vitamin C can chelate the drug;",
          "order": 3,
          "qid": "S8-Q03"
        },
        {
          "q": "How do you know this pill is truly working and not just wishful thinking?",
          "gt": "I hear how scary it feels to rely on a pill",
          "order": 4,
          "qid": "S8-Q04"
        },
        {
          "q": "Could I ever stop treatment, or is this forever?",
          "gt": "I hear how unsettling the idea of “leukemia” feels, especially when you’re already juggling a demanding tech job and a busy life—your worries are completely understandable.\n\nIn chronic‑phase CML, most patients achieve a deep molecular response (DMR) with a TKI such as imatinib, nilotinib, dasatinib, or bosutinib. If you’ve maintained a DMR (typically MR4.5 or deeper) for at least 2 years, your oncologist may discuss a *treatment‑free remission* (TFR) trial. The plan is to stop the pill, then monitor you with quantitative PCR every 3 months for the first 12 months, then every 6 months thereafter. If the BCR‑ABL1 transcript rises above the threshold, you’ll restart the same TKI—most patients regain the previous response quickly. About 40–60 % of patients who meet criteria stay in remission after stopping, but relapse rates vary by drug and individual factors.\n\nIf you’re not yet in DMR, the goal is to continue therapy until you reach that depth. Side‑effect profiles differ: imatinib may cause edema and fatigue; nilotinib can affect lipids; dasatinib may cause pleural effusion; bosutinib can cause diarrhea. Your team will tailor monitoring for any specific risks.\n\nWe’ll work together to decide the best timing and keep you closely monitored—your peace of mind is a priority.",
          "order": 5,
          "qid": "S8-Q05"
        },
        {
          "q": "I want kids in a couple years—how do we plan around pregnancy and this medication?",
          "gt": "I hear how anxious and hopeful you feel about starting a family while managing CML—balancing a life‑saving medication with the desire to have children can feel overwhelming.\n\n**Planning for pregnancy with a TKI**\n\n1. **Stop the TKI before conception** – Imatinib, dasatinib, nilotinib, bosutinib, and ponatinib are all teratogenic. Your oncologist will usually recommend discontinuing the drug at least 3 months before trying to conceive.  \n2. **Switch to a pregnancy‑safe regimen** – Interferon‑α (IFN‑α) is the preferred alternative; it has no known teratogenicity and can maintain disease control. Low‑dose hydroxyurea is generally avoided because of fetal risks.  \n3. **Fertility preservation** – Consider oocyte or embryo cryopreservation before stopping the TKI. A reproductive endocrinologist can guide you on timing and retrieval.  \n4. **Monitoring** – While on IFN‑α, check CBC and BCR‑ABL transcript levels monthly. If you achieve a deep molecular response (DMR), you may discuss a temporary TKI pause with your oncologist.  \n5. **During pregnancy** – If conception occurs, continue IFN‑α and monitor fetal growth with routine ultrasounds. Your team will adjust therapy if disease activity rises.\n\n**Next steps**  \nSchedule a joint visit with your hematologist and a fertility specialist to tailor the plan, and keep regular blood tests to ensure both your health and the baby’s safety. We’ll work together to keep your CML under control while you build the family you’re hoping for.",
          "order": 6,
          "qid": "S8-Q06"
        },
        {
          "q": "Travel matters to me—can I fly internationally and keep labs on schedule?",
          "gt": "I hear how unsettling the idea of traveling feels, especially when you’re already juggling a new diagnosis and a demanding job.\n\n**Travel & TKI therapy**  \n- Most TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) are oral and can be taken on a flight. Keep the medication in its original bottle, carry it in your hand‑carry, and avoid extreme heat or cold.  \n- Bring at least 30 days’ worth of pills plus a spare 7‑day supply in case of delays.  \n- If you’re on a drug that requires food (e.g., nilotinib), take it with a meal and avoid grapefruit products.\n\n**Keeping labs on schedule**  \n- Your oncologist usually orders a CBC, CMP, and BCR‑ABL transcript level every 3 months during the first year, then every 6 months once stable.  \n- Before you leave, schedule a lab visit at a local facility in your destination or use a reputable international lab that reports to your oncology team.  \n- Bring a copy of your recent results and a note from your doctor so the lab can match the testing method.  \n- If you notice new symptoms (fatigue, bruising, rash, jaundice), contact your oncologist immediately.\n\n**Practical tips**  \n- Check your travel insurance for coverage of chronic disease care.  \n- Keep a list of emergency contacts and the nearest U.S. hospital in case of complications.  \n\nWith these steps, you can fly internationally while staying on top of your monitoring. Your team will keep a close eye on your progress, so you can focus on enjoying your trip.",
          "order": 7,
          "qid": "S8-Q07"
        },
        {
          "q": "What if I miss doses during crunch time at work?",
          "gt": "I hear how anxious the idea of missing a dose feels, especially when you’re juggling tight deadlines and trying to stay on top of everything at work.\n\nFor chronic‑phase CML, the daily TKI (most commonly imatinib, dasatinib, nilotinib, or bosutinib) is the cornerstone of treatment. Clinical trials and guidelines show that maintaining >95 % adherence keeps BCR‑ABL transcript levels low and prevents loss of response or resistance. If you forget a single pill, take it as soon as you remember unless it’s within an hour of your next scheduled dose—then skip it and resume the regular timing. If you miss a dose for more than 24 hours, skip that dose and restart the next one; do not double‑dose to catch up. Consistently missing doses can raise the risk of disease progression, so it’s important to treat each missed dose as a cue to review your routine.\n\nPractical strategies: set a phone alarm at the same time each day, keep a pillbox in your bag, and consider a “take‑with‑lunch” routine. If you’re in a crunch, a quick text reminder or a coworker’s nudge can help. Keep a spare bottle at work and bring it to the office so you’re never without medication. If you find yourself missing doses more than once a month, let your hematologist know—your team can adjust monitoring or discuss a more forgiving schedule.\n\nRemember, a single missed pill isn’t catastrophic, but consistent adherence is key to keeping your CML in check.",
          "order": 8,
          "qid": "S8-Q08"
        },
        {
          "q": "What’s my plan if side effects hit hard at 2 a.m.?",
          "gt": "I hear how frightening the idea of a sudden, intense side‑effect at 2 a.m. feels, especially when you’re already juggling a new medication and a busy tech job—your worries are completely understandable.\n\n**What to do if a severe side‑effect hits at night**\n\n1. **Take the pill with food** (most TKIs—imatinib, dasatinib, nilotinib, bosutinib—are better tolerated when taken with a meal). If you’re on a twice‑daily schedule, keep the evening dose at least 2 h before bed to reduce nausea.  \n2. **Have a “night‑time kit” ready**: a glass of water, a small snack (e.g., crackers), an over‑the‑counter anti‑nausea (like dimenhydrinate) if your oncologist has cleared it, and a phone with your oncology nurse line number.  \n3. **If you experience severe nausea, vomiting, diarrhea, dizziness, or chest pain**:  \n   - Call your oncology nurse line or the clinic’s after‑hours number immediately.  \n   - If you feel faint, short of breath, or have chest discomfort, call 911.  \n4. **Daily monitoring**: CBC and CMP every 4–6 weeks, liver enzymes every 3 months, and an ECG every 6 months (nilotinib) to catch QT prolongation early.  \n5. **If nighttime symptoms recur**: your oncologist may reduce the dose, switch to a different TKI, or add a supportive medication (e.g., ondansetron for nausea).  \n\n**Next steps**: bring a symptom diary to your next visit so we can fine‑tune the plan together. We’ll keep a close eye on you and adjust as needed.",
          "order": 9,
          "qid": "S8-Q09"
        },
        {
          "q": "How do I tell my parents I’m okay when the word 'leukemia' makes them panic?",
          "gt": "I hear how unsettling it feels to bring up “leukemia” when your parents’ eyes widen, especially when you’re already juggling a demanding job and the weight of a chronic diagnosis.\n\n**What’s happening medically:**  \nYou’re in chronic‑phase CML, which is highly treatable with a daily oral tyrosine‑kinase inhibitor (TKI) such as imatinib, dasatinib, or nilotinib. These drugs keep the abnormal BCR‑ABL protein from driving cell growth. Most patients reach a deep molecular response (BCR‑ABL < 0.01 % on the International Scale) within 12–18 months, and the disease is essentially controlled. You’ll have routine blood tests every 4–6 weeks for the first year, then every 3–6 months once stable. Side effects are usually mild—fatigue, nausea, or a rash—and can be managed with dose adjustments or supportive care. Your oncologist will monitor you closely and adjust therapy if needed.\n\n**How to talk to your parents:**  \n1. Start with a simple frame: “I’m on a daily pill that keeps the leukemia under control.”  \n2. Emphasize the good news: “In chronic‑phase CML, the outlook is very favorable—most people live normal, healthy lives.”  \n3. Offer reassurance about monitoring: “We’ll have regular blood tests to make sure everything stays stable.”  \n4. Invite them to ask questions or join a follow‑up visit if they want to see the plan in person.\n\n**Closing reassurance:**  \nYou’re not alone—your treatment team and your family are all in this together, and the daily pill keeps the disease at bay.",
          "order": 10,
          "qid": "S8-Q10"
        }
      ]
    },
    {
      "id": "S9",
      "title": "Meeting my granddaughter (EGFR-mutated metastatic NSCLC)",
      "diagnosis": "EGFR-mutated metastatic non-small cell lung cancer",
      "treatment_plan": "Osimertinib oral therapy once daily; routine monitoring for rash, diarrhea, heart rhythm, and rare lung inflammation; imaging every 2–3 months",
      "narrative": "I'm 68, a soon-to-be grandfather with an EGFR mutation. I feel guilty about old smoking years and I'm terrified I won't be there to hold my granddaughter next month.",
      "qa": [
        {
          "q": "How quickly might my breathing ease so I can fly to meet her without gasping in the aisle?",
          "gt": "I hear how frightening the idea of struggling to breathe on a flight feels, especially when you’re already carrying so much hope for your granddaughter’s arrival.\n\nMost patients with an EGFR‑mutated lung cancer who start a first‑line TKI (e.g., osimertinib 80 mg once daily) notice a reduction in cough and shortness of breath within 1–2 weeks, though full symptomatic relief can take up to 4 weeks. Blood counts, liver enzymes, and a baseline ECG are checked every 4 weeks, and a CT scan is repeated every 8–12 weeks to confirm tumor shrinkage and monitor for interstitial lung disease. If you develop a rash, diarrhea, or worsening dyspnea, your oncologist may add a low‑dose steroid or adjust the dose.\n\nFor a flight, stay well‑hydrated, wear compression stockings, and consider a prophylactic anticoagulant if you have a high VTE risk. If you have baseline hypoxia, bring a portable oxygen concentrator or arrange for supplemental oxygen at the airport. Discuss these plans with your oncology team before you travel.\n\nWe’ll monitor your response closely and adjust the plan as needed so you can focus on being there for your granddaughter.",
          "order": 1,
          "qid": "S9-Q01"
        },
        {
          "q": "I read about dangerous lung inflammation from this pill. What would that feel like and what would we do?",
          "gt": "I hear how frightening the idea of lung inflammation feels, especially when you’re already carrying so much guilt and worry about being there for your granddaughter—your fears are completely understandable.\n\n**What to look for:**  \n- **Early signs:** a new or worsening dry cough, shortness of breath, or a feeling of tightness in the chest.  \n- **Progression:** fever, chills, or a rapid drop in oxygen saturation (you might notice your pulse‑ox reading falling below 90 %).  \n- **Timing:** ILD can appear within weeks of starting an EGFR inhibitor (e.g., osimertinib, erlotinib, gefitinib, afatinib). Some patients develop it after months, so stay alert throughout treatment.\n\n**What to do if you notice these symptoms:**  \n1. Call your oncology team immediately; they’ll likely ask you to stop the drug right away.  \n2. You’ll probably be admitted for evaluation—blood tests, chest X‑ray/CT, and pulse‑ox monitoring.  \n3. Treatment usually starts with high‑dose oral or IV corticosteroids (prednisone or methylprednisolone) and supportive care (oxygen, bronchodilators).  \n4. Once stabilized, your team will decide whether to restart the EGFR inhibitor at a lower dose, switch to a different agent, or move to another line of therapy.\n\n**Monitoring:**  \n- Baseline chest imaging before starting the drug.  \n- Repeat imaging or pulmonary function tests every 4–6 weeks if you’re at higher risk (history of smoking, prior lung disease).  \n- Keep a symptom diary and bring it to each visit.\n\nYour oncologist can tailor these steps to your specific situation, but knowing the warning signs and the quick response plan can give you a sense of control. We’ll keep a close eye on you and adjust as needed so you can focus on the moments that matter most.",
          "order": 2,
          "qid": "S9-Q02"
        },
        {
          "q": "Do I need to hide from crowds like airports and skip the baby to avoid infection?",
          "gt": "I hear how frightening it feels to worry about catching an infection while you’re already dealing with cancer treatment, especially when you’re eager to be there for your granddaughter.\n\nIf you’re on an EGFR‑targeted TKI (osimertinib, gefitinib, erlotinib), the drug itself doesn’t cause strong immunosuppression. Infection risk mainly comes from any concurrent chemo or immunotherapy.  \n\nFor airport travel, wear a mask, use hand sanitizer, and avoid long queues. Keep a 6‑ft distance, travel off‑peak, and limit time in crowds. If on chemo, discuss prophylactic antibiotics with your oncologist.  \n\nWhen meeting your granddaughter, wear a mask, wash hands, and keep the visit brief if you feel unwell. A video call is a good alternative if you’re uncomfortable with in‑person contact.  \n\nYour oncology team can tailor precautions based on your blood counts. They may schedule CBCs every 2–4 weeks and monitor for fever or sore throat, and advise on prophylaxis.  \n\nYou don’t need to skip the baby entirely; just take precautions and stay in close contact with your oncologist.  \n\nWe’ll work together to keep you safe so you can cherish those precious moments with your granddaughter.",
          "order": 3,
          "qid": "S9-Q03"
        },
        {
          "q": "Will I lose my hair or look 'sick' in photos?",
          "gt": "I hear how scary it feels to worry about looking “sick” in photos, especially when you’re already carrying so much guilt and fear about the future of your family.\n\n**Hair loss and appearance with EGFR‑targeted therapy**  \nMost EGFR inhibitors (erlotinib, gefitinib, afatinib, osimertinib) are taken orally once daily and are not associated with the dramatic hair loss seen with some chemotherapies. You may notice mild thinning or a slight change in hair texture, but complete baldness is rare. The most common cosmetic side effect is a papulopustular rash on the face, chest, and back, which usually appears within 1–2 weeks of starting treatment. Rash severity is graded 1–4; grade 1–2 can be managed with topical steroids, oral antibiotics, and sun protection, while grade 3–4 may require dose interruption or temporary discontinuation.\n\n**Monitoring and support**  \n- Baseline labs (CBC, electrolytes, liver enzymes) and a dermatology consult before starting.  \n- Weekly check‑ins (phone or clinic) during the first 4–6 weeks to assess rash, diarrhea, and any new symptoms.  \n- If rash is severe, your oncologist may reduce the dose or pause therapy until it improves.  \n- Keep a diary of skin changes and report any new symptoms promptly.\n\n**What to expect in photos**  \nYou’ll likely look very similar to how you do now, with only a mild rash that can be covered or treated. If you’re concerned about the rash, a dermatologist can suggest makeup or clothing that helps you feel confident.  \n\nYour care team will monitor you closely, and we’ll adjust the plan if anything changes—so you can focus on being there for your granddaughter.",
          "order": 4,
          "qid": "S9-Q04"
        },
        {
          "q": "I’m ashamed about past smoking. Does that change my prognosis or how you treat me?",
          "gt": "I hear how heavy the guilt feels, especially when you’re already carrying so much for your family and hoping to be there for your granddaughter—those worries are completely understandable.\n\n**Treatment and prognosis**  \nYour EGFR‑mutation status is the main driver of therapy, not your past smoking. First‑line treatment is usually a third‑generation EGFR‑TKI such as **osimertinib 80 mg orally once daily**. We’ll start with a baseline CT scan, CBC, liver enzymes, and an ECG (to check QTc). The drug is taken daily, and we’ll repeat imaging every 8 weeks to assess response (partial response ≈ 70 % of patients, median progression‑free survival 18–20 months).  \n\nSide effects to watch for include diarrhea, rash, dry skin, and, rarely, interstitial lung disease. If you develop grade ≥ 2 toxicity, we may hold the drug, give supportive care, or switch to a lower‑dose schedule.  \n\nSmoking history can influence overall health—COPD, cardiovascular disease, and reduced pulmonary reserve may affect how you tolerate treatment and other comorbidities. However, it does **not** change the choice of EGFR‑TKI or the expected response to it.  \n\nIf the cancer progresses, options include a second‑line EGFR‑TKI (e.g., osimertinib after first‑line failure) or platinum‑based chemotherapy, depending on performance status and prior toxicity.  \n\n**Next steps**  \n- Discuss the plan with your oncologist to tailor dosing and monitoring.  \n- Consider quitting smoking now; it improves lung function and overall survival.  \n- Keep a symptom diary and call the oncology team if you notice new or worsening symptoms.  \n\nWe’ll monitor closely and adjust as needed—your team is here to support you every step of the way.",
          "order": 5,
          "qid": "S9-Q05"
        },
        {
          "q": "How will we know it’s working beyond me wanting it to be?",
          "gt": "I hear how frightening it is to worry that your treatment might not be working, especially when you’re already carrying so much for your family.\n\n**What the doctors look for**  \nYour oncologist will start with a baseline CT scan of the chest, abdomen, and pelvis, plus blood tests (CBC, CMP, liver enzymes, and a QT‑interval check).  \n**Response criteria** – A partial response means a ≥30 % shrinkage of the largest tumors on imaging, while stable disease keeps the tumor size within ±20 %. Symptom relief and an improved ECOG performance status (from 2 to 1, for example) also signal benefit.  \n**Monitoring schedule** – Repeat CT scans every 6–8 weeks, labs every 4 weeks, and a symptom questionnaire at each visit. If the scans show growth or new lesions, a liquid‑biopsy (circulating tumor DNA) can detect resistance mutations (e.g., T790M).  \n**If progression occurs** – The team may switch to a second‑generation EGFR TKI, add chemotherapy, or consider clinical trials; dose adjustments are made only if toxicity limits therapy.\n\nWe’ll track these objective markers together, so you’ll know whether the treatment is truly helping you stay healthy and present for your granddaughter.",
          "order": 6,
          "qid": "S9-Q06"
        },
        {
          "q": "What happens if or when the pill stops working?",
          "gt": "I hear how frightening it feels that the pill might lose its power, especially when you’re already carrying so much hope for your granddaughter’s first birthday—your worries are completely understandable.\n\nWhen an oral EGFR‑inhibitor stops shrinking the tumor, the cancer usually develops resistance. The first step is a repeat imaging study (CT chest/abdomen every 8–12 weeks) and, if possible, a tissue or liquid biopsy to look for new mutations such as T790M. If T790M is present, the standard switch is to osimertinib (Tagrisso) at 80 mg daily, which can overcome that resistance. If the mutation isn’t present, your oncologist may consider a second‑line EGFR drug (afatinib, dacomitinib) or move to platinum‑based chemotherapy (cisplatin or carboplatin plus pemetrexed) combined with a checkpoint inhibitor if the tumor expresses PD‑L1. Many patients also enroll in clinical trials that test newer combinations or novel agents.\n\nThroughout, routine labs (CBC, CMP, liver enzymes) and symptom checks (rash, diarrhea, shortness of breath) are done every 2–4 weeks. If you notice new or worsening symptoms—especially breathing trouble or chest pain—call your team right away, as interstitial lung disease or cardiotoxicity can appear early. Your care team will tailor the next step to your overall health, preferences, and the most recent test results.\n\nWe’ll keep a close eye on your progress and adjust the plan together, so you’re not alone in navigating this next phase.",
          "order": 7,
          "qid": "S9-Q07"
        },
        {
          "q": "Can I stay active with my walking group, or should I rest more?",
          "gt": "I hear how frightening it feels to worry you might miss your granddaughter’s arrival, especially when you’re already carrying so much guilt and fear about your health.\n\nIf you’re on an EGFR‑targeted therapy (for example, osimertinib) and your cancer is stable, most guidelines encourage moderate activity—like a 30‑ to 45‑minute walk, three times a week, at a pace that lets you talk comfortably. Keep an eye on symptoms: sudden shortness of breath, chest tightness, new or worsening cough, or a sharp increase in fatigue are red flags that you should pause and rest. If you notice any of these, stop walking, sit down, and call your oncology team right away. Routine labs and imaging (usually every 8–12 weeks) will help your doctors gauge how well the drug is working and whether any side effects, such as interstitial lung disease, are developing. \n\nIn short, continue the walking group as long as you feel comfortable, but rest when you hit those warning signs. Your oncologist can fine‑tune the plan and let you know when to adjust activity or medication. You’re not alone—your care team will monitor closely and support you every step of the way.",
          "order": 8,
          "qid": "S9-Q08"
        },
        {
          "q": "Are there heart checks I need to worry about?",
          "gt": "I hear how frightening the thought of heart problems feels, especially when you’re already carrying so much for your family—your worries are completely understandable.\n\n**Heart‑monitoring for EGFR‑mutant lung cancer**\n\n1. **Baseline cardiac work‑up**  \n   • Electrocardiogram (ECG) before starting a TKI (erlotinib, gefitinib, or osimertinib).  \n   • If you have a smoking history, prior heart disease, or other risk factors, a baseline transthoracic echocardiogram (TTE) to document left‑ventricular ejection fraction (LVEF) is recommended.\n\n2. **Ongoing surveillance**  \n   • Repeat ECG every 3 months (or sooner if you develop palpitations, syncope, or new chest pain).  \n   • If you’re on a TKI that can prolong the QT interval (especially osimertinib), watch for a QTc > 500 ms; a dose hold or reduction is usually advised if this threshold is crossed.  \n   • If you’re receiving any cytotoxic chemotherapy in addition to a TKI, your oncologist may order an LVEF assessment every 3–6 months, or sooner if symptoms arise.\n\n3. **When to seek help**  \n   • Any new shortness of breath, swelling of legs, chest discomfort, or fainting should prompt an urgent cardiology evaluation.  \n   • If your ECG shows significant changes or your LVEF drops by >10 % or falls below 50 %, your oncology team will coordinate a cardiology consult and may adjust or pause therapy.\n\nDiscuss these plans with your oncologist so the schedule fits your specific treatment and risk profile. Your team will keep a close eye on your heart while you focus on being there for your granddaughter.",
          "order": 9,
          "qid": "S9-Q09"
        },
        {
          "q": "What’s my plan if diarrhea hits mid-flight?",
          "gt": "I hear how frightening it feels to worry about a sudden bout of diarrhea while you’re already carrying so much guilt and fear about your health and your future with your granddaughter—those worries are completely understandable.\n\n**Practical plan for mid‑flight diarrhea**\n\n1. **Pre‑flight prep**  \n   • Pack a small bottle of oral rehydration solution (ORS) or electrolyte drink.  \n   • Bring 2–3 sachets of loperamide 2 mg (generic) and a small bottle of diphenoxylate‑atropine (if prescribed by your oncologist).  \n   • Avoid high‑fiber, greasy, or dairy foods before and during the flight; stick to bland, low‑residue options (rice, toast, bananas).  \n   • Keep a reusable water bottle (filled after security) to sip regularly.\n\n2. **During the flight**  \n   • If you feel the urge, take 2 mg loperamide immediately; repeat every 4 h as needed, max 8 mg/day.  \n   • If symptoms worsen (≥4 loose stools in 24 h, cramping, fever, or blood), take diphenoxylate‑atropine 4 mg and contact flight medical staff.  \n   • Monitor hydration: aim for 500–750 mL of fluid per hour if you’re having diarrhea.  \n   • If you can’t keep fluids down or develop severe abdominal pain, request medical assistance and consider contacting your oncologist for guidance (they may adjust your EGFR‑TKI dose or add octreotide).\n\n3. **After landing**  \n   • Re‑hydrate with ORS or a sports drink; avoid alcohol and caffeine.  \n   • Follow up with your oncology team—if diarrhea persists >48 h, they may need to pause or modify therapy.\n\n**You’re not alone in this; your care team will monitor your symptoms closely, and we’ll adjust treatment as needed to keep you comfortable and safe.**",
          "order": 10,
          "qid": "S9-Q10"
        }
      ]
    },
    {
      "id": "S10",
      "title": "Sunday dinners matter (metastatic pancreatic cancer)",
      "diagnosis": "Metastatic pancreatic adenocarcinoma with weight loss and pain",
      "treatment_plan": "Gemcitabine + nab-paclitaxel weekly for 3 weeks, then 1 week off (28-day cycles); symptom control; nutrition and enzyme support; reassessment each cycle",
      "narrative": "I'm 72, a retired teacher. Pain steals my sleep and I’m losing weight. My family’s Sunday dinner and church choir are my anchors. The plan is gemcitabine with nab-paclitaxel.",
      "qa": [
        {
          "q": "Can you get my pain under control now so I can sit through dinner without faking a smile?",
          "gt": "I hear how frightening it feels to be in pain while you’re trying to stay strong for your family and choir—your frustration is completely understandable.\n\n**Pain‑control options you can discuss right away**  \n1. **Baseline meds** – Acetaminophen 1 g every 6 h or an NSAID (e.g., ibuprofen 400 mg q6h) if you’re not on a chemo‑related bleeding risk.  \n2. **Opioid bridge** – If pain is moderate‑to‑severe, a short‑acting opioid such as oxycodone 5–10 mg every 4–6 h or hydromorphone 1–2 mg q4–6 h can be started. For breakthrough pain, a “rescue” dose (e.g., oxycodone 5 mg) can be taken as needed.  \n3. **Adjuncts for neuropathic pain** – Gabapentin 300 mg at bedtime, titrated up to 900 mg nightly, or duloxetine 30 mg daily, can help with the numb‑tingling pain that gemcitabine/nab‑paclitaxel often causes.  \n4. **Topicals** – Lidocaine patches or capsaicin cream for localized discomfort.  \n5. **Non‑pharmacologic** – Warm compresses, gentle stretching, and relaxation breathing can complement meds.\n\n**What to watch for**  \n- Sedation, dizziness, or slowed breathing (especially with opioids).  \n- Constipation—take a stool softener or laxative with each opioid dose.  \n- Nausea or vomiting—consider ondansetron if needed.  \n- If you notice confusion, extreme drowsiness, or breathing slows, call your oncology nurse or go to the ER immediately.\n\n**Next steps**  \nCall your oncology team or nurse line today to request a prescription for the above regimen and to discuss any dose adjustments based on your current labs and overall health. They can also arrange a quick pain‑assessment visit if needed.  \n\nYou’re not alone—your care team will help you get the relief you need so you can enjoy your Sunday dinner and choir without masking the pain.",
          "order": 1,
          "qid": "S10-Q01"
        },
        {
          "q": "I can’t keep weight on and everything tastes wrong. What can actually help this week?",
          "gt": "I hear how overwhelming the loss of appetite and the taste changes feel, especially when you’re trying to keep your strength for family dinners and choir nights.\n\nTo help you gain weight this week, aim for 5–6 small, high‑calorie snacks instead of three large meals. Think protein‑rich smoothies (protein powder, Greek yogurt, peanut butter, banana, and a splash of milk), fortified meal‑replacement shakes, or a handful of nuts and dried fruit. Add a splash of lemon or a pinch of sea salt to foods to boost flavor, and try cold or room‑temperature dishes, which often taste better when taste buds are altered. Keep a food diary and note what feels most appealing; this can guide your oncologist if you need a prescription appetite stimulant (e.g., megestrol acetate or dronabinol).\n\nPain that keeps you awake can be managed with a scheduled opioid or neuropathic pain agent, and a short‑acting antihistamine or a low‑dose benzodiazepine may help with sleep. If nausea or mouth soreness is a problem, anti‑emetics (ondansetron) or a mouth rinse with mild salt water can ease eating.\n\nTrack your weight, appetite, and any new symptoms in a notebook. Bring this log to your next oncology visit; your team can adjust gemcitabine or nab‑paclitaxel doses, add supportive medications, or refer you to a dietitian or palliative care specialist.  \n\nYou’re not alone—your care team will monitor closely and adapt the plan as needed.",
          "order": 2,
          "qid": "S10-Q02"
        },
        {
          "q": "Will this treatment take all my 'good days,' or can we plan around choir and grandkids?",
          "gt": "I hear how frightening it feels to think your treatment might steal the moments you cherish, especially when you’re so devoted to your family and choir.  \n\n**Gemcitabine + nab‑paclitaxel**  \nGemcitabine 1000 mg/m² IV over 30‑60 min and nab‑paclitaxel 125 mg/m² IV over 30‑60 min are given together on days 1, 8, 15 of a 28‑day cycle.  \n\n**What to expect**  \nYou’ll likely feel fatigue, nausea, and a mild numbness in your hands or feet. Most people recover between cycles, but the neuropathy can linger.  \n\n**Monitoring**  \nWe’ll check a CBC, liver and kidney panels before each cycle and watch for neutropenia or neuropathy. If counts drop or pain increases, we’ll adjust the dose.  \n\n**Planning around activities**  \nBecause the treatment days are spaced out, you can usually attend choir or family meals on the rest days. Let your nurse know if you need a day off for a big event.  \n\n**If side effects become intense**  \nWe can pause one drug, lower the dose, or consider a different regimen. Your oncologist will tailor the plan as we go.  \n\nWe’ll keep a close eye on how you’re doing so you can keep those precious moments with your choir and grandchildren.",
          "order": 3,
          "qid": "S10-Q03"
        },
        {
          "q": "How do you know it’s working without waiting months?",
          "gt": "I hear how anxious you feel about knowing whether the gemcitabine‑nab‑paclitaxel combo is working, especially when you’re already juggling pain, weight loss, and the need to stay strong for your family.\n\nGemcitabine (1000 mg/m²) and nab‑paclitaxel (125 mg/m²) are given every 3 weeks. After the first two cycles you’ll have a CT scan of the chest, abdomen, and pelvis and a CA 19‑9 blood test. A meaningful drop in CA 19‑9 (≥30 %) or a 10–20 % reduction in tumor size on imaging is a good early sign. Clinically, look for less pain, better appetite, and weight gain—often noticeable after 1–2 cycles. Your oncology team will also monitor CBC and CMP each visit to catch neutropenia or liver changes early. If symptoms don’t improve or markers rise, the plan is to discuss switching to second‑line therapy or adding supportive measures.\n\nWe’ll keep a close eye on your progress and adjust as needed—your team is with you every step of the way.",
          "order": 4,
          "qid": "S10-Q04"
        },
        {
          "q": "What if the side effects feel worse than the disease—do I have permission to ask for less?",
          "gt": "I hear how frightening it feels to think the chemo might hurt you more than the cancer, especially when you’re already carrying so much for your family and your faith community.\n\nGemcitabine (1000 mg/m²) and nab‑paclitaxel (125 mg/m²) are given IV on days 1, 8, 15 of a 28‑day cycle. Before each cycle you’ll have a CBC, CMP, and LFTs to watch for neutropenia, liver or kidney issues, and a neuropathy exam. Common side effects are fatigue, nausea, mild hair loss, and peripheral neuropathy; more serious risks include febrile neutropenia and neuropathy that can limit daily activities. If any toxicity becomes intolerable, the oncologist can reduce the dose (to 80 % or 50 %) or pause one drug while continuing the other. In some cases, switching to gemcitabine alone or a single‑agent regimen is an option. Your team will monitor you closely and adjust the plan as needed—so you can ask for less aggressive treatment whenever the side‑effects outweigh the benefits.\n\nWe’ll work together to keep you comfortable and supported.",
          "order": 5,
          "qid": "S10-Q05"
        },
        {
          "q": "I don’t want to die in a hospital. When do we talk about those wishes without giving up?",
          "gt": "I hear how frightening it feels to think about dying in a hospital, especially when you’re already carrying so much for your family and your faith.\n\nGemcitabine 1000 mg/m² and nab‑paclitaxel 125 mg/m² are given IV on days 1, 8, 15 of a 28‑day cycle. Each infusion lasts about 30–60 minutes, and you’ll have a CBC, electrolytes, and liver panel before every cycle to catch neutropenia, neuropathy, or liver changes early. Pain and weight loss are common; we’ll titrate opioids or neuropathic agents as needed and keep a close eye on your functional status. If side effects become intolerable, we can reduce doses or pause one drug while continuing the other.\n\nAdvance care planning is best started before the first cycle—or within the first week—so you can set goals that keep you in the home or church choir while still pursuing treatment. Bring a trusted family member to the appointment, discuss a living will, durable power of attorney, and a “do‑not‑resuscitate” or comfort‑care order if that aligns with your wishes. Your oncologist, a palliative‑care specialist, and a social worker can help you document these preferences and revisit them whenever your situation changes.\n\nWe’ll keep you informed and support you in making choices that honor both your treatment goals and your desire to stay at home.",
          "order": 6,
          "qid": "S10-Q06"
        },
        {
          "q": "Will I lose my hair, and if I do, how do I handle people’s reactions at church?",
          "gt": "Feeling scared about losing your hair, especially when you’re already juggling pain and the comfort of Sunday services, is completely understandable.  \n\nGemcitabine 1000 mg/m² IV on days 1 and 8 of each 21‑day cycle, paired with nab‑paclitaxel 125 mg/m² IV on the same days. The combo is usually given for 4–6 cycles before switching to maintenance or another plan.  \n\nAlopecia is a known side effect of nab‑paclitaxel. About 30–50 % of patients experience moderate to severe hair loss, whereas gemcitabine alone rarely causes noticeable thinning.  \n\nHair loss usually starts 1–2 weeks after the first cycle, peaks around 3–4 weeks, and may be partial or near‑total. Regrowth typically occurs 6–8 weeks after stopping the drug.  \n\nDiscuss wigs, hats, or scarves with your oncology team; many find comfort in counseling or support groups. A discreet head covering during services can boost confidence.  \n\nIf you’re worried about reactions at church, share a brief note with the choir director or pastor—most will respect your privacy. Bringing a supportive friend or wearing a modest hat can ease awkward moments.  \n\nWe’ll monitor your hair and overall well‑being closely, and I’m here to help you navigate each step.",
          "order": 7,
          "qid": "S10-Q07"
        },
        {
          "q": "Can I keep taking my walks without risking a fall when I’m weak?",
          "gt": "I hear how frightening it feels to worry about falling while your body is already feeling weak, especially when you’re trying to stay active for your family and church.\n\nGemcitabine (1000 mg/m²) and nab‑paclitaxel (125 mg/m²) are given IV on days 1, 8, and 15 of a 28‑day cycle, each infusion lasting about 30–60 minutes. The most common side effects that can affect walking are peripheral neuropathy, fatigue, and myelosuppression. Neuropathy can dull your sense of balance, while fatigue can make your legs feel shaky.\n\nBecause of these risks, your oncology team will monitor you closely: a complete blood count before each cycle, a neuropathy grade assessment, and weight checks. If neuropathy scores rise or you feel unusually weak, the dose may be reduced or a cycle paused.\n\nTo keep walking safely, use supportive shoes, consider a cane or walker, and avoid uneven surfaces. In your home, clear clutter, install grab bars, and keep lighting bright. A physical‑therapy session focused on balance and strength can also help.\n\nIf you notice worsening weakness, dizziness, or a fall, contact your oncologist right away. They can adjust the regimen or add supportive medications. Your team will monitor you closely and help you stay as active and safe as possible.",
          "order": 8,
          "qid": "S10-Q08"
        },
        {
          "q": "My family is afraid to eat with me, like food will 'hurt' the cancer. What should we tell them?",
          "gt": "I hear how frightening it feels when your loved ones worry that sharing a meal could harm your cancer, especially when you’re already carrying so much weight on your shoulders.  \n\n**Food and cancer**  \nFood itself never accelerates tumor growth. In fact, adequate calories and protein help your body tolerate chemotherapy, maintain strength, and recover from side effects.  \n\n**Chemotherapy side effects**  \nGemcitabine and nab‑paclitaxel can cause nausea, vomiting, mouth sores, and decreased appetite. These symptoms are temporary and manageable with anti‑emetics, oral care, and hydration.  \n\n**Practical nutrition tips**  \nEncourage small, frequent meals, bland or soft foods, and plenty of fluids. A registered dietitian can suggest high‑calorie, high‑protein snacks and, if needed, oral supplements.  \n\n**Family’s role**  \nLet your family know that eating together is safe and supportive. They can help by preparing meals, offering gentle encouragement, and reminding you to eat before the next infusion.  \n\nTogether with your care team, we’ll keep your nutrition on track and your family’s worries at bay.",
          "order": 9,
          "qid": "S10-Q09"
        },
        {
          "q": "If this stops working, what’s next so we aren’t scrambling?",
          "gt": "I hear how frightening it feels to think that the current regimen might lose its edge, especially when you’re already juggling pain, weight loss, and the comfort of family Sunday dinners.\n\nIf gemcitabine plus nab‑paclitaxel stops controlling the disease, the usual next step is a second‑line chemotherapy that’s still active against pancreatic cancer. The most common choices are:\n\n1. **FOLFIRINOX** (5‑FU, leucovorin, irinotecan, oxaliplatin) every 2 weeks. It’s intensive, so your doctor will weigh your performance status and blood counts before starting.  \n2. **FOLFOX** (5‑FU, leucovorin, oxaliplatin) every 2 weeks, a slightly less aggressive option that still offers tumor shrinkage in many patients.  \n3. **Nanoliposomal irinotecan + 5‑FU/leucovorin** (Nal‑IRI) is approved for patients who’ve progressed on gemcitabine‑based therapy and can be given every 2 weeks.  \n4. If a BRCA or PALB2 mutation is present, a **PARP inhibitor** (olaparib) can be added after progression.  \n5. For MSI‑high or mismatch‑repair deficient tumors, **checkpoint inhibitors** (nivolumab or pembrolizumab) may be considered.  \n\nYour oncologist will schedule CBC, CMP, and neuropathy checks every cycle to catch neutropenia, liver changes, or nerve damage early. If a drug is too toxic, dose reductions or supportive agents (growth factors, anti‑nausea meds) can be used.  \n\nIf none of these options are suitable, enrolling in a clinical trial or shifting focus to intensified palliative care—pain control, nutrition support, and psychosocial counseling—helps maintain quality of life.  \n\nWe’ll keep a close eye on your response and adjust the plan as needed, so you’re not scrambling when changes arise.",
          "order": 10,
          "qid": "S10-Q10"
        }
      ]
    },
    {
      "id": "S11",
      "title": "My hands play, my bones ache (transplant-eligible multiple myeloma)",
      "diagnosis": "Multiple myeloma with lytic bone disease, transplant-eligible",
      "treatment_plan": "Induction (bortezomib/lenalidomide/dexamethasone), stem-cell collection and autologous transplant when appropriate, then maintenance (often lenalidomide)",
      "narrative": "I'm 58, a guitarist. My fingers are my identity, but my back aches from bone lesions. They're talking about transplant after several months of treatment.",
      "qa": [
        {
          "q": "Will treatment numb my fingers and steal my music?",
          "gt": "I hear how frightening it feels that the treatment might numb your fingers, especially when your music is such a core part of who you are. It’s completely natural to feel anxious about that possibility.\n\nThe transplant itself—whether it’s an autologous stem‑cell transplant for multiple myeloma or a bone‑marrow transplant for another condition—doesn’t directly numb your hands. The risk of peripheral neuropathy comes mainly from the chemotherapy agents used before and after the transplant. For example, high‑dose melphalan (200 mg/m²) and bortezomib are common conditioning drugs that can cause tingling or numbness in the fingers. Most patients experience only mild, reversible symptoms, but a small percentage develop more persistent neuropathy.\n\nYour team will monitor you closely: weekly neurologic exams, pain scales, and, if needed, nerve‑conduction studies. If symptoms appear, they can reduce the dose, switch to a less neurotoxic drug, or add neuropathic pain medications (gabapentin, duloxetine). Hand‑therapy and occupational‑therapy exercises can help maintain dexterity.\n\nMany musicians recover full sensation and return to playing after transplant, sometimes with temporary adjustments. Discuss your specific regimen and any concerns with your transplant oncologist; they’ll tailor the plan to protect your hands while treating the disease.\n\nWe’ll keep a close eye on your nerves and adjust as needed so you can keep making music.",
          "order": 1,
          "qid": "S11-Q01"
        },
        {
          "q": "What does a 'transplant' actually mean for me day to day—am I isolated for months?",
          "gt": "I hear how scary the idea of a transplant feels, especially when your fingers and music are such a big part of who you are—your worries are completely understandable.\n\nA bone‑marrow (stem‑cell) transplant is a two‑phase process. First, a conditioning regimen—usually high‑dose melphalan (sometimes combined with busulfan or cyclophosphamide)—is given over 3–5 days to wipe out diseased marrow and make room for new cells. You’ll be in the hospital during this time, with frequent blood tests and close monitoring for nausea, infection, and organ function. On day 0, the donor stem cells are infused. The next 1–2 weeks are usually spent in the hospital; you’ll be on a strict infection‑prevention protocol, which includes a neutropenic isolation room, limited visitors, and careful hand hygiene. After that, you’ll go home but still need to stay in close contact with your team: daily CBCs, drug‑level checks for immunosuppressants (tacrolimus, mycophenolate, prednisone), and routine visits every 2–4 weeks for the first 3–6 months. You’ll be advised to avoid crowds, strenuous activity, and any contact sports until your white‑cell count recovers. Isolation is typically only for the first 2–4 weeks; most of the rest of the year you’ll manage the transplant at home with regular follow‑up.  \n\nWe’ll work together to keep you safe and as active as your health allows.",
          "order": 2,
          "qid": "S11-Q02"
        },
        {
          "q": "Can you stabilize my spine so I’m not afraid to pick up my guitar?",
          "gt": "I hear how frightening it feels to think your spine might limit the music that defines you, especially when every chord you play is part of who you are.  \n\n**Stabilization options**  \nIf the lesions are causing mechanical instability, a spine surgeon can perform instrumented fusion (pedicle screws and rods) or vertebral augmentation (kyphoplasty/vertebroplasty). Surgery usually takes 1–2 hours, with a hospital stay of 1–2 days, and is followed by a 4–6‑week rehab period.  \n\n**Non‑surgical support**  \nA rigid thoracolumbar brace can temporarily limit motion while you await surgery or as an adjunct. Local radiation (5–8 Gy in 1–2 fractions) can shrink lesions and relieve pain. Bisphosphonates (zoledronic acid 4 mg IV q12 weeks) or denosumab 120 mg SC q4 weeks reduce bone resorption and help preserve stability.  \n\n**Systemic therapy & transplant**  \nYour transplant plan (likely bone‑marrow or stem‑cell) targets the underlying disease that created the lesions. Your oncologist will schedule imaging (MRI/CT) every 3–6 months and labs (CBC, calcium, renal function) to monitor response and detect new lesions early.  \n\n**Recovery & return to guitar**  \nAfter surgery, you’ll start with gentle range‑of‑motion exercises, gradually progressing to weight‑bearing as the hardware consolidates. Most patients can resume light playing within 6–8 weeks, with gradual increase as pain and strength improve.  \n\nWe’ll coordinate closely so you can feel confident that your spine is supported and your music can continue.",
          "order": 3,
          "qid": "S11-Q03"
        },
        {
          "q": "Steroids make me wired and edgy. How do I sleep and not snap at my partner?",
          "gt": "I hear how restless and irritable the steroids make you feel, especially when you’re already juggling the stress of a transplant and the need to keep your fingers sharp for music.\n\n**Managing the “wired” effect**  \n- **Timing**: Take your prednisone or methylprednisolone in the early morning (ideally before 10 am). If you must take it later, consider splitting the dose (e.g., 10 mg in the morning, 5 mg at noon) to reduce late‑day peaks.  \n- **Sleep hygiene**: Dim lights an hour before bed, avoid screens, and keep a cool, quiet room. A short 10‑minute guided breathing or progressive‑muscle‑relaxation routine can help wind down.  \n- **Adjunct meds**: Your oncologist can discuss low‑dose melatonin (0.5–3 mg) or a short‑term antihistamine (diphenhydramine 25 mg) to aid sleep. If mood swings persist, a brief trial of a low‑dose benzodiazepine (e.g., clonazepam 0.25 mg) may be considered, but only under close supervision.  \n- **Monitoring**: Check blood pressure, fasting glucose, and weight each visit; steroids can raise BP and glucose, which can worsen mood. Keep a simple log of sleep times and mood spikes to share with your team.  \n- **Communication**: Let your partner know you’re working on this—simple phrases like “I’m having a hard night, but I’m trying a new routine” can reduce frustration.  \n\n**Next steps**  \nDiscuss a possible dose taper or steroid‑sparing agent (e.g., mycophenolate or tacrolimus) with your transplant team. They’ll tailor the plan to your bone‑lesion therapy and monitor for adrenal suppression (check morning cortisol if symptoms worsen).  \n\nYou’re not alone in this; your care team will adjust the regimen to protect both your back and your relationships.",
          "order": 4,
          "qid": "S11-Q04"
        },
        {
          "q": "I heard about jaw problems with bone drugs. Do I need a dentist first?",
          "gt": "I hear how anxious you feel about your jaw health, especially when your fingers are your identity and you’re already juggling back pain and transplant considerations.\n\n**Dental evaluation is usually recommended before you start any bone‑targeting therapy.**  \nMost of the drugs used for bone lesions—bisphosphonates (e.g., zoledronic acid, pamidronate) and the RANK‑L inhibitor denosumab—carry a risk of osteonecrosis of the jaw (ONJ). A thorough dental exam within 1–2 weeks of starting treatment lets your dentist:\n- Identify and treat active cavities, periodontal disease, or any exposed bone.\n- Plan or postpone invasive procedures (extractions, implants) until you’re on therapy.\n- Provide a personalized oral‑hygiene plan and advise on avoiding trauma to the jaw.\n\nDuring therapy, you’ll need routine dental check‑ups every 6–12 months (or sooner if you develop pain, swelling, or a non‑healing extraction site). If you’re already on treatment and develop jaw symptoms, contact your oncology team immediately.\n\nYour transplant team will coordinate with your dentist to keep both bone health and immune status in balance. We’ll work together to keep your fingers—and your jaw—healthy.",
          "order": 5,
          "qid": "S11-Q05"
        },
        {
          "q": "What’s the plan if my numbers drop again after transplant?",
          "gt": "I hear how unsettling it feels to worry that your lab numbers might fall again after the transplant, especially when your fingers and music are such a big part of who you are.\n\nAfter an autologous stem‑cell transplant for multiple‑myeloma‑related bone lesions, we’ll check your complete blood count, serum calcium, creatinine, and the M‑protein (or free light chains) every week for the first month, then every 2–4 weeks for the next 5 months, and monthly thereafter. If the M‑protein rises or the free light‑chain ratio worsens, we’ll first rule out infection or graft‑vs‑host complications with a full infectious work‑up and drug‑level checks (tacrolimus or cyclosporine). If relapse is confirmed, the usual next step is salvage chemotherapy—often a combination of lenalidomide, bortezomib, and dexamethasone—or, if you’re a suitable candidate, a second autologous transplant. We’ll also consider growth factors (e.g., G‑CSF) or antibiotics if your counts fall below 0.5 × 10⁹/L or platelets drop under 50 × 10⁹/L.\n\nWe’ll keep a close eye on you and adjust the plan as needed—your team will be with you every step of the way.",
          "order": 6,
          "qid": "S11-Q06"
        },
        {
          "q": "Can I keep teaching lessons between cycles without risking infections?",
          "gt": "I hear how anxious you feel about keeping your guitar lessons running while your body fights the disease—especially when every day feels like a balancing act between healing and staying true to who you are.\n\n**Can you teach between cycles?**  \n- **Neutropenia window:** After most chemo regimens, your absolute neutrophil count (ANC) drops 7–14 days post‑infusion. If ANC > 1,500 cells/µL, the infection risk is low; if < 500, you’re high‑risk and should avoid close contact.  \n- **Immunosuppression post‑transplant:** Tacrolimus, mycophenolate mofetil, and prednisone keep rejection at bay but also blunt immune defenses. Typical trough levels (tacrolimus 5–10 ng/mL) are monitored weekly; higher levels mean greater infection risk.  \n- **Daily precautions:** Wear a mask, practice rigorous hand hygiene, and avoid teaching if you have fever > 38 °C, sore throat, or any new infection symptoms.  \n- **Monitoring schedule:** CBC and tacrolimus levels before each cycle; report any fevers or rash immediately.  \n- **If you’re feeling well and labs are stable, you can usually continue lessons, but keep the sessions brief, sit in a well‑ventilated space, and consider switching to virtual lessons if fatigue sets in.  \n\nYour oncologist can tailor these guidelines to your exact regimen, so keep that conversation open. Stay safe, and keep strumming—you’re doing an amazing job.",
          "order": 7,
          "qid": "S11-Q07"
        },
        {
          "q": "How do you decide when to collect my stem cells?",
          "gt": "I hear how frightening the idea of timing a stem‑cell harvest feels, especially when your fingers and your music are so intertwined—your worries are completely understandable.\n\n**When to collect?**  \n1. **Disease status** – We aim to harvest after you’re in at least partial remission and your bone‑lesion pain is controlled. A PET/CT or MRI showing ≤30 % residual disease and stable or improving blood counts is the usual benchmark.  \n2. **Mobilization** – We give you a short course of cyclophosphamide (e.g., 2 g/m² IV) or a combination of cyclophosphamide plus etoposide, followed by 5–7 days of G‑CSF (filgrastim 10 µg/kg SC daily). If the peripheral CD34⁺ count (≥10 cells/µL) is low, we add plerixafor.  \n3. **Timing relative to conditioning** – The collection is scheduled 2–3 weeks before the high‑dose conditioning regimen (e.g., busulfan + cyclophosphamide). This window allows you to recover from mobilization and ensures the graft is fresh for infusion.  \n4. **Safety checks** – We monitor CBC, renal and hepatic panels, and cardiac function (echo or MUGA) before mobilization and again before the transplant.  \n\nIf mobilization fails, we can repeat the G‑CSF course or consider an allogeneic donor. Your transplant team will coordinate every step, keeping your health and your guitar practice in balance.",
          "order": 8,
          "qid": "S11-Q08"
        },
        {
          "q": "What does 'MRD negative' mean and should I chase it?",
          "gt": "I hear how anxious and frustrated you feel about the next steps, especially when your fingers—your identity—are at stake.  \n\n**What “MRD‑negative” means**  \nMinimal residual disease (MRD) negative means that, after your current therapy, no cancer cells can be detected in the bone marrow or blood using highly sensitive tests (flow cytometry or next‑generation sequencing). It’s a marker that the disease is responding well.  \n\n**Why it matters for transplant**  \nIn many hematologic cancers (e.g., multiple myeloma, certain lymphomas), achieving MRD negativity before a stem‑cell transplant is associated with longer remission and lower relapse rates. However, transplant eligibility also depends on organ function, overall health, and the specific disease biology.  \n\n**How it’s measured and when**  \nYour team will draw a bone‑marrow aspirate or peripheral‑blood sample after the induction phase (usually 4–6 weeks of therapy) and again 2–4 weeks before the transplant. Results are reported as “MRD‑positive” or “MRD‑negative.”  \n\n**Should you chase it?**  \nIf your disease type and treatment plan make MRD status a key decision point, your oncologist will likely aim for MRD negativity before transplant. Discuss the risks, benefits, and whether a slightly higher MRD level could still allow a successful transplant.  \n\nYour team will guide you through the exact timing and what to expect, so you’re not alone in this decision.",
          "order": 9,
          "qid": "S11-Q09"
        },
        {
          "q": "Will I ever feel strong enough to perform a full set again?",
          "gt": "I hear how frightening it feels to wonder if you’ll ever be able to play again, especially when your guitar is such a core part of who you are.  \n\nAfter a bone‑marrow transplant, recovery is usually staged. In the first 2–3 weeks you’ll be neutropenic and may need bed rest; pain from bone lesions often improves as the conditioning regimen (cyclophosphamide + total‑body irradiation or busulfan + fludarabine) clears the tumor burden. Once your white‑cell count recovers, a gradual return to activity is typical—starting with light stretching, then progressive strength training under a physical‑therapy plan.  \n\nPain control is key: opioids for acute pain, bisphosphonates or denosumab to strengthen bone, and a multidisciplinary pain team to adjust medications as you regain function. Your transplant team will monitor blood counts, liver function, and imaging of the spine every 4–6 weeks to ensure no new lesions appear.  \n\nMost patients who complete an autologous transplant return to normal daily life within 3–6 months, and many resume playing instruments, though they may need to modify posture or take breaks during long sets.  \n\nWith close follow‑up, tailored rehab, and vigilant pain management, there’s a realistic chance you’ll feel strong enough to perform a full set again.",
          "order": 10,
          "qid": "S11-Q10"
        }
      ]
    },
    {
      "id": "S12",
      "title": "Voice on the line (HPV-positive base-of-tongue cancer)",
      "diagnosis": "HPV-positive oropharyngeal squamous cell carcinoma",
      "treatment_plan": "Definitive chemoradiation with speech/swallow therapy; consider feeding tube support if needed",
      "narrative": "I'm 49, a choir singer and call-center lead. The tumor is at the base of my tongue. The plan is chemoradiation. My voice is my livelihood and my joy.",
      "qa": [
        {
          "q": "Will I still sound like me after treatment, or is that voice gone?",
          "gt": "I hear how frightening it feels to think your voice might be lost, especially when singing is such a core part of who you are and how you connect with others.\n\nChemoradiation for a base‑of‑tongue tumor usually involves 70 Gy of external‑beam radiation delivered in 35 fractions, combined with cisplatin 100 mg/m² every 3 weeks (or weekly 30 mg/m²). The treatment can cause mucositis, xerostomia, and swelling of the tongue and larynx, all of which can temporarily alter pitch, breathiness, and vocal stamina. Most patients experience some hoarseness or reduced range during the first 6–12 weeks, but with early referral to a speech‑language pathologist, voice‑rest protocols, and targeted exercises, many regain a voice that is close to their pre‑treatment sound. Your oncologist will schedule routine laryngoscopies and voice assessments every 3–6 months to monitor for late fibrosis or persistent dysphonia. If significant changes arise, options such as voice prosthesis or surgical intervention can be discussed.\n\nLet’s keep a close eye on your voice and work together with your speech therapist to preserve the sound that defines you.",
          "order": 1,
          "qid": "S12-Q01"
        },
        {
          "q": "Everyone keeps mentioning a feeding tube. How will I know if I really need one?",
          "gt": "I hear how unsettling the idea of a feeding tube feels, especially when your voice is your livelihood and your joy. It’s normal to feel anxious about a change that could alter your daily routine and self‑image.\n\n**When a feeding tube is considered**  \nDuring chemoradiation for a base‑of‑tongue tumor, the oncology team will monitor your oral intake, weight, and swallow function. A speech‑language pathologist (SLP) usually performs a bedside swallow evaluation at the start of treatment and again after 2–3 weeks. If you’re unable to keep at least 70 % of your daily calories orally, or if you have repeated aspiration or significant weight loss (≥5 % of body weight), the team will discuss a feeding tube.  \n\n**Types and timing**  \n- **Nasogastric (NG) tube**: temporary, often used for the first 2–4 weeks while you adapt to swallowing changes.  \n- **Percutaneous endoscopic gastrostomy (PEG)**: placed when long‑term nutrition support is needed, usually after 4–6 weeks of treatment if oral intake remains inadequate.  \n\n**What to expect**  \n- Placement is done under sedation; you’ll have a small incision and a tube that stays in place.  \n- Your dietitian will tailor a liquid or pureed diet until you can resume normal foods.  \n- The SLP will continue to assess swallow safety and may recommend exercises to regain function.  \n\nIf your intake improves, the tube can be removed early; if not, it will stay until you’re ready to transition back to oral feeding. Your team will keep you informed every step of the way.",
          "order": 2,
          "qid": "S12-Q02"
        },
        {
          "q": "Is HPV something I 'gave' my spouse—do we need to stop kissing forever?",
          "gt": "I hear how anxious you feel about possibly passing HPV to your spouse, especially when your voice and your relationship are so central to you.  \n\n**HPV transmission and kissing**  \n* HPV is the most common sexually transmitted infection, and certain high‑risk types (16, 18, 31, 33, etc.) are linked to oropharyngeal cancers.  \n* The virus can be present in saliva, so oral‑oral contact—including kissing—can transmit it, but the risk is much lower than oral‑genital contact.  \n* Most oral HPV infections are asymptomatic and are cleared by the immune system within 1–2 years.  \n* There is no routine screening test for oral HPV, so a negative test is not available.  \n\n**What this means for you and your partner**  \n* If your spouse is healthy and has no symptoms of oral infection, there is no medical recommendation to stop kissing.  \n* Discussing your diagnosis openly can help your partner feel informed; if they have concerns, they can talk to their own clinician.  \n* If either of you has had an HPV vaccine (or if you’re eligible for the 9‑vaccine series), that can reduce the risk of future infections.  \n\n**Next steps**  \n* Continue your chemoradiation plan as scheduled; your oncologist will monitor tumor response and any side effects.  \n* Keep regular follow‑up appointments and report any new symptoms promptly.  \n\nYour focus on staying strong for your voice and your family is admirable, and we’ll keep monitoring your health closely.",
          "order": 3,
          "qid": "S12-Q03"
        },
        {
          "q": "Will my mouth feel like sand forever?",
          "gt": "I hear how frightening the idea of a forever‑dry, sand‑like mouth feels, especially when your voice is your livelihood and joy.\n\nChemoradiation for a base‑of‑tongue tumor usually involves 70 Gy of intensity‑modulated radiation (IMRT) over 7 weeks plus concurrent cisplatin (100 mg/m² every 3 weeks) or cetuximab (400 mg/m² loading, then 250 mg/m² weekly). The most intense oral side effect—mucositis—peaks around week 3 and typically resolves within 2–4 weeks after treatment ends. Xerostomia (dry mouth) is more persistent; with modern IMRT that spares the parotid glands, many patients report significant improvement within 6–12 months, though some may experience chronic dryness for up to 18 months. Taste changes and mild dysphagia often improve with time and speech‑language therapy.\n\nWe’ll monitor you weekly with oral exams, saliva‑flow tests, and speech assessments. If dryness persists beyond 6 months, options such as pilocarpine, saliva substitutes, or low‑dose radiation to the salivary glands can be considered. Your team will adjust supportive care as needed, so you’re not left feeling “sand forever.”",
          "order": 4,
          "qid": "S12-Q04"
        },
        {
          "q": "Can I keep working phones with a sore throat and fatigue?",
          "gt": "I hear how anxious you feel about keeping your phone job going, especially when the very voice that fuels your singing and leadership is already strained by treatment.\n\nChemoradiation for a base‑of‑tongue tumor usually involves daily external‑beam radiation with concurrent cisplatin (100 mg/m² every 3 weeks or 40 mg/m² weekly). Common side effects are sore throat, mucositis, dysphagia, xerostomia, and persistent fatigue that can last 4–6 weeks after each cycle. These symptoms often make sustained voice use difficult. Your oncologist will monitor CBC, renal function, and hearing every 3–4 weeks, and you’ll receive supportive care (anti‑emetics, steroids, pain control, and hydration). \n\nYou can try to keep working by:  \n1. Using a headset with voice‑amplification and a script to reduce vocal strain.  \n2. Taking short, frequent voice breaks and staying well‑hydrated.  \n3. Scheduling lighter call‑loads or shifting to written communication when fatigue peaks.  \n4. If dysphonia or fatigue becomes severe, discuss a temporary leave or a reduced‑intensity schedule with your employer and oncology team.  \n\nYour team will adjust the plan as needed, so let them know how you’re feeling each week.",
          "order": 5,
          "qid": "S12-Q05"
        },
        {
          "q": "How do I eat when everything burns?",
          "gt": "I hear how frightening it feels that every bite could feel like a burn, especially when your voice and your joy are tied so closely to your ability to eat and sing.\n\n**What to expect and how to manage it**  \nDuring chemoradiation the base‑of‑tongue mucosa often develops mucositis that peaks around week 2–3, producing burning, pain, and difficulty swallowing.  \n**Diet tweaks** – aim for soft, pureed, or very finely chopped foods. Use smoothies, soups, mashed potatoes, and yogurt. Keep foods cool or at room temperature; avoid hot, cold, spicy, acidic, or rough‑textured items that can sting.  \n**Hydration & comfort** – sip ice‑cold water or diluted fruit juice, and use ice chips to soothe the mouth. A mild mouth rinse (e.g., 0.12% chlorhexidine) and a topical lidocaine gel can reduce pain.  \n**Oral care** – brush gently with a soft‑bristle brush, use alcohol‑free mouthwash, and avoid tobacco or alcohol.  \n**When to call** – if pain prevents you from eating, if you lose >5 % of body weight, or if you notice severe swelling or bleeding, contact your oncology team immediately. In some cases a temporary feeding tube (NG or PEG) may be needed to maintain nutrition while your mouth heals.\n\nWe’ll monitor your oral health closely and adjust pain control and nutrition support as needed, so you can keep singing and leading with confidence.",
          "order": 6,
          "qid": "S12-Q06"
        },
        {
          "q": "Will I ever sing a solo again?",
          "gt": "I hear how frightening it feels to think your voice might be gone, especially when singing is your livelihood and joy. That worry is completely understandable.\n\nChemoradiation for a tongue‑base tumor usually involves 70 Gy of radiation delivered in 35 fractions over 7 weeks, combined with weekly cisplatin 40 mg/m² (or carboplatin AUC 5) and 5‑FU 1000 mg/m² days 1‑5. You’ll have weekly blood counts, electrolytes, and hearing checks, plus a speech‑language pathologist (SLP) visit at the start, mid‑treatment, and after completion. Acute mucositis and xerostomia peak 1–3 weeks into therapy; swallowing and voice changes are most noticeable during this period. Most patients experience a gradual return of vocal function over 3–6 months, though some may have lingering hoarseness or reduced range. Early voice rest, hydration, and targeted SLP exercises can accelerate recovery. In rare cases where the tumor or treatment causes irreversible vocal fold damage, a laryngectomy or voice prosthesis may be considered, but this is uncommon.\n\nWith diligent follow‑up, speech therapy, and your own determination, many singers regain the ability to perform solos, sometimes with a slightly altered timbre. Your oncology team will monitor your progress closely and adjust the plan if needed.",
          "order": 7,
          "qid": "S12-Q07"
        },
        {
          "q": "What happens to my teeth with all this radiation?",
          "gt": "I hear how scary it feels to think about losing your voice and your smile at the same time—especially when singing is such a big part of who you are.\n\nRadiation to the base of the tongue usually delivers 60–70 Gy to the oral cavity, which can damage the salivary glands and leave you with chronic dry mouth (xerostomia). Less saliva means bacteria can thrive, so you’ll see an increased risk of tooth decay, enamel erosion, and even gum disease. Chemotherapy (often cisplatin or carboplatin) can worsen mucosal irritation and make it harder to keep the mouth clean. To protect your teeth, most teams schedule a dental evaluation 2–4 weeks before treatment starts. Your dentist will clean the teeth, seal cavities, and may recommend fluoride varnish or high‑concentration fluoride toothpaste. If any teeth are severely decayed or infected, they’ll be extracted before radiation to prevent infection later. During treatment, you’ll get monthly dental check‑ups, use a chlorhexidine mouthwash, and avoid sugary foods. After radiation, regular dental visits every 3–6 months and continued fluoride use help keep decay at bay. If you notice pain, swelling, or a sore spot, call your oncology team right away—early treatment can prevent complications like osteoradionecrosis.",
          "order": 8,
          "qid": "S12-Q08"
        },
        {
          "q": "If I choke on water one day, is that the new normal?",
          "gt": "I hear how frightening it feels to think that choking on a sip of water could become a daily reality, especially when your voice is the heart of your work and joy.\n\nChemoradiation for a base‑of‑tongue tumor usually involves 70 Gy of radiation over 7 weeks with concurrent cisplatin (100 mg/m² every 3 weeks) or a carboplatin‑based regimen. During treatment, mucositis and swelling can narrow the airway and make swallowing difficult. It’s common to feel a “tight” sensation or to cough when drinking. Most patients experience this acutely, and it often improves as the mucosa heals over the next 4–6 weeks after therapy ends. A speech‑language pathologist will evaluate you weekly, and you’ll receive dietary counseling and swallowing exercises to reduce aspiration risk. If you choke again or feel a sudden change in swallowing, call your oncology team immediately for a swallow study; a temporary feeding tube may be needed while you recover.  \n\nYour voice and swallowing can recover, but it may take months. Working closely with your team—oncologist, radiation therapist, speech therapist, and dietitian—will help you adapt and regain function.",
          "order": 9,
          "qid": "S12-Q09"
        },
        {
          "q": "How will you check if the cancer is gone without another surgery?",
          "gt": "I hear how frightening it must feel to wonder if the tumor is truly gone, especially when your voice is your livelihood and joy.  \n\nAfter chemoradiation—typically cisplatin or carboplatin with radiation—the first check is usually at about 3 months. A flexible laryngoscopy lets the team look directly at the base of the tongue, assess mucosal healing, and spot any residual mass. A quick voice evaluation also helps gauge functional recovery.  \n\nImaging follows. An MRI of the head and neck at 3–4 months gives a detailed view of tissue changes, while a PET‑CT at the same time looks for metabolic activity that would suggest remaining cancer; a negative PET‑CT is a strong indicator of remission.  \n\nIf either laryngoscopy or imaging shows a suspicious area, a targeted biopsy—usually done transorally or with endoscopic ultrasound—is the definitive way to confirm that no viable tumor cells remain.  \n\nAfter that, repeat laryngoscopy and imaging at 6 months, 12 months, then annually for 5 years, while monitoring for late side‑effects like xerostomia or dysphagia. If residual disease is found, options include re‑irradiation, salvage surgery, or systemic therapy.  \n\nWe’ll keep a close eye on your progress, and together we’ll adjust the plan as needed to protect both your health and your voice.",
          "order": 10,
          "qid": "S12-Q10"
        }
      ]
    },
    {
      "id": "S13",
      "title": "Choice overload (early ER+/PR+ HER2- breast cancer)",
      "diagnosis": "Early-stage hormone receptor–positive, HER2-negative breast cancer",
      "treatment_plan": "Breast-conserving surgery plus radiation or mastectomy; adjuvant endocrine therapy; chemotherapy guided by genomic risk when indicated",
      "narrative": "I'm 41, engaged, and deciding between lumpectomy with radiation or mastectomy. I want to live, look like myself in photos, and still feel like me.",
      "qa": [
        {
          "q": "Is survival the same with lumpectomy plus radiation versus mastectomy, or am I gambling?",
          "gt": "I hear how frightening the idea of choosing between a lumpectomy with radiation and a mastectomy feels, especially when you’re already juggling so many thoughts about your future and your partner’s support.\n\nFor most early‑stage (I–II) breast cancers, large randomized trials and long‑term follow‑up show that overall survival with breast‑conserving therapy (lumpectomy + whole‑breast radiation) is essentially identical to that with a mastectomy, provided the surgical margins are clear and the tumor biology is favorable. Local‑recurrence rates are slightly higher after lumpectomy (≈2–4 % over 10 years) but are effectively managed with radiation and rarely impact overall survival. Mastectomy eliminates the need for daily radiation, but it carries its own surgical risks and, if reconstruction is desired, additional procedures and recovery time. Your oncologist will review your tumor size, nodal status, hormone receptor/HER2 status, and genetic risk to tailor the recommendation. Regular follow‑up (clinical exam, mammogram or MRI of the contralateral breast, and routine blood work) is the same for both paths, with adjustments for any adjuvant chemotherapy or targeted therapy you receive.\n\nWe’ll work together to weigh these factors and choose the plan that keeps you healthy while honoring how you want to look and feel.",
          "order": 1,
          "qid": "S13-Q01"
        },
        {
          "q": "Do I need chemo, or can a test spare me? Waiting for results is torture.",
          "gt": "I hear how anxious you feel about the wait, especially when you’re already juggling so many decisions for your future and your loved ones.\n\nYour oncologist will decide on chemotherapy based on several factors: tumor size, grade, lymph‑node status, hormone‑receptor (ER/PR) and HER2 status, and a genomic assay (e.g., Oncotype DX or MammaPrint).  \nIf the tumor is small, node‑negative, low‑grade, and the genomic score is low (≤18), the test often shows that chemo can be safely omitted.  \nIf the score is high (>30) or the tumor is HER2‑positive, a standard regimen is usually recommended:  \n• Anthracycline + cyclophosphamide (AC) 4 cycles, 3 weeks apart (doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m² IV)  \n• Followed by a taxane (paclitaxel 80 mg/m² IV weekly for 12 weeks or docetaxel 75 mg/m² IV every 3 weeks for 6 cycles).  \nMonitoring: CBC and liver tests before each cycle; an echocardiogram if cumulative anthracycline dose > 300 mg/m²; and routine blood work during taxane therapy.  \nSide effects include fatigue, nausea, neuropathy, and hair loss; most resolve within a few weeks after treatment ends.  \nIf your tumor is HER2‑positive, trastuzumab (Herceptin) for 1 year is added, regardless of chemo.  \nRadiation is required after lumpectomy unless you choose mastectomy; mastectomy may spare radiation but does not change the chemo decision if indicated.  \n\nYour team will review the test results and tailor the plan—so you’ll know exactly whether chemo is needed and what to expect next.",
          "order": 2,
          "qid": "S13-Q02"
        },
        {
          "q": "Will endocrine therapy make me feel old overnight?",
          "gt": "I hear how scary the idea of “feeling old overnight” feels, especially when you’re already juggling so many big decisions about surgery and your future.\n\n**What endocrine therapy does and how it feels**  \n- **Tamoxifen** (20 mg daily) is the usual choice for pre‑menopausal women, while **aromatase inhibitors** (letrozole, anastrozole, or exemestane 2.5 mg daily) are used for post‑menopausal patients.  \n- The treatment runs for 5–10 years, not a single night.  \n- Common side effects appear gradually: hot flashes, mild fatigue, mood swings, joint aches, and a small increase in bone loss. Most people notice these changes over weeks to months, not instantly.  \n- Blood tests (CBC, liver enzymes, lipids) and a bone‑density scan are usually done every 6–12 months to catch any problems early.  \n\n**Managing the “old‑feeling”**  \n- Lifestyle tweaks—regular exercise, a balanced diet, adequate sleep, and stress‑reduction techniques—can blunt hot flashes and fatigue.  \n- Calcium/vitamin D supplements and, if bone loss is significant, bisphosphonates or denosumab can protect bone health.  \n- If a side effect becomes bothersome, your oncologist can adjust the dose or switch to a different agent.\n\nSo, endocrine therapy won’t make you feel old overnight; it’s a gradual process that can be monitored and managed. Discuss these details with your oncology team to tailor the plan to how you feel and what’s best for your body.",
          "order": 3,
          "qid": "S13-Q03"
        },
        {
          "q": "Can I preserve fertility before treatment without losing precious time?",
          "gt": "I hear how anxious you feel about juggling cancer treatment and the future of your family, especially when you’re already planning a life together.\n\nFertility preservation can usually be done **before** you start chemotherapy, so it doesn’t delay your cancer care. The most common options are:\n\n1. **Embryo or oocyte freezing** – you’ll undergo a 2‑week ovarian stimulation cycle (using FSH and letrozole), then egg retrieval on day 5–6. The eggs or embryos are frozen immediately. This adds about 2–3 weeks before chemo, but you can have your lumpectomy or mastectomy first; the surgery schedule isn’t usually affected.  \n2. **Ovarian tissue cryopreservation** – a single laparoscopic procedure that can be done right after surgery, with no extra delay. It’s experimental but has led to live births.  \n3. **GnRH‑agonist (triptorelin) suppression** – given during chemotherapy to protect ovarian function; it requires no extra time before chemo.\n\nAt age 41, live‑birth rates per cycle are lower (≈10–20 %), so a fertility specialist can tailor the plan and discuss costs and insurance. Talk with your oncologist and a reproductive endocrinologist as soon as possible—this way you can preserve fertility while keeping your treatment timeline on track.",
          "order": 4,
          "qid": "S13-Q04"
        },
        {
          "q": "I’m terrified of recurrence—how will follow-up actually catch something early?",
          "gt": "I hear how frightening the thought of cancer returning feels, especially when you’re already juggling so much for your future and your loved ones—your worries are completely understandable.\n\nAfter a lumpectomy with radiation, your follow‑up plan is very similar to that after a mastectomy, because the goal is the same: catch any return of disease as early as possible.  \n• **Physical exams**: every 3–6 months for the first 2 years, then annually.  \n• **Imaging**: a mammogram of the remaining breast (or the contralateral breast if you had a mastectomy) every year; if you’re at higher genetic or family risk, add an annual breast MRI.  \n• **Ultrasound**: used only if a lump or abnormality is felt or seen on exam.  \n• **Blood tests**: not routine for surveillance, but your oncologist may order tumor markers (e.g., CA 15‑3) if clinically indicated.  \n• **Symptoms**: any new breast lump, skin changes, nipple discharge, or unexplained pain should prompt immediate imaging.  \n• **Distant recurrence**: usually detected when symptoms arise; routine CT or PET scans are not part of standard surveillance unless you have symptoms or high‑risk features.\n\nBecause the biology of the tumor, not the surgery type, drives recurrence risk, the surveillance schedule is the same for both options. Early detection through these exams and imaging gives the best chance for curative treatment if recurrence does occur.  \n\nRemember, your oncology team will adjust the plan as needed, and we’ll keep a close eye on any changes.",
          "order": 5,
          "qid": "S13-Q05"
        },
        {
          "q": "What about reconstruction if I choose mastectomy—will it feel like me?",
          "gt": "I hear how anxious you feel about whether reconstruction will let you feel like yourself, especially when you’re already juggling so many responsibilities.  \n\nIf you choose mastectomy, reconstruction can be done immediately or delayed. Immediate reconstruction uses a tissue expander that is later replaced with a permanent implant, or an autologous flap (TRAM, DIEP, or latissimus) that uses your own tissue. Delayed reconstruction is often preferred if you’ll need post‑mastectomy radiation, because radiation can compromise implant integrity.  \n\nSensation is a key concern. Implant‑based reconstruction typically offers limited breast sensation, but nerve coaptation techniques—connecting intercostal nerves to the implant pocket—can improve tactile feedback over 6–12 months. Autologous flaps usually retain more natural sensation because the transferred tissue contains its own nerve supply, and surgeons can perform nerve grafts to enhance feeling.  \n\nMost patients report a strong sense of identity after reconstruction, especially when the shape, symmetry, and skin texture closely match their pre‑surgery appearance. Psychological support and realistic expectations are essential; your plastic surgeon will tailor the plan to your anatomy, lifestyle, and any adjuvant therapies.  \n\nYour surgical team will guide you through each step so you can feel confident and supported.",
          "order": 6,
          "qid": "S13-Q06"
        },
        {
          "q": "Can I keep wedding plans, or should we postpone?",
          "gt": "I hear how anxious you feel about juggling a life‑changing surgery with a wedding you’ve already planned—especially when you’re trying to stay strong for your fiancé and family.\n\n**What to expect with each option**\n\n- **Lumpectomy + radiation**: The surgery takes a day, and you’ll need about 5–7 weeks of daily 2‑hour radiation sessions (≈ 50 Gy total). You’ll usually be back home within 1–2 weeks, but the radiation schedule will likely push the wedding date by at least 6 weeks. You’ll need to wear a breast‑support garment during treatment and may experience fatigue, skin irritation, and temporary breast swelling.\n\n- **Mastectomy (with or without reconstruction)**: The operation lasts 2–3 hours. If you opt for immediate reconstruction, you’ll need 6–12 weeks for the incision to heal and for the implant or flap to settle. If you choose delayed reconstruction, you can schedule it after the initial recovery (≈ 4–6 weeks). In either case, you’ll be home in 2–4 weeks, but the healing period may still delay the wedding by 4–8 weeks.\n\n**Practical steps**\n\n1. Discuss your wedding date with your surgeon and oncologist. They can give you a realistic timeline based on your specific surgical plan and any adjuvant therapies.  \n2. If you’re leaning toward lumpectomy, consider postponing the wedding until after radiation finishes; many couples reschedule to a few months later.  \n3. If you choose mastectomy, you can keep the wedding date if you’re comfortable with a slightly shorter recovery period, but you’ll likely need a buffer for healing and any reconstruction.\n\n**Bottom line**\n\nYou can keep the wedding plans, but you’ll almost certainly need to shift the date by 4–8 weeks to allow for surgery, radiation, and healing. Your care team will help you map out the exact timeline and keep you informed every step of the way.",
          "order": 7,
          "qid": "S13-Q07"
        },
        {
          "q": "Will exercise help, or am I supposed to rest?",
          "gt": "I hear how anxious you feel about staying strong while deciding between treatments, especially when you’re already juggling so much for your future and your partner’s support.\n\nAfter a lumpectomy or mastectomy, gentle movement is actually encouraged to promote circulation, reduce swelling, and ease recovery. In the first 24–48 hours, rest is key—avoid heavy lifting or strenuous activity. From day 3 onward, short walks (5–10 minutes) and light stretching are safe, and most surgeons recommend resuming normal daily activities within 1–2 weeks, provided the incision feels healed and pain is manageable. If you choose lumpectomy with radiation, keep the same gentle routine during each 20–30 minute radiation session; avoid vigorous exercise on the same day to prevent skin irritation. For mastectomy, the first 2–4 weeks should focus on rest and gentle shoulder mobility; heavy lifting or high‑impact sports should wait until your surgeon clears you, usually around 6–8 weeks.\n\nWatch for warning signs—persistent pain, redness, swelling, or a feeling of heaviness in the arm. If any of these occur, contact your surgical team immediately. Discuss a personalized activity plan with your surgeon or a physiotherapist; they’ll tailor recommendations to your specific incision, reconstruction plan, and overall health. \n\nRest and movement can coexist—your recovery team will guide you through the right balance.",
          "order": 8,
          "qid": "S13-Q08"
        },
        {
          "q": "Do I have to take pills for 5 years no matter what?",
          "gt": "I hear how anxious you feel about the long‑term pill routine, especially when you’re already juggling so many decisions about your future and how you’ll look and feel.\n\nWhether you’ll need a five‑year course of hormone‑therapy pills depends on the biology of your cancer, not on whether you choose lumpectomy + radiation or mastectomy. If your tumor is estrogen‑ or progesterone‑receptor positive (the most common scenario), most guidelines recommend either 5 years of tamoxifen (oral 20 mg daily) or, for women who are post‑menopausal, 5 years of an aromatase inhibitor (exemestane 25 mg daily or anastrozole 1 mg daily). These drugs reduce the risk of recurrence and are taken regardless of the surgical approach. If your tumor is hormone‑receptor negative, endocrine therapy isn’t indicated. HER2‑positive cancers receive trastuzumab (or pertuzumab) for 1 year, but that’s separate from hormone pills.\n\nMonitoring while on tamoxifen or an aromatase inhibitor includes:\n- Blood counts and liver function tests every 3–6 months\n- Bone density scans annually (especially with aromatase inhibitors)\n- Symptom check‑ins for hot flashes, mood changes, or vaginal dryness\n\nIf you’re on tamoxifen and develop a serious side effect (e.g., thromboembolism), your oncologist can switch you to an aromatase inhibitor or stop therapy early, but that decision is individualized.\n\nYour surgical choice won’t change the need for endocrine therapy if your tumor is hormone‑positive. Discuss your tumor’s receptor status with your oncologist; that will give you the definitive answer for your pill plan.",
          "order": 9,
          "qid": "S13-Q09"
        },
        {
          "q": "How do I explain all this to future in-laws without becoming 'the sick bride'?",
          "gt": "I hear how anxious you feel about sharing your cancer journey with your future in‑laws, especially when you want to stay strong and not be seen as a “sick bride.”  \n\n**How to frame it**  \n1. Keep it factual and brief: “I was diagnosed with early‑stage breast cancer. My doctor recommended either a lumpectomy with radiation or a mastectomy. I chose the option that best preserves my appearance and long‑term health.”  \n\n2. Emphasize empowerment: “I’m making an informed decision to protect my health and to look like myself in photos. It’s a proactive step, not a sign of weakness.”  \n\n3. Use a simple, reassuring script: “I’m undergoing treatment to keep my health safe and to maintain my appearance. I’ll be fine and look great in the wedding photos.”  \n\n4. If they ask questions, say: “I’m working closely with my oncologist, and I’ll keep you updated. I’m not sick; I’m taking care of my health so I can be present for the wedding.”  \n\n5. Let your partner help frame it as a joint decision, reinforcing that you’re both in control.  \n\nYou’re in control, and your future in‑laws will appreciate your strength and clarity.",
          "order": 10,
          "qid": "S13-Q10"
        }
      ]
    },
    {
      "id": "S14",
      "title": "Miles to go (metastatic left-sided RAS wild-type colon cancer)",
      "diagnosis": "Metastatic colorectal cancer, left-sided, RAS wild-type",
      "treatment_plan": "Backbone chemo (e.g., FOLFOX or FOLFIRI) with targeted therapy (anti-EGFR or bevacizumab) based on goals and side-effect profile; consider liver-directed options if response",
      "narrative": "I'm 52, a sales rep living on the road. I need a plan that controls cancer without wrecking my ability to drive and meet clients.",
      "qa": [
        {
          "q": "How do we pick between regimens when every option sounds like a trade-off?",
          "gt": "I hear how anxious you feel about picking a regimen that keeps you on the road, especially when every option feels like a trade‑off.\n\nWhen choosing a cancer plan, the oncologist weighs three pillars: **efficacy for your specific tumor**, **side‑effect profile that won’t impair driving or client meetings**, and **treatment logistics** (oral vs. infusion, frequency, and recovery time).  \n- **Oral targeted agents** (e.g., CDK4/6 inhibitors for hormone‑positive breast cancer, EGFR inhibitors for lung cancer) give you 1‑2 hour daily doses that fit a travel schedule and usually cause fatigue or mild rash, not the severe neuropathy or cardiotoxicity that can limit driving.  \n- **Immunotherapy** (pembrolizumab, nivolumab) is given every 2–3 weeks, with infusions lasting 30–60 minutes; the main risks are immune‑related fatigue and mild colitis, which can be managed with steroids and rarely require stopping treatment.  \n- **Traditional chemotherapy** (FOLFOX, CAPOX, carboplatin/paclitaxel) often produces neuropathy, myelosuppression, and longer recovery, so it’s usually reserved for when the tumor is aggressive or other options are unsuitable.\n\n**Monitoring**: CBC and CMP every 2 weeks; echocardiogram every 3 months if you’re on trastuzumab or a cardiotoxic agent; neuropathy checks at each visit; and imaging every 8–12 weeks to gauge response (tumor shrinkage or marker decline).  \n\nIf a side effect threatens your ability to drive, dose reductions, supportive meds (anti‑nausea, neuropathy pain relievers), or a switch to a less toxic agent are common next steps.  \n\nYour oncologist will tailor this plan to your tumor biology and lifestyle, so keep the conversation open—your voice is key in balancing control and mobility.",
          "order": 1,
          "qid": "S14-Q01"
        },
        {
          "q": "If I get the anti-EGFR drug and my face breaks out, am I stuck hiding at home?",
          "gt": "I hear how anxious you feel about the possibility of a severe facial rash, especially when you’re on the road meeting clients and need to look your best. It’s completely understandable to worry that a side‑effect could force you to stay home.\n\nAnti‑EGFR agents such as **cetuximab** (IV 400 mg/m² loading dose, then 250 mg/m² weekly) or **panitumumab** (IV 6 mg/kg every 2 weeks) are known to cause a papulopustular rash that typically appears 7–10 days after starting therapy. The rash is usually limited to the face, scalp, and upper torso, and most patients can continue driving and traveling once the skin is managed. Your oncologist will monitor you with a physical exam and blood work every 2–4 weeks during the first 2–3 cycles, then monthly. If the rash is mild (grade 1–2), you can treat it with a gentle cleanser, a low‑potency topical steroid (e.g., hydrocortisone 1 % cream), and oral doxycycline 100 mg twice daily for 2–4 weeks. For more intense rash (grade 3), a brief interruption of the anti‑EGFR drug and a higher‑potency steroid (e.g., clobetasol 0.05 %) may be needed, but this usually lasts only a few days.\n\nYou can keep meeting clients while the rash is under control; just avoid extreme heat, harsh soaps, or excessive sun exposure. If the rash becomes painful or you develop fever, contact your oncology team right away. Discuss with them whether a dose reduction or temporary pause is appropriate—most patients resume therapy once the skin improves.\n\nYour team will monitor the rash closely and adjust treatment as needed, so you won’t have to stay home unless the skin reaction is severe and painful.",
          "order": 2,
          "qid": "S14-Q02"
        },
        {
          "q": "Will neuropathy make it unsafe to drive?",
          "gt": "I hear how unsettling it feels to wonder if your neuropathy could put you and others at risk on the road, especially when driving is a core part of your job.\n\nChemotherapy‑induced neuropathy can impair the sensory feedback needed for safe driving—especially foot sensation for braking and hand vibration sense for steering. The American Society of Clinical Oncology (ASCO) notes that patients with **Grade 2 or higher** sensory neuropathy (moderate symptoms that interfere with daily activities) should avoid driving until symptoms improve. Mild, Grade 1 neuropathy (asymptomatic or only mild tingling) typically does not preclude driving, but it still warrants caution.\n\nA practical assessment can help: a neurologic exam (pin‑prick, vibration, reflexes), a simple reaction‑time test, and, if available, a driving simulator or occupational‑therapy evaluation. These tests gauge whether your foot‑to‑brake and hand‑to‑steering responses are within safe limits.\n\nIf neuropathy is progressing, your oncologist may reduce the dose, switch to a less neurotoxic agent, or add neuroprotective medications (e.g., duloxetine, gabapentin, or vitamin B12). Regular follow‑ups every 2–4 weeks during treatment can track changes and guide adjustments.\n\nDiscuss these concerns with your oncology team; they can coordinate a safety plan, possibly including a formal driving assessment, so you can keep traveling while protecting everyone’s safety.",
          "order": 3,
          "qid": "S14-Q03"
        },
        {
          "q": "Can the liver spots ever be removed, or is that false hope?",
          "gt": "I hear how anxious you feel about every change in your body, especially when you’re already juggling a demanding travel schedule and a cancer diagnosis—those worries are completely understandable.\n\nLiver spots (solar lentigines) are benign, age‑related pigmentations that can be safely removed if you choose. The most common, evidence‑based methods are laser therapy (e.g., Q‑switched Nd:YAG or pulsed dye laser), cryotherapy, or topical depigmenting agents such as 4‑hexylresorcinol. Laser treatment usually takes 5–10 minutes per session, with 1–3 sessions spaced 4–6 weeks apart. Cryotherapy is quick (a few seconds per spot) but may leave a temporary blister or hypopigmentation that fades over 2–4 weeks. Topical creams require daily application for 6–12 weeks and are less invasive but may take longer to see results. All procedures carry minimal risk of scarring or pigment changes, and recovery is typically short enough that you can resume driving and client meetings the next day. Discuss the best option with your dermatologist or oncologist to ensure it fits your overall treatment plan and schedule.",
          "order": 4,
          "qid": "S14-Q04"
        },
        {
          "q": "Cold drinks triggering pain—does that mean I’m stuck sipping lukewarm forever?",
          "gt": "I hear how frustrating it feels to have your daily routine disrupted by pain, especially when you’re on the road and need to stay sharp for clients.\n\nCold‑triggered pain often points to chemotherapy‑induced neuropathy or oral mucositis. It doesn’t mean you’re doomed to sip only lukewarm drinks forever. First‑line options include:\n\n1. **Neuropathic pain meds** – duloxetine (Cymbalta) 30 mg daily, titrated to 60 mg, or gabapentin 300 mg three times a day, can blunt cold‑sensation.  \n2. **Topical lidocaine** – 2 % gel or mouthwash applied before drinking can numb the oral mucosa for 30–60 min.  \n3. **Oral care** – use a soft‑bristled brush, avoid acidic or very cold foods, and rinse with a mild saline solution after meals.  \n4. **Dietary tweaks** – keep a small cooler with room‑temperature water or use a thermos that maintains a mild temperature; you can also sip through a straw to reduce direct contact with cold surfaces.\n\nYour oncologist can tailor doses, monitor for side effects (e.g., dizziness with duloxetine, renal dosing for gabapentin), and adjust chemotherapy schedules if neuropathy worsens. With these measures, you can keep driving and meeting clients while keeping pain manageable.",
          "order": 5,
          "qid": "S14-Q05"
        },
        {
          "q": "How often will I be tethered to an infusion pump?",
          "gt": "I hear how anxious the idea of being tied to an infusion pump feels, especially when you’re juggling client meetings and long drives every day.\n\nMost systemic therapies for solid tumors are given in cycles. For example, a common regimen for metastatic breast or lung cancer might be docetaxel 75 mg/m² IV over 1–2 hours every 3 weeks, followed by trastuzumab 8 mg/kg IV over 90 minutes every 3 weeks. Each infusion requires you to stay in the clinic (or at home if a portable pump is arranged) for the duration of the IV run, but you’re free to drive once the infusion is finished. If your oncologist switches to an oral maintenance phase—such as capecitabine 1,250 mg/m² twice daily for 14 days on, 7 days off—you’ll no longer need a pump at all.\n\nMonitoring is routine: CBC and CMP before each cycle, and an echocardiogram every 3 months if you’re on trastuzumab. If you’re on a home‑infusion program, the nurse will check the pump and your vitals, and you’ll still need to be near the infusion site during the run. Discuss with your team whether a portable pump or an oral alternative could fit your travel schedule. \n\nYour oncologist can tailor the exact schedule and monitoring plan to keep you on the road while keeping the cancer under control.",
          "order": 6,
          "qid": "S14-Q06"
        },
        {
          "q": "What if my bowels go haywire on a client visit?",
          "gt": "I hear how anxious you feel about a sudden bowel flare‑up on a client visit, especially when you’re on the road and need to stay sharp for meetings.\n\n**What to expect and how to manage it**  \nIf your treatment includes 5‑FU/oxaliplatin (FOLFOX) or 5‑FU/irinotecan (FOLFIRI), diarrhea can start within 24–48 h of infusion. 5‑FU is given as a 48‑hour continuous infusion, oxaliplatin 2–3 h, irinotecan 90 min.  Be on hand with a “bowel kit”: loperamide 2 mg before the first dose, then 2 mg after each loose stool; oral rehydration salts (ORS) and an electrolyte solution for 2–3 L/day if you have >3 stools/day.  Monitor CBC and electrolytes before each cycle; keep a stool diary and call your oncologist if you notice blood, fever, or >3 stools/day for 24 h.  \n\n**Practical steps for client visits**  \n- Schedule meetings when you’re likely to have a restroom nearby.  \n- Carry a small bag with loperamide, ORS, a reusable water bottle, and a discreet “bowel‑management” note for the client’s office.",
          "order": 7,
          "qid": "S14-Q07"
        },
        {
          "q": "Do second opinions slow me down or strengthen my plan?",
          "gt": "I hear how anxious and frustrated you feel about balancing aggressive cancer care with a demanding travel schedule—your determination to keep driving and meeting clients is completely understandable.\n\nA second opinion can actually strengthen your plan, but it can also add a few weeks of waiting time. Most oncologists recommend getting a second view before you start systemic therapy, especially if the first plan involves high‑toxicity drugs (e.g., anthracyclines, taxanes, or high‑dose steroids) that could impair concentration or cause neuropathy. A second specialist can confirm the diagnosis, suggest alternative regimens with fewer side‑effects (such as HER‑2‑targeted therapy alone, or a less neurotoxic chemotherapy backbone), and tailor monitoring schedules—CBC and LFTs every 2–3 weeks, echocardiogram every 3 months if you’re on trastuzumab, and baseline neuro‑toxicity assessment. If the second opinion arrives within 2–4 weeks, you can still start treatment on schedule; a delay beyond that may postpone the first cycle and could affect early tumor control.\n\nTo minimize downtime, consider a tele‑oncology review: upload your pathology, imaging, and labs to a secure portal, and schedule a video consult. Most insurers cover a second opinion, and many centers have dedicated coordinators who can arrange travel‑friendly appointments or local labs for blood work.\n\nYour team can keep you on track while ensuring the therapy you choose won’t compromise your ability to drive safely.",
          "order": 8,
          "qid": "S14-Q08"
        },
        {
          "q": "How do you know when to switch before the scan says so?",
          "gt": "I hear how frightening it feels to juggle treatment and driving, especially when you’re on the road for work—your worries are completely understandable.\n\nIn practice, oncologists look for early signs of progression before a scan confirms it.  \n1. **Biomarkers & symptoms** – If a tumor marker (e.g., PSA, CEA, or CA‑125) rises by >25 % from baseline or you notice new pain, fatigue, or weight loss, that’s a red flag.  \n2. **Routine labs** – CBC, CMP, and cardiac panels are checked every 4 weeks. For agents like anthracyclines or HER‑2 inhibitors, an echocardiogram is done every 3 months to monitor LVEF.  \n3. **Imaging schedule** – Most protocols call for CT or MRI every 8–12 weeks; if labs or symptoms worsen, the oncologist may order an earlier scan.  \n4. **Side‑effect thresholds** – If neuropathy, cardiotoxicity, or severe fatigue interferes with driving, a dose reduction or switch to a less neurotoxic agent (e.g., from paclitaxel to docetaxel) is considered.  \n5. **Switching strategy** – For targeted therapy (e.g., osimertinib in EGFR‑mutant NSCLC) you might move to platinum‑based chemo if progression is suspected. For hormone‑responsive breast cancer, a change from aromatase inhibitor to fulvestrant or chemotherapy is typical.  \n\nAlways discuss any change with your oncologist; they’ll tailor the timing and choice to your specific disease, side‑effect profile, and need to keep you on the road.",
          "order": 9,
          "qid": "S14-Q09"
        },
        {
          "q": "Is it okay to keep small goals, like hitting my sales summit, or is that denial?",
          "gt": "I hear how anxious you feel about juggling a cancer diagnosis with the demands of a traveling sales career—especially when you’re trying to stay sharp for your clients and your own sense of purpose.\n\n**Treatment options that preserve mobility**  \n1. **Oral targeted agents** (e.g., tyrosine‑kinase inhibitors like erlotinib or HER2‑directed drugs such as lapatinib) are taken at home, so you can drive and meet clients without frequent clinic visits.  \n2. **Immunotherapy** (PD‑1/PD‑L1 inhibitors such as pembrolizumab or nivolumab) is given every 2–3 weeks by IV infusion, typically lasting 30–60 minutes; most patients resume normal activities the next day.  \n3. **Low‑dose oral chemotherapies** (capecitabine, temozolomide) can be scheduled around travel, with routine CBCs every 2–3 weeks and liver panels monthly.  \n4. **Monitoring**:  \n   * CBC, CMP, and tumor markers every 3 weeks.  \n   * Cardiac ejection fraction (echo or MUGA) every 3 months if you’re on HER2‑targeted therapy.  \n   * Symptom diary for fatigue, neuropathy, or dizziness—report any new or worsening symptoms immediately.  \n\nIf a drug causes significant fatigue or neuropathy, your oncologist can adjust the dose or switch to a less burdensome agent.  \n\n**Small goals are not denial**—they’re a healthy coping strategy that keeps you motivated and grounded while your treatment proceeds.  \n\nYour oncologist can tailor this plan to your specific cancer type and keep you safe on the road.",
          "order": 10,
          "qid": "S14-Q10"
        }
      ]
    },
    {
      "id": "S15",
      "title": "Sun runner (BRAF V600E metastatic melanoma)",
      "diagnosis": "BRAF V600E positive metastatic melanoma",
      "treatment_plan": "Immunotherapy and/or targeted BRAF/MEK inhibitors depending on goals and disease features",
      "narrative": "I'm 39, a trail runner with metastatic melanoma. I want to keep moving and not lose months to side effects if there’s a path that fits me.",
      "qa": [
        {
          "q": "How do we choose between immunotherapy and targeted pills without gambling my best shot?",
          "gt": "I hear how anxious you feel about picking the right path, especially when you’re eager to keep running and avoid months of debilitating side‑effects.\n\n**Choosing the right therapy**  \n1. **Mutation status** – If your tumor has a BRAF V600 mutation, a BRAF inhibitor (vemurafenib or dabrafenib) plus a MEK inhibitor (trametinib or cobimetinib) can shrink lesions quickly (median response ~6 weeks). Side‑effects include rash, fever, and, rarely, cardiac changes; you’ll need a baseline and quarterly echocardiogram.  \n2. **Immunotherapy** – Anti‑PD‑1 agents (nivolumab 240 mg IV every 2 weeks or pembrolizumab 200 mg IV every 3 weeks) work in 40–50 % of patients and can produce durable responses, but they may take 4–8 weeks to show benefit. Common toxicities are fatigue, rash, colitis, and pneumonitis; you’ll have regular CBCs, CMPs, and prompt evaluation of any new symptoms.  \n3. **Speed vs. durability** – If you need rapid tumor control (e.g., symptomatic brain mets), start targeted therapy. If you’re in good performance status and can tolerate a longer ramp‑up, immunotherapy may offer longer‑term benefit.  \n4. **Monitoring** – Imaging every 8–12 weeks, labs every 2–4 weeks, and a clear “red‑flag” list (fever, diarrhea, shortness of breath) will guide adjustments.  \n5. **Next steps** – If progression occurs, you can switch to the other modality or add a second agent (e.g., ipilimumab with nivolumab) after discussion with your oncologist.\n\nWe’ll tailor the plan to your mutation profile, performance status, and how you feel about side‑effects, and we’ll keep a close eye on any changes.",
          "order": 1,
          "qid": "S15-Q01"
        },
        {
          "q": "What side effects stop runs versus ones I can work around?",
          "gt": "I hear how anxious you feel about keeping your running routine, especially when the fear of a sudden side‑effect could halt your progress—your determination is truly inspiring.\n\n**Side effects that usually stop running (grade 3–4 or severe):**  \n- **Severe fatigue** (often from immunotherapy like nivolumab 240 mg IV q2 weeks or pembrolizumab 200 mg IV q3 weeks).  \n- **Neuropathy** or **musculoskeletal pain** (common with BRAF/MEK combos: dabrafenib 150 mg PO BID + trametinib 2 mg PO daily).  \n- **Cardiotoxicity** (LVEF < 50 % or symptomatic heart failure).  \n- **Severe edema** or **skin ulceration** (rash or blistering from targeted therapy).  \n- **Severe GI upset** (diarrhea, nausea) that leads to dehydration.\n\n**Side effects you can often work around:**  \n- Mild fatigue, arthralgia, or rash—use pacing, rest days, and topical steroids or antihistamines.  \n- Mild neuropathy or edema—compression sleeves, physiotherapy, and dose‑holding if needed.  \n- Mild GI symptoms—anti‑emetics, anti‑diarrheals, and dietary adjustments.\n\n**Monitoring & next steps:**  \n- CBC, CMP, and LFTs before each cycle; LVEF every 3 months for BRAF/MEK.  \n- If you hit grade 3–4 toxicity, discuss dose reduction or temporary hold with your oncologist.  \n- Keep a symptom diary; call your team if fatigue spikes or pain worsens.\n\nWe’ll work together to keep you moving safely while fighting the cancer.",
          "order": 2,
          "qid": "S15-Q02"
        },
        {
          "q": "If I spike fevers on pills, am I done running for good?",
          "gt": "I hear how scary it feels to see your body flare up with fever while you’re trying to stay strong on the trails—your worry is completely understandable.\n\nFever spikes are a common side effect of many melanoma drugs, especially BRAF/MEK inhibitors (e.g., vemurafenib, dabrafenib + trametinib) and checkpoint inhibitors (nivolumab, pembrolizumab). The fever itself isn’t a sign that you must quit running forever; it’s a signal that your immune system is reacting. If your temperature rises above 38.5 °C (101 °F), pause exercise until the fever subsides, stay well‑hydrated, and monitor for chills, fatigue, or muscle aches. Once the fever resolves, you can resume light to moderate running, but keep the intensity lower than usual and listen for any lingering aches or shortness of breath. Your oncology team will schedule regular labs (CBC, CMP) and vitals checks every 2–4 weeks to ensure the drug dose is tolerable. If fevers become frequent or high‑grade, they may adjust the dose or add supportive medications (acetaminophen, antihistamines) rather than stop the therapy altogether.\n\nLet’s keep a close eye on your symptoms and work with your oncologist to tweak the plan so you can keep moving safely.",
          "order": 3,
          "qid": "S15-Q03"
        },
        {
          "q": "Will immunotherapy make my body attack my thyroid or gut forever?",
          "gt": "I hear how frightening the idea of a permanent thyroid or gut attack feels, especially when you’re already juggling the demands of trail running and a cancer diagnosis.\n\nImmunotherapy for metastatic melanoma—most commonly checkpoint inhibitors such as nivolumab, pembrolizumab, or a combination of ipilimumab with nivolumab—can trigger immune‑related adverse events (irAEs). Thyroiditis is the most frequent endocrine irAE, occurring in 10–20 % of patients. It usually presents as transient hyperthyroidism that may progress to hypothyroidism; most cases resolve with thyroid hormone replacement, but a small subset (≈5 %) develop permanent hypothyroidism requiring lifelong levothyroxine. Colitis, the most common gastrointestinal irAE, typically manifests within 2–6 weeks of therapy. Steroids (prednisone 1 mg/kg) and, if needed, biologics (e.g., infliximab) usually control inflammation, and most patients recover normal bowel function. Rarely, severe colitis can lead to chronic diarrhea or strictures, but permanent damage is uncommon.\n\nMonitoring is key: baseline and every 4–6 weeks thyroid‑stimulating hormone (TSH) and free T4, plus symptom checks for abdominal pain, diarrhea, or blood in stool. If you develop symptoms, report them immediately so we can start steroids early and avoid escalation. Your oncology team will tailor the schedule—often 2 cycles of ipilimumab (3 mg/kg) plus 3 cycles of nivolumab (240 mg) before switching to maintenance nivolumab (240 mg every 2 weeks)—and will coordinate with endocrinology and gastroenterology for any irAE.\n\nIn short, while immunotherapy can cause thyroid or gut inflammation, most cases are reversible or manageable with medication. A minority may become permanent, but this is relatively rare, and we’ll monitor closely to keep you running as much as possible.",
          "order": 4,
          "qid": "S15-Q04"
        },
        {
          "q": "Can I still race this season if scans look better?",
          "gt": "I hear how hopeful and determined you feel, especially when you want to keep running while fighting melanoma—your drive is truly inspiring.\n\nIf your recent scans show a response, most oncologists allow patients to resume moderate‑to‑high‑intensity exercise, including racing, as long as treatment‑related side effects are manageable. Immunotherapies such as nivolumab (240 mg IV over 30 min every 2 weeks) or pembrolizumab (200 mg IV over 30 min every 3 weeks) and targeted agents like dabrafenib (150 mg PO BID) plus trametinib (2 mg PO daily) are the most common regimens. You’ll need routine labs (CBC, CMP, LFTs) every 2–4 weeks and imaging every 8–12 weeks; your oncologist may add cardiac echo if you’re on a BRAF/MEK combo or have pre‑existing heart disease.\n\nWhen racing, monitor for fatigue, muscle aches, skin rash, or new pain. Keep your hydration, rest, and a post‑race cool‑down routine. If you notice worsening symptoms, call your oncology team immediately. A brief pre‑race check‑in with your oncologist or nurse practitioner can confirm that your vitals and labs are within safe limits.\n\nWe’ll work closely to keep you safe and strong on the trail, adjusting treatment or training as needed.",
          "order": 5,
          "qid": "S15-Q05"
        },
        {
          "q": "Do I need to hide from the sun now?",
          "gt": "I hear how anxious you feel about balancing your love of trail running with the need to protect your skin—especially when every moment of activity feels precious.\n\n**Sun exposure and metastatic melanoma**  \n- Any melanoma patient, even with distant disease, should limit UV exposure because new primary lesions can still arise and existing lesions can worsen.  \n- If you’re on immunotherapy (nivolumab, pembrolizumab) or BRAF/MEK inhibitors (dabrafenib, trametinib), photosensitivity is common; these drugs can make skin more reactive to sun.  \n- Practical steps: wear a wide‑brim hat, UV‑blocking sunglasses, long sleeves, and lightweight, breathable clothing.  \n- Use broad‑spectrum SPF 30+ sunscreen on all exposed skin, reapply every 2 hours and after sweating or rinsing.  \n- Avoid peak sun (10 am‑4 pm) when possible; if you run during these hours, plan to finish early, then shower and reapply sunscreen.  \n- Schedule quarterly dermatology exams and keep a skin‑photo log to catch any new changes early.\n\n**Next steps**  \nDiscuss your specific regimen with your oncologist; they can tailor sun‑protection advice to your therapy and any photosensitivity you experience.  \n\nYou can keep running safely—just add these sun‑smart habits to your routine.",
          "order": 6,
          "qid": "S15-Q06"
        },
        {
          "q": "If brain spots show up later, does that end everything?",
          "gt": "I hear how scary it feels to think that new brain lesions could shut down your treatment options, especially when you’re determined to keep running and stay active.  \n\nBrain metastases don’t automatically end all systemic therapy.  In most cases, patients continue immunotherapy or targeted therapy while adding local treatment.  \n\nIf you have a BRAF V600 mutation, dabrafenib + trametinib (daily oral) is started, with labs (CBC, CMP, LFTs) every 2 weeks and MRI brain every 8–12 weeks.  If you’re BRAF‑wild‑type, nivolumab or pembrolizumab (IV every 3 weeks) ± ipilimumab (every 6 weeks) is common; labs and MRI follow the same schedule.  Local control is usually achieved with stereotactic radiosurgery (SRS) within 2–4 weeks of detection; whole‑brain radiation is reserved for multiple or symptomatic lesions.  \n\nSteroids (e.g., dexamethasone) are used for edema, and neurologic exams are done at each visit.  Side effects include fatigue, rash, colitis, and rare neurotoxicity; your oncologist will monitor LVEF only if using certain combinations.  \n\nIf lesions progress, the team may switch to a different checkpoint inhibitor, add a second‑line agent, or enroll you in a clinical trial—always tailored to your performance status and goals.  \n\nWe’ll keep a close eye on your brain scans and adjust therapy so you can stay as active as possible.",
          "order": 7,
          "qid": "S15-Q07"
        },
        {
          "q": "Can I keep my job while doing this, or should I plan leave?",
          "gt": "I hear how anxious you feel about juggling treatment and work, especially when you’re already pushing yourself on the trails—your worries are completely understandable.\n\n**Treatment and work‑capacity overview**  \nMost metastatic‑melanoma regimens—nivolumab (240 mg IV q2 wk), pembrolizumab (200 mg IV q3 wk), or a BRAF/MEK combo (dabrafenib 150 mg PO BID + trametinib 2 mg PO daily)—are designed to fit into a regular schedule.  Blood counts, CMP, thyroid, and liver panels are checked every 2–3 weeks; imaging repeats every 8–12 weeks.  Common side effects that can impact work are fatigue, mild rash, diarrhea, and, less frequently, colitis or pneumonitis.  Most patients with grade 1–2 toxicity can continue full‑time work, often with a flexible or remote arrangement.  If fatigue becomes grade 3 (e.g., persistent exhaustion, inability to perform daily tasks), dose‑reduction or a short leave is usually advised.  Severe immune‑related events (e.g., colitis, pneumonitis, adrenal crisis) require immediate treatment interruption and hospitalization, after which you’ll need a recovery period before resuming duties.  \n\n**Practical steps**  \n- Discuss your work schedule with your oncologist and occupational health; many employers allow telework or adjusted hours.  \n- Keep a symptom diary—if you notice worsening fatigue, fever, or new pain, call your oncology team promptly.  \n- If side effects flare, your team can adjust doses or add supportive meds (e.g., steroids for colitis) so you can stay on the job safely.  \n\nYou’re not alone in this; your care team will monitor closely and help you decide when a brief leave is best for your health and career.",
          "order": 8,
          "qid": "S15-Q08"
        },
        {
          "q": "What signals tell me to call you the same day?",
          "gt": "I hear how anxious you feel about needing urgent care while you’re trying to stay active—your determination is admirable, and it’s normal to worry about what to do if something feels off.\n\n**When to call your oncology team the same day:**  \n- **Fever ≥ 38.3 °C (100.9 °F)** or chills, especially if you’re neutropenic.  \n- **Severe or persistent vomiting, diarrhea, or abdominal pain** that prevents oral intake.  \n- **Chest pain, shortness of breath, or new cough** that could signal pneumonitis or infection.  \n- **Sudden weakness, numbness, vision changes, or confusion**—any new neurological deficit.  \n- **Unexplained bleeding or bruising, severe rash, or swelling** that could indicate a severe allergic reaction or immune‑related toxicity.  \n- **Marked fatigue, dizziness, or severe pain** that pain meds can’t control.  \n- **Signs of liver injury (jaundice, dark urine, abdominal tenderness)** or thyroid dysfunction (weight changes, mood swings).  \n\nIf any of these occur, call your oncology nurse line (555‑987‑6543) or the main office (555‑123‑4567) right away. We’ll assess you promptly and decide whether you need to come in or can manage at home.  \n\nWe’ll work together to keep you safe and keep you moving.",
          "order": 9,
          "qid": "S15-Q09"
        },
        {
          "q": "If I choose wrong first, did I ruin my chance at the other option?",
          "gt": "I hear how scary it feels to worry that picking the wrong first‑line therapy could lock you out of future options, especially when you’re trying to stay active and keep your training routine.\n\nFor metastatic melanoma, the main first‑line choices are checkpoint inhibitors (pembrolizumab 200 mg IV every 3 weeks, nivolumab 240 mg IV every 2 weeks, or a combination of nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks) and, if your tumor has a BRAF V600 mutation, BRAF/MEK inhibitors (dabrafenib 150 mg PO BID + trametinib 2 mg PO daily). Each has a distinct side‑effect profile: immunotherapy can cause fatigue, rash, colitis, and requires routine CBC/CMP and imaging every 8 weeks; BRAF/MEK therapy can cause fever, rash, arthralgia and needs CBC/CMP before each cycle and imaging every 8 weeks as well.\n\nChoosing one first does not usually “ruin” the other. If immunotherapy fails, you can still switch to BRAF/MEK therapy (or vice‑versa) provided your tumor is BRAF‑positive and you’re not exhausted by cumulative toxicity. However, some patients develop resistance or intolerable side effects that limit subsequent options, so early discussion of your goals, activity level, and comorbidities with your oncologist is key to sequencing the safest, most effective plan.\n\nWe’ll work closely to monitor your response and adjust the plan so you can keep running while fighting the disease.",
          "order": 10,
          "qid": "S15-Q10"
        }
      ]
    },
    {
      "id": "S16",
      "title": "Hospital or home (newly diagnosed AML at 67)",
      "diagnosis": "Acute myeloid leukemia in a 67-year-old",
      "treatment_plan": "Either intensive inpatient induction or lower-intensity therapy (hypomethylating agent + venetoclax) with transfusion support; infection prophylaxis; consider trial",
      "narrative": "I'm 67 and blindsided by leukemia. They’re talking about weeks in the hospital or a gentler plan mostly at home. I want time, but I also want myself.",
      "qa": [
        {
          "q": "If I choose the hospital route, how long am I really there and what does a day look like?",
          "gt": "I hear how frightening the idea of spending weeks in a hospital feels, especially when you’re already juggling so much for your family—your worries are completely understandable.\n\nIf you choose the inpatient route, most induction regimens for leukemia last 4–6 weeks. For example, acute myeloid leukemia (AML) induction typically involves cytarabine 100 mg/m² IV every 12 hours for 7 days plus daunorubicin 60 mg/m² IV days 1–3. You’ll stay until your white‑cell count recovers (usually 2–3 weeks after the last dose). Consolidation cycles add another 2–3 weeks each, so the total inpatient stay can reach 6–8 weeks, though some patients transition to outpatient care for maintenance.\n\nA typical day starts with morning vitals and a CBC. You’ll receive medications (e.g., antibiotics, growth factors) and a chemotherapy infusion that lasts 1–2 hours. Nurses check you every 4–6 hours, monitor for fever or infection, and adjust supportive meds. Meals are delivered, and you’ll have time to rest or talk with a social worker. Evening vitals and a discharge‑planning meeting wrap up the day. If you develop neutropenic fever or other complications, you may need ICU care, but most patients stay on the general oncology floor.\n\nYour team will monitor your blood counts, organ function, and infection risk closely, adjusting doses as needed. If anything changes, your oncologist will discuss alternative plans right away.",
          "order": 1,
          "qid": "S16-Q01"
        },
        {
          "q": "If I choose the at-home regimen, am I less likely to be alive for my granddaughter’s birthday?",
          "gt": "I hear how anxious you feel about the timing of your granddaughter’s birthday, especially when you’re already juggling so much for her and your own health.  \n\nChoosing an at‑home regimen (often oral azacitidine + venetoclax or low‑dose cytarabine) can reduce hospital stays and allow you to stay in a familiar environment, but it is usually less intensive than a full induction course in the hospital. For many older adults with acute myeloid leukemia, the median overall survival with intensive therapy is about 12–18 months, whereas a home‑based oral regimen may yield a median survival of roughly 8–12 months—though this varies widely with disease genetics, prior health, and response.  \n\nTypical home schedules:  \n• Venetoclax 400 mg orally once daily for 28 days, tapered after 3 weeks if neutropenic.  \n• Azacitidine 75 mg/m² subcutaneously or IV on days 1–7 of a 28‑day cycle (or oral CC‑486 200 mg BID for 14 days).  \n• Weekly CBCs, infection screening, and a pharmacist call if fevers or bleeding occur.  \n\nIf counts drop or you develop infection, the plan is to pause therapy, give growth factors or antibiotics, and reassess. Your oncologist can tailor the exact schedule and give you a more precise survival estimate based on your cytogenetics and overall health.  \n\nRemember, the goal is to balance longevity with quality of life, and your team will monitor closely to adjust as needed.",
          "order": 2,
          "qid": "S16-Q02"
        },
        {
          "q": "Will I be transfusion-dependent for months?",
          "gt": "I hear how scary the idea of needing regular blood transfusions feels, especially when you’re already juggling so many new questions and decisions.\n\nIn most leukemias, transfusion needs are highest during the first few weeks of treatment—when the bone marrow is still recovering from the intensive induction chemotherapy (e.g., cytarabine plus an anthracycline for AML, or a tyrosine‑kinase inhibitor for CML). During that period you’ll likely receive packed red blood cells and platelets every 1–2 weeks, with the exact frequency guided by your CBC (hemoglobin < 8 g/dL or platelets < 20 × 10⁹/L). Once the marrow starts to recover and you achieve remission, transfusions usually taper off; many patients become transfusion‑independent within 2–3 months if the disease responds well.\n\nIf you opt for a gentler, home‑based approach, the plan often focuses on supportive care: scheduled blood tests, low‑dose maintenance therapy, and transfusions only when counts fall below the same thresholds. In that setting, transfusion dependence is typically shorter—often limited to the first 1–2 months—unless the leukemia is refractory or relapses.\n\nKey monitoring points:\n- CBCs every 2–3 days during induction, then weekly once counts stabilize.\n- Hemoglobin and platelet thresholds as above.\n- Watch for transfusion reactions (fever, chills, rash) and iron overload (serum ferritin > 1000 ng/mL) if many units are given.\n\nYour oncologist will tailor the schedule to your specific leukemia subtype and overall health. If you notice symptoms like fatigue, easy bruising, or shortness of breath, let them know right away; they may adjust transfusion timing or add growth factors (e.g., G‑CSF).  \n\nWe’ll keep a close eye on your counts and adjust the plan as needed—so you can focus on staying as independent and comfortable as possible.",
          "order": 3,
          "qid": "S16-Q03"
        },
        {
          "q": "How do we prevent infections when my immune system vanishes?",
          "gt": "I hear how frightening it feels to think about infections while your immune system is weakened, especially when you want to stay strong for your family.\n\nDuring induction or maintenance for most leukemias, we usually give a fluoroquinolone (e.g., levofloxacin 500 mg PO daily) for the first 7–10 days of expected neutropenia. If neutropenia lasts >7 days, we add posaconazole 300 mg PO daily to block mold infections.\n\nAntiviral prophylaxis with acyclovir 400 mg PO twice daily is standard for HSV‑positive patients, and we give a pneumococcal vaccine (PCV15/20) after neutrophil recovery, not during active neutropenia. We also use G‑CSF (filgrastim 5 µg/kg SC daily) to shorten low‑count periods.\n\nDaily CBCs, temperature checks, and prompt reporting of fever >38.3 °C or sore throat trigger empiric broad‑spectrum antibiotics (e.g., cefepime 2 g IV q12h). Keep your home clean, avoid crowds, wash hands often, and wear a mask if sick contacts are present.\n\nYour care team will monitor your counts closely and adjust prophylaxis as needed, so you can focus on staying safe and feeling as normal as possible.",
          "order": 4,
          "qid": "S16-Q04"
        },
        {
          "q": "What if the plan isn’t working—do we know early enough to pivot?",
          "gt": "I hear how frightening it feels to be caught between a long hospital stay and a gentler home plan, especially when you’re already carrying so much uncertainty. Your worries are completely understandable.\n\nIn an intensive induction course (e.g., cytarabine 100 mg/m² IV over 3–5 days plus daunorubicin 60 mg/m² IV over 3 days), we monitor a complete blood count (CBC) daily, lactate dehydrogenase (LDH) weekly, and perform a bone‑marrow aspirate at day 28. If the blast count remains >5 % or LDH rises, that signals the regimen isn’t working early enough to pivot. For a low‑intensity home plan (azacitidine 75 mg/m² SC for 7 days or decitabine 20 mg/m² IV for 5 days, sometimes combined with venetoclax), we check CBCs twice weekly, LDH, and assess minimal residual disease (MRD) by flow cytometry or PCR at 4‑week intervals.\n\nIf early markers show no response, we can switch to a salvage protocol (e.g., FLAG‑IDA, clofarabine‑based therapy), enroll in a clinical trial, or move to supportive care. Your oncologist will tailor the exact timing and choice based on your blood counts, molecular profile, and overall health.\n\nRest assured, your team will track these indicators closely and adjust the plan promptly if needed.",
          "order": 5,
          "qid": "S16-Q05"
        },
        {
          "q": "Can I appoint my daughter to make decisions if I’m too sick?",
          "gt": "I hear how frightening it feels to think about losing the ability to speak for yourself, especially when you’re already carrying so much for your family.\n\nYes—you can appoint your daughter as your health‑care decision maker. In most states this is done with a **Durable Power of Attorney for Health Care** (sometimes called a health‑care proxy). The form names a primary agent (your daughter) and can include a backup. It must be signed in front of two witnesses (or a notary, depending on your state) and then filed with your hospital or kept in your medical records. Once you’re incapacitated, the hospital will rely on that document to guide treatment decisions, and your daughter can discuss your wishes with the oncologist and nursing staff. You can also create a **living will** or advance directive that spells out specific treatment preferences (e.g., comfort‑focused care vs. aggressive chemotherapy).  \n\nTalk with your oncologist and a local attorney or the hospital’s legal office to get the correct form for your state and to review your wishes. Bring copies to your daughter so she knows exactly what you want. If you change your mind later, you can revoke or amend the document in the same way.  \n\nYou’re taking an important step to keep your voice heard even when you can’t speak for yourself.",
          "order": 6,
          "qid": "S16-Q06"
        },
        {
          "q": "Will chemo steal my mind or only my hair?",
          "gt": "I hear how frightening the idea of losing mental clarity feels, especially when you’re already juggling so much and want to stay sharp for your loved ones.  \n\nChemotherapy for leukemia can affect the brain, but the impact varies with the drugs and the intensity of the regimen. For a typical induction course in AML, you’ll receive cytarabine (often 100 mg/m² IV over 2 hours, every 12 hours for 7 days) plus an anthracycline such as daunorubicin (50 mg/m² IV over 30 minutes, days 1–3). These agents cause the classic hair loss, nausea, and myelosuppression you’re familiar with. Neurotoxicity is uncommon at standard doses, but high‑dose cytarabine (≥1 g/m²) can lead to cerebellar symptoms, seizures, or mild confusion. In older adults, clinicians often use a “low‑intensity” or oral regimen (e.g., ibrutinib for CLL) that has a lower risk of cognitive side effects.  \n\nYour team will monitor you closely: complete blood counts every 2–3 days, a baseline and periodic neuro‑cognitive screen (short memory and attention tests), and a quick check‑in if you notice new confusion or memory lapses. If any cognitive changes arise, the dose can be reduced or the drug switched, and supportive measures (hydration, anti‑emetics, and sometimes steroids) are added.  \n\nRest assured, most patients maintain clear thinking throughout treatment; any cognitive changes are usually mild, reversible, and manageable with close monitoring and dose adjustments.",
          "order": 7,
          "qid": "S16-Q07"
        },
        {
          "q": "Do I have to stop my daily walk?",
          "gt": "I hear how scary it feels to juggle a new leukemia diagnosis with the routine of your daily walk—especially when you’re already carrying so much uncertainty.\n\nIn most leukemia protocols, walking is actually encouraged as a gentle way to stay active, provided you’re not in a period of profound neutropenia (ANC < 500 / µL) or thrombocytopenia (platelets < 50 × 10⁶/L). During induction chemotherapy (e.g., cytarabine + anthracycline for AML, or vincristine + prednisone for ALL), you’ll have daily CBCs; if counts are low, your team will advise rest and limit exertion. If you’re on a targeted agent like ibrutinib or venetoclax (common in CLL), fatigue and occasional dizziness can occur—stop walking if you feel light‑headed or short of breath. Keep a log of how you feel; if you notice new bruising, fever, or a sudden drop in energy, contact your oncology nurse right away. Your oncologist can tailor the walking plan to your exact regimen and blood counts.\n\nRemember, staying mobile is part of your care plan—just keep an eye on your blood counts and listen to your body.",
          "order": 8,
          "qid": "S16-Q08"
        },
        {
          "q": "How do costs and caregiver time differ between options?",
          "gt": "I hear how overwhelming it feels to juggle the weight of a new diagnosis with the practical worries of cost and the time you’ll need to spend caring for yourself and your loved ones.\n\n**Costs**  \n- **In‑hospital care**: The average inpatient day for leukemia treatment (including chemotherapy, monitoring, and supportive meds) runs roughly **$2,000–$3,000**. Over a typical 4‑week course that’s $32,000–$48,000, though Medicare or private plans may cover a large portion; you’ll likely see a deductible or copay.  \n- **Home‑based care**: Home‑health nursing visits (often 2–3 per week) cost about **$200–$400** per day, plus the cost of any infusion pumps or medications you bring home. If you need a 24‑hour caregiver, the hourly rate is usually **$20–$30** per hour, which can add up to **$1,200–$2,400** per month.  \n\n**Caregiver time**  \n- **Hospital**: You’ll spend most of your time in the hospital, but the clinical team handles most tasks. Expect to be present for 2–4 hours per day for rounds, medication administration, and monitoring.  \n- **Home**: A typical home‑care plan requires **8–12 hours of direct care** per day—help with medication timing, IV access, blood draws, and daily activities—unless you have a paid caregiver or family member who can share the load.  \n\nIn short, inpatient care is more expensive per day but frees you from many caregiving tasks; home care is less costly per day but demands far more of your time and may require hiring help. Discussing your specific insurance coverage and speaking with a social worker can help you refine these numbers for your situation.",
          "order": 9,
          "qid": "S16-Q09"
        },
        {
          "q": "If I want to switch paths later, can I?",
          "gt": "I hear how scary the idea of a long hospital stay feels, especially when you’re already trying to keep your life and independence intact. It’s completely normal to feel both anxious and determined in this moment.  \n\nYes, you can switch treatment plans later, but the timing and feasibility depend on the leukemia type, your overall health, and how the disease responds. For many adults with acute myeloid leukemia (AML), the first step is an **induction phase**—usually 4–6 weeks of daily cytarabine (100 mg/m²) plus an anthracycline (daunorubicin 60 mg/m²) given over 3–5 days. We monitor you with a complete blood count (CBC) every 2–3 days, a bone‑marrow aspirate at day 14–21, and check for minimal residual disease (MRD) after induction.  \n\nIf you or your team decide the intensive schedule is too burdensome, or if you’re older or have comorbidities, we can shift to a **low‑intensity regimen** such azacitidine (75 mg/m² subcutaneously for 7 days) or decitabine (20 mg/m² IV for 5 days), sometimes combined with venetoclax. These options are usually given in outpatient settings and still aim to reduce blast counts, but they may take longer to achieve remission.  \n\nShould the disease progress or you recover enough to tolerate more aggressive care, we can re‑evaluate for a second induction or a transplant‑eligible protocol. Each transition requires a fresh assessment of organ function, infection risk, and your personal goals.  \n\nWe’ll schedule weekly CBCs, periodic MRD checks, and infection‑prophylaxis monitoring throughout. Your oncologist will tailor the exact schedule and drug doses to your evolving situation.  \n\nRemember, we’ll walk this path together, keeping your time and autonomy at the forefront.",
          "order": 10,
          "qid": "S16-Q10"
        }
      ]
    },
    {
      "id": "S17",
      "title": "Waiting feels like doing nothing (CLL watch-and-wait)",
      "diagnosis": "Chronic lymphocytic leukemia, asymptomatic",
      "treatment_plan": "Active surveillance with regular labs and exams; start treatment when specific triggers are met",
      "narrative": "I'm 63 and told we aren't treating yet. It feels like ignoring a ticking clock.",
      "qa": [
        {
          "q": "How is 'watch and wait' not just 'wait and worry'?",
          "gt": "I hear how unsettling it feels to be told “not to treat yet,” especially when you’re already worried about what might happen next. It’s normal to feel anxious and a bit powerless in that moment.\n\n**What “watchful waiting” really means**  \nWatchful waiting is an active, structured monitoring plan rather than passive silence. Your team will set a clear schedule—usually a PSA or tumor marker test, imaging (CT/MRI or ultrasound), and a physical exam every 3–6 months. If any of these tests show a significant rise (e.g., a PSA doubling time < 3 months or a measurable increase in tumor size), treatment is started immediately.  \nDuring this period you’ll keep a symptom diary (pain, fatigue, urinary changes) and report any new or worsening symptoms right away. The goal is to avoid unnecessary treatment while still catching progression early.  \nIf the disease remains stable, you’ll continue the same schedule; if it progresses, the plan will shift to the appropriate therapy (e.g., hormone therapy, targeted agents, or surgery).  \n\nYour oncologist will tailor the exact intervals and thresholds to your specific diagnosis, so you’re not left guessing.  \n\nWe’ll keep a close eye on you, and I’ll be here to answer any new questions as they arise.",
          "order": 1,
          "qid": "S17-Q01"
        },
        {
          "q": "What exact signs mean it’s time to act so I’m not guessing?",
          "gt": "I hear how frightening the idea of waiting feels, especially when you’re already carrying so much for your family—your worries are completely understandable.  \n\n**When the “ticking clock” turns into a call to action**  \n1. **New or worsening symptoms** – sudden pain, unexplained weight loss, fatigue, shortness of breath, or swelling that wasn’t there before.  \n2. **Imaging or lab evidence of progression** – a scan that shows a tumor growing or spreading, or a rise in a tumor marker (e.g., PSA, CA‑125, CEA) that exceeds the upper limit of normal or climbs steadily over two consecutive tests.  \n3. **Functional decline** – a drop in performance status (e.g., from ECOG 0–1 to 2–3), loss of ability to do daily activities, or a decline in organ function tests (e.g., creatinine, liver enzymes, LVEF <50 %).  \n4. **Biomarker thresholds** – for heart disease, a new or worsening chest pain with an ECG change or troponin rise; for cancer, a doubling time of a measurable lesion or a ≥20 % increase in size per RECIST criteria.  \n\n**What to do next**  \n- Schedule the next imaging or blood test sooner (often every 4–6 weeks).  \n- Call your oncologist or cardiologist if any of the above signs appear; they’ll decide whether to start, change, or intensify therapy.  \n- Keep a symptom diary so you can report changes accurately.  \n\nYour care team will monitor these markers closely, and they’ll let you know the exact moment when treatment becomes the safest and most effective option.",
          "order": 2,
          "qid": "S17-Q02"
        },
        {
          "q": "Can I still travel without labs every month?",
          "gt": "I hear how anxious you feel about the ticking clock, especially when you’re already juggling so many worries about your health and family.  \n\n**Answer**  \nIf you’re not yet on active therapy, the monthly labs are usually for surveillance—checking blood counts, chemistry panels, and any tumor markers that help us spot early progression. You can travel, but you’ll need to keep those labs up‑to‑date to avoid missing a change in your disease status.  \n\nDuring active treatment, labs are required every 4–6 weeks (often CBC, CMP, and specific markers) to monitor for neutropenia, liver or kidney toxicity, and tumor response. Skipping a lab could delay detection of a dangerous drop in blood counts or organ dysfunction, which could compromise your safety and the effectiveness of the next cycle.  \n\n**Practical steps if you plan to travel**  \n1. **Speak with your oncologist** about your travel dates.  \n2. **Arrange a local lab** (hospital or community lab) to draw the required tests on the same day you would normally come in.  \n3. **Bring all medications** and a copy of your treatment plan.  \n4. **Have an emergency contact** (your oncology nurse or a local doctor) in case you develop symptoms between labs.  \n\nIf your oncologist feels the labs can be delayed for a short period (e.g., a week or two), they’ll let you know. Otherwise, keeping the monthly schedule—even while traveling—helps keep your treatment on track and your health safe.  \n\nYou’re not alone in this; we’ll work together to make sure your travel plans fit safely into your care plan.",
          "order": 3,
          "qid": "S17-Q03"
        },
        {
          "q": "Will my immunity be weak even without treatment?",
          "gt": "I hear how frightening it feels to sit with a ticking clock, especially when you’re already carrying so much worry for yourself and your loved ones.\n\nEven before therapy starts, many cancers can dampen the immune system. Tumor cells release cytokines that blunt neutrophil and lymphocyte function, and the body’s own metabolic demands can lower white‑cell counts. In practice, this means you’re more prone to infections, fevers, and slower wound healing. Your oncologist will usually check a complete blood count (CBC) every 2–4 weeks to watch for neutropenia or lymphopenia, and you’ll be advised to report any fever, sore throat, or unusual fatigue right away. If your counts dip, prophylactic antibiotics or growth‑factor support (e.g., G‑CSF) may be offered.\n\nOnce treatment begins, the pattern changes: chemotherapy or targeted agents often cause a predictable drop in neutrophils for 7–14 days after each cycle, so the same CBC schedule continues, plus infection‑prevention measures (hand hygiene, avoiding crowds, vaccinations up to date). If you’re worried about a weak immune system, discuss with your oncologist about early intervention, supportive care, and any preventive strategies that fit your specific diagnosis.\n\nWe’ll keep a close eye on your blood counts and symptoms—your team is here to adjust the plan as needed.",
          "order": 4,
          "qid": "S17-Q04"
        },
        {
          "q": "Should I change my diet or supplements to slow this down?",
          "gt": "I hear how anxious and helpless you feel right now—waiting for treatment can feel like a ticking clock that’s hard to ignore.\n\n**What the evidence says about diet and supplements**  \n- A balanced, nutrient‑dense diet (Mediterranean‑style: plenty of fruits, vegetables, whole grains, legumes, nuts, olive oil, and lean protein) can support overall health, help maintain a healthy weight, and reduce inflammation.  \n- Avoid excess sugar, refined carbs, and processed meats, and limit alcohol to no more than one drink per day.  \n- Most studies show that no specific food or supplement can replace evidence‑based therapy, but a healthy diet can improve tolerance to treatment and recovery.  \n- **Supplements**:  \n  - Vitamin D and omega‑3 fatty acids may benefit bone health and inflammation, but high‑dose antioxidants (e.g., vitamin C, E) can interfere with some chemotherapies.  \n  - Herbal or “natural” supplements (e.g., ginseng, garlic, St. John’s wort) can interact with medications and should be avoided unless cleared by your oncologist.  \n- **Monitoring**: Keep regular appointments for blood counts, liver and kidney function tests, and weight checks. A registered dietitian can tailor a plan and track nutrient intake.  \n\n**Next steps**  \nDiscuss any dietary changes or supplements with your oncologist and a dietitian before starting them. They can adjust your plan based on your specific diagnosis, treatment schedule, and lab results.  \n\nYou’re not alone—your care team will monitor you closely and help you make informed choices.",
          "order": 5,
          "qid": "S17-Q05"
        },
        {
          "q": "Will insurance balk when I’m not 'actively' treated?",
          "gt": "I hear how unsettling it feels to be told to wait, especially when you’re already anxious about the clock ticking on your health. That worry is completely understandable.\n\nInsurance companies base coverage on “medical necessity.” If your oncologist has documented that active therapy isn’t indicated right now—perhaps because the tumor is stable, a biopsy shows low‑grade disease, or you’re awaiting a more definitive test—then the insurer will usually honor that plan and cover the monitoring that follows. Routine imaging, blood work, and supportive visits are considered medically necessary and are covered even when no chemotherapy or radiation is being delivered.\n\nIf you later decide to start treatment, the insurer will require the same documentation: a recent pathology report, imaging, and a physician’s note explaining why therapy is now warranted. If you delay treatment for a period that the insurer deems “unreasonable” (often more than a few months without a clear clinical reason), they may question the coverage and could deny a claim or request an appeal. To avoid surprises, keep a copy of every note that explains the decision to hold off, and ask your oncology team to provide a written statement of medical necessity that you can submit to the insurer.\n\nIf a denial ever occurs, you can file an appeal. Most plans have a formal process, and your oncology team can help gather the evidence needed. In short, as long as the decision to pause treatment is documented and medically justified, insurance should not balk—just be prepared to provide the paperwork that supports that choice.",
          "order": 6,
          "qid": "S17-Q06"
        },
        {
          "q": "Is there a benefit to clinical trials now?",
          "gt": "I hear how anxious you feel about the delay, especially when you’re trying to stay strong for your family and your loved ones.  \n\nClinical trials can give early access to promising drugs that aren’t yet approved, but they’re not guaranteed to work for everyone.  \n\nPhase I trials test safety and dosing; you’ll receive close monitoring—blood counts, liver enzymes, and imaging every 2–4 weeks.  \n\nPhase II trials focus on efficacy; if you qualify, you might receive a drug that has shown activity in similar patients—such as pembrolizumab for melanoma or olaparib for BRCA‑mutated ovarian cancer—while side‑effect profiles are already known.  \n\nPhase III trials compare the new therapy to standard care; enrolling now could mean you’re part of a study that might change future treatment guidelines.  \n\nEligibility depends on your cancer type, stage, prior treatments, and overall health. Discuss with your oncologist to see if a trial aligns with your goals and if the potential benefits outweigh the risks.  \n\nLet’s keep the conversation open—your team will monitor you closely and help you decide the best path forward.",
          "order": 7,
          "qid": "S17-Q07"
        },
        {
          "q": "How do I tell family I’m okay when the word leukemia scares them?",
          "gt": "I hear how frightening the word “leukemia” feels, especially when you’re trying to stay strong for your family—your worries are completely understandable.\n\nYour oncologist has decided to hold off on treatment for now because the disease is still in a phase where close monitoring can give you time to prepare mentally and physically. You’ll have a weekly complete blood count (CBC) and a comprehensive metabolic panel (CMP) for the first month, then every 2–4 weeks. A bone‑marrow aspirate and flow‑cytometry will be repeated every 4–6 weeks to track blast counts. Imaging (CT or PET‑CT) is usually done every 3 months unless symptoms change. If any counts drop below safe thresholds (e.g., platelets <50 × 10⁹/L or neutrophils <1.0 × 10⁹/L), you’ll be started on supportive care—growth factors, antibiotics, or transfusions—before any cytotoxic therapy.  \n\nWhen you talk to family, explain that “treatment‑free” doesn’t mean “no action.” You’re being monitored closely, and you’ll begin induction therapy (e.g., a combination of cytarabine and anthracycline) as soon as the disease shows progression or if you develop symptoms. If you feel unwell, call your oncologist right away.  \n\nWe’ll work together to keep you safe and informed, and your team will monitor you closely.",
          "order": 8,
          "qid": "S17-Q08"
        },
        {
          "q": "Can stress make this speed up?",
          "gt": "I hear how unsettling it feels to be told “not yet” while your mind keeps ticking the clock, especially when you’re already carrying so much worry for yourself and your loved ones.\n\nStress can influence the body’s immune and hormonal pathways, and in some cancers high cortisol or chronic inflammation may modestly affect tumor biology. However, there’s no clear evidence that everyday anxiety or worry will dramatically speed up disease progression. The most reliable way to keep the clock from running faster is to focus on the factors you can control—adhering to scheduled monitoring, maintaining a healthy routine, and addressing stress with proven strategies such as regular exercise, adequate sleep, balanced nutrition, and counseling or support groups.  \n\nYour care team will schedule routine labs (CBC, CMP, tumor markers) and imaging (CT/MRI or PET) every 4–6 weeks to catch any changes early. If the disease shows progression, the oncologist will discuss next‑step therapies—often a combination of targeted agents, chemotherapy, or immunotherapy—tailored to your specific diagnosis and overall health.  \n\nRemember, while stress can add discomfort, it’s the medical plan and vigilant monitoring that most directly influence outcomes. We’ll keep a close eye on your progress and adjust treatment as needed.",
          "order": 9,
          "qid": "S17-Q09"
        },
        {
          "q": "How often do people never need treatment?",
          "gt": "I hear how anxious and frustrated you feel about the pause in treatment, especially when you’re already carrying so much for your family—those worries are completely understandable.\n\nIn many early‑stage or low‑risk conditions, a “watchful waiting” or active‑surveillance approach is common, and a significant proportion of patients never receive definitive therapy for years. For example, about 70‑80 % of men with low‑risk prostate cancer stay on surveillance for 5–10 years, and a similar pattern is seen in early‑stage breast cancer where only 10–20 % of low‑grade tumors require chemotherapy. In some cases of stage I colorectal cancer, surgery alone may be curative, and many patients never need additional therapy. The exact likelihood depends on factors such as age, overall health, tumor biology, and personal preferences. Your oncologist will tailor the plan: regular PSA checks every 3–6 months, yearly digital rectal exams, routine imaging (e.g., mammograms or CT scans) every 6–12 months, and prompt treatment if any progression is detected. If the disease remains stable, you may indeed avoid treatment entirely.\n\nRest assured that the monitoring schedule is designed to catch any change early, so you’re not “ignoring a ticking clock” but rather keeping a close eye on it.",
          "order": 10,
          "qid": "S17-Q10"
        }
      ]
    },
    {
      "id": "S18",
      "title": "Finding my voice again (papillary thyroid cancer)",
      "diagnosis": "Papillary thyroid carcinoma after thyroidectomy",
      "treatment_plan": "Surgery followed by thyroid hormone replacement; consider radioactive iodine based on risk; lifelong surveillance",
      "narrative": "I'm 35, a teacher. Surgery took my thyroid. My voice is hoarse and the scar is new territory. I’m trying to feel normal again.",
      "qa": [
        {
          "q": "Will my voice return to my old classroom strength?",
          "gt": "I hear how unsettling the loss of your classroom‑level voice feels, especially when you’re already juggling the demands of teaching and caring for your students.\n\nAfter a thyroidectomy, hoarseness most often results from temporary irritation or stretching of the recurrent laryngeal nerve. In about 70–80 % of cases, the nerve recovers enough to restore normal vocal strength within 4–6 weeks, and many patients regain full function by 3–6 months. If the nerve injury is more severe, voice changes can persist longer or become permanent.  \n\nYour next steps:  \n1. **Voice rest** for the first 48–72 hours, then gentle phonation.  \n2. **ENT evaluation** with laryngoscopy at 2 weeks and again at 6 weeks; this will show vocal cord mobility and help decide if therapy is needed.  \n3. **Speech‑language pathology**: a structured voice‑therapy program (warm‑up, breath support, resonance exercises) can accelerate recovery.  \n4. If hoarseness persists beyond 3 months, the ENT may consider a **vocal‑cord injection** or **thyroplasty** to improve cord closure.  \n\nKeep a voice diary, note any pain or swelling, and report new symptoms immediately. With careful follow‑up and therapy, many teachers return to their former vocal power, but the timeline varies—your team will monitor progress closely.",
          "order": 1,
          "qid": "S18-Q01"
        },
        {
          "q": "Do I need radioactive iodine, or can we skip it safely?",
          "gt": "I hear how unsettling it feels to be left wondering whether you need radioactive iodine, especially when your voice is already strained and the scar is still fresh.\n\n**Radioactive iodine (RAI) is not automatically required after thyroidectomy.** Whether you receive it depends on the pathology of your removed tissue and your overall risk of recurrence.  \n- **Benign disease** (e.g., simple goiter or hyperthyroidism) usually does **not** need RAI.  \n- **Differentiated thyroid cancer** (papillary or follicular) is often treated with RAI if the tumor is >1 cm, has extrathyroidal extension, lymph node involvement, or high‑risk features. For low‑risk, small tumors with no residual disease, many surgeons and endocrinologists opt to **skip RAI** and monitor with thyroglobulin levels and neck ultrasounds every 6–12 months.  \n- **RAI dosing** (typically 30–150 mCi) is given 4–6 weeks after surgery, once thyroglobulin is measured and the patient is on thyroid‑suppression therapy.  \n- Because RAI can worsen voice changes and cause dry mouth, your surgeon will weigh the potential benefit against the risk of further hoarseness, especially if the recurrent laryngeal nerve was close to the surgical field.\n\n**Next steps:**  \n1. Review your final pathology report with your surgeon or endocrinologist.  \n2. Discuss your risk category and whether RAI would improve your long‑term outcome.  \n3. If RAI is recommended, schedule the dose, and plan follow‑up labs (thyroglobulin, anti‑Tg antibodies) and ultrasounds.  \n4. If RAI is deferred, keep regular surveillance appointments and report any new symptoms promptly.\n\nYour team will tailor the plan to your specific situation, and we’ll monitor closely to keep you on track toward recovery.",
          "order": 2,
          "qid": "S18-Q02"
        },
        {
          "q": "How do we set my hormone dose so I’m not anxious and sleepless?",
          "gt": "I hear how unsettling it feels to wake up anxious and sleepless after your surgery, especially when you’re already juggling a busy teaching schedule—your worries are completely understandable.\n\nAfter a total thyroidectomy, the goal is to replace the hormone you’ve lost with levothyroxine (T4). Most clinicians start you at 1.6 µg/kg/day (≈ 50–100 µg for a typical adult) or a fixed 75 µg if you’re on the lower end of the weight spectrum. Take the pill on an empty stomach, 30–60 minutes before breakfast, and keep calcium, iron, or soy products at least 4 hours away to avoid absorption interference.  \n\nCheck your TSH and free T4 4–6 weeks after the first dose. If TSH is >4 mIU/L, increase the dose by 12.5–25 µg; if TSH is <0.5 mIU/L or you feel jittery, consider a 12.5 µg reduction. Once your TSH stabilizes between 0.5–4.0 mIU/L, re‑check every 6–12 months. Persistent anxiety or insomnia after dose adjustment may signal other factors—sleep apnea, caffeine, or stress—so a holistic review is often helpful.  \n\nIf symptoms linger despite a stable TSH, your endocrinologist may tweak the dose or add a small amount of liothyronine (T3) to fine‑tune the balance.  \n\nWe’ll monitor closely and adjust together so you can feel more at ease and get a good night’s sleep.",
          "order": 3,
          "qid": "S18-Q03"
        },
        {
          "q": "Will this scar always shout 'cancer' at people?",
          "gt": "I hear how anxious you feel about the scar, especially when you’re already juggling a busy classroom and the desire to feel “normal” again.\n\nThe scar from a thyroidectomy is a normal surgical outcome, not a sign of cancer recurrence. It will gradually fade as the skin remodels—most noticeable changes happen in the first 2–4 weeks, with significant softening over 3–6 months and a more subtle appearance after 12–24 months. Sun exposure, dryness, or tension can keep it slightly raised, but it won’t “shout” cancer to others.\n\nTo help the scar heal and blend in, keep it moisturized, use a silicone gel sheet or silicone cream, and avoid direct sun for at least 6 months. Gentle massage after the initial healing period can also improve texture. If the scar remains bothersome, a scar revision procedure (e.g., excision or laser therapy) can be discussed with your surgeon when the tissue is fully healed.\n\nYour hoarseness is likely due to temporary nerve irritation from the surgery. Most patients notice improvement within 3–6 months, and voice‑therapy exercises can accelerate recovery. If symptoms persist, a laryngology referral is recommended.\n\nRest assured the scar is a healing mark, not a cancer warning, and we’ll monitor your recovery together.",
          "order": 4,
          "qid": "S18-Q04"
        },
        {
          "q": "Can I get pregnant safely on these medicines?",
          "gt": "I hear how anxious you feel about getting pregnant while on your thyroid medication, especially after the surgery and the new scar that’s still healing.\n\nAfter a total thyroidectomy you’ll be on levothyroxine (usually a brand‑name like Synthroid or generic levothyroxine). Levothyroxine is pregnancy‑category A and is safe for both mother and baby. The key is to keep your thyroid levels in the normal range before conception and throughout pregnancy.  \n• **Pre‑conception**: Check TSH and free T4 4–6 weeks before trying to conceive. Adjust the dose so TSH is 0.5–2.5 mIU/L.  \n• **During pregnancy**: TSH should be checked every 4 weeks in the first trimester, then every 6–8 weeks thereafter. Most women need a 10–20 % dose increase early in pregnancy.  \n• **Monitoring**: Watch for symptoms of hypo‑ or hyperthyroidism (fatigue, weight changes, heart rate). If you’re on any other meds (e.g., antihypertensives, antidepressants), discuss their safety with your endocrinologist or OB‑GYN.  \n\nIf you’re unsure about any medication, bring the list to your next appointment so your team can tailor the plan.  \n\nWe’ll work together to keep you healthy and give you the best chance for a safe pregnancy.",
          "order": 5,
          "qid": "S18-Q05"
        },
        {
          "q": "What follow-up keeps me safe without over-testing?",
          "gt": "I hear how unsettling the hoarseness and new scar feel, especially when you’re already juggling a busy teaching schedule—your worries are completely understandable.\n\n**Typical follow‑up after a total thyroidectomy**\n\n1. **First visit (2–4 weeks)** – Physical exam, voice assessment, and a quick blood draw for TSH and free T4. If you had a total thyroidectomy, we’ll also check thyroglobulin to screen for residual tissue.  \n2. **Calcium monitoring** – If you had parathyroid cautery, we’ll check serum calcium at  h and again at 1 week to catch hypocalcemia early.  \n3. **Subsequent labs** – Every 6 months for the first 2 years, then annually, unless symptoms change.  \n4. **Imaging** – Only if you develop new neck pain, swelling, or abnormal labs. Routine ultrasounds or CT scans are not needed.  \n5. **Voice follow‑up** – If hoarseness persists beyond 6–8 weeks, a laryngoscopy can confirm vocal‑cord function; otherwise, watchful waiting is usually sufficient.  \n\n**When to call your surgeon or endocrinologist**  \n- New or worsening hoarseness, throat pain, or difficulty swallowing  \n- Signs of low calcium (tingling, muscle cramps, seizures)  \n- Any sudden neck swelling or bruising  \n\nThis schedule balances safety with avoiding unnecessary tests. Your team will adjust the plan if any of these red‑flag symptoms appear.",
          "order": 6,
          "qid": "S18-Q06"
        },
        {
          "q": "Is my calcium low forever after surgery?",
          "gt": "I hear how scary it feels to worry about your calcium levels, especially after a big surgery and while you’re already juggling so much as a teacher.\n\nAfter a thyroidectomy, low calcium (hypocalcemia) is common because the parathyroid glands can be injured or removed. Most people’s calcium levels return to normal within a few weeks to a few months as the remaining parathyroids recover. We usually check serum calcium and intact PTH 24–48 hours after surgery, then again weekly for 2–4 weeks, and monthly until the values stabilize. If calcium stays low after about 6 months, it’s likely permanent hypoparathyroidism, and you’ll need lifelong oral calcium (often 1,200–2,400 mg/day of calcium carbonate) plus vitamin D (800–1,000 IU/day, or calcitriol if needed). Severe low calcium may require IV calcium in the hospital. Watch for tingling, muscle cramps, or seizures—call your surgeon or endocrinologist right away if these occur.\n\nYour team will monitor your levels closely, and most patients recover fully or manage their calcium with supplements. We’ll keep working together to keep you safe and comfortable.",
          "order": 7,
          "qid": "S18-Q07"
        },
        {
          "q": "Can I sing in choir again?",
          "gt": "I hear how anxious and hopeful you feel about getting back to choir, especially after the shock of surgery and the new scar on your neck.  \n\nAfter a thyroidectomy, the recurrent laryngeal nerves that control your vocal cords can be stretched or irritated, which explains the hoarseness you’re experiencing. Most people’s voice improves within 4–6 weeks, but the exact timing depends on whether there was any nerve injury.  \n\n**What to do next**  \n1. **Voice rest** for the first 1–2 weeks: avoid speaking loudly, whispering, or singing.  \n2. **Hydration & gentle warm‑ups**: sip water, do light humming, and avoid throat clearing.  \n3. **Speech‑language pathology**: a voice therapist can assess your vocal fold function (often with a laryngoscopy) and give you targeted exercises.  \n4. **Gradual return**: once your voice feels steady and you can sing a few notes without fatigue, start with short, low‑volume practice sessions, gradually increasing duration.  \n5. **Monitor**: if hoarseness persists beyond 6 weeks, or you notice breathiness, throat pain, or difficulty swallowing, schedule an ENT follow‑up.  \n\nWhen you’re cleared, you can re‑join the choir, but start with a microphone and keep the volume moderate until your voice fully recovers. We’ll keep a close eye on your progress together.",
          "order": 8,
          "qid": "S18-Q08"
        },
        {
          "q": "Do I need to avoid certain foods because of iodine?",
          "gt": "I hear how uncertain you feel about every little detail after your surgery, especially when you’re already juggling a busy teaching schedule and the new scar on your neck.\n\nAfter a total thyroidectomy, your body no longer produces thyroid hormone, so iodine isn’t needed for hormone synthesis. Levothyroxine (the synthetic hormone you’ll take) is absorbed regardless of how much iodine you eat, and normal dietary iodine—found in dairy, seafood, and iodized salt—doesn’t interfere with your medication. In fact, iodine is an essential nutrient for many other bodily functions, so there’s no medical reason to cut it out.  \n\nThe only time you might need to be cautious is if you have a separate iodine allergy or a condition that requires limiting iodine (for example, certain kidney disorders). In those rare cases, your endocrinologist can advise a tailored plan. Otherwise, you can continue your usual diet, keep your levothyroxine dose on schedule, and monitor your thyroid‑stimulating hormone (TSH) levels every 6–12 weeks as your doctor recommends.  \n\nIf you notice any new symptoms—such as swelling, difficulty breathing, or unusual fatigue—reach out to your care team right away. You’re not alone in this; we’ll keep a close eye on your recovery together.",
          "order": 9,
          "qid": "S18-Q09"
        },
        {
          "q": "How do I keep from defining myself by this scar?",
          "gt": "I hear how overwhelming it feels to see a new scar on your body, especially when you’re used to being the steady presence in your classroom.  \n\n**Scar care & voice recovery**  \n- Keep the scar clean and dry; apply a thin layer of silicone gel sheet or silicone cream daily for 12–18 months—this helps flatten and fade the mark.  \n- Massage the area gently with a moisturizing lotion 2–3 times daily to improve pliability.  \n- Protect from sun (SPF 50+) and avoid tight clothing that rubs the scar.  \n- For hoarseness, start vocal rest for 24–48 h, then begin gentle voice‑therapy exercises (breathing, humming, gentle pitch glides) under a speech‑language pathologist. Most teachers notice improvement in 4–6 weeks; if hoarseness persists beyond 3 months, schedule an ENT follow‑up.  \n\n**Psychological coping**  \n- Remind yourself that a scar is a physical reminder of resilience, not a defining trait.  \n- Practice self‑affirmation: write three strengths you bring to your students each day.  \n- Join a support group or talk with a counselor to explore identity beyond the body.  \n- Use mindfulness or brief grounding exercises when the scar’s presence feels intrusive.  \n\n**Monitoring**  \n- Watch for redness, itching, or pain—contact your surgeon or dermatologist if these occur.  \n- If the scar becomes raised or painful, a dermatologist can recommend laser or steroid injections.  \n\nYou’re more than a scar; we’ll work together to keep you feeling whole and confident.",
          "order": 10,
          "qid": "S18-Q10"
        }
      ]
    },
    {
      "id": "S19",
      "title": "Runner with a new scar (high-grade thigh sarcoma)",
      "diagnosis": "High-grade soft tissue sarcoma of the thigh",
      "treatment_plan": "Limb-sparing surgery with radiation (pre- or post-operative) and rehabilitation",
      "narrative": "I'm 46, a half-marathoner. A deep thigh mass turned out to be sarcoma. I want to keep my leg strong and my life moving.",
      "qa": [
        {
          "q": "Will surgery steal my stride, or can I run again?",
          "gt": "I hear the uncertainty you feel about whether the surgery will “steal” your stride, especially after all the training you’ve put into half‑marathons. It’s natural to worry about how your leg will function once the tumor is removed.\n\nFor a deep‑thigh sarcoma, surgeons aim for a wide local excision that preserves as much muscle and nerve as possible. If the tumor is close to major nerves or the quadriceps, a more extensive resection may be needed, but limb‑sparing procedures are common in adults. After surgery, you’ll start with a short period of protected weight‑bearing (often 4–6 weeks) using crutches or a walker. A structured physical‑therapy program follows, focusing on restoring quadriceps strength, hip stability, and gait mechanics. Most patients can return to running after 3–6 months, once they meet strength and endurance milestones and have no residual pain or instability. Your oncologist will schedule regular imaging (MRI or CT every 3–6 months) and functional assessments to ensure the limb remains healthy and to catch any recurrence early.\n\nIn short, while the surgery may temporarily alter your stride, a carefully planned, progressive rehab plan can help you regain full running ability. Your team will monitor progress closely and adjust the plan as needed.",
          "order": 1,
          "qid": "S19-Q01"
        },
        {
          "q": "Pre-op or post-op radiation—what protects my leg best?",
          "gt": "I hear how frightening the idea of radiation‑related leg weakness feels, especially when you’re used to pushing your limits on the trail. It’s natural to worry about keeping that strength.\n\n**Pre‑operative (neoadjuvant) radiation** is often given 50 Gy in 25 fractions before surgery. It can shrink the tumor, sometimes allowing a smaller, more muscle‑preserving resection. However, the dose is delivered to living tissue, so you may experience early fibrosis, temporary swelling, and a higher risk of wound‑healing complications after the operation.  \n\n**Post‑operative (adjuvant) radiation** follows surgery, usually 60 Gy in 30 fractions, targeting any microscopic disease left behind. Because the tissue has already been cut, the risk of wound problems is lower, but the higher dose can still lead to late fibrosis, neuropathy, and gradual loss of muscle tone.  \n\nFor limb‑sparing surgery, many multidisciplinary teams favor pre‑op radiation when the tumor is large or close to critical structures, as it can reduce the surgical margin needed. If the tumor is already resectable with clear margins, post‑op radiation may be chosen to spare the muscle from early radiation exposure.  \n\nYour oncologist and surgeon will weigh tumor size, location, and your functional goals. They’ll monitor wound healing, perform serial MRIs, and assess strength with gait analysis to adjust the plan if needed.  \n\nWe’ll work closely to keep your leg as strong as possible while treating the sarcoma.",
          "order": 2,
          "qid": "S19-Q02"
        },
        {
          "q": "How do I avoid lymphedema or swelling that ends training?",
          "gt": "I hear how anxious you must feel about keeping your training on track while protecting your leg, especially after a major surgery that could change how your body feels.\n\n**What you can do to keep swelling at bay**\n\n1. **Early monitoring** – Measure your thigh circumference at the same points (mid‑calf, mid‑thigh, just above the knee) every week for the first 8 weeks, then monthly. A rise of >2 cm or a new “tight‑ness” flag is a red flag.  \n2. **Compression garment** – A 20–30 mmHg compression sleeve or stocking worn during activity and for at least 6 hours after training can reduce lymphatic stasis. Keep it clean, replace it if it’s worn out, and remove it at night unless your surgeon says otherwise.  \n3. **Targeted physiotherapy** – Start gentle range‑of‑motion and low‑impact cardio (cycling, swimming) as soon as your surgeon clears you. A physical therapist trained in oncologic rehab can add manual lymphatic drainage and progressive strengthening while avoiding high‑impact jumps or heavy squats until you’re fully healed.  \n4. **Lifestyle tweaks** – Maintain a healthy weight, stay hydrated, and avoid prolonged standing or sitting. If you feel a “heavy” sensation, elevate the leg for 15–20 min and apply a cool compress.  \n5. **When to call your team** – If swelling increases, skin changes (tightness, discoloration), pain, or you develop a fever, contact your oncologist or surgeon right away. Early referral to a lymphedema specialist can prevent progression.\n\n**Next steps**  \nYour surgeon and oncologist will set a schedule for follow‑up visits (often every 4–6 weeks in the first year). Bring your measurements and any new symptoms to those appointments. With vigilant monitoring, compression, and rehab, you can keep your leg strong and your training moving forward.",
          "order": 3,
          "qid": "S19-Q03"
        },
        {
          "q": "If margins are close, does that mean I’ll lose the leg?",
          "gt": "I hear how frightening the idea of losing your leg feels, especially when you’re a half‑marathoner who relies on that strength for every run and every day.\n\nClose surgical margins mean the tumor was removed with only a few millimeters of healthy tissue left. That does **not** automatically mandate amputation. Surgeons first try to achieve a wider margin by re‑resecting the area if it’s feasible, or by adding adjuvant radiation (typically 50–60 Gy in 25–30 fractions) within 4–6 weeks after the initial operation. If the margin remains close or positive after re‑resection, the multidisciplinary team will weigh the risks of a second surgery versus limb‑sparing radiation or, in rare cases, amputation. Your oncologist will tailor the plan based on tumor size, location, and your overall health.\n\nAfter treatment, you’ll have imaging (MRI or CT) every 3 months for the first 2 years, then every 6 months. Blood tests and physical exams will monitor for recurrence and assess functional recovery. Physical therapy will help restore strength and range of motion, and you’ll be encouraged to resume training gradually as healing allows.\n\nWe’ll work closely to keep your leg functional—amputation is a last resort, not a default outcome.",
          "order": 4,
          "qid": "S19-Q04"
        },
        {
          "q": "Can I work remotely during recovery?",
          "gt": "I hear how anxious you feel about staying active and productive, especially when a serious diagnosis like sarcoma can feel like a sudden halt to your routine.\n\nRemote work is usually feasible during sarcoma recovery, but it hinges on your treatment phase. After surgery you’ll likely need to keep weight off the leg for 4–6 weeks, so a desk job with a supportive chair and a standing‑desk option can help you stay mobile without over‑loading the limb. If you’re on chemotherapy, fatigue and neuropathy are common; short, frequent breaks and a quiet workspace can mitigate these effects.\n\nKeep an eye on wound healing, pain levels, and blood counts (CBCs every 2–3 weeks during chemo). Report any sudden swelling, redness, or severe pain to your oncologist right away. Avoid heavy lifting, prolonged standing, and driving if your balance or coordination is impaired.\n\nTalk with your oncologist and an occupational therapist about a tailored ergonomic setup and a flexible schedule that lets you adjust hours as fatigue fluctuates. Your team can help you balance recovery with work, so you stay strong and engaged.",
          "order": 5,
          "qid": "S19-Q05"
        },
        {
          "q": "What about nerve damage—will my foot drop?",
          "gt": "I hear how scary the idea of foot drop feels, especially when you’re used to keeping your legs strong for running and everyday life.\n\nFoot drop most often results from injury to the common peroneal nerve, which runs just below the knee and supplies the muscles that lift the foot. In thigh sarcomas, the risk of nerve damage depends on the tumor’s size, depth, and proximity to the neurovascular bundle. If the nerve is encased, the surgeon may need to sacrifice it or perform a nerve graft; if it’s only stretched, the nerve can often recover over weeks to months. Radiation can cause delayed neuropathy, but this usually appears after several months and is less common than surgical injury.\n\nAfter surgery, your team will monitor you with:\n- Daily neurologic checks for weakness or numbness\n- An EMG/nerve‑conduction study at 4–6 weeks if symptoms appear\n- Physical therapy starting immediately to strengthen the dorsiflexors and prevent contractures\n\nIf foot drop develops, an ankle‑foot orthosis can keep your foot clear, and targeted physiotherapy can improve strength. Many patients regain full function with time and rehab. Discuss your specific surgical plan with your surgeon; they can explain whether nerve preservation or grafting is planned and what your recovery timeline might look like.",
          "order": 6,
          "qid": "S19-Q06"
        },
        {
          "q": "Are scans forever, and how often?",
          "gt": "I hear how anxious you feel about the idea of endless scans, especially when you’re already juggling a demanding training schedule and a strong desire to keep your leg powerful.\n\nAfter definitive surgery (and any adjuvant therapy) the usual surveillance for a deep‑thigh soft‑tissue sarcoma follows a stepped‑down pattern. In the first 2–3 years, most guidelines recommend imaging every 3–6 months: a chest CT to catch pulmonary metastases and an MRI of the thigh (or CT if MRI isn’t available) to look for local recurrence. From years 3–5, the interval typically widens to every 6–12 months, and after 5 years many clinicians switch to annual scans or stop routine imaging if the patient remains disease‑free and the tumor was low‑grade. However, high‑grade or large tumors, or those that were incompletely resected, may warrant lifelong surveillance because late recurrences, though rare, can occur. Your oncologist will tailor the schedule to your specific risk factors, so it may be a bit longer or shorter than the standard plan.\n\nIf you notice new pain, swelling, or any other concerning symptom, you should get an imaging study sooner—symptom‑driven imaging is always an option. Keep a log of any changes in your leg and bring it to appointments; it helps the team decide whether an earlier scan is needed.\n\nRemember, the goal is to catch recurrence early while minimizing unnecessary radiation and anxiety. Your care team will adjust the plan as your situation evolves, so you’re not alone in navigating this.",
          "order": 7,
          "qid": "S19-Q07"
        },
        {
          "q": "Is chemo part of this?",
          "gt": "I hear how frightening it feels to wonder whether chemotherapy will be part of your plan, especially when you’re already anxious about keeping your leg strong and staying active.\n\nFor a deep‑thigh sarcoma, the cornerstone is usually wide surgical resection, sometimes followed by radiation to reduce local recurrence. Chemotherapy is not mandatory for all extremity sarcomas, but it is often recommended for high‑grade tumors, large lesions, or if there’s a risk of micrometastatic disease. The most common regimens are:\n\n- **Doxorubicin (Adriamycin) 60 mg/m² IV over 15–30 min** plus **ifosfamide 10 g/m² IV over 24 h** (often split into 2 days).  \n- Alternatively, **ifosfamide 10 g/m²** with **dacarbazine 300 mg/m²** on day 1, repeated every 3 weeks for 6–8 cycles.\n\nKey monitoring: CBC and renal panel before each cycle; echocardiogram or MUGA scan every 3–6 months to track left ventricular ejection fraction (especially with doxorubicin). Expect side effects such as nausea, fatigue, myelosuppression, and, rarely, neuropathy or cardiotoxicity. Recovery between cycles is usually 2–3 weeks.\n\nYour oncologist will tailor the plan—if your tumor is low‑grade or small, they may skip chemo; if it’s high‑grade or large, they’ll likely add it. Discuss the exact regimen, timing, and what to expect with your team so you can stay informed and keep your leg as strong as possible.",
          "order": 8,
          "qid": "S19-Q08"
        },
        {
          "q": "How do I fuel healing without gaining weight when I can’t run?",
          "gt": "I hear how anxious and determined you feel, especially when the thought of losing your running edge feels like a loss of identity.  \n\n**Nutrition** – Aim for 1.2–1.5 g of protein per kilogram of body weight daily (e.g., 90–110 g if you weigh 75 kg). Keep calories about 10–15 % below your maintenance level to avoid excess weight while still fueling healing. Focus on whole‑food carbs (vegetables, whole grains), healthy fats (nuts, olive oil), and plenty of vitamin‑D and calcium‑rich foods to support bone and muscle health.  \n\n**Exercise** – Replace running with resistance training and low‑impact cardio. Do 2–3 strength sessions per week (leg presses, squats, resistance‑band work) and 30–45 min of stationary bike, swimming, or water aerobics to maintain leg strength and cardiovascular fitness without high impact.  \n\n**Monitoring** – Weigh yourself weekly and track body composition (e.g., skinfold calipers or bioimpedance). Adjust calories by 200–300 kcal if you gain >0.5 kg in a week. Report any swelling, fatigue, or changes in appetite to your oncology team.  \n\n**Support** – Work with a registered dietitian who specializes in oncology nutrition and a physiotherapist for a tailored exercise plan. Discuss any medication‑related appetite changes or side effects with your oncologist so the plan can be fine‑tuned.  \n\nWith a personalized plan and your team",
          "order": 9,
          "qid": "S19-Q09"
        },
        {
          "q": "What if I trip on fear every time I lace up?",
          "gt": "I hear how frightening it feels to lace up each time, especially when you’re already carrying so much weight on your shoulders.  \n\nFear after a sarcoma diagnosis is common, and it can interfere with the very activity that keeps you strong.  The first step is to treat the fear as a medical issue that can be managed.  Your oncologist can review your pain control plan—opioids, NSAIDs, or nerve blocks—so that discomfort doesn’t trigger anxiety.  A physical‑therapy referral can help you rebuild strength gradually, starting with low‑impact exercises (stationary bike, water aerobics) and progressing to walking with a supportive shoe or orthotic.  Cognitive‑behavioral therapy (CBT) or a sports‑psychology specialist can teach exposure techniques: start by simply tying the laces, then walking a short distance, and slowly increase distance as confidence builds.  Mindfulness breathing or guided imagery before each session can reduce the physiological arousal that fuels the “trip.”  \n\nIf anxiety remains intense, your team can discuss short‑term anxiolytics (e.g., low‑dose benzodiazepine or SSRI) to give you a safety net while you work on coping skills.  Keep a simple log of pain, swelling, and mood; review it with your oncologist every 4–6 weeks to adjust treatment or therapy.  \n\nYou’re not alone—your care team will monitor both your tumor response and your emotional well‑being, and we’ll adjust the plan as needed.",
          "order": 10,
          "qid": "S19-Q10"
        }
      ]
    },
    {
      "id": "S20",
      "title": "Left the field mid-game (stage II testicular cancer)",
      "diagnosis": "Stage II testicular cancer (seminoma or nonseminoma)",
      "treatment_plan": "Orchiectomy followed by surveillance, chemotherapy, or radiation depending on type and spread; fertility preservation recommended",
      "narrative": "I'm 28, play in a weekend soccer league, and just lost a testicle to cancer. I’m scared about fertility, masculinity, and telling my team.",
      "qa": [
        {
          "q": "Is banking sperm urgent, or can I wait until after the next scan?",
          "gt": "I hear how frightening the uncertainty about your future fertility feels, especially when you’re already dealing with a cancer diagnosis and the pressure of sharing this with your teammates.\n\nSperm banking is ideally done **before** any chemotherapy or radiation, because those treatments can severely damage sperm production. If you’re still awaiting your next scan and have not yet started systemic therapy, you can technically wait until after the scan, but you risk missing the window if chemo is scheduled soon. With only one testicle left, sperm counts may be lower, but many men still produce viable sperm. A single semen sample—collected by masturbation—can be frozen in liquid nitrogen within a few days; the process takes about 1–2 hours and can be done at most fertility clinics. Stored sperm retains 80–90 % viability after thawing, giving you a realistic chance of future conception.\n\nDiscuss the exact timing with your oncologist and a reproductive specialist. They can confirm whether you’re about to start chemo and advise whether immediate banking is safest. If you’re not yet on treatment, you can still bank now to avoid any future delays.\n\nLet’s keep the conversation open so you feel supported as you decide the best timing for sperm banking.",
          "order": 1,
          "qid": "S20-Q01"
        },
        {
          "q": "Will chemo wreck my lungs or stamina permanently?",
          "gt": "I hear how scary it feels to worry that chemo could permanently damage your lungs or leave you feeling drained, especially when you’re used to keeping up on the field.\n\nFor most testicular‑cancer patients, the standard BEP regimen (bleomycin 30 mg/m² IV on days 1, 8, 15; etoposide 100 mg/m² IV days 1‑5; cisplatin 20 mg/m² IV days 1‑5) is given in 3 cycles over 3‑4 months. Bleomycin is the only drug with notable pulmonary toxicity, but the cumulative dose is kept below 400 units, which keeps the risk of permanent lung damage very low. Your oncologist will usually order a baseline chest X‑ray and pulmonary‑function test (PFT) before starting, then repeat a chest X‑ray after the second cycle and monitor for new cough, shortness of breath, or a drop in oxygen saturation. If any symptoms appear, bleomycin is stopped immediately and a high‑dose steroid pulse may be given.\n\nFatigue is common after each cycle—peaking 48–72 hours later and usually resolving within 1–2 weeks. Most patients return to their pre‑treatment stamina within a month of completing therapy. Long‑term lung or endurance loss is rare, but if you have pre‑existing lung disease or develop symptoms, your team will adjust the plan right away.\n\nYour oncologist can give you a personalized monitoring schedule, but rest assured that the standard BEP course is designed to minimize lasting pulmonary harm while effectively treating the cancer.",
          "order": 2,
          "qid": "S20-Q02"
        },
        {
          "q": "Do I need a prosthesis to feel 'normal'?",
          "gt": "Feeling scared and uncertain about how to feel “normal” after losing a testicle is completely understandable, especially when you’re juggling the demands of soccer, work, and your own sense of masculinity.\n\nA testicular prosthesis is not medically required for fertility or hormone production; the remaining testicle usually produces enough sperm and testosterone. The prosthesis is purely cosmetic, designed to restore symmetry and help you feel more comfortable in tight‑fitting clothing or when you want to avoid the visual reminder of the loss. Most surgeons recommend waiting until the incision has fully healed—typically 2–3 weeks—before placing the implant. The procedure is a small outpatient surgery, usually under local or general anesthesia, and complications are rare but can include infection, extrusion, or a slight change in sensation. Insurance coverage varies; many plans cover the implant as a reconstructive procedure, so discuss with your urologist and insurance. Ultimately, the decision is personal: if the idea of a prosthesis would boost your confidence and ease social anxiety, it’s a reasonable option; if you’re comfortable without one, you can skip it.\n\nWhatever choice you make, we’ll support you every step of the way.",
          "order": 3,
          "qid": "S20-Q03"
        },
        {
          "q": "Is radiation still used, and will it affect fertility?",
          "gt": "I hear how scary the idea of radiation feels, especially when you’re already juggling the loss of a testicle and worries about your future on the field.\n\nRadiation is still a standard option for **stage I seminoma** after a radical orchiectomy, usually 20–30 Gy to the retro‑peritoneal nodes. For **non‑seminoma** (the most common type in men your age), radiation is rarely used; instead, a cisplatin‑based chemotherapy regimen (e.g., BEP—bleomycin, etoposide, cisplatin) is preferred. If radiation is planned, the field is carefully shaped to spare the remaining testis, but any exposure can reduce sperm production. Because of this, most urologists and oncologists recommend **sperm banking before any adjuvant therapy**. After treatment, you’ll have regular semen analyses and testosterone checks; most men maintain normal testosterone levels with one testis, but fertility may be reduced if the remaining testis receives radiation.\n\nDiscuss your specific stage and histology with your oncologist; they’ll tailor the plan and let you know whether radiation is indicated and how to protect fertility.  \n\nYou’re not alone—let’s keep the conversation open and make sure every step is clear.",
          "order": 4,
          "qid": "S20-Q04"
        },
        {
          "q": "What if tumor markers bounce—am I relapsing?",
          "gt": "I hear how frightening a sudden spike in your tumor markers feels, especially after the big changes you’ve already gone through.  \n\nA temporary rise in AFP, hCG, or LDH after orchiectomy can happen for a few weeks as the body clears tumor debris—this is called a “bounce” and isn’t always a sign of recurrence.  \nGuidelines recommend checking markers every 3–4 weeks for the first 2 years, then every 3 months until year 5, and annually thereafter. Your oncologist will tailor the schedule to your risk.  \nIf a marker climbs again, the next step is a repeat blood test within 1–2 weeks and a cross‑sectional scan (CT chest/abdomen/pelvis or MRI) to look for new lesions. A biopsy may be needed if imaging is suspicious.  \nShould imaging confirm relapse, standard care is cisplatin‑based chemotherapy (e.g., BEP: bleomycin, etoposide, cisplatin) or, for non‑seminoma, a platinum‑based regimen tailored to the site and extent. Your team will discuss options and timing.  \n\nWe’ll monitor closely together, and any change will be addressed promptly.",
          "order": 5,
          "qid": "S20-Q05"
        },
        {
          "q": "Can I be intimate during treatment?",
          "gt": "Feeling scared and anxious about intimacy right now is understandable, especially after a sudden loss and uncertain treatment.  \n\nAfter a testicular removal, the incision usually heals in 1–2 weeks. You can resume sex once the wound is closed and you feel comfortable, but avoid activity that strains the area.  \n\nIf you’re on chemotherapy, most regimens (cisplatin–bleomycin–vinblastine or docetaxel–ifosfamide) are given every 3 weeks. You can resume sex 48–72 h after the infusion once nausea and fatigue subside. Avoid intercourse if you have fever, bleeding, or a urinary tract infection.  \n\nCertain drugs increase bleeding risk (e.g., anticoagulants or high‑dose steroids). If you’re on such meds, discuss with your oncologist before resuming intimacy. Testosterone replacement may cause acne or mood changes; monitor closely.  \n\nSperm banking should be done before treatment; most men can still conceive after one testicle, though testosterone may drop temporarily. Discuss fertility options with your urologist and oncologist.  \n\nKeep open communication with your partner and teammates. If you feel exhausted, it’s okay to postpone. Your oncologist will monitor blood counts and organ function every 2–3 weeks to ensure safety.  \n\nYou’re not alone—let’s work together to keep you healthy and connected.",
          "order": 6,
          "qid": "S20-Q06"
        },
        {
          "q": "How do I tell my teammates without jokes swallowing the room?",
          "gt": "I hear how scary it feels to share something so personal, especially when you’re still trying to keep the game spirit alive—your nerves are completely understandable.\n\n**Fertility**: After a unilateral orchiectomy, most men retain normal fertility if the remaining testicle is healthy. Sperm banking before surgery is the safest option; if you already banked, you can use those samples later. If your sperm count is low, assisted reproductive techniques (IVF with ICSI) can still help. **Masculinity**: Losing one testicle rarely changes testosterone production. If you notice fatigue, mood changes, or low libido, your oncologist can refer you to an endocrinologist for a hormone panel and discuss testosterone‑replacement therapy if needed.\n\n**How to tell your teammates**: Pick a quiet moment—maybe after a warm‑up or during a break—so you’re not rushed. Start with, “I want to share something personal with you.” Then say, “I had surgery and lost a testicle, but I’m still healthy and playing. I’m not worried about my performance or masculinity, and I’ve talked to my doctor about fertility and hormones.” Keep it straightforward; let them know you’re open to questions but you’d prefer to keep the conversation respectful, not joking. If you feel uneasy, practice what you’ll say or bring a trusted teammate or coach to help set the tone.\n\n**",
          "order": 7,
          "qid": "S20-Q07"
        },
        {
          "q": "Will insurance question a prosthesis?",
          "gt": "I hear how scary it feels to think about another medical decision after cancer, especially when you’re already juggling so much anxiety about your future.\n\nMost U.S. insurance plans treat a testicular prosthesis as a reconstructive device, not a cosmetic one, so it’s usually covered after an orchiectomy. Coverage is still plan‑specific: you’ll need to provide the insurer with the operative report and a letter from your urologist stating that the prosthesis is medically necessary. Many carriers require prior authorization, so call your member services early and ask for the exact documentation they need. If you have a high deductible or are close to your out‑of‑pocket limit, you may have to pay the cost until you hit that threshold. If your plan initially denies coverage, you can file an appeal—most insurers have a formal appeal process, and you can request a review by a medical director. If coverage remains denied, some prosthetic manufacturers offer payment plans or patient assistance programs.\n\nYou’re not alone in navigating this; let’s keep the lines open so you can get the support you need.",
          "order": 8,
          "qid": "S20-Q08"
        },
        {
          "q": "Does losing a testicle change my hormones forever?",
          "gt": "I hear how scary the idea of a permanent hormonal shift feels, especially when you’re already juggling the emotional weight of cancer and the desire to stay strong on the field.\n\nAfter a unilateral orchiectomy, the remaining testicle usually ramps up testosterone production to keep levels within the normal range. Most men keep total testosterone, LH, and FSH in the mid‑normal range within a few weeks, and most experience no lasting change in libido or energy. However, a small drop (often 10‑20 %) can occur, and if it falls below 300 ng/dL you might notice fatigue, mood swings, or decreased muscle mass. Your oncologist will order a baseline testosterone panel and repeat it at 3 months, 6 months, and annually thereafter; if levels stay low, testosterone replacement therapy can be started safely.\n\nFertility is a separate issue. One testicle can produce enough sperm for many men, but the risk of subfertility or azoospermia is higher after surgery. If you’re concerned, discuss sperm banking before treatment. If you’re comfortable, you can share your experience with teammates when you feel ready; most people respond with support, and it can even strengthen team bonds.\n\nRemember, hormone levels are monitored and can be managed—so you’re not alone in this.",
          "order": 9,
          "qid": "S20-Q09"
        },
        {
          "q": "If I relapse, is cure still on the table?",
          "gt": "I hear how frightening the idea of a relapse feels, especially when you’re already juggling so much about your future and your team—your worries are completely understandable.  \n\nIf testicular cancer returns, the chance of cure is still very real, especially for an early relapse (within 12 months of initial therapy).  Most patients are treated with a cisplatin‑based salvage regimen such as BEP (bleomycin, etoposide, cisplatin) or EP (etoposide, cisplatin).  In high‑risk or late relapse, high‑dose chemotherapy with autologous stem‑cell rescue is an option, and overall cure rates for salvage therapy are roughly 70–80 % for early relapse.  \n\nDuring treatment you’ll have tumor‑marker checks (AFP, hCG, LDH) and CT scans every 2–3 weeks to gauge response.  Blood counts, kidney and liver panels, and hearing tests are monitored weekly because cisplatin can affect these systems.  \n\nDiscuss the plan with your oncologist—he’ll tailor the regimen, timing, and supportive care to your specific situation.  If you’re concerned about fertility, sperm banking from the remaining testicle before starting salvage therapy is strongly recommended.  \n\nWe’ll work closely with your care team to keep you informed and supported every step of the way.",
          "order": 10,
          "qid": "S20-Q10"
        }
      ]
    },
    {
      "id": "S21",
      "title": "Keys and the road (brain metastases, stereotactic radiosurgery)",
      "diagnosis": "Limited brain metastases from solid tumor",
      "treatment_plan": "Stereotactic radiosurgery (SRS) to brain lesions; systemic therapy continues or adjusts; seizure precautions and neuro follow-up",
      "narrative": "I'm 56, I drive for work and play piano at church. Small brain spots showed up on my scan. They recommend focused radiation.",
      "qa": [
        {
          "q": "Can I still legally drive after SRS?",
          "gt": "Feeling anxious about whether you can keep driving after SRS is completely understandable, especially when you rely on your car for work and your piano practice.  \n\nSRS is an outpatient procedure that delivers a single, high‑dose radiation beam to a small brain lesion. Most patients experience only mild fatigue or a brief headache, so the procedure itself rarely precludes driving.  \n\nHowever, any new or worsening symptoms—headaches, visual disturbances, dizziness, seizures, or cognitive changes—can impair safe driving. Most clinicians recommend waiting at least 2–4 weeks after SRS before resuming driving, unless symptoms appear sooner.  \n\nDriving laws vary by state, but most require a physician’s clearance once you feel symptom‑free. Your radiation oncologist or a neurologist can issue a written statement confirming you meet the functional criteria.",
          "order": 1,
          "qid": "S21-Q01"
        },
        {
          "q": "Will radiation change how I think or play music?",
          "gt": "I hear how unsettling it feels to think that a treatment could alter the way you think or play piano, especially when music is such a big part of your life and you’re already juggling a demanding job.\n\nFocused brain radiation—most often stereotactic radiosurgery (SRS) or a short course of fractionated stereotactic radiotherapy (FSRT)—delivers a high dose to the lesion while sparing surrounding tissue. For small, well‑localized spots, the risk of lasting cognitive changes is low. Common short‑term effects are mild fatigue, a brief headache, and sometimes a transient “brain fog” that usually resolves within a week or two. Long‑term neurocognitive decline is rare, especially when the target is away from critical language, memory, or motor areas. Your team will perform a baseline neurocognitive screen (memory, attention, executive function) and repeat it a few months after treatment to catch any subtle changes early. If the spot sits near the motor cortex or auditory pathways, the team may adjust the dose or add a protective strategy, but most patients retain full musical and driving abilities.\n\nRest assured that your radiation oncologist will tailor the plan to minimize risk, and you’ll have regular MRI and cognitive follow‑ups to monitor progress. If you notice any new memory lapses, difficulty with coordination, or changes in your piano playing, let your team know right away so we can address it promptly.",
          "order": 2,
          "qid": "S21-Q02"
        },
        {
          "q": "Do I lose my hair in patches?",
          "gt": "I hear how frightening the thought of hair loss feels, especially when you’re already juggling a demanding job, driving, and playing piano for your church community—your worries are completely understandable.\n\nFocused radiation—often stereotactic radiosurgery or stereotactic body radiation therapy—delivers a high dose to a very small brain lesion while sparing the surrounding brain and scalp. Because the scalp is usually outside the treatment field, patchy hair loss is uncommon. If the lesion is near the skull base or the beam must pass through the scalp, you might experience temporary, patchy alopecia that typically appears 1–3 weeks after treatment and usually regrows within 3–6 months. The radiation dose to the scalp is kept as low as possible, so the risk is much lower than with whole‑brain or whole‑body radiation.\n\nYou won’t need special monitoring for hair loss beyond routine follow‑up visits. If you do notice patchy hair loss, your team can discuss supportive options—such as wigs, scarves, or topical treatments—to help you feel comfortable.  \n\nRest assured, your oncologist will tailor the plan to keep the scalp out of the beam whenever feasible, and we’ll monitor you closely for any side effects.",
          "order": 3,
          "qid": "S21-Q03"
        },
        {
          "q": "How do you decide which lesions to treat now versus watch?",
          "gt": "I hear how anxious you feel about deciding which lesions to treat, especially when you’re balancing driving for work and playing piano at church.\n\nWhen a radiation oncologist chooses which brain spots to treat immediately, they look at several key factors:  \n1. **Symptoms** – Any headache, weakness, seizures, or visual changes usually prompt treatment right away.  \n2. **Size and growth** – Lesions larger than about 2–3 cm or those that have shown rapid growth on serial scans are prioritized because they’re more likely to cause mass effect.  \n3. **Location** – Spots near critical structures (e.g., brainstem, optic pathways) or in eloquent cortex may be treated sooner to prevent functional loss.  \n4. **Number of lesions** – A single or a few small lesions (≤4–5) are ideal for stereotactic radiosurgery (SRS). If there are many (>10) or diffuse lesions, whole‑brain radiation or a watch‑and‑wait approach may be considered.  \n5. **Overall disease burden and performance status** – If the patient has limited life expectancy or poor functional status, the risks of radiation may outweigh the benefits, and monitoring with MRI every 2–3 months is reasonable.  \n\nIf a lesion remains asymptomatic, is small (<2 cm), deep, and the patient’s overall prognosis is limited, we often “watch” it, re‑scanning every 2–3 months. Should it grow or symptoms appear, we’ll shift to SRS or, if many lesions are involved, to whole‑brain radiation.  \n\nWe’ll keep a close eye on you, adjusting the plan as needed while preserving your ability to drive and play piano.",
          "order": 4,
          "qid": "S21-Q04"
        },
        {
          "q": "Does this mean my systemic treatment failed?",
          "gt": "I hear how frightening it feels to see new spots on your brain scan, especially when you’re trying to stay strong for your family and your church community.\n\nSmall brain lesions can be metastases, benign cysts, or other changes. Focused radiation—often stereotactic radiosurgery—is the standard treatment for isolated brain metastases because many systemic drugs don’t cross the blood‑brain barrier. Therefore, the appearance of a brain spot does **not automatically mean your systemic therapy has failed**; it may simply be a site that the current drugs can’t reach. Your oncologist will review your latest imaging, your current systemic regimen (chemotherapy, targeted therapy, or immunotherapy), and your extracranial disease status. If the rest of your cancer is still controlled, they may keep the same systemic therapy and add a CNS‑penetrant agent or switch to one that better reaches the brain.  \n\nYou’ll likely get an MRI brain every 3 months and routine blood tests to monitor for new neurological symptoms or extracranial progression. If new symptoms arise, or if imaging shows growth, the team may adjust the systemic plan or add additional CNS‑directed therapy.  \n\nWe’ll keep a close eye on your overall picture and adapt the plan together.",
          "order": 5,
          "qid": "S21-Q05"
        },
        {
          "q": "If a new spot appears later, do we do SRS again?",
          "gt": "I hear how frightening it feels to think about another spot appearing, especially when you’re balancing work and music.\n\nIn most cases, a new brain lesion can be treated with a second round of stereotactic radiosurgery (SRS) if it’s small (typically ≤ 5 mm) and located in a safe area. The decision depends on several factors: the size and location of the new spot, the cumulative dose the surrounding brain has already received, and whether the lesion is symptomatic. Your radiation oncologist will review the prior dose map and the new MRI to ensure the total dose to normal tissue stays below safe limits (usually < 12 Gy in a single fraction for most brain regions). If the new lesion is larger, in a critical area, or if you’ve already received a high cumulative dose, alternative strategies—such as fractionated stereotactic radiotherapy, surgical resection, or even systemic therapy—might be considered.\n\nYou’ll typically have MRI scans every 3–6 months after the first SRS. If a new spot shows up, the team will discuss whether a repeat SRS is appropriate, weighing the benefits against risks like radiation necrosis or cognitive changes. Your neurologist and radiation oncologist will tailor the plan to your overall health and preferences.\n\nRest assured, we’ll monitor closely and adjust the plan as needed to keep you safe and comfortable.",
          "order": 6,
          "qid": "S21-Q06"
        },
        {
          "q": "What symptoms should make me call immediately?",
          "gt": "I hear how frightening it can feel to discover new brain spots, especially when you’re juggling driving and playing piano for your church—your worries are completely understandable.\n\nIf you notice any new or worsening neurological symptoms, call your oncologist right away. These include sudden weakness or numbness on one side of the body, slurred speech, or difficulty walking.  \nSevere or persistent headaches that change in character, especially if accompanied by vomiting, visual disturbances, or confusion, should prompt immediate evaluation.  \nAny episode of seizure activity—whether a brief loss of consciousness, shaking, or staring spells—requires urgent medical attention.  \nSigns of increased intracranial pressure, such as sudden vision changes, double vision, or a feeling of pressure behind the eyes, warrant prompt care. Keeping a daily log of headaches, vision changes, or new symptoms can help your team assess progress.  \nAlso, if you develop fever, neck stiffness, or signs of infection, or if you experience sudden loss of consciousness, go to the nearest emergency department.\n\nWe’ll monitor your symptoms closely, and you can always reach out if anything feels off—your health team is here to support you.",
          "order": 7,
          "qid": "S21-Q07"
        },
        {
          "q": "Can I fly for work next week?",
          "gt": "I hear how anxious you feel about flying after your treatment, especially when you’re juggling a demanding job and your role as a church pianist.  \n\nFocused radiation (often stereotactic radiosurgery) is minimally invasive and usually delivered in a single session. Most patients can safely board a plane 24–48 hours after the procedure, provided they have no signs of increased intracranial pressure or seizures. If you experience new or worsening headaches, nausea, vomiting, or any neurological changes, you should postpone travel and contact your radiation oncologist immediately. Your team will schedule a follow‑up MRI in 4–6 weeks and a neurological exam to confirm stability. Bring any prescribed medications, and keep a seizure‑alert plan handy in case you feel unwell during the flight.  \n\nWe’ll monitor your recovery closely, and I’m here to help you navigate any concerns that arise.",
          "order": 8,
          "qid": "S21-Q08"
        },
        {
          "q": "Will steroids make me jittery or hungry?",
          "gt": "I hear how unsettling it can feel to think about new medications, especially when you’re already juggling driving and playing piano.  \n\nSteroids such as dexamethasone are often prescribed before or during focused radiation to reduce swelling around the brain spots. The usual starting dose is 4 mg once daily, which can be increased to 8 mg if needed, and then tapered over 1–2 weeks.  \n\nCommon side effects include increased appetite, mild weight gain, and mood swings. Some people feel a little jittery or restless, especially when the dose is high. Insomnia, muscle aches, and a slight rise in blood sugar are also possible.  \n\nYour team will monitor blood pressure, weight, and blood glucose each visit. If you notice significant mood changes, insomnia, or a sudden increase in appetite, let your oncologist know right away.  \n\nIf the side effects become bothersome, the dose can be lowered or a different steroid (e.g., prednisone) may be tried. In rare cases, a short course of antihistamines can help with jitteriness.  \n\nWe’ll keep a close eye on how you feel, and we’ll adjust the plan together so you can stay comfortable while your treatment progresses.",
          "order": 9,
          "qid": "S21-Q09"
        },
        {
          "q": "How often are MRIs after this?",
          "gt": "I hear how unsettling it feels to have “brain spots” and to be staring at a new treatment plan—especially when you’re juggling a driving job and piano practice, and you want to stay sharp and safe on the road.\n\nAfter focused radiation (often stereotactic radiosurgery), most centers schedule a baseline MRI right before treatment, then an MRI at about 1–3 months to confirm the lesion’s response. If the spot looks stable, the next scans are usually every 3–6 months for the first 2 years, then annually thereafter. Some patients with very small, low‑risk lesions may skip the 3‑month scan and go straight to a 6‑month follow‑up, but that decision is made with your radiation oncologist. If you develop new headaches, vision changes, or neurological symptoms, an MRI is ordered sooner, regardless of the routine schedule. The scans help us spot any radiation‑induced changes or new lesions early, so we can intervene promptly.\n\nYour team will tailor the exact timing to your specific lesion size, location, and overall health, so keep the lines of communication open—any change in symptoms or concerns should prompt an earlier scan.",
          "order": 10,
          "qid": "S21-Q10"
        }
      ]
    },
    {
      "id": "S22",
      "title": "Second chances (liver cancer with cirrhosis)",
      "diagnosis": "Hepatocellular carcinoma in the setting of cirrhosis",
      "treatment_plan": "Locoregional therapy (e.g., ablation or embolization) or systemic therapy; transplant evaluation when appropriate; manage liver function",
      "narrative": "I'm 64 with cirrhosis and now a liver tumor. I quit drinking last year. I want to live long enough to walk my daughter down the aisle.",
      "qa": [
        {
          "q": "Am I a transplant candidate, or did I miss that window?",
          "gt": "I hear how scary it feels to wonder if you’ve missed the transplant window, especially when you’re already carrying so much hope for your daughter’s wedding day.\n\nA 64‑year‑old who stopped drinking a year ago still meets the basic abstinence requirement (≥6 months). Age alone is not a hard cutoff—many centers accept candidates up to 70–75 years if liver function and overall health allow. The key question is whether your liver tumor falls within the transplant‑eligible “Milan criteria”: a single lesion ≤5 cm or up to three lesions each ≤3 cm, with no macrovascular invasion or extra‑hepatic spread. If your imaging shows that, you’re likely still a transplant candidate. If the tumor is larger or more extensive, the transplant team may consider down‑staging with locoregional therapies (e.g., TACE, radioembolization) or systemic therapy while you’re evaluated.\n\nThe next step is a formal transplant work‑up: a hepatology referral, repeat MRI/CT, liver function labs, a MELD score calculation, and a multidisciplinary board review. Your team will discuss candidacy, timing, and any needed bridging treatments.  \n\nWe’ll keep you informed every step of the way, so you can focus on the moments you want to cherish.",
          "order": 1,
          "qid": "S22-Q01"
        },
        {
          "q": "Does treatment hurt my liver more than the cancer does?",
          "gt": "I hear how frightening the idea of liver damage feels, especially when you’re already carrying so much for your family—your worries are completely understandable.  \n\n**What the treatment does to your liver**  \nIn patients with cirrhosis, the goal is to control the tumor while preserving as much liver function as possible.  The most common approaches are:  \n• **Transarterial chemoembolization (TACE)** – a catheter delivers doxorubicin (or cisplatin) mixed with lipiodol, then blocks the feeding artery for 30–60 min.  It’s usually repeated every 6–8 weeks, and the liver is monitored with LFTs and imaging.  \n• **Radioembolization (Y‑90 microspheres)** – a single infusion of 30–60 min; the radiation is targeted, sparing healthy tissue.  \n• **Surgical resection or ablation** – if the tumor is small and the liver reserve (Child‑Pugh A) is adequate, removal can be curative with minimal long‑term impact.  \n• **Systemic therapy** – sorafenib (400 mg twice daily) or lenvatinib (8–12 mg daily) are taken orally; they can cause mild transaminase elevations (≤3× ULN) but rarely lead to acute liver failure in well‑controlled cirrhosis.  \n\n**Monitoring and safety**  \n- Baseline and every 2–4 weeks: CBC, CMP, INR, AFP.  \n- Imaging (CT/MRI) every 8–12 weeks to assess tumor response.  \n- If LFTs rise >3× ULN or bilirubin >2 mg/dL, dose is reduced or treatment paused.  \n- Your team will adjust the regimen if liver function declines.  \n\n**Next steps**  \nDiscuss with your hepatologist‑oncologist which modality best matches your liver function and tumor characteristics.  They’ll tailor the schedule and monitoring to keep the cancer under control while protecting your liver.  \n\nWe’ll work closely to keep your liver as healthy as possible while fighting the tumor.",
          "order": 2,
          "qid": "S22-Q02"
        },
        {
          "q": "What if my legs swell and I can’t fit shoes—does that mean it’s all downhill?",
          "gt": "I hear how frightening the idea of swelling that makes shoes fit feels, especially when you’re already carrying so much hope for your daughter’s wedding day.\n\nIn cirrhosis, leg edema is a common sign of portal hypertension and low albumin. It doesn’t automatically mean a rapid decline, but it does signal that the liver’s synthetic function is slipping. Your hepatologist will usually start a diuretic regimen—spironolactone 100 mg daily plus furosemide 20 mg daily—while keeping sodium intake below 2 g/day. Albumin infusions (20 g IV every 3–4 days) can help if serum albumin drops below 2.5 g/dL. You’ll be asked to weigh yourself daily, track the weight trend, and report any sudden increase of >2 kg or new pain. Blood tests (CMP, INR, bilirubin) and a liver ultrasound every 3–4 months monitor tumor size and liver function. If swelling worsens rapidly, shortness of breath appears, or you feel chest tightness, seek urgent care—this could signal heart failure or acute decompensation.\n\nYour team will adjust diuretics, review imaging, and consider more aggressive liver support if needed. We’ll keep a close eye on the picture, so you can stay as healthy as possible for the big day.",
          "order": 3,
          "qid": "S22-Q03"
        },
        {
          "q": "Do I have to swear off every celebration forever?",
          "gt": "I hear how anxious you feel about balancing celebrations with your health, especially when you’re already carrying so much hope for your daughter’s wedding day.\n\nWith cirrhosis, even a single drink can worsen liver inflammation, impair clotting, and interfere with cancer therapies. The safest approach is to abstain from alcohol entirely during any celebration. You can still enjoy the event by choosing non‑alcoholic beverages—sparkling water, mocktails, or specialty sodas—and focusing on food, music, and company. If you’re receiving systemic therapy (e.g., targeted agents or chemotherapy), alcohol can increase toxicity and reduce drug efficacy, so your oncologist will advise against it. Regular liver‑function tests (ALT, AST, bilirubin, INR) every 4–6 weeks will help monitor any changes, and your care team can adjust treatment or supportive measures if needed. Discuss any planned celebrations with your hepatology and oncology teams so they can guide you on safe choices and any necessary precautions.\n\nYou don’t have to give up celebrations, just the alcohol—your team will keep a close eye on your liver health while you enjoy the moments that matter most.",
          "order": 4,
          "qid": "S22-Q04"
        },
        {
          "q": "How risky is bleeding during procedures with my platelets low?",
          "gt": "I hear how scary the idea of bleeding feels, especially when you’re already juggling so much for your family’s future.\n\nBleeding risk during a procedure depends on several factors: your platelet count, INR, fibrinogen level, the type of procedure, and the overall severity of your liver disease. In general, a platelet count below 50 × 10⁶/L is considered high risk for major invasive procedures (e.g., liver biopsy, surgery), while counts under 20 × 10⁶/L raise the risk for even minor interventions. For procedures that can be done with local anesthesia or endoscopic guidance, the threshold is often lower, but many centers still transfuse platelets if the count is <30 × 10⁶/L.\n\nTypical management steps before a procedure include:\n\n1. **Platelet transfusion** – usually 1–2 units to raise the count to ≥50 × 10⁶/L for major work, or ≥20–30 × 10⁶/L for minor work.  \n2. **Correction of INR** – 4 – 6 mL/kg of fresh‑frozen plasma or 10 mg/kg of vitamin K if the INR is >1.5.  \n3. **Antifibrinolytics** – tranexamic acid 1 g IV 30 min before the procedure, then 1 g every 8 h for 24 h, can reduce bleeding in high‑risk patients.  \n4. **Local measures** – use of endoscopic clips, cautery, or ultrasound‑guided needle placement to minimize tissue trauma.  \n5. **Post‑procedure monitoring** – check hemoglobin, hematocrit, and a repeat platelet count 6–12 h after the intervention; watch for signs of hematoma or drop in blood pressure.\n\nYour hepatology and oncology teams will tailor these thresholds to your specific platelet count, liver function tests, and the urgency of the procedure. Discussing the exact numbers and your comfort level with the team will help you feel more in control.  \n\nWe’ll work closely to keep bleeding risk as low as possible while you pursue the best care for your liver tumor.",
          "order": 5,
          "qid": "S22-Q05"
        },
        {
          "q": "If the tumor shrinks, can I get on a transplant list?",
          "gt": "I hear how anxious you feel about the future, especially when you’re already carrying so much hope for your daughter’s wedding day.\n\nIf the tumor responds to treatment and your liver function improves, you can be considered for a transplant. The transplant team will look at several factors:  \n1. **Tumor size and number** – you must fall within the Milan criteria (single tumor ≤5 cm or up to three tumors each ≤3 cm, no vascular invasion).  \n2. **Response to therapy** – shrinkage that brings the tumor into those limits is a key criterion.  \n3. **Liver function** – your MELD score, bilirubin, INR, and albumin must be stable and not too high; a score >15 often delays listing.  \n4. **Overall health** – age alone (64 years) is not a barrier, but comorbidities, performance status, and psychosocial support are evaluated.  \n\nThe typical pathway: after each imaging cycle (usually every 4–6 weeks) and labs (CBC, CMP, AFP), your hepatologist and oncologist will review the data. If you meet the criteria, they’ll refer you to a transplant center for a formal evaluation, which includes a cardiopulmonary assessment, psychosocial interview, and a transplant‑specific work‑up.  \n\nKeep close contact with your team; they’ll adjust therapy and timing based on your response. If the tumor shrinks into the transplant window, you’ll be added to the waiting list—your goal of walking your daughter down the aisle becomes a realistic possibility.",
          "order": 6,
          "qid": "S22-Q06"
        },
        {
          "q": "What does a bad day look like so my family knows when to act?",
          "gt": "I hear how frightening it is to worry about a bad day, especially when you’re trying to stay strong for your daughter.  \n\n**Red‑flag signs your family should watch for:**  \n1. **Sudden confusion, drowsiness, slurred speech, or disorientation**—a",
          "order": 7,
          "qid": "S22-Q07"
        },
        {
          "q": "Can I still walk the neighborhood safely?",
          "gt": "I hear the anxiety that comes with wondering if you can walk safely, especially when you’re already carrying so much hope for your daughter’s wedding.  \n\n**Liver function and safety**  \nYour cirrhosis and liver tumor mean your liver’s synthetic and detoxifying abilities are reduced. A baseline MELD score, liver‑function panel, and abdominal ultrasound will tell us if you’re at risk for ascites, encephalopathy, or spontaneous bacterial peritonitis—conditions that can make walking difficult or unsafe.  \n\n**Physical capacity**  \nCirrhosis often causes muscle wasting and fatigue, and portal hypertension can lead to variceal bleeding if you strain. A cardiopulmonary evaluation (ECG, echocardiogram, and a simple exercise test) will assess whether your heart and lungs can handle moderate exertion.  \n\n**Practical precautions**  \nIf you’re cleared, start with short, flat walks, wear supportive shoes, and walk with a companion or a safety harness if you have balance issues. Watch for dizziness, sudden abdominal pain, swelling, or easy bruising—call your hepatologist if any of these occur.  \n\n**Next steps**  \nSchedule a hepatology visit for a full assessment, discuss a graded exercise plan, and keep a log of energy levels and any new symptoms.  \n\nWe’ll work together to keep you safe and give you the best chance to enjoy that walk.",
          "order": 8,
          "qid": "S22-Q08"
        },
        {
          "q": "Will I itch forever?",
          "gt": "I hear how unsettling the constant itch feels, especially when you’re already juggling so much for your family’s future—your worry is completely understandable.\n\nIn cirrhosis, itching usually stems from bile salt accumulation, histamine release, and sometimes increased endogenous opioids. It can flare with tumor progression or liver function decline, but it isn’t inevitable for life. Many patients notice relief after stopping alcohol, and the itch often improves as liver enzymes stabilize.\n\nStandard management starts with cholestyramine 4 g orally twice daily, which binds bile salts in the gut. If that’s insufficient, rifampicin 300 mg twice daily, naltrexone 50 mg once daily, or sertraline 25–50 mg daily can be added. Most people report noticeable improvement within 1–2 weeks, though some may need several months to find the right combination. Your hepatologist will monitor liver panels, pruritus scores, and adjust doses as needed.\n\nIf you’re a transplant candidate, a successful liver transplant usually resolves pruritus entirely. Until then, regular follow‑ups every 4–6 weeks will track both tumor status and itch severity. Discuss these options with your team so they can tailor therapy to your specific situation.",
          "order": 9,
          "qid": "S22-Q09"
        },
        {
          "q": "How do I keep hope without pretending this isn’t serious?",
          "gt": "I hear how frightening the diagnosis feels, especially when you’re already carrying so much for your family—your worries are completely understandable.\n\nFor a liver tumor on top of cirrhosis, the goal is to balance aggressive treatment with preserving liver function. If the tumor is resectable, surgery is the most curative option, but only about 30–40 % of patients with cirrhosis are candidates. If surgery isn’t feasible, transarterial chemoembolization (TACE) or radiofrequency ablation can control local disease while sparing the liver. Systemic therapy—sorafenib (400 mg twice daily) or lenvatinib (8–12 mg daily)—is used for advanced disease; newer immunotherapies (nivolumab 240 mg IV every 2 weeks) are available in clinical trials. Your oncologist will tailor dosing to your liver function (e.g., adjust sorafenib if bilirubin >2 mg/dL).  \n\nMonitoring is key: liver function tests, INR, platelets, and AFP every 4–6 weeks; imaging (CT/MRI) every 3 months. If labs worsen or the tumor progresses, the team may switch agents or add supportive measures (e.g., beta‑blockers for portal hypertension).  \n\nKeep hope realistic by setting short‑term goals—surviving the next treatment cycle, maintaining quality of life, and staying symptom‑free—while acknowledging that outcomes vary. Your team will track progress closely, and you can discuss any concerns or changes in your plan at each visit.",
          "order": 10,
          "qid": "S22-Q10"
        }
      ]
    },
    {
      "id": "S23",
      "title": "Stigma and steel (locally advanced cervical cancer)",
      "diagnosis": "Locally advanced cervical cancer",
      "treatment_plan": "Definitive pelvic radiation with weekly cisplatin and brachytherapy; survivorship sexual health support",
      "narrative": "I'm 37 and a mom of two. The word 'cervical' makes me feel judged. Treatment is radiation with weekly chemo and internal radiation later.",
      "qa": [
        {
          "q": "I feel ashamed telling people what kind of cancer I have. How do I carry this without hiding?",
          "gt": "I hear how heavy the shame feels, especially when you’re already juggling the demands of being a mom and a caregiver—those worries are completely understandable.  \n\nIt’s normal to feel judged about a diagnosis that carries a lot of stigma. You don’t have to share every detail with everyone; you can decide who gets a brief “I’m being treated for cervical cancer” and who learns more. Setting clear boundaries—like saying, “I’m focusing on my treatment right now, so I’m not ready to talk about it in depth”—helps you protect your emotional space while still keeping loved ones in the loop.  \n\nPractical steps can ease the load:  \n1. **Choose a trusted confidant** (partner, close friend, or a counselor) and share your feelings with them first.  \n2. **Prepare a short, neutral script** (“I’m undergoing treatment for cervical cancer”) to use when you need to disclose quickly.  \n3. **Explore support groups**—many hospitals and online communities offer peer support where you can share anonymously or with a small circle.  \n4. **Consider therapy or counseling** to work through shame and build coping skills.  \n\nRemember, you’re not alone, and sharing when you feel ready can actually lighten the burden—your team and loved ones will be there to support you every step of the way.",
          "order": 1,
          "qid": "S23-Q01"
        },
        {
          "q": "Will sex ever feel normal again?",
          "gt": "I hear how anxious and frustrated you feel about the word “cervical” and the impact on your intimate life, especially while juggling your role as a mom.\n\n**What to expect after treatment**  \nExternal‑beam radiation plus weekly cisplatin (or carboplatin) and planned brachytherapy can cause vaginal dryness, stenosis, and decreased elasticity. Nerve irritation and fatigue may also lower libido.  \n\n**How recovery usually unfolds**  \nMost patients notice gradual improvement in sensation and comfort within 3–6 months, though it can take up to a year for full recovery. Daily water‑based lubricants, vaginal dilators (used for 6–12 months), and pelvic‑floor exercises are often recommended. If dryness persists, low‑dose vaginal estrogen or topical therapy can help, but only after your oncologist clears it.  \n\n**Support and monitoring**  \nRegular follow‑up visits (every 3–6 months) include pelvic exams and discussion of sexual function",
          "order": 2,
          "qid": "S23-Q02"
        },
        {
          "q": "Do I need a port for the weekly chemo?",
          "gt": "I hear how anxious you feel about every new step in your treatment, especially when you’re already juggling so much for your family—your worries are completely understandable.\n\nFor the weekly chemotherapy you’re receiving (most commonly cisplatin 40 mg/m² given over 30–60 minutes, sometimes combined with paclitaxel 80 mg/m²), a central venous port is **not required**. A well‑placed peripheral IV is usually sufficient for each infusion. A port is typically reserved for patients who have difficult peripheral access, need to receive multiple different drugs, or are on a long‑term infusion schedule. If you ever find your peripheral veins becoming hard to access or you’re scheduled for additional infusions, your oncology team can discuss placing a port, but it’s not mandatory for the weekly cisplatin.\n\nYou’ll have routine labs before each cycle—CBC, electrolytes, renal function—to monitor for toxicity. Common side effects include nausea, vomiting, and kidney irritation; your team will give pre‑meds and hydration to help. If you notice severe pain, swelling at the IV site, or fever, contact your oncologist right away.\n\nRest assured, your care team will monitor you closely and adjust the plan as needed—together we’ll keep you as comfortable and safe as possible.",
          "order": 3,
          "qid": "S23-Q03"
        },
        {
          "q": "What if childcare blows up on treatment days?",
          "gt": "I hear how anxious and overwhelmed you feel about juggling treatment and childcare—especially when you’re already carrying so much for your family.  \n\nYour radiation schedule is usually 5 days a week, with weekly cisplatin (40 mg/m² IV over ~1 hour) and 2 Gy per day of external beam. Brachytherapy (internal radiation) follows after the external phase, often on a separate day. Because the treatment is tightly scheduled, missing a day can delay the entire plan.  \n\nHere are practical steps:  \n1. **Talk to your oncology team** about your childcare concerns. They can sometimes shift your appointment to a later slot or offer a “make‑up” day if you miss one.  \n2. **Explore hospital or clinic childcare services**—many centers have on‑site daycare or can connect you with local providers.  \n3. **Ask family or friends for a backup plan**—a trusted adult can step in on a single day, and you can arrange a “safety net” phone call to the clinic if a last‑minute change occurs.  \n4. **Keep a calendar of your treatment days** and share it with your support network so they know when you’re unavailable.  \n5. **If a childcare crisis happens** and you can’t attend, call the oncology office immediately. They’ll advise whether to reschedule or, if urgent, how to proceed safely.  \n\nYour team will monitor your blood counts weekly and adjust doses if needed, so you’re not alone in navigating these challenges.",
          "order": 4,
          "qid": "S23-Q04"
        },
        {
          "q": "Will I burn or peel from radiation?",
          "gt": "I hear how scary the idea of skin burning or peeling feels, especially when you’re already juggling so much for your family. It’s completely normal to worry about how your body will react to treatment.\n\n**What to expect from the external‑beam radiation (5–7 weeks) with weekly cisplatin (40 mg/m² IV):**  \n- **Early skin reaction:** Mild redness (erythema) usually appears within the first 1–2 weeks.  \n- **Progression:** As the dose builds, the skin may develop a dry, flaky desquamation (peeling). Moist desquamation (blistering) is less common but can occur if the dose is high or if the skin is already irritated.  \n- **Timing:** Most skin changes peak 2–4 weeks into therapy and typically resolve 2–4 weeks after the last radiation fraction, once the skin has had time to heal.  \n- **Monitoring:** Your team will check the skin at each visit. If you notice severe pain, blistering, or signs of infection (redness spreading, fever), let them know right away.  \n- **Supportive care:** Use gentle, fragrance‑free cleansers, apply a thin layer of petroleum‑based ointment or a prescribed moisturizer, avoid hot showers, and protect the area from sun exposure.  \n- **Brachytherapy (internal radiation):** Later, you may experience vaginal dryness or mild irritation, but skin peeling is usually limited to the external area.\n\nIf the peeling becomes uncomfortable or you see signs of infection, your oncologist can adjust the dose or give topical steroids to help. You’re not alone—your care team will monitor closely and support you every step of the way.",
          "order": 5,
          "qid": "S23-Q05"
        },
        {
          "q": "How do you make sure the internal radiation isn’t traumatic?",
          "gt": "I hear how scary the idea of another procedure feels, especially when you’re already juggling chemo, radiation, and the demands of two kids—your worries are completely understandable.\n\nBrachytherapy (internal radiation) is a highly targeted, short‑duration procedure that most patients find manageable. Before the day of treatment, the radiation oncologist and a dedicated brachytherapy nurse will walk you through the plan, explaining the exact dose, the type of applicator (usually a small, flexible tube inserted into the cervix), and how imaging (ultrasound or CT) will guide placement. Most people receive light sedation or local anesthesia so the insertion is painless; you’ll be awake but relaxed. The whole process takes about 30–60 minutes, and you’ll stay in the treatment room for a brief observation period afterward.\n\nTo keep the experience as calm as possible, bring a supportive person if you wish, practice deep‑breathing or guided imagery, and let the team know any anxiety triggers. Pain is typically controlled with oral or IV meds, and the team will monitor for bleeding, infection, or discomfort—signs that should prompt an immediate call. Afterward, routine follow‑up includes a blood count, a pelvic exam, and imaging to confirm the applicator was correctly positioned and the dose delivered.\n\nYou’re not alone in this; your care team will monitor every step and adjust the plan if anything feels off.",
          "order": 6,
          "qid": "S23-Q06"
        },
        {
          "q": "Can I keep working, or should I plan leave?",
          "gt": "I hear how anxious you feel about juggling work while fighting cancer, especially when the diagnosis feels like a judgment on you and your family’s strength.\n\n**What to expect during concurrent chemoradiation**  \n- **Chemo**: Weekly cisplatin 40 mg/m² IV over about 1 hour, usually for 5–6 weeks.  \n- **External‑beam radiation**: 45–50 Gy in 25 fractions (5 days a week) over 5 weeks.  \n- **Brachytherapy**: High‑dose‑rate (HDR) after external beam, typically 3–4 fractions over 1–2 weeks.  \n- **Side‑effects**: Fatigue, nausea, mucositis, diarrhea, urinary irritation, vaginal dryness, and occasional neuropathy.  \n- **Monitoring**: CBC, electrolytes, renal function before each chemo cycle; weekly symptom check‑ins; dose adjustments if neutropenia (ANC < 1 × 10⁹/L) or severe toxicity occurs.\n\n**Work considerations**  \n- Many patients keep a part‑time or remote schedule, especially during the first 4–6 weeks when fatigue peaks.  \n- Avoid heavy lifting, long commutes, and high‑stress tasks.  \n- If fatigue becomes moderate‑to‑severe (unable to complete daily tasks, frequent headaches, or infections), a short leave or short‑term disability may be safer.  \n- Discuss accommodations with your employer and your oncology team; they can help tailor a plan that protects your health while maintaining your role.\n\n**Next steps**  \n- Bring a list of current medications and side‑effects to each appointment.  \n- Call your oncologist immediately if you develop fever, chills, or persistent vomiting.  \n- Your team will adjust the plan as needed—keep the dialogue open, and we’ll work together to keep you as functional and safe as possible.",
          "order": 7,
          "qid": "S23-Q07"
        },
        {
          "q": "Does this mean I can’t have more children?",
          "gt": "I hear how frightening the idea of losing future fertility feels, especially when you’re already juggling the demands of two kids and a busy life—your worries are completely understandable.\n\n**Fertility impact of your plan**  \n- **Chemotherapy**: Weekly cisplatin (usually 40 mg/m²) is the standard agent for locally advanced cervical cancer. Cisplatin can reduce ovarian reserve, especially in women over 35, but the degree varies.  \n- **Radiation**: External‑beam radiation (≈45–50 Gy to the pelvis) and brachytherapy (≈30–40 Gy to the cervix) expose the ovaries and fallopian tubes to high doses, often leading to premature ovarian failure.  \n- **Combined effect**: The overlap of chemo‑ and radiation‑induced damage makes natural conception after treatment unlikely, though not impossible.\n\n**What you can do now**  \n1. **Fertility preservation**: Discuss ovarian transposition (surgically moving ovaries out of the radiation field) or oocyte/embryo cryopreservation before treatment starts.  \n2. **Post‑treatment monitoring**: Your team will check FSH, AMH, and antral follicle count every 6–12 months to gauge ovarian reserve.  \n3. **Future options**: If ovarian function is lost, IVF with donor eggs or adoption remain viable paths.\n\nTalk with your oncologist and a reproductive endocrinologist to tailor a plan that fits your goals. You’re not alone—your team will support you every step of the way.",
          "order": 8,
          "qid": "S23-Q08"
        },
        {
          "q": "How will you know it worked without surgery?",
          "gt": "I hear how scary it feels to rely on imaging and exams instead of a surgical specimen, especially when you’re already juggling so much for your family.  \n\nAfter the external‑beam phase (≈45–50 Gy) and the weekly cisplatin (40 mg/m² IV) you’ll receive brachytherapy (≈30–35 Gy). We’ll assess response in several ways:\n\n1. **Imaging** – A pelvic MRI or CT at 3 months post‑treatment, and a PET/CT if the mass is still large or the SCC‑antigen is high, will show whether the tumor has shrunk or disappeared.  \n2. **Tumor markers** – Serial SCC‑antigen levels are checked every 4–6 weeks; a falling trend supports a good response.  \n3. **Clinical exam** – A pelvic exam and symptom review (pain, bleeding, discharge) are done at each visit.  \n4. **Biopsy if needed** – If a residual mass >3 cm or suspicious activity remains on PET/CT, a needle biopsy can confirm whether cancer is still present.  \n5. **Follow‑up schedule** – Every 3 months for the first 2 years, then every 6 months, with imaging and labs to catch any recurrence early.  \n\nYour oncologist will tailor the exact timing and tests to your situation, so feel free to ask any follow‑up questions.  \n\nWe’ll monitor closely together, and you’ll know the treatment worked when imaging, markers, and symptoms all point to a complete or partial response.",
          "order": 9,
          "qid": "S23-Q09"
        },
        {
          "q": "What if the cancer comes back—what’s next?",
          "gt": "I hear how frightening the idea of cancer returning feels, especially when you’re already juggling the demands of being a mom and staying strong for your family.  \n\nIf the cancer returns, a restaging scan (CT/MRI or PET‑CT) will map its size and location. Your team will then choose between salvage surgery, systemic therapy, or a clinical trial.  \n\nSalvage surgery—radical hysterectomy or pelvic exenteration—is for localized recurrence and usually requires 4–6 weeks of recovery, depending on your overall health and prior radiation.  \n\nSystemic therapy often starts with cisplatin 50 mg/m² IV every 3 weeks plus paclitaxel 175 mg/m² IV every 3 weeks. If progression occurs, adding bevacizumab 15 mg/kg IV every 3 weeks can improve response; PD‑L1 positive tumors may receive pembrolizumab 200 mg IV every 3 weeks.  \n\nClinical trials are worth exploring; many test PARP inhibitors, targeted agents, or new immunotherapies. Your oncologist can help you find a trial that matches your disease profile.  \n\nMonitoring includes CBC and CMP before each cycle, imaging every 6–8 weeks, and watching for neutropenia, neuropathy, or hypertension. If progression continues, we’ll shift to palliative radiotherapy or supportive care.  \n\nRemember, we’ll monitor closely and adjust the plan as needed—your strength and support system will help you navigate each step.",
          "order": 10,
          "qid": "S23-Q10"
        }
      ]
    },
    {
      "id": "S24",
      "title": "Fixing the fence (diffuse large B-cell lymphoma)",
      "diagnosis": "Diffuse large B-cell lymphoma, curative intent",
      "treatment_plan": "R-CHOP every 3 weeks for 6 cycles (or tailored regimen); interim PET after a few cycles",
      "narrative": "I'm 66 and run a small farm. A fast-growing node appeared in my neck. They’re aiming to cure this with chemo.",
      "qa": [
        {
          "q": "Does 'curative intent' really mean cure for someone my age?",
          "gt": "I hear how frightening the idea of “curative intent” feels, especially when you’re already juggling the demands of a farm and the worry of a fast‑growing neck node. It’s natural to feel uncertain about what that term really means for someone your age.  \n\n“Curative intent” means the treatment plan is designed to eradicate the cancer, not just control it. In head‑and‑neck cancers, the most common regimens that aim for cure are combinations of platinum‑based chemotherapy (cisplatin 75 mg/m² IV on day 1 of a 21‑day cycle) with 5‑fluorouracil (500 mg/m² IV continuous infusion days 1‑5) or a targeted agent like cetuximab (initial 400 mg/m² IV, then 250 mg/m² weekly). The exact drugs and schedule depend on the tumor’s histology, stage, and your overall health.  \n\nSuccess is measured by imaging (CT/MRI) every 2–3 months, tumor marker trends if applicable, and symptom relief. A response is usually defined as at least a 30 % reduction in the largest tumor diameter. Side effects can include nausea, mucositis, neuropathy, and myelosuppression; blood counts and electrolytes are checked before each cycle.  \n\nIf the disease progresses or you develop intolerable toxicity, the oncologist may switch to a different agent, reduce the dose, or consider palliative care options. Your age alone isn’t a barrier to cure, but factors like performance status, organ function, and comorbidities influence the likelihood of a successful outcome.  \n\nWe’ll monitor your response closely and adjust the plan as needed, so you’re not alone in this journey.",
          "order": 1,
          "qid": "S24-Q01"
        },
        {
          "q": "How sick will I be after each cycle—will the animals still get fed?",
          "gt": "I hear how frightening it is to think about how each chemo cycle might affect your health, especially when you’re already carrying so much responsibility for your farm.  \n\nChemotherapy for a rapidly growing neck node (often head‑and‑neck cancer) is usually given every 3–4 weeks with a regimen such as cisplatin + 5‑FU or docetaxel. Each infusion lasts 1–2 hours, followed by a recovery period of about 1–2 weeks. Common side effects are fatigue, nausea, mouth sores, hair loss, and low blood counts. You’ll likely feel tired for a few days after a cycle, but most people regain enough energy to resume normal activities within a week. Your oncologist will check a CBC, liver and kidney panels each cycle and adjust doses if counts fall.  \n\nIf you’re worried about feeding animals, arrange for a trusted neighbor or farmhand to help during the first 48–72 hours after a cycle when fatigue peaks. If you need more support, consider a short break or temporary help. Discuss your specific regimen and any pre‑meds with your oncology team to tailor the plan.  \n\nWe’ll work closely to keep you healthy enough to care for your animals while fighting the cancer.",
          "order": 2,
          "qid": "S24-Q02"
        },
        {
          "q": "Will I lose my hair and beard?",
          "gt": "I hear how scary the idea of losing your hair—and even your beard—feels, especially when you’re already juggling a farm and a family that depends on you.\n\nHair loss is a common side effect of many chemotherapy agents used for head‑and‑neck cancers. If your plan includes cisplatin plus 5‑fluorouracil (or a similar regimen), you’ll likely see hair thinning or complete loss within 1–3 weeks after the first cycle. The effect is usually temporary; most patients’ hair regrows to its original texture and color within 3–6 months after finishing treatment. Beard hair can be affected, but because facial follicles are slightly more resistant, many patients keep a stubble or short beard while scalp hair falls out. If a taxane (e.g., docetaxel) or a targeted agent like cetuximab is added, the risk of hair loss is lower, but it can still occur.\n\nYour oncologist will monitor your complete blood count (CBC) before each cycle and watch for signs of neutropenia or other toxicities. If hair loss becomes severe, dose adjustments or supportive measures (e.g., scalp cooling caps) can be discussed. Keep a list of any new symptoms and bring it to your appointments.\n\nRest assured, your care team will tailor the plan to minimize side‑effects while fighting the tumor, and we’ll support you through every step.",
          "order": 3,
          "qid": "S24-Q03"
        },
        {
          "q": "I’m worried about infection from hay dust and barns. Is that a real risk?",
          "gt": "I hear how frightening it feels to worry about infections while you’re already dealing with a new cancer diagnosis, especially when your daily life revolves around the farm and its dusty barns.\n\nChemotherapy can lower your white‑blood‑cell count, especially neutrophils, which makes you more vulnerable to bacterial, viral, and fungal infections. Hay dust often contains Aspergillus spores and bacteria that can cause sinusitis, pneumonia, or even invasive fungal disease when your immune system is weakened. So, yes—exposure to hay dust and barn environments is a real risk during chemo.\n\nWatch for fever (≥38 °C), chills, sore throat, cough, or any new sore or swollen area. Your oncologist will check your complete blood count (CBC) before each cycle; a neutrophil count below 1,000 cells/µL (neutropenia) heightens infection risk. If you develop a fever or other infection signs, call your oncology team right away.\n\nTo reduce exposure, try to stay indoors during chemo periods, wear a mask when you must be in dusty areas, keep barns clean, and consider HEPA filtration. Your doctor may recommend prophylactic antibiotics or antifungals if your neutrophil count drops low. Keep a list of all medications and any new symptoms, and schedule regular follow‑ups to adjust your plan as needed.\n\nWe’ll monitor your blood counts closely and adjust your treatment or protective measures so you can stay as safe as possible while you focus on your health.",
          "order": 4,
          "qid": "S24-Q04"
        },
        {
          "q": "What does the interim PET actually change?",
          "gt": "I hear how anxious you must feel about the fast‑growing neck node, especially when you’re already juggling the demands of running a farm—your worries are completely understandable.\n\nAn interim PET scan is usually done after 2–3 cycles of chemotherapy. It measures the metabolic activity of the tumor with a radioactive glucose tracer. If the PET shows a significant drop in uptake (often >50 % reduction), it suggests the cancer is responding well, and the oncologist may keep the current regimen, possibly shorten the overall treatment duration and reduce cumulative toxicity. If the PET shows little or no change, the team may decide to switch to a different chemotherapy agent (e.g., from cisplatin‑based to docetaxel‑based), add targeted therapy, or plan for concurrent radiation. In some cases, a poor interim PET can prompt an earlier surgical evaluation.  \n\nYou’ll still have routine blood counts, liver and kidney panels, and symptom checks every cycle. If the PET indicates a good response, you’ll likely continue the same schedule; if not, the oncologist will discuss alternative plans, which may involve a different drug, dose adjustment, or adding radiation.  \n\nRest assured, your care team will monitor closely and adjust the plan based on the PET findings.",
          "order": 5,
          "qid": "S24-Q05"
        },
        {
          "q": "Can heart issues happen with this regimen?",
          "gt": "I hear how frightening the idea of heart damage feels, especially when you’re already juggling a farm and the uncertainty of treatment—your worries are completely understandable.\n\nMost head‑and‑neck regimens (e.g., cisplatin + 5‑FU + docetaxel) don’t target the heart directly, but some agents can still cause cardiac strain. Cisplatin is mainly nephrotoxic, while docetaxel can lead to fluid overload and, rarely, arrhythmias. If an anthracycline (doxorubicin) or trastuzumab were part of your plan, the risk of left‑ventricular dysfunction rises markedly. Your oncologist will usually do a baseline ECG and an echocardiogram (LVEF) before starting. After that, an echo every 3 months (or sooner if symptoms appear) and troponin checks during the first two cycles help catch early changes. Symptoms to watch for are chest pain, shortness of breath, palpitations, or swelling of the legs. If any of these arise, the team may hold the offending drug, reduce the dose, or refer you to a cardio‑oncology specialist.  \n\nWe’ll monitor closely and adjust as needed—your heart health is a top priority.",
          "order": 6,
          "qid": "S24-Q06"
        },
        {
          "q": "Will steroids make me edgy and sleepless?",
          "gt": "I hear how unsettling it feels to worry about new side‑effects, especially when you’re already juggling the demands of a farm and a new treatment plan.\n\n**Steroids and restlessness/insomnia**  \nMost chemotherapy regimens that include a steroid use dexamethasone (the most common choice). A typical schedule is 8 mg PO 12 hours before the infusion, followed by 6 mg IV 6 hours before the start of chemo. These doses are short‑acting enough to reduce nausea, allergic reactions, and inflammation, but they can still trigger anxiety, agitation, and trouble sleeping in many people. The effect usually peaks within a few hours of the dose and can last 12–24 hours, especially if you’re sensitive to stimulatory effects.\n\n**What to watch for and how to manage it**  \n- **Blood glucose & blood pressure**: steroids can raise both; your oncology team will check labs and vitals before each cycle.  \n- **Mood and sleep**: keep a simple log of how you feel each night. If insomnia or restlessness becomes bothersome, let your nurse or oncologist know.  \n- **Sleep hygiene**: take the steroid dose as close to bedtime as possible, avoid caffeine after 2 pm, and keep a cool, dark room.  \n- **Dose adjustment**: if the side‑effects are severe, your team can lower the steroid dose or switch to a different agent (e.g., methylprednisolone) that may be less stimulating.\n\n**Next steps**  \nDiscuss your concerns with the oncology team before the first cycle. They can tailor the steroid dose, timing, and supportive measures to keep you comfortable while still protecting you from chemo‑related side‑effects.  \n\nWe’ll monitor closely and adjust as needed so you can focus on staying healthy and keeping your farm running.",
          "order": 7,
          "qid": "S24-Q07"
        },
        {
          "q": "If a cycle is delayed, does that ruin my chance of cure?",
          "gt": "I hear how anxious you feel about a possible delay, especially when you’re already juggling farm duties and caring for your family.  \n\nA short pause—say a few days to a week—usually doesn’t wipe out the chance of cure, but the impact depends on the cancer’s biology. For aggressive head‑and‑neck tumors (often treated with cisplatin 75 mg/m² IV over 30 min plus 5‑FU 1 000 mg/m² IV infusion for 24 h) or for aggressive lymphomas (R‑CHOP: rituximab 375 mg/m² IV over 1 h, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, vincristine 1.4 mg/m² IV, prednisone 100 mg PO daily ×5 days), a delay of more than 2 weeks can reduce response rates.  \n\nYour oncologist will monitor CBCs before each cycle, perform imaging every 2–3 cycles, and watch for neutropenia or infection. If a delay occurs, they may adjust the dose, add a bridging steroid, or switch to a maintenance regimen.  \n\nWe’ll keep the schedule as tight as possible, but a brief postponement is unlikely to ruin your chance of cure—just keep the lines of communication open.",
          "order": 8,
          "qid": "S24-Q08"
        },
        {
          "q": "Should I get extra vaccines now?",
          "gt": "I hear how anxious you feel about adding more shots while you’re already facing a tough treatment plan—especially when you’re juggling farm work and family responsibilities.\n\n**Vaccines that are safe and recommended during chemotherapy**  \n1. **Influenza** – an inactivated shot is advised each fall; give it before the first chemo cycle if possible, but it can be administered anytime during treatment.  \n2. **Pneumococcal** – PCV20 (or PCV15 followed by PPSV23) is recommended for adults ≥ 65 years; give it at least 2 weeks before chemo or during a period of stable neutrophil count.  \n3. **Shingles (Shingrix)** – a two‑dose series (0 + 2 months) is safe in immunocompromised patients; the first dose can be given before chemo or during a neutropenic window, but avoid it if absolute neutrophil count < 500 /µL.  \n4. **COVID‑19** – a booster (mRNA or recombinant protein) is recommended every 6 months; it can be given at any time, even during chemo, and is well tolerated.  \n\n**Vaccines to avoid**  \nLive‑attenuated shots (MMR, varicella, yellow fever) are contraindicated while on cytotoxic therapy.  \n\n**What to expect**  \nMost patients feel a mild sore arm and low‑grade fever that resolves in 24–48 h. If you develop a high fever, rash, or severe fatigue, contact your oncology team right away.  \n\nDiscuss the exact timing and any specific concerns with your oncologist or an infectious‑disease specialist—they’ll tailor the schedule to your neutrophil counts and overall health.  \n\nYou’re not alone in this; we’ll keep a close eye on your immune status and adjust as needed.",
          "order": 9,
          "qid": "S24-Q09"
        },
        {
          "q": "What happens if it doesn’t respond?",
          "gt": "I hear how frightening it feels to worry that the chemo might not work, especially when you’re already carrying so much on your shoulders.  \n\nIf the node doesn’t shrink after 2–3 cycles, it’s considered refractory. The mass may grow, spread, or start causing pain, hoarseness, or difficulty swallowing.  \n\nYour oncologist will review the latest imaging and blood work. They may adjust the dose, switch to a different drug, or add a second agent.  \n\nCommon second‑line options for head‑and‑neck cancers include cisplatin (75 mg/m² IV over 30–60 min) plus paclitaxel (175 mg/m² IV over 3 h), or targeted agents like cetuximab or pembrolizumab, depending on tumor markers.  \n\nIf chemo fails, radiation or surgery can control local disease, and palliative care can manage pain and maintain quality of life. Throughout, CBC, CMP, and imaging every 2–3 months monitor response; any new symptoms should prompt immediate contact.  \n\nWe’ll keep a close eye on your progress and adjust the plan together, so you’re not alone in this.",
          "order": 10,
          "qid": "S24-Q10"
        }
      ]
    },
    {
      "id": "S25",
      "title": "Trailhead ahead (metastatic kidney cancer)",
      "diagnosis": "Metastatic renal cell carcinoma",
      "treatment_plan": "Combination immunotherapy or immunotherapy plus targeted therapy; monitor for immune-related side effects",
      "narrative": "I'm 61 and love national parks. I want a plan that lets me keep hiking without ignoring warning signs.",
      "qa": [
        {
          "q": "How do we choose between combinations without wrecking my stamina?",
          "gt": "I hear the mix of excitement and anxiety you feel about staying strong on those trails—especially when you’re eager to keep exploring while protecting your stamina.\n\n**A practical, evidence‑based plan**\n\n1. **Baseline check** – Have a quick cardiovascular screen (blood pressure, resting ECG, and a simple VO₂‑max or sub‑max test if possible). This gives you a safe “max heart rate” (≈220‑age) and a target training zone (60‑75 % for endurance, 75‑85 % for tempo).  \n2. **Structured training** – Aim for 3–4 sessions per week:  \n   * 1 long, steady hike (70‑75 % HR zone, 2–3 hrs)  \n   * 1 interval session (4 × 10 min at 80‑85 % HR, 5 min recovery)  \n   * 1 strength/ mobility day (body‑weight or light resistance)  \n   * 1 rest or active recovery (yoga, walking).  \n3. **Pacing & monitoring** – Use a heart‑rate monitor or GPS watch. Stop if you hit >85 % HR for >10 min, feel chest tightness, dizziness, or severe fatigue.  \n4. **Nutrition & hydration** – 30–60 g carbs per hour on long hikes, electrolytes, and 2–3 L water per day.  \n5. **Progression** – Increase distance or elevation by no more than 10 % per week.  \n6. **Safety net** – Carry a first‑aid kit, a phone, and let someone know your route. If any warning signs appear, pause and seek medical advice.\n\n**You’re not alone—let’s keep your hikes safe and sustainable.**",
          "order": 1,
          "qid": "S25-Q01"
        },
        {
          "q": "What immune side effects should make me stop the trail and call?",
          "gt": "I hear how anxious you feel about keeping your hiking routine safe, especially when you’re already navigating the challenges of age‑related health changes.\n\n**What immune‑related signs should prompt you to stop the trail and call for help?**  \n1. **Fever or chills** > 38 °C (100.4 °F) that lasts more than 24 h, or a sudden spike in temperature.  \n2. **Skin changes** – a rash that covers >10 % of the body, is itchy or painful, or shows blistering or ulceration (grade ≥ 2).  \n3. **Swelling** – sudden, pronounced edema of the face, lips, tongue, or throat, or any swelling that makes swallowing or breathing difficult.  \n4. **Respiratory symptoms** – new or worsening shortness of breath, wheezing, chest tightness, or cough that isn’t typical for you.  \n5. **Gastrointestinal upset** – persistent diarrhea (≥ 3 loose stools/day), vomiting, or abdominal pain that is severe or doesn’t improve after a few hours.  \n6. **Neurologic changes** – new headaches, confusion, vision changes, or weakness that appears suddenly.  \n7. **Cardiac signs** – chest pain, palpitations, or a feeling of “tightness” in the chest that isn’t related to exertion.\n\nIf any of these occur, pause your hike, sit in a cool, shaded spot, and contact your healthcare team immediately. Keep a simple log of temperature, rash size, and symptom onset so you can relay accurate information. Discuss with your provider a personalized “stop‑hike” threshold and any pre‑hike precautions (e.g., carrying a thermometer, having a plan for rapid descent).  \n\nYou’re taking a proactive step—your vigilance will help keep your adventures safe and enjoyable.",
          "order": 2,
          "qid": "S25-Q02"
        },
        {
          "q": "Can I camp far from hospitals?",
          "gt": "I hear how anxious you feel about staying safe while enjoying the parks, especially when you’re determined to keep hiking.\n\nCamping far from hospitals is possible, but it demands meticulous preparation. First, get a medical clearance from your primary care or cardiologist—especially if you have heart disease, diabetes, or other chronic conditions. Bring a 24‑hour supply of all prescribed medications, plus a backup in a waterproof bag. Pack a comprehensive first‑aid kit that includes antihypertensives, nitroglycerin (if prescribed), glucose tablets, and an epinephrine auto‑injector if you’re allergic. Use a satellite phone or personal locator beacon to call for help; know the exact distance to the nearest ranger station or medical facility and the typical response time. Have a buddy system and a written emergency plan that lists evacuation routes, contact numbers, and any medical alerts. If you’re prone to altitude sickness, acclimate gradually and carry acetazolamide. Finally, confirm that your insurance covers medical evacuation and that you have a pre‑arranged plan with a local EMS provider.\n\nWith these precautions, you can enjoy the trails while staying prepared for any medical need.",
          "order": 3,
          "qid": "S25-Q03"
        },
        {
          "q": "Will high altitude be a problem?",
          "gt": "I hear how anxious you feel about pushing your limits at higher elevations, especially when you’re so passionate about exploring every trail.\n\n**Altitude and a 61‑year‑old hiker**  \nAt elevations above 2,500 m (≈8,200 ft), the air pressure drops, so the oxygen available to your muscles and lungs is lower. Older adults often have reduced pulmonary reserve and may be more prone to shortness of breath, fatigue, and, in rare cases, high‑altitude pulmonary or cerebral edema. If you have heart or lung disease, the risk is higher, so a pre‑trip check‑up with your primary care or a sports‑medicine specialist is wise.\n\n**Practical steps to stay safe**  \n1. **Acclimatize gradually**: spend 1–2 days at each 300–500 m (1,000–1,600 ft) increase in elevation.  \n2. **Hydrate and eat well**; dehydration worsens altitude symptoms.  \n3. **Pace yourself**: use a heart‑rate monitor or perceived exertion scale; stop if you feel dizzy, nauseous, or have a pounding chest.  \n4. **Know the warning signs**: headache, nausea, rapid breathing, confusion, or swelling of the face/legs. If any appear, descend 300–500 m immediately.  \n5. **Carry a plan**: have a phone, a first‑aid kit, and a list of local emergency contacts.  \n\nIf you’re unsure about your cardiovascular or pulmonary status, a quick evaluation (e.g., spirometry, ECG) can help you decide whether a particular park’s elevation is appropriate.  \n\nYou’re not alone—let’s keep your adventures safe and rewarding.",
          "order": 4,
          "qid": "S25-Q04"
        },
        {
          "q": "Does diet matter for these meds?",
          "gt": "I hear how anxious you feel about keeping your hiking routine safe while managing your medications—especially when you’re already balancing the excitement of new trails with the responsibility of staying healthy.\n\nDiet can influence how many common medications work and how they feel. For example, statins (atorvastatin, simvastatin) are best taken with a light meal to reduce stomach upset, while beta‑blockers (metoprolol, atenolol) are more predictable when taken at the same time each day. ACE inhibitors (lisinopril, enalapril) should be taken with food to lessen cough, and some diuretics work better when you’re well‑hydrated. Grapefruit and grapefruit juice can raise levels of statins, certain calcium channel blockers, and some antidepressants, so it’s wise to avoid them. High‑fat meals can delay absorption of drugs like levothyroxine or certain antibiotics, so a balanced, moderate‑fat breakfast is ideal before a long hike.\n\nWhen you’re on warfarin or other anticoagulants, keep vitamin K intake consistent (green leafy vegetables, broccoli) and limit sudden changes. If you’re taking antiplatelet agents (aspirin, clopidogrel), avoid excessive alcohol and be mindful of NSAID use. For diabetes medications, pair meals with consistent carbohydrate portions to prevent hypoglycemia during exertion. Staying hydrated—aim for 2–3 L of water per day—helps maintain blood pressure and kidney function, especially on hot days.\n\nPractical hiking tips: pack small, protein‑rich snacks (nuts, jerky, cheese) and a fruit or energy bar to keep glucose steady. Eat a moderate, balanced lunch before the trail, and avoid heavy, high‑fat meals that can cause sluggishness. Bring a refillable water bottle and sip regularly; dehydration can mask medication side effects. If you notice dizziness, palpitations, or unusual fatigue, pause the hike and reassess.\n\nBecause each medication has its own nuances, it’s best to review your specific drugs with your prescriber or pharmacist. They can tailor dietary recommendations to your regimen and help you adjust timing or food choices for optimal efficacy and safety.\n\nYou’re taking a thoughtful approach—let’s keep that momentum and make sure your hiking adventures stay both thrilling and safe.",
          "order": 5,
          "qid": "S25-Q05"
        },
        {
          "q": "What about blood pressure spikes I’ve heard about?",
          "gt": "I hear how unsettling the idea of a sudden blood‑pressure spike feels, especially when you’re trying to keep exploring the parks you love.\n\nBlood‑pressure spikes during hiking usually happen when exertion, dehydration, or high altitude push the heart harder than usual. The key is to stay below a safe threshold—ideally <140/90 mm Hg—and to keep your heart rate in a moderate zone (about 50‑70 % of your age‑based max, 220‑61 ≈ 159 bpm, so aim for 80‑110 bpm). Bring a portable cuff or a smartwatch that tracks BP/HR, check it before you start, every 30‑60 minutes, and after any rest break. Stay hydrated, avoid caffeine or salty snacks, and pace yourself with short climbs and easy descents.\n\nIf you’re on antihypertensives, discuss with your cardiologist whether a beta‑blocker or ACE inhibitor might help blunt exertional surges. Keep your medication schedule consistent, and carry a small emergency kit (water, electrolyte tablets, a note with your meds). If your BP rises above 180/110 mm Hg, chest pain, dizziness, or shortness of breath, stop immediately, sit down, and call 911 or your local emergency number. Have a trusted contact in the park who can alert help if you’re alone.\n\nWith a clear monitoring plan and your doctor’s guidance, you can enjoy hiking while keeping your blood pressure in check.",
          "order": 6,
          "qid": "S25-Q06"
        },
        {
          "q": "Can I still donate blood to the park drives?",
          "gt": "I hear how excited you are to keep hiking and giving back, especially when you’re balancing the demands of staying active and caring for your health.\n\nYes, you can still donate blood for the park drives—as long as you meet the standard eligibility criteria. For most adults, the guidelines are: age 18‑65, weight ≥110 lb, no recent illness or infection, no chronic conditions that require daily medication (e.g., anticoagulants, uncontrolled hypertension), and no recent travel to high‑risk areas. Before each donation, the center will ask a brief health questionnaire and perform a quick check of your blood pressure, pulse, and hemoglobin. If you’re healthy and meet these criteria, you can donate up to twice a year. After donation, rest for a few hours, stay hydrated, and avoid strenuous activity for 24–48 hours. If you feel light‑headed, dizzy, or unusually fatigued, stop hiking and seek medical advice. If you have any underlying health concerns, discuss them with your primary care provider or the blood bank staff to confirm you’re cleared to donate. \n\nYou’ll be able to keep enjoying the trails while contributing to the park drives—just keep an eye on how you feel after each donation and let us know if anything changes.",
          "order": 7,
          "qid": "S25-Q07"
        },
        {
          "q": "If scans show stable disease, is that a win or just holding pattern?",
          "gt": "I hear how anxious you feel about the scans, especially when you’re eager to keep exploring the parks—your worries are completely understandable.\n\nA “stable disease” result means the tumor hasn’t grown or spread since your last imaging, which is a positive sign that your current treatment is keeping the cancer in check. It isn’t a cure, but it’s a win in that the disease is not progressing. Most oncologists will keep you on the same regimen—whether that’s a targeted agent like **erlotinib** (once daily) or an immunotherapy such as **pembrolizumab** (every 3 weeks)—and schedule routine monitoring: blood counts and chemistry every 4–6 weeks, and a repeat CT or MRI every 8–12 weeks. Watch for side‑effects: fatigue, rash, or immune‑related symptoms (rash, colitis, thyroiditis). If any of these worsen, or if imaging shows new lesions, we’ll discuss switching to a second‑line therapy or adding a supportive agent. Your oncologist will tailor the exact timing and labs to your specific diagnosis and treatment plan.\n\nWe’ll keep a close eye on the scans and your well‑being so you can enjoy those hikes with confidence.",
          "order": 8,
          "qid": "S25-Q08"
        },
        {
          "q": "What if my joints ache too much to hike?",
          "gt": "I hear how frustrated and scared you feel when the joint ache seems to block the trails you love, especially when every step feels like a test of your resilience.\n\n**Pain‑management basics**  \n- Start with over‑the‑counter options: ibuprofen 400 mg or naproxen 250 mg every 8–12 h, or acetaminophen 500 mg every 6 h up to 3 g/day.  \n- If you have kidney, liver, or GI concerns, your doctor may prefer a topical NSAID (diclofenac gel 1 % twice daily) or a COX‑2 inhibitor (celecoxib 200 mg once daily).  \n- Monitor blood pressure, kidney function (creatinine), and liver enzymes if you’re on chronic NSAIDs.\n\n**Adjunctive strategies**  \n- A physical‑therapy program focused on quadriceps and hip‑strengthening, plus gentle range‑of‑motion stretches, can reduce load on painful joints.  \n- Low‑impact cardio (swimming, cycling, elliptical) keeps fitness without over‑loading knees and hips.  \n- Use supportive footwear with good arch support, or custom orthotics, and consider a walking stick or trekking poles for balance and joint off‑loading.\n\n**Lifestyle and pacing**  \n- Maintain a healthy weight; even a 5‑10 % loss can cut joint stress by 20‑30 %.  \n- Plan hikes with short, frequent breaks; use a “listen‑to‑your‑body” rule—stop if pain exceeds 4/10 or lasts >30 s.  \n- Keep a pain diary to share with your clinician; it helps adjust medication or therapy.\n\n**When to seek escalation**  \n- Persistent pain despite OTC meds, swelling, or morning stiffness >30 min warrants a rheumatology referral.  \n- Consider intra‑articular corticosteroid or hyaluronic acid injections for isolated knee/hip pain.  \n- In severe, refractory cases, joint replacement surgery may restore mobility and allow you to hike again.\n\nWe’ll work together to fine‑tune this plan so you can keep enjoying the parks while honoring your body’s limits.",
          "order": 9,
          "qid": "S25-Q09"
        },
        {
          "q": "If this stops working, what’s next?",
          "gt": "I hear the mix of anxiety and frustration you’re feeling about keeping your hiking routine safe—especially when you’re so determined to keep exploring the parks you love.\n\nHere’s a practical “if‑this‑stops‑working” roadmap:  \n1. **Pre‑hike check** – Have a quick medical review (cardiac, joint, and hydration status) and carry a basic first‑aid kit.  \n2. **Daily plan** – Map your route, note water sources, set a realistic pace, and share your itinerary with someone off‑trail.  \n3. **On‑trail vigilance** – Watch for warning signs: sudden fatigue, dizziness, cramps, or changes in weather. If any appear, stop, rest, and hydrate.  \n4. **Emergency trigger** – If you can’t recover within 15–20 minutes, use a personal locator beacon or call 911; park rangers can also be reached via the nearest visitor center.  \n5. **Post‑incident care** – Seek medical evaluation for any injury or heat/altitude‑related symptoms; follow up with your primary provider to adjust your activity plan.  \n6. **Long‑term tweak** – If the same issues recur, consider lower‑intensity hikes, guided tours, or indoor fitness alternatives to keep your passion alive safely.\n\nYou’re not alone—your park staff and medical team can help you stay on track, and we’ll keep adjusting the plan until it works for you.",
          "order": 10,
          "qid": "S25-Q10"
        }
      ]
    },
    {
      "id": "S26",
      "title": "Hope in a cooler (CAR-T for relapsed lymphoma)",
      "diagnosis": "Relapsed/refractory large B-cell lymphoma, candidate for CAR-T",
      "treatment_plan": "Leukapheresis, bridging therapy as needed, lymphodepleting chemo, CAR-T infusion; monitor for CRS/ICANS; caregiver required",
      "narrative": "I'm 59 and my lymphoma came back. They say my own cells can be turned into medicine. I’m hopeful and scared of the side effects I’ve read about.",
      "qa": [
        {
          "q": "How long am I away from home from collection to infusion?",
          "gt": "I hear how scary the idea of being away from home feels, especially when you’re already juggling so much for your family—your worries are completely understandable.\n\nFor most autologous stem‑cell transplants, the timeline looks like this:  \n1. **Cell collection (pheresis)** – a single day in the hospital; you’ll stay overnight for monitoring.  \n2. **Processing & cryopreservation** – done in the lab; you’re discharged the next day.  \n3. **Conditioning chemotherapy** – usually 1–2 weeks after collection; you’ll be in the hospital for 2–3 days of chemo and supportive care.  \n4. **Infusion** – the day after conditioning ends; you’ll stay 1–2 days for close observation of side effects.  \n\nAdding it up, you’ll be away from home for roughly **2 to 3 weeks** from the day of collection to the day after the infusion, with a few days of inpatient care interspersed. Your oncology team will tailor the exact schedule to your health status, so discuss any adjustments with them.  \n\nYou’re not alone in this—your care team will monitor you closely every step of the way.",
          "order": 1,
          "qid": "S26-Q01"
        },
        {
          "q": "What does a caregiver actually do, and for how long?",
          "gt": "I hear how scary the idea of side effects feels, especially when you’re already juggling so much hope and worry. It’s completely normal to feel that mix of fear and uncertainty.\n\nA caregiver’s job in autologous cell therapy (like CAR T‑cell treatment) is to be your patient’s on‑hand advocate and support system. They help with transportation to the infusion center, coordinate appointments, and ensure you’re ready for each step—collection of your own cells, the conditioning chemotherapy, the infusion itself, and the post‑infusion monitoring. During the 7‑14‑day inpatient stay, the caregiver watches for fever, neurological changes, and blood‑count shifts, and assists with hydration, medication schedules, and any comfort measures. After discharge, they stay close for the first 2–4 weeks when cytokine release syndrome and neurotoxicity are most likely, then for routine outpatient visits (weekly for the first month, then monthly for 6–12 months) to track remission and manage late side effects.\n\nIn practice, most caregivers are needed from the day of collection through the first 3–6 months of follow‑up, though the exact duration depends on how quickly you recover and whether any complications arise. Your oncology team will tailor the support plan to your specific needs.",
          "order": 2,
          "qid": "S26-Q02"
        },
        {
          "q": "What does cytokine release syndrome feel like?",
          "gt": "I hear how frightening the idea of a severe reaction feels, especially when you’re already carrying so much hope and worry for your own health.\n\nCytokine release syndrome (CRS) is the most common side effect of CAR‑T or other autologous cell therapies. It usually starts within 24–48 hours after infusion, but can appear up to a week later. Early signs are fever (often >38 °C), chills, headache, fatigue, and a rapid heart rate. As it progresses, you may notice low blood pressure, shortness of breath, a rash, or swelling from capillary leak. In severe cases (grade 3–4), organ dysfunction—such as kidney injury, liver enzyme elevation, or neurologic changes—can occur.\n\nYour team will monitor you closely: vitals every 4–6 hours for the first 48 hours, then every 12 hours; blood counts, electrolytes, liver and kidney panels, and CRP or ferritin levels. If CRS develops, treatment starts with aggressive IV fluids and vasopressors for low blood pressure, followed by tocilizumab (an IL‑6 blocker) and, if needed, high‑dose steroids. Most patients recover within a few days; severe cases may require ICU care.\n\nRemember, your oncologist will tailor the monitoring schedule and rescue plan to your specific CAR‑T product and health status. If you notice any of these symptoms, call your team right away. \n\nWe’ll keep a close eye on you and adjust the plan as needed—your safety is our top priority.",
          "order": 3,
          "qid": "S26-Q03"
        },
        {
          "q": "What about the brain side effects—will I know if my words tangle?",
          "gt": "I hear how scary the idea of brain changes feels, especially when you’re already juggling so much hope and worry. It’s completely natural to feel anxious about whether your words might start to tangle.\n\nIf you’re moving forward with an autologous cell‑based therapy such as CAR‑T, the most common neurotoxicity is immune‑cell‑associated neurotoxicity (ICANS). It usually appears 3–10 days after infusion, peaks around day 7, and can last 1–3 weeks. Symptoms range from mild confusion and word‑finding difficulty to more severe aphasia, tremor, seizures, or altered consciousness. Your team will perform a baseline neurologic exam and daily checks using the ICE (Immune Effector Cell‑Associated Encephalopathy) score; any drop in score or new symptoms triggers immediate evaluation.\n\nManagement is prompt: low‑dose steroids (dexamethasone 10 mg IV q6 h) are first‑line for mild to moderate ICANS, while severe cases may need high‑dose steroids or even therapeutic plasma exchange. Tocilizumab helps if cytokine release syndrome (CRS) is also present, but it does not treat neurotoxicity directly. Most patients recover fully, though some may need a short course of steroids or a brief neurorehabilitation period.\n\nYour oncologist will tailor the monitoring schedule to your specific product and risk factors. If you notice any slurred speech, difficulty finding words, or confusion, call your team right away—early recognition is key to preventing progression. \n\nWe’ll keep a close eye on your neurologic status and adjust treatment as needed, so you’re not alone in this.",
          "order": 4,
          "qid": "S26-Q04"
        },
        {
          "q": "Can I work remotely during all this?",
          "gt": "I hear how frightening the idea of side‑effects feels, especially when you’re already juggling so much for your family—your worries are completely understandable.  \n\n**Can you work remotely?**  \nMost patients who receive autologous cell therapy (CAR T‑cell or autologous stem‑cell transplant) can keep a remote job, but the feasibility depends on the treatment phase and how you feel.  \n\n1. **Induction/conditioning** – 2–3 weeks of high‑dose chemotherapy (e.g., cyclophosphamide, fludarabine) usually done in the hospital. You’ll need frequent blood tests (CBC, electrolytes) and may experience nausea, vomiting, and fatigue. Remote work is possible if you can manage these side‑effects and have a quiet, supportive environment.  \n\n2. **Infusion** – 1 day in the infusion center. You’ll be monitored for cytokine‑release syndrome (CRS) and neurotoxicity; if CRS is mild (grade 1–2), you can often stay home the same day. Severe CRS (grade 3–4) requires inpatient care and will preclude work.  \n\n3. **Post‑infusion** – 1–2 weeks inpatient stay for close monitoring (daily vitals, labs, infection surveillance). Remote work is not feasible during this period.  \n\n4. **Outpatient follow‑up** – 4–6 weeks of weekly visits for CBC, infection checks, and supportive care. Remote work is usually safe, but you may need to take short breaks for infusion or lab appointments.  \n\n**Practical tips**  \n- Discuss your job’s flexibility with your oncologist and HR.  \n- Keep a symptom diary; if you feel extreme fatigue, fever, or confusion, call your oncology team immediately.  \n- Arrange a backup plan (e.g., a trusted colleague covering urgent tasks) during inpatient stays.  \n\nWe’ll work together to keep you safe and productive while you focus on recovery.",
          "order": 5,
          "qid": "S26-Q05"
        },
        {
          "q": "If the cells don’t grow in the lab, then what?",
          "gt": "I hear how unsettling it feels that the cells you’re giving back might not grow, especially when you’re already juggling so many worries about side‑effects and outcomes.\n\nIf the harvested lymphoma cells fail to expand in the laboratory, the autologous cell therapy (e.g., CAR‑T products like Kymriah or Yescarta) simply cannot be infused. The lab will notify your oncology team immediately, and the infusion schedule will be canceled. Your team will then discuss a “next‑step” plan, which may include:\n\n1. **A second collection** – sometimes a repeat harvest can succeed, though it takes time and may delay treatment.\n2. **An alternative product** – if available, a different CAR‑T product or an allogeneic (donor‑derived) therapy might be offered.\n3. **Standard salvage therapy** – regimens such as R‑CHOP, ICE, or a high‑dose chemotherapy with autologous stem‑cell rescue can be considered.\n4. **Allogeneic stem‑cell transplant** – if you’re eligible, a donor transplant is an option, though it carries its own risks.\n\nThroughout, your team will monitor blood counts, infection markers, and organ function, and will keep you informed of any new options or clinical trials that might fit your situation. Your oncologist can give you the most tailored guidance based on your overall health and disease status.",
          "order": 6,
          "qid": "S26-Q06"
        },
        {
          "q": "Is infection risk higher after CAR-T?",
          "gt": "I hear how frightening the thought of side",
          "order": 7,
          "qid": "S26-Q07"
        },
        {
          "q": "Will I lose my hair again?",
          "gt": "I hear how frightening the thought of hair loss feels, especially when you’re already carrying so much hope and worry for your own health.  \n\n**Hair loss with your upcoming therapy**  \nIf your plan is an autologous stem‑cell transplant, you’ll receive a high‑dose “conditioning” chemotherapy (often the BEAM regimen: carmustine, etoposide, cytarabine, melphalan). That level of chemotherapy almost always causes total hair loss within 1–2 weeks, and hair typically starts to regrow 3–6 months after the transplant. Your team will give you scalp‑protective measures (cool caps, gentle hair care) and monitor your blood counts closely (CBCs every 2–3 days during the aplastic phase).  \n\nIf instead you’re moving toward CAR T‑cell therapy, the process usually involves only a short, low‑dose “fludarabine + cyclophosphamide” pre‑conditioning. That regimen rarely causes full‑body alopecia; most patients keep their hair or experience only mild thinning. Your oncologist will confirm which approach you’re taking and can give you a precise schedule for blood tests and symptom monitoring.  \n\n**Next steps**  \nAsk your team to explain the exact conditioning plan and what to expect for hair. They’ll also discuss supportive care options and when to call if you notice severe scalp pain or infection.  \n\nYou’re not alone in this—your care team will keep a close eye on you every step of the way.",
          "order": 8,
          "qid": "S26-Q08"
        },
        {
          "q": "How soon will I know if it worked?",
          "gt": "I hear how frightening the idea of intense side effects feels, especially when you’re already carrying so much hope and worry for yourself and your loved ones.\n\nIf your plan is an autologous cell‑based therapy—most commonly a CAR‑T product (e.g., tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) or a high‑dose chemotherapy followed by a stem‑cell transplant—the first clear sign of whether it’s working usually appears within the first month.  \n• **Day 0–7**: After infusion, you’ll be monitored closely for cytokine‑release syndrome (CRS) and neurotoxicity; these peak within 48–72 hours.  \n• **Day 30**: A routine blood count, chemistry panel, and a PET/CT scan are performed. A ≥30 % drop in the target lymph node size or a negative PET scan is a strong early indicator of response.  \n• **Day 90–180**: Subsequent scans and clinical exams confirm durable remission; if the disease persists, your team will discuss salvage options.  \n\nYour oncologist will tailor the exact schedule and thresholds to your specific lymphoma subtype and overall health.  \n\nRemember, your care team will be monitoring you closely every step of the way.",
          "order": 9,
          "qid": "S26-Q09"
        },
        {
          "q": "If it works, how long can it last?",
          "gt": "I hear how frightening the side‑effect worries feel, especially when you’re already carrying so much for your family—your fears are completely understandable.\n\nIf the autologous cell therapy (most often a CAR‑T‑cell infusion or a high‑dose autologous stem‑cell transplant) works, the durability varies by product and disease. For relapsed B‑cell lymphoma, CAR‑T‑cell remission lasts a median of 12–24 months, with about 30–40 % of patients achieving longer‑term control beyond 3 years. An autologous stem‑cell transplant can extend overall survival to 5–10 years in many patients, though relapse still occurs in 30–50 % over time.  \n\nYou’ll be monitored closely: CBCs and chemistry panels every 2–4 weeks for the first 3 months, then every 3 months; PET‑CT scans at 3, 6, and 12 months, then annually if stable. Watch for cytokine‑release syndrome (fever, hypotension, organ dysfunction) and neurotoxicity (confusion, seizures) after CAR‑T, and for infections or organ toxicity after transplant.  \n\nIf disease recurs, your team may consider maintenance therapy (e.g., low‑dose rituximab), additional CAR‑T cycles, or enrollment in clinical trials. Discuss the exact plan and timelines with your oncologist, as the course is highly individualized.",
          "order": 10,
          "qid": "S26-Q10"
        }
      ]
    },
    {
      "id": "S27",
      "title": "Semester on hold (acute lymphoblastic leukemia, young adult)",
      "diagnosis": "Ph-negative acute lymphoblastic leukemia in a 24-year-old",
      "treatment_plan": "Multi-phase chemotherapy (induction, consolidation, maintenance); CNS prophylaxis; central line; fertility counseling",
      "narrative": "I'm 24 and in grad school. The schedule looks like a second full-time job. I want to live—and still graduate.",
      "qa": [
        {
          "q": "How much of my semester is realistically salvageable?",
          "gt": "I hear how overwhelmed you feel, especially when your schedule feels like a second full‑time job and you’re still trying to keep your grades up.  \n\nWhile I don’t have a medical question to answer, I can share some practical strategies for salvaging your semester.  \n1. **Identify core priorities** – list required courses, thesis milestones, and mandatory meetings.  \n2. **Block focused study time** – aim for 2–3 uninterrupted hours in the morning when you’re most alert.  \n3. **Use a planner or digital calendar** – map out deadlines and add buffer days for unexpected assignments.  \n4. **Prioritize by impact** – tackle high‑grade assignments, research deadlines, and exam prep first.  \n5. **Seek flexibility** – many professors will accommodate extensions or lighter loads if you explain your workload.  \n6. **Leverage support** – join a study group or hire a tutor for time‑intensive subjects.  \n7. **Schedule breaks and self‑care** – a 5‑minute walk or quick meditation can reset focus and prevent burnout.  \n\nWith disciplined scheduling, you can realistically complete about 70–80 % of your semester workload while maintaining well‑being.  \n\nYou’re not alone in this—let’s keep refining your plan together.",
          "order": 1,
          "qid": "S27-Q01"
        },
        {
          "q": "Will a central line change how I sleep or shower?",
          "gt": "I hear how anxious you feel about how a central line might disrupt your sleep and shower routine, especially when you’re already juggling a demanding grad‑school schedule.\n\nA central line—whether a PICC, tunneled line, or port—can stay in place while you sleep. Most people sleep comfortably, but it’s wise to avoid lying directly on the side of the line. Use a pillow or a small cushion to keep the line off the bed, and you can sleep in any usual position. If you’re prone to restless legs or night sweats, the line itself won’t worsen those symptoms.\n\nYou can shower with a central line, but keep the dressing dry. For a PICC or tunneled line, cover the site with a waterproof dressing or a shower cap and avoid soaking the area. Hot showers can increase infection risk, so moderate the water temperature. A port sits under the skin; you can shower normally, just keep the port area dry and avoid submerging it.\n\nIf you notice redness, swelling, or drainage around the site, contact your oncology team right away. Routine dressing changes and regular line‑care checks will keep the line healthy.\n\nYour team will monitor the line closely, and with a few simple habits you can keep your routine—and your studies—on track.",
          "order": 2,
          "qid": "S27-Q02"
        },
        {
          "q": "How do I handle friends who say 'you don’t look sick' when I’m exhausted?",
          "gt": "I hear how exhausting it feels to be constantly “under the radar” of friends, especially when you’re already carrying a heavy academic load—your frustration and resentment are completely understandable.\n\nWhen exhaustion shows up as a persistent, unrelenting fatigue that interferes with sleep, mood, or daily functioning, it can be a sign of several medical or psychological conditions. Common contributors include chronic sleep deprivation, anemia, thyroid dysfunction, or mood disorders such as depression or anxiety. A brief evaluation by a primary‑care clinician—complete blood count, thyroid panel, and a mental‑health screening (e.g., PHQ‑9)—can help rule out underlying causes. If a medical issue is ruled out, a mental‑health professional can assess for burnout or depressive symptoms and recommend therapy, medication, or lifestyle changes.\n\nIn the meantime, set clear boundaries with friends: use “I feel” statements (“I feel drained and need rest”) and ask for concrete support (e.g., “Can you help me with this assignment?”). Prioritize sleep hygiene, short power naps, balanced meals, and brief movement breaks. If exhaustion persists, consider a short break or a reduced course load to protect your well‑being.\n\nYou’re not alone—reaching out for professional help and honest communication can make a real difference.",
          "order": 3,
          "qid": "S27-Q03"
        },
        {
          "q": "What does 'maintenance' actually feel like?",
          "gt": "I hear how exhausting and anxious this feels, especially when you’re trying to keep your grades up while still living a life outside of school.  \n\n**What “maintenance” actually feels like**  \n- **Energy dips**: You’ll notice a steady decline in alertness after long study blocks, often followed by a crash that makes even short breaks feel like a luxury.  \n- **Sleep erosion**: Nights of 4–5 h of fragmented sleep become the norm, and you may feel “wired” yet exhausted the next day.  \n- **Mood swings**: Small setbacks (a missed deadline, a late‑night email) can trigger irritability or a sense of overwhelm that lingers for hours.  \n- **Physical signs**: Headaches, muscle tension, and a slower digestion cycle are common because the body is in a constant “fight‑or‑flight” mode.  \n\n**How to monitor and manage it**  \n1. Keep a brief daily log: hours slept, meals, caffeine, mood on a 1–10 scale.  \n2. Set a “shutdown ritual” (no screens 30 min before bed, light stretching).  \n3. Schedule 15‑minute micro‑breaks every 90 min of focused work to reset.  \n4. Reach out to a counselor or peer group if you notice persistent low mood or anxiety spikes.  \n\n**Next steps**  \nDiscuss these patterns with your advisor or a mental‑health professional; they can help you adjust workload or negotiate deadlines. You’re not alone—small, consistent changes can make maintenance feel less like a marathon and more like a sustainable rhythm.",
          "order": 4,
          "qid": "S27-Q04"
        },
        {
          "q": "Can we preserve fertility without delaying induction?",
          "gt": "I hear how anxious you feel about juggling grad school and future family plans, especially when you’re already stretched thin.\n\nYes—fertility preservation can be done without delaying your program, but it does require a brief window of time. The most common option is oocyte (egg) freezing: you’ll undergo 10–14 days of hormone stimulation (e.g., FSH + hMG), followed by a single retrieval day where eggs are collected and vitrified. The entire process takes about 3 weeks, and you can schedule the stimulation and retrieval around your class schedule, often in the evenings or weekends. Ovarian‑tissue cryopreservation is another quick, experimental option that can be done in a single day, but it’s less widely available and requires a transplant later. A GnRH‑agonist protocol can be used for short‑term suppression, but it’s less effective for long‑term fertility preservation.\n\nPlan a consultation with a fertility clinic as soon as possible to discuss timing, costs, and insurance coverage. They can coordinate the stimulation cycle to fit your academic calendar, so you can start grad school on time while still preserving your fertility options.",
          "order": 5,
          "qid": "S27-Q05"
        },
        {
          "q": "Do I have to give up my apartment with roommates?",
          "gt": "It sounds like the pressure of grad school is leaving you feeling overwhelmed and anxious, especially when you’re trying to keep your living situation stable.  \n\nFirst, talk to your advisor or a student support office about your workload. They can help you prioritize deadlines and may offer extensions or a lighter course load that reduces the need for a quiet environment.  \n\nNext, have an honest conversation with your roommates. Explain that you need a dedicated study space and see if you can agree on quiet hours or a shared study room. If the apartment’s noise level is still a problem, look into nearby libraries, co‑working spaces, or on‑campus housing that offers a quieter setting.  \n\nIf you’re considering a move, weigh the costs and benefits. A temporary lease or a roommate swap can give you the focus you need without a long‑term commitment.  \n\nYou’re not alone—let’s explore options that keep you focused and supported.",
          "order": 6,
          "qid": "S27-Q06"
        },
        {
          "q": "What if chemo brain wrecks my studying?",
          "gt": "I hear how frightening the idea of “chemo brain” feels, especially when you’re already juggling a demanding grad‑school schedule—your worries are completely understandable.\n\n**What to expect and how to manage it**  \nChemo‑induced cognitive changes are common (up to 60 % of patients) and usually involve short‑term memory lapses, difficulty concentrating, and slowed processing. They most often appear during or shortly after treatment and tend to improve within 6–12 months, though some people experience lingering effects.  \n\n**Monitoring**  \nYour oncology team may perform baseline neurocognitive testing (e.g., Trail‑Making Test, Digit Span) and repeat it every 3–6 months. If you notice worsening symptoms, let them know right away; they can adjust the regimen or add supportive measures.  \n\n**Practical strategies**  \n- **Structured study blocks**: work when you feel most alert (often morning).  \n- **Memory aids**: use digital calendars, sticky notes, and spaced‑repetition apps.  \n- **Breaks & movement**: short walks or stretching every 45–60 min help maintain focus.  \n- **Sleep, nutrition, hydration**: aim for 7–8 h sleep, balanced meals, and plenty of water.  \n- **Cognitive rehab**: a neuropsychologist can teach targeted exercises and coping techniques.  \n\n**When to talk to your oncologist**  \nIf symptoms interfere with daily life, discuss dose modifications, supportive medications (e.g., low‑dose donepezil is sometimes considered off‑label), or alternative agents with a lower neurotoxicity profile.  \n\nYou’re not alone in this—your care team will monitor closely and adapt the plan to keep both your health and studies on track.",
          "order": 7,
          "qid": "S27-Q07"
        },
        {
          "q": "How strict is infection prevention during exams on campus?",
          "gt": "I hear how anxious you feel about staying healthy while juggling a heavy grad‑school schedule—especially when exams feel like a second full‑time job.\n\n**Infection‑prevention during campus exams** is guided by CDC and university health‑service policies. Most campuses now require a valid COVID‑19 vaccination or a recent negative rapid test for in‑person exams, and mask‑wearing is still encouraged in crowded or poorly ventilated rooms. Hand‑sanitizer stations are placed at every exam hall, and many institutions have installed HEPA filters or increased ventilation. If you’re immunocompromised or have a chronic illness, the university typically offers a “protected‑exam” option: a private room, a virtual proctor, or a scheduled time when fewer students are present.  \n\nIf you’re unsure of your status, check the campus health portal for the latest testing and vaccination requirements, and contact the student health center to discuss any accommodations. Bringing a mask, hand sanitizer, and a small water bottle can help you feel more in control. If you develop symptoms or a positive test, the university’s policy is to postpone the exam and arrange a makeup date or a remote proctoring session.  \n\nYou’re not alone—your campus health team is there to support you, and they’ll keep you updated on any policy changes.",
          "order": 8,
          "qid": "S27-Q08"
        },
        {
          "q": "If a phase is delayed, does it ruin the whole plan?",
          "gt": "I hear how anxious you feel about a possible delay, especially when juggling a demanding grad‑school schedule and the pressure to finish on time.\n\nIn most multi‑phase treatment plans—whether for chemotherapy, targeted therapy, or radiation—short pauses (typically up to 1–2 weeks) are built into the protocol and usually don’t compromise overall efficacy. For example, a standard induction phase of 5‑FU/cisplatin might be postponed for a week if you need a blood‑work clearance or a minor infection; the oncologist can then resume the cycle with the same dose or a slight adjustment. However, delays beyond 3–4 weeks can reduce the cumulative dose intensity, potentially lowering response rates and increasing relapse risk.  \n\nKey steps if a delay occurs:  \n1. **Notify your oncology team immediately** so they can reassess your labs, imaging, and any new symptoms.  \n2. **Adjust the schedule**—often the next cycle is simply postponed, but dose reductions or a switch to a maintenance regimen may be considered if the delay is prolonged.  \n3. **Maintain monitoring**—regular CBCs, renal panels, and imaging per the original schedule, plus any additional tests your team deems necessary.  \n\nUltimately, a brief delay usually won’t derail your entire plan, but the sooner you communicate with your oncologist, the better they can tailor the next steps to keep you on track.",
          "order": 9,
          "qid": "S27-Q09"
        },
        {
          "q": "What’s plan B if remission isn’t complete?",
          "gt": "I hear how scary it feels to think the remission might not be complete, especially when you’re already juggling a full‑time study load and a demanding treatment schedule—your worries are completely understandable.\n\n**Plan B if remission isn’t complete**\n\n1. **Re‑assessment** – A CT/MRI and tumor marker panel (e.g., CA‑125, AFP, CEA) every 6–8 weeks to confirm residual disease.  \n2. **Second‑line chemotherapy** – If you received an anthracycline‑taxane backbone, a platinum‑based combo (carboplatin AUC 5 + paclitaxel 80 mg/m² IV every 3 weeks) is standard.  \n3. **Targeted or immunotherapy** – For HER2‑positive disease, trastuzumab‑based maintenance (trastuzumab 6 mg/kg IV every 3 weeks) or a HER2‑directed antibody‑drug conjugate (T-DM1 3.6 mg/kg IV every 3 weeks). For MSI‑high or PD‑L1‑positive tumors, pembrolizumab 200 mg IV every 3 weeks.  \n4. **Clinical trials** – Many trials offer novel agents (e.g., PARP inhibitors, CAR‑T, bispecific antibodies) that may fit your tumor profile.  \n5. **Supportive care** – Growth factor support (filgrastim) if neutropenia, anti‑emetics, and dose‑adjusted schedules to manage toxicity.  \n6. **If progression persists** – Discuss palliative options or hospice to focus on quality of life.\n\nYour oncologist will tailor the exact drugs, doses, and monitoring to your specific diagnosis and prior response. We’ll keep a close eye on blood counts, liver function, and imaging, and adjust the plan as needed.",
          "order": 10,
          "qid": "S27-Q10"
        }
      ]
    },
    {
      "id": "S28",
      "title": "Which way do I pee (muscle-invasive bladder cancer)",
      "diagnosis": "Muscle-invasive urothelial carcinoma",
      "treatment_plan": "Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with urinary diversion (ileal conduit or neobladder)",
      "narrative": "I'm 65. They’re removing my bladder after chemo, and I have to choose how I’ll pee for the rest of my life. I want dignity and practicality.",
      "qa": [
        {
          "q": "Is there a way to avoid removing the bladder if chemo works well?",
          "gt": "I hear how frightening the thought of losing your bladder feels, especially when you’re already carrying so much for your family—your worries are completely understandable.\n\nIf your chemotherapy shows a strong response, there is a bladder‑preservation pathway called trimodal therapy (TMT). It combines transurethral resection of the bladder tumor (TURBT) with concurrent cisplatin‑based chemotherapy and external‑beam radiation.\n\nTypical TMT schedules: 3–4 cycles of cisplatin 70–75 mg/m² every 3 weeks, followed by 50–55 Gy of radiation over 5–6 weeks. Response is assessed 4–6 weeks after completion with cystoscopy, imaging, and urine cytology.\n\nA complete clinical response (no visible tumor, negative cytology) allows you to keep the bladder, but you’ll need intensive surveillance: cystoscopy every 3 months first year, then every 6 months, plus imaging annually.\n\nIf the response is partial or the tumor recurs, the standard recommendation is radical cystectomy. The decision hinges on your individual tumor biology, performance status, and preferences, so it must be discussed with your oncologist.\n\nBladder preservation is possible only if the chemo‑radiation combo works; otherwise surgery remains the safest option. Your team will monitor closely and adjust the plan as needed.  \n\nWe’ll work together to keep you informed and supported every step of the way.",
          "order": 1,
          "qid": "S28-Q01"
        },
        {
          "q": "Which diversion lets me travel without constant bathroom scouting?",
          "gt": "I hear how anxious the idea of choosing a diversion feels, especially when you’re already juggling so many changes and want to keep your independence intact.\n\n**Ileal conduit** is the most travel‑friendly option. A small bowel segment is attached to the ureters and drains into an external pouch that you can empty every 3–4 hours in any hotel bathroom. No catheterization is needed, so you can move freely without hunting for a specific restroom.  \n**Continent cutaneous reservoir** (e.g., Indiana pouch) lets you catheterize yourself every 4–6 hours, keeping the bag internal. It’s less visible but requires carrying a catheter kit and finding a private space to catheterize, which can be a bit more cumbersome on the road.  \n**Orthotopic neobladder** recreates a bladder‑like pouch that you void spontaneously. It offers the most natural feel, but you may need to catheterize if retention occurs, and you’ll still need to locate a bathroom for each void, which can be unpredictable while traveling.  \nFor most people who want minimal bathroom scouting, the ileal conduit offers the simplest, most reliable solution for long trips.  \n\nRemember, your surgical team can tailor the pouch size and drainage schedule to fit your lifestyle, so discuss any concerns before the operation.",
          "order": 2,
          "qid": "S28-Q02"
        },
        {
          "q": "Will intimacy be possible after surgery?",
          "gt": "I hear how anxious you feel about the future of intimacy, especially when you’re already juggling so many changes after your chemo and upcoming cystectomy.\n\nAfter a cystectomy, sexual function depends largely on the type of urinary diversion and whether nerve‑sparing techniques were used.  \n• **Men**: If nerves are preserved, erectile function can be maintained, but many still experience erectile dysfunction (ED) due to vascular or nerve injury. ED can often be managed with oral phosphodiesterase‑5 inhibitors, vacuum erection devices, or penile prostheses.  \n• **Women**: Vaginal dryness and reduced lubrication are common, but topical lubricants, vaginal moisturizers, and low‑dose vaginal estrogen can restore comfort.  \n• **Both**: A urinary diversion (ileal conduit, orthotopic neobladder, or ureterostomy) changes the way you pee but does not inherently block sexual activity. Pelvic floor therapy and counseling can help you adapt and maintain intimacy.  \n\nDiscuss these options with your urologist and a sexual health specialist before surgery; they can tailor a plan that preserves dignity and practicality for you.  \n\nYou’ll have support every step of the way, and many patients find fulfilling intimacy after cystectomy with the right resources.",
          "order": 3,
          "qid": "S28-Q03"
        },
        {
          "q": "How visible is an external bag under clothes?",
          "gt": "I hear how anxious you feel about the bag’s visibility, especially when you’re trying to keep your dignity while caring for your family.  \n\n**Visibility of an external urinary bag**  \nMost external bags (the “bladder bag” or external catheter collection bag) are about 1–2 inches tall and 3–4 inches wide. When attached to the abdomen, they sit just above the hips and can be concealed under most shirts, blouses, or jackets. The key factors that determine how noticeable it is are:  \n\n1. **Bag size and profile** – A low‑profile, “compact” bag is less likely to show through thin fabrics.  \n2. **Clothing choice** – Dark, loose‑fitting tops and layered garments (e.g., a cardigan over a shirt) help mask the bag’s outline.  \n3. **Bag color** – Many manufacturers offer neutral or skin‑tone colors that blend with your skin and clothing.  \n4. **Attachment method** – Some bags come with a small, discreet pouch or a “cover” that can be tucked into a pocket or under a belt.  \n\nIn practice, most people find the bag is invisible under a standard shirt or jacket, especially if they use a low‑profile bag and choose darker, thicker fabrics. If you’re concerned, you can try a few different bag styles and clothing combinations during a trial period to see what feels most comfortable and discreet.  \n\nFeel free to discuss specific bag models with your urologist or wound‑care team; they can recommend a size and style that best matches your lifestyle.",
          "order": 4,
          "qid": "S28-Q04"
        },
        {
          "q": "Will chemo damage my hearing or nerves permanently?",
          "gt": "I hear how scary it feels to worry about lasting side‑effects, especially when you’re already juggling so much about your surgery and future quality of life.\n\nMost bladder‑cancer regimens that include cisplatin or carboplatin carry a risk of ototoxicity—high‑frequency hearing loss that is usually permanent. The risk rises with cumulative dose, pre‑existing hearing issues, and dehydration or low blood pressure during infusion. Audiograms are typically done before treatment, midway, and after completion to catch changes early. If hearing loss appears, dose adjustments or switching to carboplatin (which is less ototoxic) can help, but the damage that has already occurred is often irreversible.\n\nPeripheral neuropathy is common with taxanes (paclitaxel, docetaxel) and, to a lesser extent, with cisplatin and ifosfamide. Symptoms include tingling, numbness, or weakness in the hands and feet. Most neuropathies improve over several months after stopping the drug, but a small percentage can persist or even worsen. Your oncologist may monitor nerve function with physical exams and consider dose reductions or neuroprotective agents if needed.\n\nUltimately, the likelihood of permanent damage depends on the specific drugs, doses, and your overall health. Discuss your concerns with your oncology team; they can tailor the plan, schedule audiology and neurologic checks, and adjust therapy to minimize risk while still treating the cancer effectively.",
          "order": 5,
          "qid": "S28-Q05"
        },
        {
          "q": "Can I swim with a stoma?",
          "gt": "I hear how anxious you feel about staying active and maintaining dignity after your surgery, especially when you’re already juggling so many responsibilities.\n\nYes—you can swim with a stoma. Most people use a waterproof pouch that’s designed for water activities. The pouch should be sealed and kept dry; you’ll want to avoid pressure on the stoma site, so a pouch that can be secured with a strap or a “water‑proof” sleeve is ideal. After swimming, change the pouch and wash the area with mild soap and water. If you’re swimming in a pool, you can use a standard pouch; for open‑water or long‑duration swims, a pouch that’s specifically labeled “water‑proof” and “pressure‑resistant” is best. Keep the pouch away from the stoma for a few minutes after you get out of the water to allow the skin to dry. Your surgeon or stoma nurse can show you the exact pouch type and how to attach it so it stays secure without causing irritation. \n\nWe’ll work together to find the right pouch and routine so you can enjoy swimming confidently and with dignity.",
          "order": 6,
          "qid": "S28-Q06"
        },
        {
          "q": "What if I can’t pee with a neobladder at first?",
          "gt": "I hear how unsettling it feels to worry that you might not be able to pee with a neobladder right after surgery—especially when you’re already juggling so much from chemo and the operation.\n\nA neobladder is made from a piece of your small intestine that’s shaped into a new “bladder.” In the first 2–4 weeks, most people still need a catheter to empty the new reservoir. Your surgeon will usually keep the catheter in for 3–5 days, then remove it and let you try to void on your own. If you can’t empty the neobladder or your post‑void residual is >200 mL, you’ll be taught intermittent catheterization (usually 3–4 times a day) until you gain reliable voiding. Most patients regain spontaneous voiding by 6–8 weeks; if not, a urodynamic study will guide whether a permanent catheter or an alternative conduit (like an ileal conduit) is needed. Your team will monitor residual urine, bladder capacity, and any leakage, and they’ll adjust the plan if you’re still struggling.\n\nRemember, the first few weeks are a learning curve—your care team will be there to help you every step of the way.",
          "order": 7,
          "qid": "S28-Q07"
        },
        {
          "q": "How often are follow-ups after surgery?",
          "gt": "I hear how anxious you must feel about the next steps, especially when you’re already juggling so many changes after surgery.\n\n**Typical follow‑up schedule after a cystectomy with urinary diversion**\n\n- **First visit (2–4 weeks post‑op):** wound check, stoma assessment, pain control, and review of any complications.  \n- **Subsequent visits:** 3 months, 6 months, then every 6 months for the first 2 years, and yearly thereafter for at least 5 years. After that, many teams schedule visits every 1–2 years if you remain disease‑free.  \n- **Imaging:** A CT scan of the chest, abdomen, and pelvis is usually done every 6 months during the first 2 years, then yearly. Your oncologist may adjust this based on your pathology or risk factors.  \n- **Laboratory tests:** CBC, CMP, and any tumor markers (e.g., PSA if applicable) are checked at each visit.  \n- **Stoma care:** A stoma nurse will see you at 2 weeks, 6 weeks, and 3 months, then as needed for any issues with the appliance or skin.  \n- **Specialty visits:** Your urologist and oncologist will coordinate to monitor for recurrence, manage the diversion, and address any functional concerns.\n\nYour exact schedule may vary, so discuss any adjustments with your surgical and oncology teams.  \n\nWe’ll keep a close eye on your recovery and help you maintain both dignity and practicality.",
          "order": 8,
          "qid": "S28-Q08"
        },
        {
          "q": "Will I smell or leak?",
          "gt": "I hear how anxious you feel about the next steps, especially when you’re already juggling so much for your family.  \n\nThe three main diversions are an ileal conduit, a continent catheterizable channel (like a Mitrofanoff), and an orthotopic neobladder made from bowel.  \n\nAn ileal conduit drains urine into a small external pouch. It can produce a mild, persistent odor if the pouch isn’t emptied or cleaned regularly, but leakage is rare once the system is set up.  \n\nA continent channel lets you catheterize yourself; it has no external bag, so there’s no pouch odor. Leakage can occur if the channel isn’t catheterized on schedule, but with proper technique it’s usually minimal.  \n\nAn orthotopic neobladder is a reservoir that replaces the bladder. It can have a slight odor from the bowel tissue, and occasional leakage is common in the first 6–12 months while you learn to sense fullness.  \n\nAll options require routine follow‑up: pouch cleaning, catheterization training, and periodic imaging or urodynamic studies. Good hygiene, regular emptying, and early reporting of foul smell or persistent leakage will keep problems mild.  \n\nWe’ll keep a close eye on any changes, and I’ll be here to help you adjust as needed.",
          "order": 9,
          "qid": "S28-Q09"
        },
        {
          "q": "If pathology shows worse disease than expected, do we have backup options?",
          "gt": "I hear how unsettling it feels to think that the final pathology might reveal more extensive disease, especially when you’re already navigating the big decision about how you’ll live with a new urinary system.\n\nIf the pathology shows a higher stage (e.g., pT3‑T4) or positive lymph nodes, the surgical team can still adjust the plan. First, an extended lymph‑node dissection is often performed intra‑operatively if not already done, which can remove additional cancerous nodes. After the operation, most patients with node‑positive or high‑stage disease receive adjuvant cisplatin‑based chemotherapy (gemcitabine + cisplatin or dose‑adjusted cisplatin + gemcitabine) within 6–12 weeks, provided kidney function and performance status allow. If cisplatin is contraindicated, carboplatin‑based regimens or clinical‑trial options are considered.  \n\nRegarding the diversion itself, the surgeon can switch from a continent neobladder to an ileal conduit if the cancer extent or operative findings make a neobladder unsafe. In rare cases where the pathology shows metastatic disease, systemic therapy or palliative care pathways are discussed.  \n\nYour team will monitor blood counts, renal function, and imaging every 3–4 weeks during adjuvant therapy, and they’ll keep you updated on any needed changes.  \n\nWe’ll walk through each step together, so you’re never alone in this.",
          "order": 10,
          "qid": "S28-Q10"
        }
      ]
    },
    {
      "id": "S29",
      "title": "Swallowing my fear (esophageal cancer)",
      "diagnosis": "Locally advanced esophageal or gastroesophageal junction cancer",
      "treatment_plan": "Neoadjuvant chemoradiation followed by surgery when appropriate; nutrition support",
      "narrative": "I'm 60 and losing weight because food gets stuck. Treatment is chemoradiation and possibly surgery. I want to eat with my family again.",
      "qa": [
        {
          "q": "How do I keep weight on when every bite scares me?",
          "gt": "I hear how frightening each bite feels, especially when you’re trying to stay strong for your family—your worry is completely understandable.\n\n**What you can do to keep weight while eating safely**\n\n1. **Swallow‑support** – A speech‑language pathologist can teach compensatory techniques (chin‑tuck, head‑turn) and safe swallowing positions.  \n2. **Texture‑modified foods** – Soft, minced, or pureed meals reduce the risk of food getting stuck.  \n3. **High‑calorie oral supplements** – Drinks like Ensure® or Boost® add 400–600 kcal per serving; aim for 2–3 servings daily if tolerated.  \n4. **Anti‑emetic & reflux control** – Your oncologist may prescribe ondansetron 8 mg PO q8 h and dexamethasone 8 mg PO q12 h, plus a proton‑pump inhibitor (omeprazole 20 mg PO daily) to reduce nausea and reflux.  \n5. **Monitoring** – Weigh yourself weekly, track serum albumin/pre‑albumin, and have a dietitian review your intake every 2–4 weeks.  \n6. **Enteral feeding** – If you lose >5 % of body weight in 2 weeks or dysphagia worsens, a percutaneous endoscopic gastrostomy (PEG) tube can provide reliable nutrition while you recover.  \n\nDiscuss these options with your oncology team; they’ll tailor the plan to your treatment schedule and keep you and your family nourished and connected.",
          "order": 1,
          "qid": "S29-Q01"
        },
        {
          "q": "Will chemoradiation make swallowing worse before it gets better?",
          "gt": "I hear how scary it feels that swallowing might get even harder before it improves, especially when you’re hoping to share meals with your family again.  \n\nChemoradiation for head‑and‑neck cancer (often cisplatin or carboplatin plus 5‑FU or cetuximab with 60–70 Gy of radiation over 6–7 weeks) can cause acute mucositis, edema, and inflammation that peak around 2–4 weeks into treatment. During that window many patients notice increased difficulty swallowing and may need softer foods or a feeding tube. After the acute phase, as the mucosa heals, swallowing usually starts to improve over the next 4–6 weeks, though late fibrosis can cause a slower, more chronic decline that your team will monitor.  \n\nYour oncologist will schedule weekly swallow assessments, weight checks, and nutrition labs. If swallowing worsens, a speech‑language pathologist can guide exercises, and a percutaneous endoscopic gastrostomy (PEG) tube may be placed temporarily. Dose adjustments or a brief break can also be considered if symptoms become severe.  \n\nRest assured, your team will track these changes closely and adjust the plan so you can regain safe, enjoyable eating as soon as possible.",
          "order": 2,
          "qid": "S29-Q02"
        },
        {
          "q": "If surgery is needed, will I ever eat normally?",
          "gt": "I hear how frightening it feels to think you might never sit down with your family again, especially when you’re already carrying so much worry about your health.\n\nIf the plan moves to surgery, the most common operation for a tumor that’s causing food to get stuck is an esophagectomy or a partial gastrectomy, often performed after chemoradiation to shrink the tumor. In most cases, surgeons aim to preserve the esophageal or gastric conduit so that swallowing can return to near‑normal function. Recovery usually starts with a liquid diet 4–6 weeks after surgery, progressing to pureed foods, then soft solids, and finally regular foods over 8–12 weeks, guided by a speech‑language pathologist and dietitian. You’ll have swallow studies and endoscopies every 2–4 weeks to check for strictures or leaks. If a temporary feeding tube is needed, it’s usually removed once you can tolerate at least a soft diet.\n\nWhile many patients regain normal eating, some may need long‑term dietary adjustments or occasional tube feeding if strictures or aspiration risk remain. Your team will monitor weight, nutrition labs, and swallowing function closely, and adjust the plan if complications arise.  \n\nWe’ll keep a close eye on your progress and support you every step of the way.",
          "order": 3,
          "qid": "S29-Q03"
        },
        {
          "q": "Am I going to choke or aspirate at home?",
          "gt": "I hear how frightening it feels to worry about choking, especially when you want to share meals with your family. That fear is completely understandable.\n\nThe risk of aspiration at home depends on how severe your swallowing difficulty is after chemoradiation and any surgery. A speech‑language pathologist can perform a formal swallow evaluation to see if you can safely eat soft foods, need thickened liquids, or require a feeding tube. If you can swallow, the team will give you specific diet modifications—small, moist bites, chewing slowly, and avoiding dry or sticky foods—to reduce the chance of food getting stuck. You’ll also be taught simple swallowing exercises and taught to watch for signs of aspiration: coughing, wheezing, or a sudden change in breathing during a meal. If you notice any of these, call your oncologist or go to the emergency department right away. Chemoradiation can cause mucositis and xerostomia, which worsen dysphagia, but many patients recover enough to eat safely with these precautions. Your oncology team will monitor weight, hydration, and swallow function regularly and adjust the plan if needed.\n\nWe’ll work closely to keep you safe and comfortable while you enjoy family meals.",
          "order": 4,
          "qid": "S29-Q04"
        },
        {
          "q": "Can I still drink coffee or wine?",
          "gt": "I hear how anxious you feel about keeping family meals alive, especially when the treatment feels so overwhelming and your body is already fighting to stay nourished.\n\n**Coffee**: Most chemoradiation regimens (e.g., cisplatin‑based or 5‑FU) don’t prohibit caffeine, but the acid and heat can irritate a mucositis‑prone esophagus. A single cup of decaf or a low‑acid coffee, taken early in the day, is usually tolerated. Avoid large volumes, late‑night caffeine, and very hot drinks that could worsen swallowing discomfort.\n\n**Wine**: Alcohol is a known irritant to inflamed mucosa and can increase nephrotoxicity with cisplatin or ototoxicity with carboplatin. It also interferes with liver metabolism of many chemo agents, potentially raising toxicity. During active chemotherapy and especially before any planned surgery, it’s safest to abstain or limit to a very small glass (≤ 2 oz) on rare occasions, after consulting your oncologist.\n\n**Practical tips**  \n- Keep water or non‑acidic herbal teas handy to stay hydrated.  \n- If you do sip wine, choose a dry, low‑residue variety and drink slowly.  \n- Monitor for worsening dysphagia, weight loss, or new pain; report any changes immediately.  \n\n**Monitoring**  \n- Weekly weight checks, oral mucositis grading (CTCAE), and routine labs (CBC, CMP) guide adjustments.  \n- Your oncology team will review any beverage‑related side effects at each visit.\n\nWe’ll keep a close eye on how your body responds, and I’ll be here to adjust the plan so you can enjoy meals with your loved ones as safely as possible.",
          "order": 5,
          "qid": "S29-Q05"
        },
        {
          "q": "How long before I know if surgery is on the table?",
          "gt": "I hear how anxious you feel about when the surgery decision will be made, especially when you’re already worried about losing weight and missing meals with your family.\n\nAfter completing chemoradiation, most teams schedule a response assessment about 4–6 weeks later. During that window you’ll have routine labs (CBC, electrolytes, liver enzymes), a nutritional review, and a cross‑sectional scan—usually a contrast‑enhanced CT or PET‑CT—to see how the tumor has responded. The imaging results, along with your performance status and any new symptoms, are then presented at a multidisciplinary tumor‑board meeting. If the board agrees that the tumor is resectable and you’re fit for surgery, the operating room is booked within 2–4 weeks after the meeting. If the response is inadequate or the tumor remains unresectable, the team will discuss alternative systemic options or palliative measures. Your oncologist will keep you updated after each step, so you’ll know the exact date for the board review and, if approved, the surgery schedule. In the meantime, focus on nutrition support and any symptom‑management measures your team recommends.",
          "order": 6,
          "qid": "S29-Q06"
        },
        {
          "q": "Do I need to sleep upright forever?",
          "gt": "Feeling scared and anxious about how your swallowing changes will affect family meals is completely understandable, especially when you’re already carrying so much for your loved ones.\n\nSleeping upright can help reduce reflux and aspiration, but the duration depends on how your esophagus heals after chemoradiation and any surgery. If you develop a feeding tube (PEG) or a tracheostomy, you’ll likely need to stay upright for the first 4–6 weeks while the tract matures. Once the tube is removed and swallowing function improves—often assessed by a speech‑language pathologist with a bedside swallow study—you can usually transition to a more neutral position. In many patients, the need for an upright sleep position resolves within 3–6 months, but some may need it longer if fibrosis or strictures persist. Your oncologist, ENT, and swallowing therapist will monitor weight, aspiration risk, and esophageal motility, and adjust the recommendation as you recover.\n\nWe’ll keep a close eye on your progress, and I’m here to help you feel confident about each step.",
          "order": 7,
          "qid": "S29-Q07"
        },
        {
          "q": "How do you keep me safe from dehydration?",
          "gt": "I hear how anxious you feel about staying hydrated while you’re fighting cancer, especially when you’re trying to share meals with your family—your worries are completely understandable.  \n\nThe first step is to aim for about 30–35 mL of fluid per kilogram of body weight each day, which for a 60‑year‑old adult usually means roughly 2–3 L of water, oral rehydration solution, or clear broths.  \n\nBecause food gets stuck, sip small amounts of fluid between bites, use",
          "order": 8,
          "qid": "S29-Q08"
        },
        {
          "q": "What does a 'good day' look like during treatment so I can plan moments with my spouse?",
          "gt": "I hear how anxious you feel about staying strong for your family, especially when each day feels like a battle.\n\n**Chemoradiation schedule**  \n- Cisplatin 100 mg/m² IV over 1 hour every 3 weeks (or cetuximab 400 mg/m² IV over 1 hour, then 250 mg/m² weekly).  \n- Radiation 2 Gy per fraction, 5 days a week for 6–7 weeks.  \n- Weekly labs (CBC, electrolytes, weight) and a swallow assessment help catch problems early.\n\n**What a “good day” looks like**  \nMild mucositis (grade 1–2), controlled nausea with anti‑emetics, and enough energy to sit for 30–60 minutes with your spouse. Small, soft, frequent meals—smoothies, pureed soups, or soft finger foods—are easier to manage.\n\n**Practical tips for shared moments**  \n- Schedule meals after radiation when pain is lowest.  \n- Keep a water bottle and a straw to reduce effort.  \n- Plan a short walk or light activity after eating to boost appetite.  \n- Bring a snack pack for your spouse to share; it keeps the experience enjoyable and less stressful.\n\n**Safety check**  \nWatch for dehydration, aspiration, or pain >4/10. Call your oncology team if you can’t swallow safely or if symptoms worsen; dose adjustments or supportive meds can be added.\n\nYour team will monitor closely, and together we’ll keep those moments with your spouse as meaningful as possible.",
          "order": 9,
          "qid": "S29-Q09"
        },
        {
          "q": "If I can’t face surgery, is there still a path?",
          "gt": "I hear how frightening the idea of surgery feels, especially when you’re already trying to keep your family meals together—your worries are completely understandable.\n\nIf surgery isn’t an option, you can still pursue definitive chemoradiation and a range of supportive measures. A common regimen for esophageal or hypopharyngeal tumors is cisplatin 40 mg/m² weekly plus 5‑FU 1000 mg/m² continuous infusion days 1‑5, repeated for 5–6 weeks. Alternatively, carboplatin AUC 2 with paclitaxel 50 mg/m² weekly is used when cisplatin is contraindicated. Blood counts, electrolytes, and renal function are checked before each cycle; hearing and neuropathy are monitored for cisplatin toxicity. Imaging (CT or PET‑CT) is usually repeated 6–8 weeks after completion to assess tumor shrinkage; a ≥70 % reduction often allows omission of surgery.\n\nFor the swallowing problem, endoscopic stenting can relieve obstruction and restore oral intake in many patients. If the stent fails or the tumor progresses, a percutaneous endoscopic gastrostomy (PEG) tube can provide reliable nutrition while you continue therapy. A dietitian can tailor texture‑modified meals and high‑calorie supplements to help you regain weight.\n\nDiscuss these alternatives with your oncologist and palliative‑care team; they’ll tailor the plan to your health status and preferences.  \n\nWe’ll work together to keep you nourished and comfortable while you enjoy meals with your loved ones.",
          "order": 10,
          "qid": "S29-Q10"
        }
      ]
    },
    {
      "id": "S30",
      "title": "Fast and furious (extensive-stage small cell lung cancer)",
      "diagnosis": "Extensive-stage small cell lung cancer",
      "treatment_plan": "Platinum/etoposide chemotherapy with immunotherapy; symptom control; imaging to assess response",
      "narrative": "I'm 63 and this cancer showed up fast. They want to start chemo-immunotherapy now. I need relief and a plan that keeps my days meaningful.",
      "qa": [
        {
          "q": "How quickly might my cough and breathlessness improve?",
          "gt": "I hear how anxious you feel about the cough and breathlessness, especially when you’re already juggling so much uncertainty about the next steps.\n\n**What to expect with chemo‑immunotherapy**  \nMost regimens for advanced solid tumors combine a platinum‑based chemo (e.g., carboplatin + paclitaxel or docetaxel) with a checkpoint inhibitor (pembrolizumab, nivolumab, or atezolizumab). Infusions last 1–2 hours, and you’ll receive a cycle every 3 weeks.  \nSymptom relief can begin as early as the first cycle, but meaningful improvement in cough and dyspnea usually appears after 2–4 weeks, when the tumor burden starts to shrink. Your oncologist will monitor you with CBC, CMP, and LFTs before each cycle, and a CT scan 6–8 weeks after treatment starts to gauge response.  \nIf you develop worsening cough or shortness of breath, the team may add low‑dose steroids, bronchodilators, or supplemental oxygen, and will watch for immune‑related pneumonitis (check for fever, new infiltrates on chest X‑ray).  \nIf symptoms persist or worsen, the plan may shift to a different chemo backbone or a maintenance strategy, but the goal remains to reduce tumor load and improve breathing while keeping you active.\n\nWe’ll keep a close eye on your progress and adjust as needed—your team is here to help you stay as comfortable and engaged as possible.",
          "order": 1,
          "qid": "S30-Q01"
        },
        {
          "q": "What makes this cancer different from the others I read about?",
          "gt": "I hear how frightening the rapid onset feels, especially when you’re already juggling so much and want to keep your days meaningful—your worries are completely understandable.\n\n**What makes this cancer stand out from the others you’ve read about**\n\n1. **Speed of growth** – Unlike many solid tumors that progress over months, this type can double in size within weeks, so treatment starts sooner to curb further spread.  \n2. **Molecular profile** – It often carries specific driver mutations (e.g., EGFR, ALK, or high PD‑L1 expression) that make it uniquely responsive to a combination of chemotherapy and immune checkpoint inhibitors.  \n3. **Treatment regimen** – The standard induction cycle is usually 3 weeks: a platinum‑based chemo (cisplatin or carboplatin) plus a taxane (paclitaxel) followed by a checkpoint inhibitor (pembrolizumab or nivolumab).  \n4. **Monitoring schedule** – CBC and CMP before each cycle, imaging (CT chest/abdomen) every 6–8 weeks, and echocardiogram every 3 months if a cardiotoxic agent is used.  \n5. **Response expectations** – A partial response is defined as ≥30 % tumor shrinkage; stable disease can still translate to meaningful symptom relief.  \n6. **Side‑effect profile** – Expect fatigue, nausea, and immune‑related events (pneumonitis, colitis). Your team will adjust doses or add steroids if needed.  \n\nIf the cancer shows progression, the plan usually shifts to a second‑line immunotherapy or targeted agent, or to a maintenance strategy. Your oncologist will tailor every step to your health status and goals.  \n\nWe’ll keep a close eye on you and adjust as needed, so you can stay as active and present as possible.",
          "order": 2,
          "qid": "S30-Q02"
        },
        {
          "q": "Will I be stuck in bed after each cycle?",
          "gt": "I hear how scary the idea of being bedridden after every treatment feels, especially when you’re trying to stay active for yourself and those you love.\n\nMost chemo‑immunotherapy regimens (e.g., a platinum‑based chemo plus a checkpoint inhibitor) are given over 1–2 hours and you can usually go home the same day. You’ll have a blood count and chemistry panel checked before each cycle, and if you’re on an anthracycline or a drug that affects heart function, an echocardiogram every 3 months.  \n\nCommon side effects are fatigue, nausea, and a temporary drop in white‑blood cells. The fatigue usually peaks 24–48 hours after infusion and then eases enough for you to resume light activities. You can walk, do gentle stretches, or sit at a table—just pace yourself and rest when you feel worn.  \n\nSupportive care—anti‑emetics, a growth‑factor injection if counts fall low, and plenty of fluids—helps keep you up and moving. Your team will adjust doses or add supportive meds if fatigue becomes severe.  \n\nIf you notice extreme tiredness, dizziness, or any new symptoms, call your oncologist right away; they can tweak the plan or provide additional support.  \n\nWe’ll monitor closely and keep you as active and comfortable as possible.",
          "order": 3,
          "qid": "S30-Q03"
        },
        {
          "q": "Can immunotherapy cause dangerous side effects?",
          "gt": "I hear how frightening the idea of serious side effects feels, especially when you’re already juggling so much to keep your days meaningful.  \n\nCheckpoint inhibitors (e.g., pembrolizumab, nivolumab) and CAR‑T cells are the most common forms of immunotherapy used today.  \nPembrolizumab is given IV over 2 hours every 3 weeks; ipilimumab is 30–60 minutes every 3 weeks; CAR‑T is a single infusion.  \nDangerous immune‑related events include colitis, pneumonitis, hepatitis, endocrinopathies, and, for CAR‑T, cytokine release syndrome (CRS) and neurotoxicity. These reactions can be life‑threatening if not treated promptly.  \nBaseline labs (CBC, CMP, thyroid, cortisol) are checked before each cycle; repeat labs every 2–3 weeks and imaging every 8–12 weeks. Your oncologist will tailor the schedule to your specific cancer type and overall health.  \nIf symptoms such as severe diarrhea, shortness of breath, or new rash appear, contact your team immediately; high‑dose steroids or therapy hold may be needed.  \n\nYour oncology team will monitor closely and adjust treatment as needed, so you’re not alone in navigating these challenges.",
          "order": 4,
          "qid": "S30-Q04"
        },
        {
          "q": "Should I quit smoking now, or is it too late to matter?",
          "gt": "I hear how anxious you feel about the timing of quitting, especially when you’re already juggling a new treatment plan and the weight of caring for your family.\n\nQuitting smoking now is still a powerful step. Even at 63, stopping tobacco use can improve your immune response, reduce the risk of infection and cardiovascular events, and enhance the effectiveness of chemo‑immunotherapy. Studies show that patients who quit before or during treatment experience fewer complications and better overall outcomes. Nicotine replacement (patches, gum), prescription aids (varenicline, bupropion), and counseling can help you manage cravings and withdrawal. Your oncologist can tailor a cessation plan that fits your schedule and supports your treatment. If you’re unsure how to start, call your local quitline (1‑800‑QUIT‑NOW) or ask your nurse for resources. Remember, every day you stay smoke‑free adds to your health and quality of life—so the sooner you quit, the more benefits you’ll gain.",
          "order": 5,
          "qid": "S30-Q05"
        },
        {
          "q": "If my brain scan later shows spots, what then?",
          "gt": "I hear how frightening the thought of new brain spots feels, especially when you’re already juggling the demands of treatment and trying to keep your days meaningful.\n\nIf a follow‑up MRI shows new lesions, the first step is a quick neuro‑oncology consult. We’ll usually start a short course of oral or IV steroids (dexamethasone 4–8 mg/day) to reduce swelling and monitor for neurological changes. A repeat scan in 1–2 weeks will confirm whether the spots are stable, growing, or resolving.\n\nOnce we confirm metastases, the next options depend on the number, size, and location of the lesions and your overall health. For a single or few small lesions, stereotactic radiosurgery (SRS) can deliver a high dose to the tumor while sparing healthy brain tissue. If there are many or diffuse lesions, whole‑brain radiation therapy (WBRT) may be preferred. In select cases—especially if the lesion is causing focal symptoms—a neurosurgeon may consider a limited resection. If your cancer has a targetable mutation (e.g., EGFR, ALK, BRAF), we can add or switch to a targeted agent that penetrates the brain.\n\nWe’ll continue your systemic chemo‑immunotherapy unless a drug’s toxicity or the brain findings dictate a pause. Your oncologist will schedule MRI scans every 3 months and monitor blood counts, liver function, and cardiac status (e.g., echocardiogram every 3–6 months for agents like trastuzumab). Steroid side effects—hyperglycemia, mood changes, insomnia—will be managed with dose tapering and supportive meds.\n\nBeyond the medical plan, we’ll arrange for a pain specialist, a neurologist for seizure prophylaxis if needed, and a social worker to help you maintain daily routines and connect you with support groups. Your team will keep you informed at every step, so you’re never alone in making these decisions.",
          "order": 6,
          "qid": "S30-Q06"
        },
        {
          "q": "Can I keep my morning walks with my dog?",
          "gt": "I hear how scary it feels to juggle a new chemo‑immunotherapy plan while still wanting to keep your morning walks with your dog—your anxiety is completely understandable.\n\n**Can you keep walking?**  \nYes, most patients can continue moderate‑intensity walks, but timing and safety are key.  \n- **Treatment schedule**: Check‑point inhibitors (e.g., pembrolizumab, nivolumab) are usually given every 3 weeks, while cytotoxic agents (e.g., docetaxel, carboplatin) are given every 3–4 weeks. Infusions last 30–60 min for immunotherapy and 1–2 hrs for chemo.  \n- **Side‑effect window**: The first 48–72 hrs after chemo are when neutropenia and fatigue peak. If you feel unusually weak, short‑term rest is advised.  \n- **Monitoring**: CBC, CMP, and LVEF (if anthracyclines) are checked before each cycle; report fevers, chills, or new aches immediately.  \n- **Walk safety**: Keep the walk brisk but not exhausting, stay in low‑traffic areas, keep your dog up‑to‑date on vaccines, and avoid contact with sick animals or crowds. Bring water, wear a mask if you’re feeling unwell, and consider a shorter walk if you’re fatigued.  \n\nDiscuss your specific regimen and any concerns with your oncologist; they can tailor the plan to your energy levels and infection risk.  \n\nYou’re not alone—your care team will monitor closely and adjust as needed.",
          "order": 7,
          "qid": "S30-Q07"
        },
        {
          "q": "How long does this treatment last?",
          "gt": "I hear how frightening the idea of a long treatment plan feels, especially when you’re already juggling so many responsibilities and hoping to keep your days meaningful.\n\nMost chemo‑immunotherapy regimens start with an **induction phase** of 4–6 cycles, each cycle lasting about 3 weeks. For example, a common lung‑cancer combo is carboplatin (1‑hour infusion) + pemetrexed (30‑minute infusion) + pembrolizumab (30‑minute infusion). After induction, many patients switch to a **maintenance phase** that continues the immunotherapy (e.g., pembrolizumab every 3 weeks) for up to 2 years or until the cancer stops responding. In melanoma, a typical plan is ipilimumab + nivolumab for 4 cycles, then nivolumab alone every 2 weeks for 1–2 years.  \n\nYou’ll have blood tests (CBC, CMP) before each cycle, a chest CT or PET‑CT every 8–12 weeks, and, if you’re on a drug that can affect the heart, an echocardiogram every 3 months. Side‑effect monitoring is built into each visit—fever, fatigue, nausea, or immune‑related symptoms will be checked right away.  \n\nIf you develop significant toxicity, the oncologist may pause or reduce doses, or switch to a less intensive maintenance plan. The exact length of your treatment will be tailored to how your tumor responds and how you tolerate the drugs, so your team will adjust the schedule as needed.  \n\nRemember, we’ll keep a close eye on your progress and adapt the plan so you can stay as active and comfortable as possible.",
          "order": 8,
          "qid": "S30-Q08"
        },
        {
          "q": "What happens if it grows back fast?",
          "gt": "I hear how scary the idea of a rapid return feels, especially when you’re already juggling the weight of treatment and the desire to keep your days meaningful.\n\nIf the cancer recurs quickly—typically within 3–6 months of starting chemo‑immunotherapy—it usually signals that the tumor has become resistant to the drugs you’re using. Clinically, you’ll see new or enlarging lesions on the next CT scan, rising tumor markers (if applicable), or worsening symptoms such as pain or fatigue. Your oncologist will then:\n\n1. **Re‑evaluate the regimen**:  \n   • Switch to a second‑line chemotherapy (e.g., a platinum‑based agent like carboplatin or cisplatin combined with a different partner such as paclitaxel).  \n   • Add or change the immunotherapy (e.g., switch from pembrolizumab to nivolumab or add a checkpoint inhibitor like atezolizumab).  \n   • Consider targeted therapy if a driver mutation (EGFR, ALK, BRAF, etc.) is present.\n\n2. **Adjust monitoring**:  \n   • CT scans every 8–12 weeks instead of 12–16 weeks.  \n   • Blood tests (CBC, CMP, liver enzymes) before each cycle to catch neutropenia or organ toxicity early.  \n   • Cardiac monitoring (echocardiogram) if the new regimen includes cardiotoxic agents.\n\n3. **Supportive care**:  \n   • Growth factor support (filgrastim) to reduce infection risk.  \n   • Antiemetics, pain control, and nutrition counseling to keep you functional.\n\n4. **Explore alternatives**:  \n   • Clinical trials that test novel agents or combinations.  \n   • Palliative‑care referral if disease control becomes unlikely, focusing on symptom relief and quality of life.\n\nYour team will tailor these steps to your specific cancer type, overall health, and personal goals. Stay in close contact with your oncologist—any new symptoms or side‑effects should prompt an immediate call.",
          "order": 9,
          "qid": "S30-Q09"
        },
        {
          "q": "How do we protect good days for time with my family?",
          "gt": "I hear how scary the idea of losing a good day feels, especially when you’re trying to stay strong for your family.  \n\n**Practical plan to protect those moments**\n\n1. **Treatment schedule** – Most chemo‑immunotherapy regimens run in 3‑week cycles. For example, a typical combo might be carboplatin + paclitaxel (infused over 1–2 h) plus pembrolizumab (30–60 min). Your oncologist will set the exact dates, but you can usually plan family time on the two days between cycles.  \n\n2. **Monitoring** – CBC, CMP, and a baseline echocardiogram (if a cardiotoxic drug is used) are done before each cycle. Imaging (CT or PET) is repeated every 2–3 months to gauge response. Keep a symptom diary and report new fatigue, nausea, or skin changes right away.  \n\n3. **Supportive care** – Anti‑emetics, growth‑factor support, and low‑dose steroids can blunt nausea and fatigue. Hydration and a balanced diet help you recover faster. If you feel overwhelmed, ask for a palliative‑care consult to manage symptoms and coordinate home‑health aides for errands.  \n\n4. **Family logistics** – Schedule visits on “off‑days,” use telehealth for routine labs, and consider home infusion if available. Let your caregivers know your treatment days so they can plan meals and rest periods.  \n\n5. **When to pause** – If you develop severe immune‑related side effects (e.g., colitis, pneumonitis), the immunotherapy may be held or stopped while you treat the adverse event; chemotherapy can often continue at a reduced dose.  \n\n**We’ll monitor closely and adjust as needed, so you can keep those precious family moments as bright as possible.**",
          "order": 10,
          "qid": "S30-Q10"
        }
      ]
    }
  ]
}